Skip to content

Opening Doors:

Doug and Yvonne Mendenhall on Research, Mentorship and the Gift of Possibility.

The Mendenhalls
(L-to-R): Yvonne, Doug, and Heather Mendenhall

Doug and Yvonne Mendenhall say mentorship, exposure and confidence can help students discover what is possible.

For Doug and Yvonne Mendenhall, supporting the UW School of Pharmacy’s Nelson-Mendenhall Summer Scholars Program is about more than philanthropy. It is about creating the kind of opportunity that can shape a student’s future.

Doug Mendenhall knows that firsthand.

As an undergraduate, he joined a summer research program because he needed paid work and had always enjoyed lab science. What he found was far more than a job. Surrounded by graduate students and researchers, he began to see science not just as coursework, but as a field where curiosity, collaboration and discovery could lead to a meaningful career.

“It opened the door for me,” Doug said. “I participated in one when I was a student. At the time, I was putting myself through school, so I needed to do something that provided compensation. I had always liked lab work, but doing it every day, in that environment, changed the way I saw things.”

If this program opens a door for a student the way one opened for me, then it has done something very worthwhile.

Doug Mendenhall

That experience helped launch a career in pharmaceutical science and drug development. Today, Doug and Yvonne hope their support will help other students gain that same kind of exposure — the kind that builds confidence, broadens horizons and helps students better understand their own potential.

Their vision for the summer scholars’ program is not to steer students toward one specific path, but to give them the chance to explore. Through research experience, mentorship and collaboration, students can test their interests, build practical skills and learn more about how science can improve lives.

“I hope it opens doors for them,” Doug said. “I hope they see it as a transition point in their lives — a moment when they were exposed to things they did not know before.”

That kind of early exposure matters, he said, because many students make academic and career decisions before they have had a real opportunity to explore the possibilities available to them. Research experiences can help students make more informed choices — and sometimes reveal a future they had not yet imagined.

The Mendenhall’s also emphasize that the value of a summer research experience extends beyond technical training. Students learn how to work on teams, communicate ideas, interpret results and present their work with confidence.

In Doug’s view, those skills are essential in any scientific career.

“One of the hardest things to teach is how to work with other smart people,” he said. “Students need to learn how to connect, how to communicate, how to listen and how to understand other people — even those with different kinds of knowledge.”

For Yvonne Mendenhall, one of the clearest examples of the program’s impact came from meeting a student who had traveled from North Carolina to Seattle to participate.

The student arrived unsure of how her background and goals would fit, Yvonne recalled, but left with a stronger sense of confidence and possibility.

“She did not know exactly what she was getting into,” Yvonne said. “She was unsure whether her background and goals would fit. But she went. And what stood out to me was how empowered she seemed afterward.”

For the Mendenhall’s, that transformation reflects the deeper value of research opportunities. A single summer may not determine an entire career, but it can help students discover what excites them, what challenges them and what they want to pursue next.

Doug also believes those opportunities matter well beyond the individual student. Continued investment in research, he said, is essential to scientific progress and to preparing the next generation of researchers, innovators and health care leaders.

“Much of life is about hope,” Doug said. “Science is one of the places where hope becomes something you can work on.”

That belief also shapes how the Mendenhall’s think about mentorship. Doug credits mentors in his own life with giving him confidence, perspective and encouragement, and he sees supporting students now to extend that same gift to others.

In the end, the Mendenhall’s say the goal is simple: help students discover what is possible.

Maybe a student finds a passion for research and chooses that path. Maybe another realizes research is not the right long-term fit, but gains confidence and skills that will serve them elsewhere. Either outcome has value.

“What matters is that they had the chance to find out,” Doug said.

The Long Game

Ryan OftebroFor UW School of Pharmacy alumnus Ryan Oftebro, independent pharmacy is personal — a practice of community, humility and learning when to get out of the way.

Ask Ryan Oftebro about his success, and he will almost inevitably begin talking about someone else.

A mentor who believed in him before he fully believed in himself. A professor who pushed him beyond his comfort zone. A classmate who became a lifelong friend, co-worker and business partner. His father, whose example still shapes the culture of Kelley-Ross Pharmacy decades later. The employees who show up every day to care for patients. The patients themselves.

It is a revealing habit. Because while Oftebro serves as CEO of Kelley-Ross, one of Seattle’s most enduring independent pharmacies, he rarely tells his story as a story about individual achievement. Instead, he tells it as a story about relationships, responsibility and the quiet obligation to leave something better than he found it

“My goal has been to make myself irrelevant,” he says.

It is a striking thing to hear from a CEO. But for Oftebro, a 2003 graduate of the University of Washington School of Pharmacy, the line is not a throwaway. It is a philosophy of leadership, learned over time from mentors, colleagues, patients and family. The best leaders, he believes, do not make themselves indispensable. They build a culture strong enough to keep growing without them — one rooted in trust, service, imagination and the steady work of putting people first.

A Community That Stayed With Him
When Oftebro thinks back on his time at the UW School of Pharmacy, he does not begin with a single course, rotation or lecture. He begins with people.

“The thing that sticks with me is that sense of community and relationships and friendships,” he says. “My classmates became my best friends, and they became my co-workers and eventually my business partners.”

Those relationships became part of the architecture of his life. So did the faculty members who helped shape his understanding of pharmacy and leadership: Nancy Murphy, Sid Nelson, Karan Dawson, Mickey Karski, Gary Elmer, Jackie Gardner, Don Downing and others. They were teachers, but also mentors — people who noticed potential, offered encouragement and helped him imagine a wider version of what a pharmacist could be.

That mentorship extended well beyond the classroom. Through student leadership, professional conferences, legislative advocacy and involvement with the Washington State Pharmacy Association, Oftebro began to step into roles he had not pictured for himself. He learned how to speak up. How to participate. How to take a place in the profession rather than simply enter it.

“I learned to step out of my comfort zone,” he says. “These folks helped inspire me and ignite the passion in pharmacy that drives me in everything I do today.”

For Oftebro, that lesson has only become more important with time. Pharmacy, he says, often attracts people who like clarity — people who are analytical, careful, evidence-driven and drawn to the right answer. The profession needs those qualities. But patient care does not always arrive in neat categories. Neither does leadership. Neither does public health.

“There are going to be times when, in order to serve that patient, you may not have that black-and-white answer,” he says. “You need to become a decision maker. You need to be comfortable dealing with risk.”

The Work of Meeting People Where They Are
That comfort with uncertainty has become essential at Kelley-Ross, where the work has never been limited to dispensing medications.

Over the decades, the pharmacy has moved into compounding, long-term care, specialty pharmacy, clinical services, overdose prevention and public health. It has served patients during the HIV/AIDS crisis, responded to vulnerable communities during COVID and continued to look for gaps in care where an independent pharmacy could make a meaningful difference.

The phrase often used for this kind of work is “meeting patients where they are.” Oftebro remembers first hearing it from Micki Kedzierski during a UW elective on substance use disorder. At the time, he says, he did not fully understand the depth of the idea. But he recognized it later in the people around him — especially his father, John.

For Oftebro, meeting patients where they are is not a slogan. It is a daily discipline. It means asking what someone needs before deciding what the system is willing to offer. And it means being creative, practical and humane all at once.

“It’s a responsibility to bring your very best to every patient experience without judgment of the person that you’re serving,” he says. “It’s also an opportunity to be creative and innovative and problem-solve.”

That kind of service, he says, is an expression of servant leadership — a phrase that can sound formal until you hear Oftebro describe it. In his telling, servant leadership is less about posture than practice. It is about staying close enough to the work to understand it, humble enough to listen and confident enough to let others lead.

A Father’s Example
Much of that, Oftebro learned from his father.

“Working with my dad has been the highlight of my career,” he says.

John Oftebro is no longer formally at Kelley-Ross every day, but Ryan says his influence remains everywhere. Many longtime employees were hired by him. His standards helped shape the pharmacy’s culture: strong customer service, a can-do attitude, a willingness to innovate and take risks, and a belief that the right thing is worth doing even when it is difficult.

“He set the tone here,” Oftebro says.

That tone has mattered in a business where longevity is anything but guaranteed. Independent pharmacies operate in a challenging healthcare landscape, often squeezed by market forces far larger than themselves. For a small business in healthcare to last a century, Oftebro says, is humbling. But what matters most to him is not simply that Kelley-Ross endured. It is how.

Kelley-Ross celebrated its 100th anniversary last year — a milestone Oftebro describes with pride, but also with humility. As CEO, he is proud of the company’s longevity. As a pharmacist, he is proud of the way the pharmacy has continued to serve its community.

“We put people first,” he says. “The people we serve, our community — that’s why we exist. When we do that, when we put people first, the business success follows.”

The Strength of Being Independent
As an independent pharmacy, Kelley-Ross has the ability to respond quickly and locally. It can see a need, try something, learn from it and adapt. It can build services that reflect the neighborhood rather than importing a model from somewhere else.

“We can create a service that reflects the community that we live in,” Oftebro says. “It’s organic. It really is purpose-built to the needs of our community.”

That, he believes, is the particular strength of independent pharmacy. No two communities are identical, so no two independent pharmacies should be exactly alike. Each is shaped by the needs around it, the people inside it and the willingness to keep adjusting.

Oftebro does not pretend to have a rigid 10- or 15-year map for Kelley-Ross. The work, he says, is more responsive than that. Opportunities arise. Needs become visible. Sometimes survival forces creativity. Sometimes passion follows opportunity rather than the other way around.

“If an opportunity comes along that fits with our mission of caring for our community, and we can find a sustainable business case, then we will pursue it,” he says.

For Oftebro, the mission is not preserved by standing still. It is preserved by paying attention — to patients, to public health, to the profession and to the community just beyond the pharmacy counter.

Building What Comes Next
Oftebro sees significant opportunities ahead for pharmacists, especially in public health and community-based care. He also sees real challenges. Graduating students, he says, are entering a complicated landscape. But they are also entering a profession with the training, trust and accessibility to fill gaps that other parts of the healthcare system cannot.

His advice to the next generation is direct: figure out what your community needs, and be willing to fight for it.

“Nobody’s going to hand anything to the profession of pharmacy on a silver platter,” he says. “We’re going to have to go out and build it.”

That means refusing to be confined by the way things have always been done, advocating for patients,  being nimble, taking risks and applying pharmacy training in new ways.

In Washington state, he sees particular promise because pharmacists have a strong scope of practice. But opportunity, he says, only matters if pharmacists are willing to step into it.

“We’ve got to be advocates for the people we care for and for our profession,” he says.

That sense of responsibility is also why Oftebro has remained closely connected to the UW School of Pharmacy through teaching, precepting, advisory service and campaign leadership. He sees his continued engagement as a way of honoring what was given to him.

“What I received from the School of Pharmacy was a gift,” he says. “I wouldn’t be where I am today without people who invested their time and care in me.”

Mentorship, he has learned, is not a simple transfer from one generation to the next. It gives something back to the mentor, too. His work with the School and with students renews the same sense of purpose that first drew him deeper into pharmacy.

“I get so much back from the time and energy that I put back into the School and into the profession,” he says.

Learning to Let Go
That may be the clearest throughline in Oftebro’s story: the idea that a meaningful career is not built by holding tightly to what you know, but by giving enough of it away that others can carry the work forward.

He has seen leaders cling to authority. He understands the temptation. But he has chosen a different approach.

“The more I let go, the better this place does,” he says. “I just need to, as I learned from my dad, attract great people and then get out of their way.”

For Oftebro, the future of Kelley-Ross is not about preserving the past exactly as it was. It is about carrying forward the values that made that past matter: compassion, imagination, service, courage and a deep attentiveness to community need.

He wants Kelley-Ross to keep doing “Kelley-Ross things” long after he is gone. He wants UW-trained pharmacists to keep finding new ways to use their skills, and he wants the profession to recognize that its future may not arrive as a clear invitation. It may appear as a gap, a need, a person standing in front of you who has nowhere else to go.

“We may not have the luxury of chasing our passions,” he says. “But we can chase opportunities and bring our passion with us.”

That is the long game Oftebro is playing. Not to be remembered as the person who held everything together, but as someone who helped build a culture where other people could lead, serve and imagine what comes next.

It is a lesson that began, in many ways, at the UW School of Pharmacy — in the relationships that formed him, the mentors who pushed him, and the community that helped him see pharmacy not only as a profession, but as a way of showing up for people.

And then, when the moment is right, getting out of the way.

 

*Ryan served as Guest Speaker at the 2026 UW School of Pharmacy Graduate Recognition Ceremony.

The Art of Listening

Patient Interview DayAt the UW School of Pharmacy, older adults from University House Wallingford and Era Living help students build confidence, strengthen communication skills and better understand what matters most in caring for older adults.

The room may look like an ordinary classroom, with students seated at tables and conversation rising in a low, steady hum. But on Patient Interview Day at the University of Washington School of Pharmacy, the atmosphere feels more personal than instructional. There are no mock cases or scripted scenarios here. Instead, older adults from University House Wallingford, one of Era Living’s seven Seattle-area Retirement Communities, sit down with student pharmacists to talk about their lives, their health and what matters most to them.

For students completing the Plein Certificate in Geriatric Pharmacy, the experience offers something difficult to teach through lectures alone: the chance to practice care as a human relationship.

According to organizer and Plein Center for Aging Assistant Director for Outreach and Associate Teaching Professor Abby Winter, the event, now in its second year, is designed to help students build confidence before they begin clinical rotations, while deepening their understanding of what it means to care for older adults with skill, empathy and respect.

“The goal is to give students an opportunity to speak with and interview older adults so that, when those conversations become part of clinical practice, they feel familiar and natural,” she said.

Another primary purpose for the program, says Winter, is helping students understand that communication is central to good care.

“We work so much on the intricacies of each medicine and how things work in the body,” she noted, “but I think one of the most important things is the communication. If you can’t communicate all that knowledge you have, or understand someone else’s concerns, you’re not going to be a great practitioner.”

Learning beyond the medication list

At the heart of Patient Interview Day is a simple but important idea: caring well for older adults begins with listening. Winter encourages students to focus not only on medications and medical histories, but also on the rhythms and priorities that shape a person’s daily life — family, friendships, independence, favorite routines and the things they most want to preserve.

The goal is not simply to collect information. It is to understand that good care begins with knowing who a person is and what matters to them.

In a profession that asks students to master complex science and clinical decision-making, Patient Interview Day makes space for something quieter, but no less essential: presence, curiosity and trust. It reminds students that expertise matters most when it is paired with the ability to connect.

A partnership that invites older adults into the classroom

For University House Wallingford, the partnership carries meaning of its own. Phyllis Fischer, executive director of the community, said many residents are drawn to the experience because they value hands-on, real-world learning and welcome the chance to contribute to the education of future pharmacists.

“Many of our residents are retired teachers, professors and longtime volunteers,” she said. “Some are curious about pharmacists and the role they can play in patient care. Others are simply interested in the opportunity to spend time with students and take part in something new.”

For residents, the experience also offers something that can be unexpectedly rare: focused attention. Fischer said one of the most meaningful aspects of the day is the opportunity to have someone actually listen to residents’ stories or their concerns, and having the focus be on them exclusively for a short time.

“I also see the value of intergenerational exchange,” she said. “Older adults can help students understand concerns that may not always be visible in a textbook — independence, mobility, isolation, family, resources and the ability to continue making choices about one’s own life.”

Fischer’s hope is that students leave the event seeing older adults as “interesting and credible”, and that they will feel more comfortable approaching and engaging with much older people throughout their careers.

What students carry forward

For Katie Daugherty, a UW PharmD student, the experience offered both perspective and reassurance. She came into the event a little nervous, unsure whether she would be able to keep the conversation going. But she also knew the residents genuinely wanted to be there and wanted to talk with students, which helped put her at ease. Once the conversation began, she found that it unfolded naturally.

“Even though I didn’t talk a lot, my partner shared so much about their life and experiences,” she said. “It was incredibly valuable.”

What stayed with Daugherty afterward was the resident’s individuality — the details of a life that extended far beyond health care. She was struck by how active and engaged residents were in their community, and by the stories they shared about jazz clubs, themed celebrations and other resident-led activities. The experience reinforced something important: older adults want to be seen as individuals with interests, independence and full lives, not simply as patients.

The conversation also deepened her understanding of trust.

“Building trust starts with being present and really listening,” Daugherty said. “Once trust is there, people open up more.”

That lesson, she said, sharpened her understanding of patient-centered care — not as an abstract ideal, but as something built in real time, through attention, empathy and responsiveness to what a person values.

Perhaps most meaningfully, the day changed the way she thought about her own role.

“This experience reinforced how important it is to get to know the person and determine what matters to them, both their health and their personal life, so that we can best care for them,” she said.

One of her strongest takeaways was also a personal one: “Even as a quieter person, I could still have a meaningful and effective interaction.”

A lesson that stays with students

Patient Interview Day helps students strengthen communication skills, think clinically in the moment and become more comfortable engaging with older adults. But its value runs deeper than that. By bringing students and older adults together in conversation, the experience asks future pharmacists to practice one of the most important parts of care: making room for another person’s story.

In that sense, the lesson is both practical and lasting. Before pharmacists can help people manage medications, navigate side effects or make informed decisions about treatment, they first have to understand the lives those decisions are meant to support. Patient Interview Day offers students that understanding in the most direct way possible — by teaching them to listen first.

UW School of Pharmacy’s Sean Sullivan receives ISPOR lifetime achievement award

Honor recognizes decades of leadership in health economics and outcomes research through scholarship, policy impact and mentorship.

Sean Sullivan headshotSean D. Sullivan, Professor and former Dean in the University of Washington (UW) School of Pharmacy, and longtime leader of the Comparative Health Outcomes, Policy, and Economics Institute, or CHOICE Institute, has received the Avedis Donabedian Lifetime Achievement Award from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the Professional Society for Health Economics and Outcomes Research. The award recognizes a career of sustained contribution to the science and practice of improving healthcare quality, value and decision-making.

Over more than three decades, Sullivan has helped shape the field of health economics and outcomes research through scholarship, policy leadership, teaching and mentorship. He also serves on the ISPOR Board of Directors as its current Treasurer and has previously served as President of the Society. Colleagues who nominated him for the award described his career as one defined by “scientific excellence, methodological rigor, and health policy,” and credited him with helping build CHOICE into one of the world’s leading academic centers in the field.

His work has had a lasting effect on how evidence is developed and used by payers, policymakers and clinicians, and Sullivan has played a pivotal role in advancing the Academy of Managed Care Pharmacy Format, budget impact analysis methods and value-based formulary design — contributions that helped change how clinical and economic evidence are presented and applied in coverage and reimbursement decisions in the United States.

Sullivan’s scholarship is both broad and influential. He has authored more than 440 peer-reviewed publications across a wide range of health conditions, with research that has informed clinical guidelines, payer and government policies, and health technology assessment processes. Most recently, his work has helped bring clarity to the complex and evolving policy landscape surrounding Medicare drug price negotiation under the Inflation Reduction Act.

Just as significant is the reach of his mentorship. Over the course of his career, Sullivan has mentored more than 90 trainees and faculty members, many of whom now serve in leadership roles across academia, state and federal governments, industry and payer organizations. That legacy has extended his influence far beyond his own scholarship.

Those who have worked alongside Sullivan point not only to the significance of his scholarship, but to the community of inquiry and mentorship he helped build around it.

“Simply put, I came to UW to work with and be trained by Sean Sullivan,” said Jonathan H. Watanabe, Professor and Goyan Presidential Chair, Department of Clinical Pharmacy, University of California, San Francisco School of Pharmacy. “The environment he has cultivated, the innovations he has fostered, the friendships he has nurtured that have all nucleated from the steadfast notion of applying scientific thinking and principles to better understand, quantify, and promote health in the real-world is unique on earth.”

Shelby Reed, Professor in Population Health Sciences and Medicine, Duke University, emphasized both the quality and relevance of Sullivan’s work, as well as the example he has set for others in the field.

“Sean’s massive body of research exemplifies best practice in addressing questions that matter,” Reed said. “His recent work investigating the impact of changes in drug pricing in the U.S. sheds light on the thorny intersection of affordability, innovation, and improving health outcomes for patients.” She added, “Sean’s impact on health economics and outcomes research is exponentiated through his steadfast commitment to lifelong mentoring to so many people in the field. I am lucky to be one of them.”

Andy Stergachis, Professor of Pharmacy and Global Health at the UW School of Pharmacy, said Sullivan’s career has left a lasting mark on both the profession and the many people shaped by his work.

“Having known Sean since his graduate school days, I have had the privilege of witnessing the truly remarkable trajectory of his academic and professional career and its impact,” Stergachis said. “His achievements have yielded lasting benefits for generations of his mentees, the profession of pharmacy, the healthcare system, and society at large. This lifetime achievement honor is a fitting recognition of his pioneering and enduring leadership and many contributions to the economic evaluation of health care technologies and practices, as well as to pharmaceutical and medical technology pricing and policy.”

Scott Ramsey, Director of the Hutchinson Institute for Cancer Outcomes Research at Fred Hutch Cancer Center, Professor of Medicine, and Adjunct Professor of Pharmacy, underscored the breadth of Sullivan’s influence as a scholar, teacher and mentor.

“Through his leadership, mentorship of generations of students, and scholarship, Sean has elevated the School of Pharmacy, launched dozens of successful careers, and built a legacy of research and teaching that is without peer,” Ramsey said. “He is a true giant in the field, and an incredibly positive force for the profession.”

Ryan Hansen, Professor and Chair at the UW Department of Pharmacy was first introduced to the field of Health Economics and Outcomes Research by Sullivan, and was mentored by him through graduate school.  Hansen said: “Sean has had a lasting impact on so many lives around the globe, from patients to clinicians, and of course scientists in the field of HEOR. The Donabedian Award is a wonderful testament to his many scientific achievements and ongoing career.”

The field has evolved over the course of Sullivan’s career. When he entered health economics and outcomes research, the discipline was still establishing itself. Over time, the questions it raised — about value, affordability and evidence — moved from the margins to the center of healthcare decision-making.

Still, the central responsibility of the field has not changed: to produce rigorous evidence, communicate it clearly and ensure that it is used appropriately.

“It isn’t about data or methods,” Sullivan said. “It’s about patients who need medicines they can afford, and policymakers who need evidence they can trust.”

Sullivan’s career has also been recognized through his election to the National Academy of Medicine, designation as a Fellow of the American Association for the Advancement of Science, and the Academy of Managed Care Pharmacy Foundation Steven G. Avey Award for sustained and distinguished service to managed care pharmacy.

Along with the Donabedian Award, these honors reflect a career devoted not only to advancing a field, but to strengthening the connection between evidence and better healthcare decisions.

About the UW School of Pharmacy
The University of Washington School of Pharmacy advances better health through innovative research, education and service, and prepares the next generation of scientists, pharmacists and health care leaders.

Pharmacy Offers Second-Highest ROI Among Graduate Degrees

New research highlighted by The Washington Post found that pharmacy offers the second-highest return on investment among the graduate degrees studied—underscoring the profession’s distinctive blend of purpose, stability and opportunity. 

Choosing a career in healthcare is about more than earning potential. It’s about finding a path that reflects your strengths, connects with your values and gives you the chance to make a meaningful difference in people’s lives.

Pharmacy offers that rare combination. Grounded in science and centered on care, it is a profession that allows you to work closely with patients, improve health outcomes and serve communities in lasting ways. It also offers strong long-term value. New research highlighted by The Washington Post found that pharmacy ranks No. 2 for return on investment among the graduate degrees studied, behind only medicine and ahead of law.

The numbers help tell that story. In the analysis, average annual earnings for pharmacy students rose from $49,892 before graduate school to $132,460 after graduate school.

But the value of a pharmacy degree goes beyond financial return. Pharmacists are essential members of the healthcare workforce, helping people use medications safely and effectively, manage chronic conditions and navigate increasingly complex systems of care. The profession calls for curiosity, compassion and problem-solving, and it offers the chance to make a difference every day.

For students thinking about what comes next, pharmacy stands out as a path that is both practical and deeply meaningful. It is a career that offers room to grow, opportunities to lead and the ability to have a real impact on the health and well-being of others.

At the UW School of Pharmacy, we are proud to prepare future pharmacists and pharmaceutical scientists for careers that combine purpose with possibility.

For those seeking a future rooted in care, connection and lasting opportunity, pharmacy remains a compelling path forward.

Cheryl Wright-Wilson and Raymond Wilson bequest supports UW’s School of Pharmacy

Gift will provide additional support for medicinal chemistry research and undergraduate summer training at the School of Pharmacy.

Cherie and Ray

In the fall of 1965, during Cheryl Wright’s first week at the University of Washington, she went to Suzzallo Library to complete a chemistry assignment. She needed help with a math problem and saw a boy across the reading room who had a slide rule — an analog calculator. The young pharmacy student who helped her that day was Raymond Wilson. Together the couple, who go by Cherie and Ray, did far more than solve a mathematical equation — they married and formed a bond that’s lasted more than six decades.

Cherie and Ray, both members of the Class of 1969, went on to have successful academic and professional careers. Over the years, their connections to the UW have deepened. They have supported scholarships, created alumni communities, built friendships and professional relationships, and cheered for Husky athletics, including the volleyball, basketball and football teams.

Now, the Wilsons have made a bequest of more than $8 million to be shared among the College of Education, the School of Pharmacy and UW Medicine’s BRaIN Laboratory. Bequests allow donors to direct their assets to causes after their death. The bequest brings the Wilsons’ total giving to more than $10 million and they now will be recognized by the UW as Presidential Laureates.

“This remarkable bequest reflects not only Cherie and Ray Wilson’s generosity, but a lifetime of connection to the University of Washington. It represents an enduring relationship grounded in gratitude, trust and a shared belief in the power of education and discovery,” said UW President Robert J. Jones. “From their earliest days as students to this extraordinary commitment, they have invested in people, ideas and communities across our university. Cherie and Ray’s impact will be felt for generations, expanding opportunity for students and advancing research that improves lives.”Several decades after Ray received financial assistance to attend the UW School of Pharmacy, he teamed up with classmates and launched the Class of 1969 Scholarship Fund. Set up in the 2000s, it was the first School of Pharmacy alumni class to create a fund to help students.

“I came from a small town in Eastern Washington with almost no money, and yet, the University provided me with scholarships and completely covered my tuition,” Ray said.Wendel L. Nelson, a professor and pioneer in medicinal chemistry, recognized Ray’s talents early on and hired him to work in a lab. The research helped Ray advance his career,and the extra money helped pay for food and housing. More than that, the combination of scholarships and laboratory work enabled Ray to graduate debt-free.

With this bequest, the Wilsons’ generosity supports two additional funds in the School of Pharmacy: The Wendel L. Nelson Endowment in Medicinal Chemistry, named for Ray’s mentor, will support graduate students involved in basic laboratory research in medicinal chemistry. The gift also adds to the Nelson-Mendenhall Summer Scholars Program Fund, which brings undergraduates to the UW School of Pharmacy for a 10-week intensive in pharmaceutical sciences.

“From their longstanding financial support to their ongoing participation in School events,to Ray’s past volunteer leadership, Ray and Cherie have already contributed so much to our School of Pharmacy community, and they have done so with a genuine desire to help students and the School thrive,” said School of Pharmacy Dean Jay Panyam. “The Wilsons’ estate commitment is yet another example of their incredible generosity, and I know it will have a significant and lasting impact for our students.”

The Wilsons’ bequest reflects a longstanding connection to the UW School of Pharmacy and a commitment to supporting students and research. Their impact will be felt by generations of students to come.

Photo: Dennis Wise/University of Washington

UW School of Pharmacy Expands Strategic Collaboration with Johnson & Johnson to Advance AI-Enabled Drug Design

The University of Washington School of Pharmacy has expanded its longstanding collaboration with Johnson & Johnson* through a focused collaboration within the School’s Institute for Innovations in Drug Disposition and Delivery (I2D3). The initiative reflects a shared commitment to strengthening the scientific foundations that enable more predictive, data-driven drug development.

At the center of the collaboration is an effort to design and experimentally evaluate a large number of peptides for cellular permeability. These high-quality measurements will form the basis of a robust dataset used to train artificial intelligence models capable of predicting cell permeability directly from molecular structure—an important determinant of whether potential therapies can move successfully through development.

“Predictive computational models require robust data,” said Rheem Totah, professor of Medicinal Chemistry and Associate Dean for Research and Graduate Programs at the UW School of Pharmacy. “By combining rigorous laboratory measurements with advanced computational tools, we can build models that are reliable and more informative in guiding therapeutic peptide design.”

The collaboration builds on years of engagement through consortia participation and advisory partnerships and is now extended through I2D3’s focused work in computational therapeutics design. I2D3 will bring together researchers from the School of Pharmacy, UW Medicine adjacent institutions and corporate partners to develop AI-powered models to predict drug safety and efficacy, accelerating the drug development pipeline while reducing development costs and reliance on animals.

Beyond advancing research, the initiative supports the School’s educational mission. Students and postdocs will gain hands-on experience working at the intersection of experimental pharmacology and advanced computational modeling—preparing the next generation of scientists to lead in an increasingly data-driven pharmaceutical landscape.

As I2D3 continues to grow, collaborations such as this underscore a central principle: durable progress in drug development depends on sustained collaborations between academia and industry that are grounded in strong science and shared purpose.

*Legal entity: Janssen Reseach & Development, LLC.

SOP Students Turn Out in Force for Legislative Day

Pharmacy Legislative Day Group shot

This week’s Legislative Day in Olympia, Washington, was a strong example of what’s possible when students, faculty, alumni, and professional partners come together in shared purpose. In partnership with the Washington State Pharmacy Association, the UW School of Pharmacy community showed up in record numbers to engage directly with state lawmakers.

In total, 115 pharmacy students and 20 pharmacists—including six faculty members and several alumni—participated in 60 meetings with Washington State legislators. Conversations focused on pharmacist prescriptive authority and educating lawmakers on how policy can improve patient access to care while helping address healthcare affordability across the state. Student participation reached an all-time high.

Several factors contributed to the day’s success: legislation that resonated deeply with students’ training and future roles, and—most importantly—the leadership of a dedicated, well-prepared group of student leaders who helped guide and organize their peers. Legislative Day gives students a meaningful opportunity to represent the School and the profession while developing practical skills in advocacy, leadership, and state health policy.

A special thank you to everyone who helped make the day productive and impactful, including Walgreens and QFC for their support of our students’ participation.

Nina Isoherranen Named 2025 ASPET Fellow

Nina Isoherranen headshot
Nina Isoherranen

Professor and Milo Gibaldi Endowed Chair of the Department of Pharmaceutics Nina Isoherranen was recently named a 2025 Fellow by The American Society for Pharmacology and Experimental Therapeutics (ASPET) Council. Selection as a Fellow of the American Society for Pharmacology and Experimental Therapeutics (FASPET) is an honor bestowed on ASPET members for their meritorious efforts to advance pharmacology through their scientific achievements, mentorship, and service to the Society. Nina will be recognized at the 2026 ASPET Annual Meeting Awards Luncheon May 20, 2026. Learn more

The Costs of Dementia Begin Long Before the Diagnosis

Jing Li Headshot
Jing Li, Associate Professor and Associate Director of the CHOICE Institute, and faculty member of the Plein Center for Aging

By the time dementia becomes visible in daily life, the financial consequences may already be well underway.

Years before a diagnosis, subtle changes in memory and judgment can begin to interfere with how people manage money—missing a payment, overlooking an account, or failing to respond to market shifts. These early lapses are often dismissed as ordinary forgetfulness. But over time, they can compound into significant financial losses, leaving households more vulnerable just as the costs of cognitive illness begin to rise.

Jing Li, Associate Professor and Associate Director of the CHOICE Institute, and faculty member of the Plein Center for Aging, studies this long, largely invisible period before cognitive decline is clinically recognized. Her research—published in JAMA Neurology and by National Bureau of Economic Research—shows that financial decision-making often deteriorates well before dementia is diagnosed, quietly eroding household wealth at a moment when families are least prepared to absorb the loss.

“We all know dementia has serious consequences for health and health care,” Li said. “But the financial aspects are much less understood—especially what happens before people develop full-on dementia.”

A Slow and Quiet Decline

Cognitive decline does not begin at diagnosis. It unfolds gradually, sometimes over decades, affecting memory, attention, and executive function long before dementia is formally detected.

“The decline is a very long process,” Li explained. “Even before dementia becomes clinically detectable, something is already going on in the brain. Decisions can start to get impaired without the person knowing—and often without other people, such as family members, knowing.”

During this period, most people continue handling finances as they always have (paying bills, managing checking accounts, and overseeing investments that may have taken a lifetime to build). Older adults also tend to hold a large share of household wealth, making the consequences of even modest errors more serious.

Small lapses often come first. A forgotten bill payment can trigger late fees or penalties. Repeated mistakes can snowball into credit problems or mounting debt. More complex assets, such as stocks or investment accounts, pose even greater risks.

“For assets that need to be actively managed, we see a really clear, large drop in value,” Li said. “Even inattention—just not knowing when to buy or sell—can lead to substantial wealth loss.”

Vulnerability to Fraud and Exploitation

Cognitive decline can also make older adults more vulnerable to financial exploitation. Even cognitively healthy older adults are disproportionately targeted by scams. For those experiencing memory or judgment impairments, the risks increase sharply.

“They may feel more generous, more trusting, or less able to evaluate whether something makes sense,” Li noted. “And it’s not always strangers. Sometimes the perpetrators are people within their own family.”

The true scale of financial exploitation is difficult to measure. Many victims never realize they have been scammed. Others may feel ashamed or reluctant to report losses. As a result, available data likely understates the scope of the problem.

What researchers can document, however, is a consistent pattern: wealth begins to decline well before dementia is diagnosed, and financial decision-making appears to play a central role.

Who Faces the Greatest Risk

Risk is not evenly distributed. Older adults who live alone are particularly vulnerable, in part because there is no one nearby to notice subtle changes or intervene early.

“If you live alone, there’s no one looking over your shoulder,” Li said. “That makes it much easier for mistakes to go unnoticed.”

This is where communities, health systems, and financial institutions may have an important role to play. Routine cognitive screening during annual wellness visits can help identify early impairment. Even brief conversations about memory or decision-making can prompt earlier planning.

“Health care providers can’t do everything,” Li acknowledged. “But even talking about these risks and referring patients to other resources—like social workers—can be hugely helpful.”

Some financial institutions have begun exploring safeguards, such as flagging unusual transactions, simplifying account options, or allowing trusted contacts to monitor accounts when concerns arise.

“I’ve actually been approached by financial institutions wanting to understand this problem better,” Li said. “Many recognize there is a real risk when clients are in that early, pre-dementia stage.”

Planning Before It’s Too Late

For individuals and families, timing is critical. Once cognitive decline becomes apparent, it may be difficult—or impossible—to put protections in place.

“People need to be prepared before things go wrong,” Li said. “Once they do, it’s sometimes too late.”

Proactive steps can include designating trusted financial contacts, establishing durable powers of attorney, and considering financial products that provide stable income without requiring ongoing decisions. Simpler, lower-risk arrangements can offer security when decision-making capacity diminishes.

At the policy level, Li sees opportunities for broader intervention. Strengthening consumer protections against fraud, improving financial literacy, and expanding access to fiduciary services could all reduce vulnerability.

“There’s a larger role for policymakers,” she said, pointing to early detection, consumer protections, and support from agencies such as the Consumer Financial Protection Bureau. “This really requires action at multiple levels.”

A Universal Risk

Perhaps the most sobering message of Li’s research is that cognitive decline is not a niche concern. It is a risk every household faces.

“No one can guarantee they won’t develop dementia in the future,” she said. “Because it can be such a long process, you really need to start taking action early.”

Protecting household finances from dementia, Li argues, requires the same mindset used in preventive health: planning ahead, accepting uncertainty, and building resilience before a crisis occurs.

“Good policy planning and product design,” she said, “can make households more resilient when the risk hits—even though we don’t know when that will be for any given individual.”

 

What Families Can Do

  • Talk early: Begin conversations about finances and decision-making long before problems appear.
  • Designate a trusted contact: Many banks allow clients to name someone who can be alerted if unusual activity occurs.
  • Set up legal protections: Establish durable powers of attorney while decision-making capacity is intact.
  • Simplify finances: Consolidate accounts and reduce reliance on complex, actively managed investments.
  • Watch for warning signs: Missed bills, unusual purchases, or sudden generosity may signal cognitive changes.
  • Use routine screenings: Encourage cognitive screening during annual wellness visits.
  • Ask for help: Social workers, financial advisors, and community organizations can provide guidance and oversight.

UW–Mt. Sinai Team Advances “Kidney-on-a-Chip” Toward FDA Qualification, Opening a New Era for Safer, Faster Drug Development

Cathy Yeung and Ed Kelly
Cathy Yeung and Ed Kelly

A University of Washington–Mount Sinai School of Medicine research team has reached a major milestone in its effort to modernize how new medicines are evaluated for safety. The collaborative Translational Centers for Microphysiological Systems (TraCE)-MPS group—co-led at UW by Dr. Ed Kelly and Dr. Cathy Yeung from the School of Pharmacy—has been accepted into the FDA’s ISTAND program, a competitive pathway for validating cutting-edge tools that could one day transform drug development.

Their focus: qualifying a “kidney-on-a-chip” as a reliable way to predict kidney injury and understand how the kidney processes medicines—long before a drug ever reaches human trials.

A Human-Relevant Tool Designed to Improve Safety

Drug-induced kidney injury remains one of the major safety challenges in developing new medications. Traditional approaches often rely on animal testing, which does not always accurately predict human responses. The kidney-on-a-chip, however, recreates part of the human kidney’s structure and function using real human kidney cells.

“The UW kidney chip is a credit card–sized device that models part of the human kidney using live cells,” said Dr. Yeung. “It allows scientists to predict if a new drug might cause kidney damage without having to test the drug in lots of animals or humans.”

This system lets researchers directly compare how a new drug behaves relative to similar drugs known to cause kidney injury, helping FDA reviewers make quicker, better-informed decisions about whether a drug is ready for human studies or requires additional testing.

Supporting the 3Rs: Reduce, Refine, Replace

A key advantage of the kidney-on-a-chip is its alignment with the global 3Rs principle in toxicology—Reduce, Refine, and Replace animal experimentation.

“The UW kidney chip directly supports the 3Rs,” said Dr. Kelly. “It uses cells derived from kidneys that were not viable for transplant, reducing the need for animal studies while providing more human-relevant information about drug safety.”

This approach is fully consistent with the FDA Modernization Act 2.0, which encourages the use of “new approach methodologies” (NAMs) like organ chips and organoids to bring more human-predictive tools into drug development.

Beyond Safety: A Tool With Broad Future Uses

While predicting kidney injury is the primary focus of FDA qualification, the chip has additional applications.

“We’ve also used the kidney chip to estimate kidney clearance—how quickly the kidney removes drugs from the body,” said Dr. Yeung. “In the future, we believe it will help determine optimal dosing for both healthy individuals and people with kidney disease.”

These capabilities could support safer prescribing, clearer dosing guidance, and more individualized treatment strategies.

A Nationally Significant Collaboration

The TraCE MPS project brings together expertise across institutions. At the University of Washington, investigators from the School of Pharmacy (Kelly, Yeung) and School of Medicine (Freedman) work closely with colleagues at the Icahn School of Medicine at Mount Sinai (Himmelfarb).

The UW Pharmacy team is leading the FDA qualification work for assessing nephrotoxicity and estimating kidney clearance, while UW collaborators Beno Freedman and Ying Zheng are advancing qualification of a kidney organoid model for polycystic kidney disease drug development.

As of November 2025, this team is only the second TraCE group in the nation to advance to the Qualification Plan phase of the ISTAND process.

A Potential Turning Point for Drug Development

If successful, the kidney-on-a-chip could become an integrated, FDA-qualified tool used routinely by pharmaceutical companies:

  • Faster decision-making: Regulators could more quickly evaluate the safety of new drugs entering human studies.
  • Better patient protection: Human-derived tissues offer more accurate predictions of kidney injury.
  • Reduced reliance on animal testing: The chip provides meaningful, human-relevant data that aligns with ethical and scientific goals.
  • More efficient drug development: Improved early safety insights can help promising medications reach patients sooner.

“Our aim is simple,” said Dr. Kelly. “We want to make drug development faster, safer, and more human-centered. If the kidney chip becomes part of the drug development process, it could benefit patients everywhere.”

The TraCE-MPS team’s progress represents a significant step toward that future—one where innovative human-based technologies help ensure that lifesaving treatments reach the public both more safely and more swiftly.

Three Decades of CHOICE: Honoring the Past, Shaping the Future

Thirty years ago, a quietly ambitious idea began to take shape at the University of Washington—one that would go on to redefine how we measure value in healthcare, train generations of leaders, and build a model for collaborative, human-centered research. 

Today, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute—stands as one of the world’s leading centers for health economics and outcomes research (HEOR). But its origins were humble. Its growth, deliberate. And its impact, profound.

The first graduating PhD cohort in 2001: Eric Johnson, Sean D. Sullivan, Todd Lee, Mitch Higashi, Dave Veenstra, Nui Chaiyakunapruk, Tom Hazlet, Holly Trautman, Jackie Gardner.

A Foundation of Vision: The Early Years 

The story begins in 1989, when Dr. Andy Stergachis joined the UW School of Pharmacy. With a background in pharmacy and public health, Stergachis saw an opportunity to create something beyond the traditional academic mold. In 1990, he began laying the groundwork for what would become the Pharmaceutical Outcomes Research and Policy Program—PORPP, the academic forerunner to CHOICE. Stergachis envisioned an institute that would anchor rigorous graduate training in applied pharmaceutical outcomes research—and help shape pharmacy’s broader role in public health.  

From the start, the work was policy-relevant and globally impactful. Stergachis’ own research helped shift World Health Organization guidelines on anti-malarial drug safety during pregnancy. The ethos was clear: CHOICE would be about science, but also service. “The field has grown, and CHOICE has grown with it,” he said. From substance use and tobacco cessation to maternal health and medical devices, CHOICE faculty and alumni are tackling the most complex issues in healthcare today—always with collaboration at the core. But Stergachis believes CHOICE’s most lasting contribution may be its people.

“Our alumni are change makers,” Stergachis said. “They’re leading in government, industry, and global health. That’s the legacy.” 

He and his wife Joanne have helped ensure that legacy continues—through endowments supporting global learning, faculty leadership, and future scholars. “It’s about investing in the future,” he said. “Because we’re not done. Not even close.”


Building a Research Engine: The Rise of Outcomes Science 

Soon, Stergachis was joined by epidemiologist Dr. Jackie Gardner, and pharmacist and recent PhD health economist from UC Berkeley, Dr. Sean D. Sullivan. Together, they formed a nucleus of scholars committed to rigorous science, collaborative inquiry, and the belief that pharmacy should be as much about population health as pills. When Sullivan arrived in 1991, the idea of evaluating “value for money” in healthcare was still novel, and they saw an urgent need to ask better questions in this space—and train people to answer them. 

“CHOICE is a community,” Sullivan said. “A home for educators, researchers, and students who are passionate about improving health outcomes through better decision-making.” 

Andy and Sean at that historic APhA Meeting
Andy and Sean at the historic APhA Meeting where the idea of PORPP was put into motion.

In 1995 the team, support, and funding were in place; the time was right to officially establish PORPP and a new graduate program. Under Sullivan’s leadership—as faculty, the Director of PORPP, and later dean—CHOICE helped pioneer the field of Health Economics and Outcomes Research (HEOR). Its graduate program became a launchpad for policy-influencing scientists. And its faculty—like Josh Carlson, Lou Garrison, Beth Devine, Dave Veenstra, Ryan Hansen, Aasthaa Bansal, and others—produced work that shaped real-world access, pricing, and regulation. “We’re often cited as a top institute globally,” Sullivan noted. “Not because of marketing—but because of the quality of our work, our dynamic students, and the staff behind it.” 

The Institute’s impact can be seen in federal reforms, precision medicine policy, and groundbreaking cost-effectiveness methods. But its greatest influence, Sullivan said, may be its leadership pipeline: “Seven of the 30 ISPOR presidents have come from CHOICE. That’s not an accident. That’s a culture.”


Careers Defined: Purpose and Progress 

For Dr. Beth Devine, CHOICE has been more than an academic home, it has been her purpose. “It wasn’t yet called CHOICE when I joined,” she recalled. “But the energy and ambition were unmistakable.” 

PORPP scanned group photo from 1999
Denise Boudreau, Shelby Reed, Kristin Marciante, Beth Devine

Across her career, Devine’s work has helped transform electronic health records, genomic screening, and evidence synthesis for national guidelines. She partnered across disciplines and continents, always keeping science in service to patients. “What sets CHOICE apart,” she said, “is that our research is never in isolation. It’s connected—to medicine, public health, informatics, and global policy.” 

Reflecting on the evolution of CHOICE, Devine sees the next chapter of the Institute already underway. “We’re entering an era of real-world data, machine learning, and global collaboration,” she said. “But the core remains: rigorous, patient-centered science—and a culture of mentorship that multiplies our impact.” 

Professor Emeritus Lou Garrison echoes Dr. Devine’s perspectives and is pleased to see the evolution and success of CHOICE over these 30 years and its contribution to the science of HEOR. Having mentored many students and junior colleagues, including Dr. Devine, he said, “I have had the privilege and pleasure of working with the dedicated and talented CHOICE faculty, students, and staff over this entire period—first, at Roche, as collaborator and mentor, and then, as a faculty member.  My debt is immense—as is my gratitude for my good fortune.” In September 2022, Garrison received the Avedis Donabedian Outcomes Research Lifetime Achievement Award from ISPOR.

CHOICE Group Photo 2012
2012 Graduation Ceremony. Top row: Cara McDermott, Sean D. Sullivan, Beth Devine, Dave Veenstra, Josh Carlson, Denise Boudreau, Veena Shankaran. Bottom Row: Ryan Hansen, Heidi Wirtz, Jon Watanabe, Rafael Alfonso Cristancho, Josh Roth, Joanna Sanderson.

Dr. Josh Carlson, who serves as Graduate Program Director, sees collaborative culture as central to CHOICE’s success. “It’s not about individual excellence. It’s about building something together,” Carlson said.  

His work with the Institute for Clinical and Economic Review (ICER) has led to more than 25 health technology assessment models used across the country. “It’s been a way to stay connected to both the policy implications and the methodological frontiers of our field. That dual relevance—rigor and impact—is what keeps CHOICE vibrant.”


A Broader Identity: Redefining Choice 

Initial strategic plan brainstorming for The CHOICE Institute.

In 2014, when Sullivan became the Dean, he initiated the search for a new Director of PORPP. The search Committee, led by Andy Stergachis, identified Dr. Anirban Basu as the clear successor and he was appointed in 2015. At that time, the transformation from PORPP was already underway. But it was Basu who helped lead the redefinition. “Our faculty were working on vaccines, Alzheimer’s, financial behavior,” he said. “We needed a name—and an identity—that reflected that breadth.” 

Brainstorming the CHOICE name
What’s in a name? Early brainstorming for PORPP’s new name: CHOICE.

Once CHOICE made its debut, it became an official university institute, unlocking broader scope and institutional support. Under Basu’s leadership, the Institute deepened its focus on real-world evidence, health insurance, and machine learning. Faculty like Noémi Kreif, Douglas Barthold, Jing Li, and Kyu Lee have brought new energy—and new questions. 

“What sets CHOICE apart,” Basu said, “is that we train people not just to run models, but to interpret them. To connect economics, data, and ethics. That’s the work of a social scientist.” 

He sees growing demand for that kind of thinking—and sees CHOICE rising to meet it.

“Healthcare is complex. Our job is to make sense of that complexity, and to train the next generation to do the same.”


A Culture of Belonging: Mentorship and Meaning 

Since 1995, CHOICE has trained over 35 postdoctoral fellows, 90 master’s students, 84 PhD students, and more than 600 certificate students. CHOICE Institute alumni are a diverse community of experts who continue to shape the field—and their stories reflect the heart of the program.

Dr. Mark Bounthavong(’18) chose CHOICE not for the prestige—but for the people. He remembers entering the program with uncertainty, unsure whether he belonged in a rigorous PhD environment. But the culture he found at CHOICE quickly reshaped his expectations. “There were no stupid questions—only a shared mission to learn, grow, and contribute,” he recalled. “They made me feel like part of a team.”

That mentorship extended far beyond the classroom. When Bounthavong’s father passed away, it was CHOICE faculty and peers who reached out with support, compassion, and presence. “That meant the world to me,” he said. “It wasn’t just academic—it was deeply human.” 

CHOICE alumni and students connecting at an ISPOR dinner organized by Mark Bounthavong in 2022.

Today, as an Associate Professor of Clinical Pharmacy at UC San Diego, Bounthavong sees his work and mentorship style as a direct reflection of what CHOICE instilled in him—modeling the same accessibility and generosity he received, and carrying the CHOICE ethos into new institutions and communities.

“We’re all products of this place,” Bounthavong reflects. “And the way we honor it is by paying it forward—by mentoring others, by spreading the values, and by building environments that feel like CHOICE, wherever we go.” 

CHOICE Grads group photo
Felipe and his mentor Professor Basu at the 2025 Graduate Recognition Ceremony.

This culture of mentorship resonates with our most recent alumni. Dr. Felipe Montano-Campos (’25) shared, “For me, the most important part of CHOICE has been the mentorship and the chance to work with so many faculty across a range of topics. It also meant having the resources to attend conferences, meet more people in the field, and reconnect with CHOICE friends who are making their contributions all over the globe.” 

As Felipe begins a Postdoctoral Fellowship at the University of Southern California, he carries with him memories of friendship and a soft spot for his home of the past four years. “When I think of CHOICE, I think of a group of incredibly respected researchers in the field—who also happen to be people I genuinely enjoy being around. And, of course, I can’t help but think of Seattle too.”


The People Behind the Progress

For Penny Evans, a longtime staff member who joined UW in 1991, CHOICE’s growth mirrored her own journey. When she first arrived, she had no idea she would be a part of one of the country’s leading centers for health economics, outcomes research, and policy. 

“I became involved when they were developing the program,” she recalled. “I helped write and distribute the quarterly PORPP reports and then continued producing the annual reports until I retired. It was quite a journey.” 

But her contributions extended well beyond reports and logistics. She welcomed new students, supported faculty research efforts, and helped organize national conferences. Through it all, she found joy and meaning in the relationships she built.

“The students were my favorite part,” Evans said. “They’re just phenomenal—so smart, so motivated. It gave me hope for the future.” 

Penny’s last retreat as a full-time staff member prior to her retirement.

Though she retired in 2017, Penny Evans still carries her CHOICE memories with pride. “It was bittersweet to leave, but I was proud of what we built. And I know it’s in good hands—still growing, still evolving.” For Penny, CHOICE wasn’t just a workplace, it was a community that mattered—and still does. Her legacy lives on through the Penny Evans UW ISPOR Student Chapter Support Fund, established in 2017 to honor her lasting impact on the program. The fund supports student activities within the UW ISPOR chapter, fostering professional development and engagement with the global HEOR community.  

Today, the administrative leadership of The CHOICE Institute is guided by Marina Gano, who joined in 2019 as the Graduate Program and Operations Manager. In 2023 she was joined by Leana de la Torre, serving as the CHOICE Online Certificate Manager. Their leadership, dedication, and genuine care for our students have helped carry forward Penny’s legacy and sustain the supportive culture that defines CHOICE.


Data and Decency: The New Generation Carries It Forward 

Faculty such as Jing Li, Douglas Barthold, Kyu Lee, and Noémi Kreif are advancing CHOICE’s mission through innovative, data-driven research. At the same time, they remain deeply committed to the human-centered values that have long defined the Institute. 

CHOICE Group Photo 2024
CHOICE faculty, staff, and graduating students the 2024 SOP Graduate Recognition Ceremony.

Dr. Jing Li, Associate Director of CHOICE, reflects that commitment in her research, which spans Medicare policy, pharmaceutical marketing, and end-of-life care. “We’re asking hard questions—about how we define value, how incentives affect prescribing, how policy changes affect patients in the real world,” she said.  

One of her recent studies on advance care planning showed how Medicare reimbursement shifted end-of-life outcomes for patients, which has opened new national healthcare practice discussions on how policy can align with patient preferences. “That’s what we strive for—research that not only advances knowledge, but helps people live better lives.” 

Douglas Barthold, Associate Graduate Program Director, brings a health policy lens to his work on chronic disease management and cognitive decline. He emphasizes the importance of interpretation and empathy in a field increasingly driven by data.

“AI is coming,” Barthold said. “But we have to teach what machines can’t: judgment, critical thinking, compassion. That’s the heart of our teaching mission.” 

CHOICE faculty at ISPOR 2025 in Montreal.

Through complex simulation modeling, Kyu Lee’s work forecasts the future burden of diseases and how sound health policies can mitigate their impact on individuals and communities. Her latest research, focused on optimizing the timing of seasonal influenza vaccine selections, exemplifies the power of interdisciplinary and international collaboration by bringing together global experts in decision science, epidemiology, and clinical medicine.

Noémi Kreif adds another dimension to CHOICE’s evolving research landscape by combining causal inference and machine learning to improve health policy and economic evaluations. Her work focuses on using healthcare data in flexible, equitable ways to inform personalized decision-making. She is also deeply committed to training the next generation of graduate students and researchers. 

CHOICE’s impact is felt not only through its research, but also in the experiences of the students who shape and are shaped by the program. Current PhD students Karris Jeon, Carlos Pineda-Antunez, and Satoshi Koiso share what drew them to CHOICE—and what makes it stand out.

Jeon shared, “As someone who came to the U.S. for a PhD program, CHOICE has been a gateway to new and diverse ideas—and a community of kind, brilliant people, where purpose meets possibility.” 

Koiso added, “I chose CHOICE because of its close-knit community, the diversity of its students and faculty, and its strong commitment to impactful research that contributes to society. This combination of a supportive environment and meaningful work felt unique compared to other programs.” And for Pineda-Antunez, the decision was simple: “Once I made my choice, I loved my CHOICE!” 

Together, this new generation is exploring the intersection of economics, innovative methods, equity, and human behavior—expanding the scope of CHOICE while upholding its enduring mission.

As Li puts it, “This is where ideas grow—and where people support each other in making them better.”


Looking Forward

CHOICE Faculty, Staff, and Students – May 2024

As the institute marks its 30th anniversary, its legacy is clear. Not only in the research it produces or the policies it informs—but in the people it has trained, the questions it has asked, and the values it has carried forward. Basu is clear-eyed about what lies ahead for the institute. “Healthcare inefficiencies aren’t going away. The pressure to improve outcomes and control costs will only grow. And CHOICE is uniquely positioned to contribute to that conversation, both nationally and globally.” 

And as for what makes it all worth it? 

“Coming to work every day with people who care deeply, who challenge you, who make your ideas better—that’s what CHOICE is,” Basu said. “And that’s why it matters.”

Authored by Scott Braswell, with our appreciation for bringing this piece to life.

Pharmaceutics Award Winners at ISSX Conference

ISSX Students group photo
Pictured in photo: Aurora Authement (far left), Arzoo Thakkur (2nd from left), and Yik Pui (Tim) Tsang (2nd.

The 2025 International Society for the Study of Xenobiotics (ISSX) International Meeting got underway last month, and Department of Pharmaceutics students Tim Tsang, Aurora Authement and Arzoo Thakkur took home awards in the poster competition. In the graduate student competition, Tim won first place, and Aurora took third place. Arzoo placed second in the post-doc category. Additionally, PCeut Professor and Milo Gibaldi Endowed Chair Nina Isoherranen presented the event’s Opening Plenary presentation. Congratulations to our winners!

ISSX Names Jash Unadkat 2026 President-Elect

The International Society for the Study of Xenobiotics this week named Department of Pharmaceutics Professor Jash Unadkat as 2026 President-Elect of ISSX.

“My election as President Elect of ISSX could not have been possible without the support of wonderful colleagues within the SOP, and a dream team of graduate students, postdocs and scientific collaborators,” said Unadkat. “My scientific journey has exceeded my wildest dreams.”

Unadkat’s appointment begins January 1, 2026.

SOP students shine at NCPA competition

Students pictured (left to right): Joel Jones, Lee Chinn, Arielle Mamaril, Dandan Johannessen, Caitlin Lazaro, and Jackson Gilmour.

In honor of National Pharmacy Week, let’s take a moment to celebrate some of our fantastic future pharmacists, including our PY3 and PY2 students, who recently placed 3rd nationally in the NCPA Business Plan Competition.

This annual competition requires students to submit a 40-page business plan requesting a bank loan to buy or start a pharmacy. The written plans are graded by judges from across the U.S., and the top 3 teams are invited to the NCPA annual convention to present those plans to judges for the live competition.

Over the last year, these students have spent countless hours creating this plan to bring their ideas to life. It required dedication, entrepreneurship, and above all teamwork. We are proud to say they represented UW well at the live competition and are leading the way to a bright future for community pharmacy.

Larissa Robinson-Cooper Named to Washington Fellows Program

Larissa Robinson-Cooper, a PhD candidate in Melissa Barker-Haliski’s lab in the #SoP Department of Pharmaceutics, was recently named by #ASPET among 13 awardees to participate in the 2025-2026 Washington Fellows Program. The program offers developing and early-career scientists interested in science policy an opportunity to learn about and engage in public policy issues.

“I’m honored to be selected for the 2025-2026 ASPET Washington Fellows Cohort,” said Larissa. “Now more than ever, it is important for scientists to learn how to effectively advocate for our research and the funding that supports it. I’m grateful to have this unique and exciting opportunity to learn more about science policy, and travel to Capitol Hill to support policies that promote biomedical research.”

Welcome Department of Pharmacy Assistant Professor, Jessica Beers

A very special welcome to new Department of Pharmacy Assistant Professor, Dr. Jessica Beers, who officially joined the School September 2. Dr. Beers earned her PharmD in 2018 from Lipscomb University College of Pharmacy and completed her PhD in Pharmaceutical Sciences in 2023 at the University of North Carolina at Chapel Hill. She is passionate about improving drug safety in understudied populations, and her previous research has focused on precision medicine, drug-induced liver injury, and the use of advanced cell culture models to predict drug metabolism and toxicity. Her current work integrates both basic and clinical research to investigate drug metabolism and disposition during pregnancy and lactation.

Everyday Cleaners, Everyday Exposure: Disinfectants’ Impact on Human Health

Disinfecting wipes. Antibacterial sprays. The cleaners we reach for without a second thought are part of our daily routines at home, at school, and at work. But new research is showing that these familiar products may come with hidden risks.

Libin Xu, associate professor of medicinal chemistry at the University of Washington School of Pharmacy, studies quaternary ammonium compounds—or “QACs”—a class of chemicals found in many disinfectants, particularly benzalkonium chlorides. His team has found that exposure to QACs is nearly universal.

“Almost every human sample measured so far has certain amounts of this compound, from very low to, occasionally, pretty high amounts,” Xu says. Traces have been detected in human blood, urine, feces, and breast milk, and even in the house dust—underscoring how easily these chemicals become part of our everyday lives.

Why does this matter? Recent studies by the Xu Lab found that QACs could affect cholesterol biosynthesis and lipid metabolism in neonatal mouse brains during the critical embryonic development period and disrupt gut microbiome homeostasis and metabolism in a mouse exposure model.1, 2 These compounds can be taken up via oral exposure or inhalation. The Xu Lab further found that QACs can be metabolized by human cytochrome P450 enzymes,3, 4 but they can accumulate in certain organs, such as the kidney and lung. Collaboration between the Xu Lab and Joanne Wang’s Lab found that while some QACs can be transported by transporters, they are not excreted efficiently,5 which may contribute to their accumulation in certain organs, such as the kidney. Furthermore, evidence suggests that QACs are preferentially excreted into the GI tract, hence the impact on the gut microbiome, which has been found to have numerous beneficial effects on human health. The figure below illustrates the fate of QACs in the human body based on the current knowledge.

 

While abundant studies in animals have demonstrated the potential detrimental effects of QACs, more research is needed to understand their effects on people. The Xu Lab’s ongoing projects funded by the National Institutes of Health (R01ES031927 and R01ES035021) aim to address the mechanistic gaps of QAC toxicity and their impact on human health.

“We’re not saying to stop cleaning,” Xu notes. “But it’s worth being aware of the potential health impact and choosing safer alternatives when you can.”

Simple changes—like checking labels, improving ventilation while cleaning, or using soap and water—can reduce your exposure without sacrificing safety. Because when it comes to protecting our health, knowledge is one of the most powerful tools we have.

 

 

1. Herron, J. M.; Hines, K. M.; Tomita, H.; Seguin, R. P.; Cui, J. Y.; Xu, L., Multiomics investigation reveals benzalkonium chloride disinfectants alter sterol and lipid homeostasis in the mouse neonatal brain. Toxicol. Sci. 2019, 171, 32-45.
2. Lopez, V. A.; Lim, J. L.; Seguin, R. P.; Dempsey, J. L.; Kunzman, G.; Cui, J. Y.; Xu, L., Oral Exposure to Benzalkonium Chlorides in Male and Female Mice Reveals Alteration of the Gut Microbiome and Bile Acid Profile. Tox. Sci. 2024, 202 (2), 265–277.
3. Seguin, R. P.; Herron, J. M.; Lopez, V.; Dempsey, J. L.; Xu, L., Metabolism of Benzalkonium Chlorides by Human Hepatic Cytochromes P450. Chem. Res. Toxicol. 2019, 32 (12), 2466-2478.
4. Nguyen, R.; Seguin, R. P.; Ross, D. H.; Chen, P.; Richardson, S.; Liem, J.; Lin, Y. S.; Xu, L., Development and Application of a Multidimensional Database for the Detection of Quaternary Ammonium Compounds and Their Phase I Hepatic Metabolites in Humans. Environ Sci Technol 2024, 58 (14), 6236-6249.
5. Vieira, L. S.; Seguin, R. P.; Xu, L.; Wang, J., Interaction and Transport of Benzalkonium Chlorides by the Organic Cation and Multidrug and Toxin Extrusion Transporters. Drug Metab Dispos 2024, 52 (4), 312-321.

Pharmaceutics Professor Jash Unadkat Elected to Washington State Academy of Sciences

 

We are proud to share that Dr. Jash Unadkat, Professor in the Department of Pharmaceutics at the UW School of Pharmacy, has been elected as a member of the Washington State Academy of Sciences (WSAS).

The WSAS recently announced the election of 36 new members whose scientific and technical expertise will help guide evidence-based policymaking in Washington state. Dr. Unadkat was recognized for his pioneering contributions to pharmaceutical and translational sciences, including influential research on drug transporters, physiologically based pharmacokinetic (PBPK) modeling, and maternal-fetal pharmacology. His work has informed drug safety policies and continues to shape the way we understand drug disposition and response.

Election to the WSAS is a significant honor that reflects both Dr. Unadkat’s scientific impact and his ongoing commitment to advancing public health through research and collaboration.

“I am honored to have been elected to this prestigious organization,” said Jash, “and I look forward to contributing to its mission.”

Congratulations on this well-deserved recognition.

NCPA Foundation Names Matt Binder 2025 National Preceptor of the Year

Photo, left to right: Matt Binder, Alexis Jasmine Quisao, Tiffany Tran, Amanda Bryan, and Anna Dimak.
Photo, left to right: Matt Binder, Alexis Jasmine Quisao, Tiffany Tran, Amanda Bryan, and Anna Dimak.

A special congratulations to UWSoP alum and owner of Ostroms Drug & Gift, Matt Binder, who has been named the 2025 National Preceptor of the Year by the Board of Trustees of the NCPA Foundation. This award recognizes a pharmacist who has made a significant contribution to the education of pharmacy students as a preceptor in a community practice setting.

Upon receiving notice of his award, Matt first took a moment to thank his students. “I am blown away by the level of talent our stores have had student-wise,” he said. “We have some future national leaders in our ranks. Some of you will continue to bless the independent pharmacy world. Some of you will excel in other fields and at least have some more context on how community pharmacy fits in.

“Thank you all for bringing fun, good ethics, and determination every day you clock in – and thank you for creating a place of joy for patients who have been through rough times.”

The National Preceptor of the Year Award will be presented during the NCPA Foundation Awards Ceremony on Sunday, October 19, followed by a reception at NCPA’s Annual Convention in New Orleans, LA.

Shelly Gray Named 2025 Fulbright Scholar

Congratulations to Plein Center for Aging Director Shelly Gray for being named a 2025 Fulbright Scholar. Fulbright Scholars are college and university faculty, administrators and researchers, as well as artists and professionals, who build their skills and connections, gain valuable international insights and return home to share their experiences with their students and colleagues.

One of four UW researchers selected for this prestigious award, Shelly will be hosted by the China Medical University (Taiwan) in the College of Pharmacy, in September. She will pursue a project entitled, “Adverse drug effects of medication use on sedentary time and physical activity in older adults.”

“I’m deeply honored to have been named a Fulbright Scholar and am excited to spend six months in Taiwan researching medication safety among older adults,” said Shelly. “During my time there, I look forward to collaborating with Taiwanese researchers and clinicians amid Taiwan’s highly regarded healthcare landscape—famed for its universal health coverage, advanced facilities, and infrastructure for epidemiology research. I hope to enhance my research skills, develop cross cultural perspectives on medication safety, and forge lifelong international partnerships that will inform my future work in healthy aging.”

The Fulbright Scholar Program for academics and professionals awards more than 1,700 fellowships each year, enabling 800 U.S. scholars to go abroad and 900 visiting scholars to come to the United States. The Fulbright Program is the flagship international exchange program sponsored by the U.S. government. The UW is one of 17 institutions nationwide recognized in 2022-2023 as a “Top Producer” of both Fulbright scholars and students.

Read more about the 2025 Fulbright Scholars.

Celebrating the Excellence and Impact of Our 2025 Student Award Honorees

At the UW School of Pharmacy, excellence takes many forms. We celebrate not only academic success and groundbreaking research, but also the passion, initiative, and innovation our students bring to every challenge. This month, we’re proud to honor six exceptional students who embody the very best of our community through their creativity, leadership, and dedication to making a difference.

HUI-HSUAN CHAN – 2025 MAGNUSON SCHOLAR

Hui-Hsuan ChanCHOICE PhD student Hui-Hsuan Chan was selected as the School’s 2025 Magnuson Scholar—an honor presented annually to one student from each of UW’s six Health Sciences schools. Funded by the Warren G. Magnuson Institute, the award recognizes both academic achievement and the potential for impactful research in fields like diabetes and public health.

“I’m honored to be selected as a 2025 Magnuson Scholar representing the School of Pharmacy,” Hui-Hsuan said. “This award provides generous support for my continued research into improving healthcare sustainability and managing high-cost chronic conditions like diabetes. I’m grateful for the opportunity to contribute to meaningful, lasting impact.”

 

ZIZI ELSISI – OUTSTANDING DISSERTATION AWARD

Zizi ElsisiZizi Elsisi, a PhD graduate of the CHOICE Institute, was honored with the 2025 Outstanding Dissertation Award for her rigorous and timely work on subscription-based payment models for Hepatitis C treatment in Louisiana and Washington.

“It’s an incredible honor to receive the Outstanding Dissertation Award for my research on subscription-based payment models for hepatitis C treatment in Louisiana and Washington,” Zizi said. “This work highlights how innovative financing strategies can improve access to cure medications for vulnerable populations. I’m proud to contribute to research that bridges policy and real-world impact. I’m especially grateful to my advisor, Dr. Anirban Basu, and the CHOICE Institute for their invaluable mentorship and support throughout this journey.”

 

CHRIS ARIAN – OUTSTANDING DISSERTATION AWARD

Chris ArianChris Arian, from the Department of Pharmaceutics, also received the 2025 Outstanding Dissertation Award for his development of an intestinal microphysiological system (MPS) using a long-term cultured enteroid monolayer model. His innovative research is poised to significantly advance the field of drug metabolism and drug–drug interaction (DDI) prediction.

“It is an incredible honor to receive the School of Pharmacy’s Outstanding Dissertation Award,” said Chris. “Achieving this award would not have been possible without the support of my mentors, Dr. Ken Thummel and Dr. Ed Kelly, my partner Marelle for her encouragement and presence in my life, and my lab mates for their friendship and scientific discussions.”

 

AURORA AUTHEMENT – GRADUATE STUDENT LEADERSHIP AWARD (PHARMACEUTICS)

Aurora AuthementPhD candidate Aurora Authement was recognized with the School’s 2025 Graduate Student Leadership Award for her outstanding contributions to the Pharmaceutics Department and her mentorship within the student community.

“I’m honored to receive the Graduate Student Leadership Award,” said Aurora. “This recognition affirms the importance of fostering an inclusive, collaborative scientific community, and I’m grateful for the opportunity to contribute to the growth and success of my peers. I’m also deeply thankful to my mentors, including Ken Thummel and Nina Isoherranen, whose guidance and support have been instrumental in shaping my development as a leader.”

 

ALESI ESCOBEDO – GRADUATE STUDENT LEADERSHIP AWARD (MEDICINAL CHEMISTRY)

Alesi EscobedoMedicinal Chemistry PhD candidate Alesi Escobedo was selected for the 2025 Graduate Student Leadership Award in recognition of her exceptional service, mentorship, and positive impact across the department.

“I’m truly honored to receive this award,” said Alesi. “It’s been a privilege to contribute to our department and support the next generation of scientists coming up behind me. Receiving this recognition reinforces my belief that a supportive community empowers us all to grow and succeed together.”

 

 

TORI DAYER – GRADUATE STUDENT LEADERSHIP AWARD (CHOICE)

Tori DayerTori Dayer, PharmD and current PhD student at the CHOICE Institute, received the 2025 Graduate Student Leadership Award for her lasting impact on the program and her peers.

“Being part of the CHOICE and School of Pharmacy community has continually inspired me to grow and collaborate,” Tori said.  “I am very honored to receive this award and to have had the opportunity to contribute to such a wonderful community!”

 

 

 

These students represent the best of what our School stands for: academic excellence, leadership, and a deep commitment to improving healthcare for all. Please join us in congratulating Hui-Hsuan, Zizi, Chris, Aurora, Alesi, and Tori on their outstanding accomplishments. Their work is shaping the future of pharmacy and public health—and we couldn’t be prouder.

SoP Researchers Awarded $200K Population Health Grant

The University of Washington School of Pharmacy is proud to announce that a team of SoP faculty researchers has been awarded a $200,000 Tier 3 pilot research grant from the UW Population Health Initiative.

The interdisciplinary team from the SoP includes Dr. Clayton English, Dr. Ryan Hansen, Dr. Jenny Bacci, and alumna Dr. Jenny Arnold. Their project was one of only four selected for funding in this competitive round, which awarded a total of nearly $900,000 to support impactful, cross-disciplinary research addressing urgent public health challenges. Additionally, SoP researchers will be working closely with Dr. Anthony Floyd (Department of Psychiatry and Behavioral Sciences) and Boris Zhang (Washington state Pharmacy Association) to advance this project.

The SoP team’s work aims to address one of the most pressing health crises in Washington State: the rise in opioid overdose deaths, increasingly driven by fentanyl. While access to opioid use disorder (OUD) treatment remains inconsistent across many communities, the team’s project explores the potential of community pharmacies to serve as more accessible points of care. With recent regulatory changes expanding who can prescribe medications for opioid use disorder (MOUD), community pharmacists are uniquely positioned to deliver life-saving treatment and support.

The team’s focus aligns with the Population Health Initiative’s mission to improve health outcomes for all people through interdisciplinary collaboration. Dr. Ali H. Mokdad, the university’s chief strategy officer for population health, praised the awardees for tackling wide-ranging challenges. “These innovative projects will take on a range of pressing challenges in the areas of youth mental health, opioid use disorder, decarbonization and fall-related injury prevention,” he said.

Learn more about the Population Health Initiative and this round of grant recipients:
Population Health Initiative 2025 Tier 3 Pilot Research Grants

UW Pharmacy Students Place in Top Five of AMCP National P&T Competition Finals

Congratulations to Michiko Hunter, Chloe Miranda, Howard Nguyen and Kathryn Versteeg for placing among the top five teams in the AMCP Foundation’s 25th Annual National Pharmacy & Therapeutics (P&T) Competition – a major achievement!

Hosted by the Academy oUW Pharmacy Students Place in Top Five of AMCP National P&T Competition Finalsf Managed Care Pharmacy (AMCP), this prestigious competition invites student pharmacists to take on the role of formulary decision-makers, tackling complex clinical and economic data to make evidence-based recommendations – just like the professionals shaping real-world healthcare policies.

This year, six teams of UW PharmD candidates entered the local competition, analyzing Velsipity (etrasimod) – a new small molecule therapy for ulcerative colitis – using a comprehensive product dossier provided by Pfizer.

Over winter break, students dug into the research, synthesized data and developed a full formulary monograph and strategic presentation for a mock health plan’s P&T committee.

Kathryn, Chloe, Michiko and Howard won the UW round and advanced through two highly competitive national phases. Out of 43 participating pharmacy schools, they were one of just five teams invited to present live at the AMCP Annual Meeting in Houston – a top-five national finish that reflects both academic excellence and outstanding professionalism.

Dr. John Watkins – affiliate professor and residency program director for the UW School of Pharmacy – served as the team’s faculty advisor. “Kathryn, Chloe, Michiko and Howard delivered a polished presentation, clearly the result of much study and practice,” reflects Watkins. “Together, they handled the judges’ questions with ease, indicating in-depth knowledge of the drug and disease state. I’m pleased that the Foundation is honoring their achievement.”

Before their national success, the team earned first place at the local level, where a team of first-year PharmD candidates – Zoe Friedman, Jackson Gilmour, Jamie Paik and Jackson Yu – also impressed the judges, earning second place. Under the mentorship of third-year pharmacy student Jenna Wildeman, the team sharpened their skills and grew their confidence through the venture.

“We were thrilled to place second,” Paik says. “More importantly, the experience deepened our understanding of formulary decision-making and the critical evaluation of clinical and economic data.”

With more than 4,800 members nationwide, AMCP plays a key role in shaping the future of managed care pharmacy – and UW student pharmacists are making their mark. As the healthcare landscape grows increasingly complex, opportunities like the P&T Competition equip Husky Pharmacists with the skills to lead with insight, precision and purpose.

We’re proud of all the Huskies who stepped up to the challenge this year – and especially proud to see our students earning national recognition on one of pharmacy’s most competitive stages.

First-Year Student Pharmacist Fellow of the UW Latino Center for Health

Malik WilliamsFirst-year PharmD candidate Malik Williams has been selected for the UW Latino Center for Health (LCH) Graduate Student Fellowship, a noteworthy program supporting future healthcare leaders dedicated to serving Latinx communities.

As part of an elite cohort of 16 graduate students across Washington State, Williams will receive financial support, mentorship and interdisciplinary collaboration opportunities aimed at expanding access to bilingual and culturally responsive healthcare.

“I’m incredibly blessed and honored to be selected as one of the 2025 Graduate Student Fellows,” Williams reflects. “Thank you to the Latino Center for Health for this opportunity and for continuing to invest in the next generation of healthcare leaders dedicated to equity and inclusion,” he continues. “It’s a privilege to join a dynamic cohort of graduate students from across Washington State who are passionate about expanding access to bilingual and culturally responsive care for Latine communities. I’m committed to using my platform – and future career – to help advance healthcare equity.”

With a growing demand for Latinx and Spanish-speaking healthcare professionals, this program plays a crucial role in strengthening the future of equitable healthcare in Washington state.

We’re so proud of you, Malik! Your pharmacy community can’t wait to see what you do next.

The Future of Community Pharmacy Depends on Advocacy

According to Dr. Jennifer Bacci, community pharmacies are at a crossroads and advocacy is the key to ensure their survival.

In a recent interview with Drug Topics, Bacci – endowed associate professor of Innovative Pharmacy Practice – emphasized the urgent need for policy support and collaboration across healthcare professions to sustain community pharmacy services.

With pharmacists playing an essential role in accessible, patient-centered care, challenges like reimbursement issues and workforce shortages threaten their ability to provide critical services.

Bacci highlights how interprofessional support and legislative action can help strengthen pharmacies as frontline healthcare providers, ensuring patients continue to receive the care they need, when and where they need it.

Get the complete conversation on DrugTopics.com.

Melissa Barker-Haliski Leads Grant-Winning Epilepsy Research

Melissa Barker-Haliski
Dr. Melissa Barker-Haliski

Dr. Melissa Barker-Haliski and her lab have been awarded a grant from the American Epilepsy Society, strengthening a new collaboration with Dr. Jeff Carroll, associate professor in neurology at the UW School of Medicine. A leader in epilepsy research, Barker-Haliski’s work focuses on developing novel therapies for drug-resistant epilepsy and age-related neurological disorders. Her lab addresses the growing prevalence of epilepsy in older adults, particularly in patients with Alzheimer’s disease. This funding supports ongoing “n of 1” trials for DRPLA, furthering personalized medicine for rare seizure disorders.

CHOICE PhD Student Predicts 13 of 15 Drugs Selected for the Medicare Drug Price Negotiation Program

Emma CousinLast autumn, CHOICE Institute PhD student Dr. Emma Cousin (PharmD, ‘22) – alongside pharmacy faculty members Dr. Sean Sullivan, professor of pharmacy and Dr. Ryan Hansen, pharmacy department chair – published an article in the Journal of Managed Care and Specialty Pharmacy, titled: “Drugs Anticipated to be Selected for the Medicare Drug Price Negotiation Program in 2025.”

The study was completed in collaboration with Dr. Inma Hernandez and her research team at the University of California, San Diego. Authors of the study identified high-spending Part D products likely to be included in the second round of negotiations in the Medicare Drug Price Negotiation Program.

In January, the Centers for Medicare and Medicaid Services (CMS) released their list of 15 Part D drugs to be negotiated in the next round of drug price talks. “Back in September, we published our predictions of 13 drugs and identified 7 drugs with uncertain negotiation status to complete the list of 15. We correctly predicted 13 of the 15,” Cousin explained. “All 15 of the drugs are small molecules, 10 of the 15 have multiple indications and only semaglutide has multiple brands (Ozempic, Rybelsus and Wegovy)… We missed Otezla and Vraylar, which presumably have had recent increases in utilization since 2022.”

Husky Pharmacists Advocate for Expanded Prescriptive Authority

UW student pharmacistsEarlier this winter, UW student pharmacists headed to Olympia to push for expanded prescriptive authority, standing alongside the Washington State Pharmacy Association (WSPA) in a powerful showcase of solidarity.

Donning white coats and a powerful message, our PharmD candidates advocated with lawmakers and elected officials to modernize the way pharmacy works in Washington State. Guided by faculty, legislators and local pharmacy leaders, our students are working to cut through red tape, empowering pharmacists to focus on what matters most – patient care.

In an era where Primary Care Physicians are in short supply, pharmacists are uniquely positioned to fill a gap in the healthcare system – one where their impact will be felt immediately, especially when it comes to preventative care and treating minor conditions. Right now, millions of Washingtonians reside in areas with lengthy wait times for medical appointments.

Here’s the good news: Pharmacists are already in our communities – right here, right now – well-established and ready to meet the need.

As highly trained, doctorate-level healthcare providers, pharmacists are the medication experts you see in clinics, hospitals and local pharmacies, managing everything from chronic conditions to vaccines to quick, everyday health needs.

In other words, pharmacists are doctors, too – professional healthcare providers with the capacity to treat everyday conditions like UTIs, strep throat, seasonal allergies and more. So why not give them the power to make healing happen? This is the question our student pharmacists brought to lawmakers in the Washington State legislature.

When pharmacists are empowered to prescribe, finding care becomes quicker and easier – especially for those time-sensitive issues that can quickly escalate from everyday ailment to all-out emergency. Rising above public policy, expanding prescriptive authority for pharmacists is about our neighbors getting the care they need, when they need it. And that’s something worth celebrating.

FY25 Legislative Day student groupshotFY25 Legislative Day student groupshotFY25 Legislative Day discussion imageFY25 Legislative Day discussion groupshotFY25 Legislative Day discussion groupshotFY25 Legislative Day discussion groupshotFY25 Legislative Day discussion groupshotFY25 Legislative shot of student

Clayton English Named AAPP Fellow for Leadership in Psychiatric Pharmacy

Clayton EnglishAt the UW School of Pharmacy, innovation and compassion go hand in hand – just ask Assistant Professor Dr. Clayton English, whose dedication to advancing mental health care and psychiatric pharmacy has earned him recognition as a 2025 Fellow of the American Association of Psychiatric Pharmacists (AAPP).

English’s journey – from a small-town pharmacy to a leading educator, researcher and advocate – is deeply intentional. “My life has been touched by close friends whose lives had been turned upside down by behavioral health issues,” he shared. “That spurred me to wanting to know more and to learn more in that area and find out if there was a role for pharmacists in that arena.” His work is all the more vital as millions of Americans navigate mental illness in times marked by economic stress, political upheaval and global uncertainty.

With broad clinical and research interests spanning psychiatric medication safety, deprescribing, mood disorders, adult ADHD and drug-induced behavioral conditions, English is a champion for interprofessional education, team-based care and student well-being.

His leadership extends beyond the classroom, too; English is a Senior Editor for the AAPP Psychiatric Pharmacotherapy Review Book and has been recognized nationally for his excellence in teaching, mentorship and advocacy for the pharmacy profession. Last month, he moderated a panel discussion on the groundbreaking intersection of addiction medicine and psychedelic therapies at Husky Days in the Bay. Joined onstage by experts from UW Medicine, UC Berkeley and UC San Francisco, English led a dynamic conversation on the transformative potential of psychedelics to address substance use disorders for Bay Area UW alumni.

The inaugural cohort of the AAPP fellowship honors professionals who’ve made a lasting impact on psychiatric pharmacy, advancing the practice setting with service and leadership.English will be formally recognized at the 2025 AAPP Annual Meeting in Salt Lake City this spring – a well-earned distinction for an educator and advocate whose work is shaping the future of medication therapy for behavioral health.

Revolutionizing Healthcare

How AI is Transforming Drug Discovery with Dr. Gaurav Bhardwaj.

Imagine a world where life-saving medicines are designed in minutes instead of years. Thanks to artificial intelligence (AI), that future is rapidly becoming a reality, and one of the key figures at the forefront of this revolution is Dr. Gaurav Bhardwaj, an Assistant…

Pharmaceutics PhD Student Honors the Legacy of Martin Luther King Jr. Through Mentorship in STEM Education


Wellbeing is a collective endeavor – one caught in an inescapable network of mutuality and tied by a single garment of destiny.

In January, we reflected on the enduring legacy of Rev. Dr. Martin Luther King Jr., whose unwavering commitment to justice continues to inspire our relentless pursuit of health equity on campus and beyond.

His words remind us that our health is deeply interconnected; More than absence of illness, our wellbeing is a fundamental human right, bound to social, economic and environmental means that should empower everyone to thrive. The alternative? A growing chasm of health inequality with terrible costs.

Today and every day, we hold Dr. King’s words from Birmingham Jail: “Injustice anywhere is a threat to justice everywhere.”

As this year’s recipient of the Martin Luther King Jr. Community Service Award for the School of Pharmacy, we’re proud to honor Keiann Simon, a PhD candidate in Pharmaceutics who exemplifies Dr. King’s call to service.

On January 16, before the University of Washington Health Sciences community, we celebrated Keiann’s dedication to mentoring underrepresented students and promoting STEM education through mentorship, outreach and diversity.

“This award is going to propel me forward to do more for my community,” Keiann reflects. “I feel like I haven’t done enough. I want to do much, much more. I’m so grateful for the people who encouraged me and nominated me and supported me in this.”

Keiann’s work embodies Dr. King’s legacy while inspiring us to reflect on our shared responsibility to lift each other up: “The arc of the moral universe is long, but it bends towards justice.”

Join us in honoring Keiann’s impactful work, Dr. King’s vision for a better world and continuing the pursuit of a more equitable future.

Heavy Hits, Healing Hands: How One Student Pharmacist Fights for Excellence in Athletics and Academia

It’s not every day you meet someone who can throw a jab as effectively as they ace pharmacokinetics, but Michelle Nguyen – a fourth-year PharmD candidate – is anything but ordinary.

By day, she’s studying hard to master her craft as a future pharmacist. By night, she’s…

Summer of Discovery: Inaugural Nelson-Mendenhall Scholars Reflect on Mentorship, Science and Opportunity

Summer ScholarsOver the summer, six eager undergrads set forth on a pilgrimage of scientific discovery at the University of Washington School of Pharmacy.

The inaugural cohort of Nelson-Mendenhall Summer Scholars has emerged on the other side of an inspiring experience rooted in cutting-edge research and providing the kind of priceless perspective shifts that only come in college – one that’s transformed their perspective on pharmacy, science and the future.

Launched in June 2024, the Nelson-Mendenhall Summer Scholars Program (NMP) offers undergraduate students the rare opportunity to pursue high-level research under the mentorship of first-rate faculty and researchers from the UW School of Pharmacy.

Designed to inspire the next generation of healthcare innovators and underrepresented communities in STEM, the Summer Scholars Program provides students with funded, hands-on experience in the lab as they tackle the most pressing medical challenges of our time.

Supported by a $7,500 stipend, our Summer Scholars immersed themselves in meaningful work, from developing an HIV vaccine to understanding the effects of medications on babies in utero. Before the first cohort kicked off in June, applicants submitted a statement of purpose, a resume and the names of two references to be considered for this unique opportunity.

For first-generation college students like Claire Truongdang, a biochemistry major at UW Bothell, the Summer Scholars Program was a lifeline in more ways than one: “When I found out I was selected, I was extremely happy – I even missed my bus stop that morning! My mom was laid off this summer when her company moved out of state. It gave us a lot of stress. Thanks to the Summer Scholars Program, the stipend helped us keep up with our bills during a tough time.”

Claire’s work in the lab this past summer – RNA extraction from placenta tissue – gave her a new perspective on interdisciplinary research and how it could shape her future in medicine.

“This project helped me align my interest in chemistry to the career path I’m pursuing in medicine,” she said. “I see myself doing interdisciplinary work that connects clinical and scientific questions. Through my work in the lab, I came to realize that science is rarely focused on female bodies, nor do researchers put female bodies at the center of their scientific process. I want to address these questions and the limitations of our current system.”

When you ask Vincent Chan – a biochemistry major at Seattle University – about his experience in the program, he’ll tell you it was a huge step toward his dream of earning a PhD in pharmaceutics.

“This research gave me hands-on experience with drug formulation and delivery, which is foundational for my future plans,” he said. “I applied because I was eager to get more lab experience. When I found out I was selected, I was absolutely over the moon! It felt like a huge opportunity to advance in my academic goal.”

Vincent, whose research focused on the synthesis of polymeric prodrug nanoparticles for drug delivery, found that the program pushed him to grow as both a scientist and a researcher. “I learned how detailed and innovative pharmacy research needs to be, especially when working on advanced drug delivery methods,” he said, noting that the unpredictability of nanoparticle sizes challenged him to think more critically and adaptively. Vincent added that this hands-on experience brought him one step closer to his goal of becoming Dr. Vincent Chan.

Sydney Arnzen, another biochemistry major, had a deeply personal connection to her work in the lab of Dr. Ed Kelly, which focused on the transport of nephrotoxic mycotoxins – organic contaminants in the body that can cause kidney damage.

“Kidney disease runs in my family, so research like this hits close to home,” Sydney explained. “Working in a lab that revolves around kidney health is a great source of pride for me and the people I love.”

As one who knew she was destined to help others through science, pursuing research has always been a passion for Sydney. “Through my coursework at the UW, I learned about the world of pharmacy and the breadth of research and impact happening there,” she reflected. “I committed myself to finding a niche in research that helped others and fulfilled my own passions. This led me to drug discovery, medicinal chemistry and pharmaceutics. Research has given me the opportunity to make life-sized impact through microscopic means.”

For Sarah Stone of Eastern Washington University, the Summer Scholars Program offered her the opportunity to dive headfirst into research, immersing herself fully for the very first time. “I was worried I wouldn’t enjoy research as a career because I could never focus on it during the school year,” she admitted. “Having this kind of preview into lab work really settled those doubts by allowing me to give it my full, undivided attention.”

Working in the lab of Dr. Rodney Ho, Sarah’s summer research involved pancreatic cancer cells, which required her to develop new lab skills and gave her a better understanding of the complexity of experimental design. “I asked to work with Dr. Ho because his lab seemed to be doing more chemistry-based research, and I thought it would mesh well with my lab experience,” she said “I wound up doing cell culturing with pancreatic cancer cells, then doing cell viability assays after treatment with antibodies. I’m likely going to be using similar techniques in the near future, and cell culture training can take a while since you’re limited by the growth rate of the cells.It’s an incredibly valuable skill to have that I’m fairly certain I’m going to need in my career.”

These opportunities were made possible through the generosity of Doug Mendenhall, a community-minded alumnus of the School of Pharmacy, whose own celebrated career in pharmaceutical chemistry was shaped by a similar experience.

Encouraged by his friend and fellow undergraduate, Sid Nelson – who would later become Dean of the School of Pharmacy from 1994 to 2008 – Doug embarked on a summer research internship that ignited his passion for scientific discovery. Their friendship and mutual inspiration continued to shape Doug’s journey, personally and professionally, for years to come. He made significant contributions to the development of 70 marketed products, with his innovations reflected in three patents.

“That program was very impactful for me,” remarked Doug. “I always had a significant box to check in my estate planning – I’m going to give back to the schools that allowed me to get where I am. That was always a given. It was just a question of what to do.”

Cut to today, and Doug is paying it forward. By endowing this program, he has ensured that promising students have access to the same kind of transformational experiences that launched his career so many years ago.

The inaugural class of Nelson-Mendenhall Summer Scholars worked alongside top researchers at the University of Washington, building skills and making discoveries that will fuel their academic and professional futures. Doug’s vision for the program is simple – to provide students from diverse backgrounds with access to research opportunities they wouldn’t have encountered otherwise.

“I wanted to ensure our first cohort of students came from beyond the University of Washington,” he remarked, elaborating on his belief in diversity of thought for better research, and expanded career possibilities for students.

Claire, for example, discovered how even the smallest moments in the lab could have a major impact: “At one point, I realized that my sample storage methods were causing bad data. It reminded me of my fundamental chemistry coursework and how important that basic knowledge is.”

Given her family history with kidney disease, Sydney’s time in the Kelly Lab gave her a new sense of passion and purpose. “On one of my first days in the lab, I sat down with Dr. Kelly and we talked about the gene that caused my father’s Polycystic Kidney Disease. It was incredible to hear about the real progress being made,” she recalled. “I’ve never been so proud to work in this space.” Sydney plans to continue working with the Kelly Lab through the school year, building on the knowledge and skills she developed over the summer as a result of NMP.

Beyond the skill-sharpening, career-building and memory-making, the Summer Scholars Program instilled a deep sense of community for those who took part.

In the lab of Dr. Shijie Cao, Vincent described the environment as a “close-knit” space where he worked closely with graduate students and faculty. “They consistently offer insights and share their knowledge every day,” he said. “Their guidance and support was crucial to my project.” Similarly, Sydney was moved by the outreach and mentorship she received during her experience over the summer: “The Kelly Lab is passionate about nurturing future scientists, and I’ve been supported in every way,” Sydney stated. “I especially appreciate the moments spent discussing my passions and having mentors take time out of their day to put me on the path toward my dreams. I know the connections I made this summer will guide me into the next stages of my career.”

For Doug, this kind of mentorship is precisely what he envisioned when he created the program. “Pharmacy is very structured… Because there’s a good, reliable professional endpoint, there’s little reason to deviate from that path,” he explained.

Doug’s hope for the Nelson-Mendenhall Summer Scholars Program is straightforward: to broaden students’ horizons, open doors to research and introduce career opportunities beyond the traditional paths of pharmacy. “As a student in STEM, if you get the chance to look into some lesser known directions to take your career, you might say, ‘I want to try that.’ And that was the whole idea – opening doors for bright students to consider directions for their career they never knew existed.”

With the first year of the Summer Scholars Program in the rearview, Doug sees our success as the beginning of an impactful legacy. “This is a great seed program – money well spent,” he stated. “The hope is that it catches on and spreads.” Doug’s ultimate goal for the program is to inspire not only current students, but also alumni and friends of the University to invest in the next generation of trailblazers in pharmacy, science and healthcare.

Moving forward, our Summer Scholars have big plans ahead: For Sarah, she’s looking forward to her senior thesis on infant encephalopathy planned. “Even if none of the knowledge I gained this summer is especially relevant, I’m far more comfortable in a lab now and will be able to work more efficiently.” Claire plans to continue her research at UW Medicine in collaboration with the Wang Lab.

For Doug, giving back is a personal mission. “To me, everyone should be doing some level of giving back to inspire the next generation,” he says. And with the Nelson-Mendenhall Summer Scholars Program, Doug is doing just that – opening doors for curious minds, just as a few were opened for him all those years ago.

Pharmaceutics Students Win Big at ASPET Conference

Earlier this spring, pharmaceutics students Aprajita Yadav, Amelia Shan and Winnie Wen were awarded travel grants for their poster presentations at the American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting in Arlington, VA.

Aprajita took third place in the drug metabolism and disposition competition for her innovative research on diabetic kidney disease and RBP4/TTR ratios.

Amelia’s work on aging, sex and xenobiotic transporters at the blood-CSF barrier also earned her recognition, while Winnie presented her novel pharmacokinetic model for predicting renal clearance and CYP2D6 activity during pregnancy.

Both Amelia and Winnie earned Travel Awards for their work.

Aprajita Yadav
Aprajita Yadav
Amelia Shan
Amelia Shan
Winnie Wen
Winnie Wen

Join us in offering our congratulations to these outstanding students! We can’t wait to see what you do next.

Nina Isoherranen, Chair of Pharmaceutics, Receives North American Scientific Achievement Award

Nina IsoherranenThe International Society for the Study of Xenobiotics (ISSX) has honored Dr. Nina Isoherranen with the 2024 North American Scientific Achievement Award. At the University of Washington School of Pharmacy, Nina is a professor and the Milo Gibaldi Endowed Chair of the Department of Pharmaceutics. This prestigious award, sponsored by XenoTech, recognizes Nina’s exceptional contributions to the fields of vitamin A disposition and pharmacokinetic modeling.

The ISSX Awards Program highlights significant scientific accomplishments across the society’s areas of study. Recipients are evaluated on their publication record, sustained scientific achievements, international impact, contributions to education and active participation within ISSX. Nina was honored with the award at the 26th North American Meeting of ISSX in Honolulu, Hawaii earlier this summer.

Nina’s research focuses on vitamin A disposition, drug-drug interactions and pharmacokinetic modeling. Her innovative work on the role of enzymes in vitamin A homeostasis and her studies on drug metabolism during pregnancy have drawn attention and acclaim from around the world.

She received her PhD in Pharmaceutical Sciences from the Hebrew University of Jerusalem and has been a faculty member at the University of Washington School of Pharmacy since 2004.

Congratulations, Nina!

First Year Reflections

To our pharmacy community,

With my first year as the Dean of UW School of Pharmacy now in the rearview, I would like to take this opportunity to share my experiences and observations. This past year, I have enjoyed meeting each of you personally and learning about your hopes, ambitions and expectations for our institution, as well as your frustrations and challenges (FT, anyone?). Through these meaningful interactions, I also began to learn about the culture, people, policies and procedures both in the SoP and at UW.

The last 12 months have been a personal rollercoaster ride. We sold our home in Philly and bought a home near Seattle, celebrated our son’s high school graduation and admission to Caltech, bid farewell to our friends in Philly, made some new friends here, and (re)learned how painful moving was. I also navigated how to be productive (or not) during my six-hour cross-country flights – and how great melatonin is in taking the edge off jetlag. I deeply appreciate your patience during this time and your flexibility in meeting with me virtually. Your understanding and support have been invaluable.

In addition to those personal travails, we also faced many workplace challenges, including the trials and tribulations brought about by FT. We have had several staff and leadership transitions, which required you to be flexible and patient and go the extra mile to get things done. Your resilience and commitment to your research, school and our students in the face of these challenges has been truly commendable. Thank you for your grace and dedication.

Despite these challenges, we have made significant progress this past year. We successfully recruited for many key positions, including the Assistant Dean for Finance, Associate Dean for Research, Associate Dean for Professional Pharmacy Education, and Assistant Dean for Advancement. We also just launched a national search for a newly created Associate Dean for DEI position. Our Advancement team is nearly complete, and
our other units and departments have hired for key staff positions and are now stable and thriving.

We established new endowments to support summer undergraduate research and graduate students, received a planning grant from the Washington Research Foundation to explore establishing a Drug Delivery Institute, and are working closely with prospective donors on this and other exciting initiatives. Stay tuned!

We also made some strategic decisions. At a time when most other schools have been increasing tuition, we announced a bold plan to reduce tuition by 14% for non-resident students and hold steady the resident tuition. I expect this will help us recruit highly qualified out-of-state students who otherwise go to our peer schools.

The School’s leadership team, in collaboration with the Elected Faculty Council, has been working on streamlining the composition and charges of the various elected and appointed committees to achieve an equitable and streamlined workload among faculty. This work is nearly done, and we hope to socialize these changes in the next few months.

I am proud of the recognition our students, staff and faculty have received this past year. Our faculty and staff have been recognized by the university for their work on lab safety, our students have won awards at the national level, and our faculty have been elected to
prestigious organizations and have received awards for their achievements. We are who we are because of your hard work, dedication, and commitment.

While summer is a great time to reflect on the past year, it is also a time to plan. The leadership team and I intend to work on several important goals for the school. Our strategic plan ends next year, and we will soon begin planning our next 5-year initiative to solidify the SoP as a leader in cutting-edge research in drug discovery/development and health outcomes, as well as practice transformation. We will work to ensure the SoP is the school of choice for top professional and graduate students, and I will meet with several of our alumni and donors to continue fundraising. We will continue to fine-tune our marketing and communications strategies to improve the image of the profession and the school’s reputation. Finally, we have strengthened our work to enhance our students’ success in NAPLEX and MPJE – a key priority.

Being part of this community has been an honor, and I eagerly anticipate another exceptional year together.

Warm regards,

Jay Panyam signature
Jay Panyam
Dean, UW School of Pharmacy

Department of Pharmaceutics Welcomes Two New Faculty

Melissa Barker-Haliski
Melissa Barker-Haliski, PhD

We are delighted to welcome two new Associate Professors to the Department of Pharmaceutics: Melissa Barker-Haliski, PhD, and Swayam Prabha, MBA, PhD.

Swayam Prabha
Swayam Prabha, MBA, PhD

Dr. Barker-Haliski expands our expertise in behavioral pharmacology, disease models and the relationships between drug exposure and pharmacological outcomes.

Dr. Prabha, renowned for her work in novel drug delivery approaches and targeted cancer therapies, will significantly enhance our research and instruction in this area.

Please join us in welcoming these outstanding scientists to our pharmacy family!

School of Pharmacy Student Winnie Wen Named 2024-2025 Magnuson Scholar

Winnie WenWe are delighted to announce that Yue (Winnie) Wen, an outstanding student from the School of Pharmacy, has been named a Magnuson Scholar for the 2024-2025 academic year. This prestigious award, funded by a $2 million endowment from the Warren G. Magnuson Institute for Biomedical Research and Health Professions Training, celebrates Winnie’s exceptional academic performance and her promising contributions to health sciences research.

A Passion for Research and Innovation
Winnie, who graduated with a bachelor’s degree in pharmaceutical sciences from the University of Michigan, joined the University of Washington Department of Pharmaceutics driven by her passion for scientific research. Her thesis projects focus on liver fatty acid binding protein (FABP1) and its role in drug distribution and metabolism. “Studies have linked the genetic diversity of FABP1 with Type 2 diabetes,” Winnie explains. “I am keen to improve my understanding of this variant in metabolic disorders, diabetes and their treatments.”

Using a blend of experimental, mathematical and statistical methods, Winnie aims to translate her findings into practical clinical applications informed by lab-based analysis and research conducted in living organisms. The result? Enhanced clinical decision making for patient-centered care. Winnie’s work in diabetes research showcases her expertise while deepening her commitment to advancing drug development.

Dr. Nina Isoherranen, professor and chair of the department of pharmaceutics, praises Winnie for her analytical skills and independent research capabilities. “During Winnie’s rotation in my lab, she impressed me with her ability to analyze literature, develop and verify PBPK models, and apply her findings to a pregnancy PBPK model,” Dr. Isoherranen shares. “Her work can predict drug disposition in the treatment of gestational diabetes and has potential applications for diabetic kidney disease.”

Winnie’s Reflections on the Award
Being named a Magnuson Scholar is a significant milestone for Winnie. “This award is an immense honor and a profound validation of my efforts and dedication,” she says. “It recognizes the hard work and perseverance I’ve invested in my studies and research and inspires me to continue pushing the boundaries of knowledge and innovation.”

As a grad student in relentless pursuit of life-changing research, a scholarship of this magnitude offers a financial lifeline despite Seattle’s notoriously high cost of living. For Winnie, however, being named a Magnuson Scholar goes deeper than that: “This award not only recognizes the hard work and perseverance I’ve invested in my studies and research but also inspires me to continue pushing the boundaries of knowledge and innovation. It signifies the trust and belief that the University of Washington has in my potential to contribute meaningfully to the field.” While money may appear to be the ultimate resource when it comes to furthering research, the greatest takeaway from this award is something you can’t count. “Being named a Magnuson Scholar boosts my confidence and reinforces my belief in my abilities and potential,” Winnie reflects. “With this renewed confidence, I am motivated to help develop innovative solutions and therapeutic strategies that address pressing health challenges. Ultimately, this scholarship not only alleviates financial burdens but also empowers me to make a significant impact on the nation’s health through my research.”

Winnie’s $32,000 award will allow her to attend workshops and courses outside of UW that align with her interests, enhancing her knowledge and skills in drug metabolism and disposition. These opportunities will allow her to incorporate cutting-edge techniques and insights into her research, in a win-win maneuver that benefits both the academic community and public health outcomes at large.

A Journey Toward Personalized Medicine
Winnie’s journey into pharmacy began with a bachelor’s degree in pharmaceutical sciences from the University of Michigan, Ann Arbor. There, she developed a mathematical model to understand muscle atrophy, igniting her passion for scientific research. Since her arrival at UW, Winnie has thrived in an environment that nurtures healthcare innovation. Cut to today, and Winnie’s research digs deep into the complexities of drug metabolism, pregnancy pharmacokinetics and metabolic dysregulation.

When it comes to her plans for the future, Winnie is thinking big. “My ambition is to become a forefront thinker in science.” By pioneering personalized medicine and therapies tailored to the individual, Winnie envisions a future with happier patients and enhanced outcomes. “I am driven to make an impact,” Winnie states. “Through my coursework in drug metabolism, pharmacokinetics, biostatistics and applied mathematics, I aim to build a future where such diseases are effectively managed and no longer pose threats to patients.”

Looking Ahead
The Magnuson Scholar Program is a key component of the Warren G. Magnuson Institute for Biomedical Research and Health Professions Training. The program honors the legacy of the late U.S. Senator Warren G. Magnuson, who was instrumental in establishing the National Institutes of Health, Medicare and Medicaid. Each year, at least one of the Magnuson Scholars must be engaged in research related to diabetes, its antecedents or treatment, continuing Magnuson’s commitment to improving the nation’s health through biomedical research.

With her fellow Magnuson Scholars, Winnie is well-positioned to continue her impactful research in pharmaceutical sciences. Her dedication to improving the nation’s health through biomedical research exemplifies the values and mission of the School of Pharmacy at the University of Washington. We are proud to celebrate Winnie’s achievements and look forward to her future contributions to healthcare and scientific discovery.

Celebrating Excellence in Assessment: Four UWSoP Faculty & Staff Honored with Prestigious AACP Award

We’re thrilled to announce four esteemed members of our faculty and staff have been honored with the prestigious Award for Excellence in Assessment by the American Association of Colleges of Pharmacy (AACP). Rachel Allen, Matthew Elamparo, Teresa O’Sullivan and Curtis Jefferson have been selected as recipients of this distinguished accolade, recognizing their outstanding contributions to advancing pharmacy education and assessment practices.

The AACP, comprising 142 accredited schools of pharmacy and over 6,400 faculty members, plays a pivotal role in promoting excellence in pharmaceutical education and training. Among its annual recognitions, the Award for Excellence in PharmD Program Assessment stands out for acknowledging initiatives that enhance curricula, student learning and program quality. This award highlights the commitment of its recipients to fostering innovative approaches in education and continuous improvement within the pharmacy profession.

For the UW School of Pharmacy, this recognition is particularly noteworthy, as it reflects the dedication and expertise of our faculty members and staff in assessment and accreditation endeavors. The award-winning assessment initiative is titled, “Closing the Loop: Incorporating Preceptor Feedback from Advanced Pharmacy Practice Experience (APPE) Data to Measure Program Outcomes and Make Rapid-Cycle Program Improvements.” This initiative involved the design and implementation of a “point-in-time” assessment approach to analysis and review of APPE data for more timely feedback and improvements to experiential education and student achievement. Winning entries were selected following a competitive submission process.

We’re proud to celebrate the following members of our staff and faculty for their outstanding work:

Curtis JacksonCurtis Jefferson – Director of Assessment and Accreditation – has demonstrated exemplary leadership in overseeing academic assessment initiatives, ensuring the quality and effectiveness of our nationally recognized PharmD degree program.

Rachel AllenRachel Allen – Assistant Teaching Professor and Director of Experiential Education Assessment – has made significant contributions to scholarship from the halls of our School, with a keen focus on student skill development and experiential education assessment. Her commitment to mentoring students and enhancing learning experiences has been instrumental in shaping future pharmacy professionals.

Teresa O'SullivanTeresa O’Sullivan – Associate Professor and Experiential Education Metrics Specialist – brings a wealth of experience and expertise to her role, contributing to the advancement of practice-based learning and fostering collaboration with volunteer faculty and preceptors. Her dedication to UW pharmacy students is commendable as she continually works to enrich experiential education through research and mentorship.

Matthew ElamparoBefore moving on from his role as Director of Operations for Experiential Education, Matthew Elamparo demonstrated a passion for expanding clinical practice at the UW and mentoring future #HuskyPharmacists. His leadership as a program manager and student advisor played a vital role in guiding PharmD candidates through their prospective career paths. Matthew has since taken his expertise to a new role with the VA Puget Sound Healthcare System as PGY1 Pharmacy Residency Program Director.

With honor and distinction, we recognize Rachel, Matthew, Teresa and Curtis and their shared commitment to excellence and innovation in pharmacy education. Their contributions are far-reaching, as they impact the learning experience of our students while elevating the reputation of our School on the national stage. We couldn’t be prouder of their achievements!

The awards will be formally presented during a special session at the AACP annual meeting in Boston this July, providing an opportunity for our staff and faculty awardees to showcase their innovative assessment initiative on a national stage. We extend a heartfelt congratulations to Rachel, Matthew, Teresa and Curtis and express our gratitude for their continued dedication to advancing pharmacy education and practice.

Andy Stergachis Named AAAS Fellow

Two University of Washington researchers have been named AAAS Fellows, according to an April 18 announcement by the American Association for the Advancement of Science. They are among 502 newly elected fellows from around the world, who are recognized for their “scientifically and socially distinguished achievements” in science and engineering.

A tradition dating back to 1874, election as an AAAS Fellow is a lifetime honor, and all fellows are expected to meet the commonly held standards of professional ethics and scientific integrity.

Empower 2024: Inspiration, Practical Tips and Tools For Your Next Steps

A reminder to join us Saturday, April 13 for a brand new, hot-off-the-presses event brought to you by the UWSoP Professional Development Program.

Our special guests will empower you with practical information and tools for success at work and at home:

Tim Ulbrich
Speaker #1 Tim Ulbrich (Financial)
Co-Founder and CEO of Your Financial Pharmacist
Title: “Rx for $ Wellness: Preparing to Be Financially Fit”
https://www.linkedin.com/in/timulbrich/

Diane Schultz
Speaker #2 Diane Schultz (Interviewing/CV/Resume/Networking)
Pharmacist and Senior Coach at Pharmacy Career Coach
Title: “Rx for Joy in Your Career: From the Paperwork to the Relationships”
https://www.linkedin.com/in/diane-schultz-rph-cpps/

Katrina Azer
Speaker #3 Katrina Azer (LinkedIn & Personal Branding)
Leading voice in inspiring excellence in pharmacy practice
Title: “Rx for a Thriving Pharmacy Career: How to build a personal brand that brings endless career opportunities”
https://www.linkedin.com/in/katrina-azer/

Here are the details:

Saturday, April 13 – 8 a.m. to 1 p.m. PT
Streaming virtually via Zoom: https://lnkd.in/gZ9Y47km

SOP Welcomes New CAO, Daniel Webb

Following an extensive nationwide search, the UW School of Pharmacy is thrilled to announce the appointment of Daniel Webb as our new Chief Advancement Officer (CAO).

In this role, Daniel will serve as the school’s principal fundraiser, provide strategic fundraising leadership, and oversee the development and marketing and communications teams.

Daniel returns to the UW, having previously served in the College of the Environment between 2012 and 2019, where he closed more than $15 million in current and planned gifts from environment-focused donors.

Daniel most recently worked at City Year Seattle as managing director of development. In this role, he led a dynamic development and communications team and held a hybrid role with City Year’s national development team, providing strategy support to the organization’s eight largest fundraising markets.

In addition to welcoming to Daniel, we would like to express our heartfelt appreciation to Anne Fitzmaurice Adams for her dedicated service as Pharmacy’s Interim CAO over the past year. Anne’s contributions have been invaluable, and we are grateful for her steadfast leadership.

University of Washington Embarks on a New Era with Murdock Charitable Trust Grant

We are proud to announce a significant grant from the Murdock Charitable Trust to the University of Washington, earmarked for the acquisition of a cutting-edge research instrument: the Bruker timsTOF-fleX spatial mass spectrometer. This state-of-the-art mass spectrometer will be housed within the UW School of Pharmacy’s Mass Spectrometry Center (MSC) and represents a critical cornerstone instrument in the new MSC’s Imaging Center. This prestigious grant is more than just a financial contribution to our work –– it’s a triumph for the public good and our shared commitment to unleashing human potential through clinical research and discovery.

The Murdock Trust: A Catalyst for Scientific Progress

The Murdock Trust has been a pivotal force in driving leading-edge research across diverse scientific disciplines. With a profound belief in the power of scientific research to inspire innovation and improve quality of life, the Trust has contributed over $225.6 million to date, aiding researchers, educators, and institutions throughout the Pacific Northwest and beyond. In line with our vision of being a global leader in pharmacy education, research, and service, this grant aids both the UW School of Pharmacy and School of Medicine in providing a transformative learning experience in a collaborative and diverse environment. It resonates with our mission of inspiring education, discovering solutions, serving people and their communities.

Enhancing Research and Educational Excellence

A sophisticated tool for molecular analysis, this spatial mass spectrometer will revolutionize our research potential, empowering users to conduct in-depth studies with unparalleled precision and imaging resolution. Combined with microgrid technology, the advanced capabilities of the spectrometer will provide insights into the intricate spatial distribution of lipids, glycans, metabolites and proteins in a range of peripheral and central tissues. Such detailed analysis is vital for understanding neurodevelopment and the pathogenesis of various diseases, including diabetes, Alzheimer’s disease and more.

Empowering Our Community and Beyond

Led by Assistant Professor Dr. Kimberly M. Alonge, UW SoP Department of Medicinal Chemistry, Joint UW SoM Department of Medicine, Division of Metabolism, Endocrinology & Nutrition, this initiative is a testament to our University’s collaborative spirit across schools and departments, showcasing our singular commitment to life-changing research. As Principal Investigator (PI) of the project, Kim has partnered with Co-PI Dr. Karin Bornfeldt (SoM, Professor of Medicine), Dr. Jarrad Scarlett (SoM, Associate Professor of Pediatrics), Mike Guttman (SoP, Associate Professor of Medicinal Chemistry) and Libin Xu (SoP, Associate Professor of Medicinal Chemistry). At the end of the day, Kim represents a lynchpin between the UW Schools of Pharmacy and Medicine. Utilizing a range of mass spectrometry techniques, Kim’s research focuses on the detection and analysis of sulfated glycosaminoglycans in biological materials. Her expertise and leadership are instrumental in advancing our scientific capabilities and training the next generation of researchers.

In her words:

“My colleagues and I are grateful to receive the Bruker timsTOF-fleX imaging mass spectrometer from the Murdock Foundation, which represents a beacon of support to UW’s scientific community. We see this powerful instrument as a catalyst for translational discoveries in both pharmacy and medicine research.”

Driven by Service, Impact and Excellence

As we celebrate this milestone, we look forward to making significant contributions in the pharmacy world and beyond, embodying the transformative impact envisioned by the Murdock Trust. Run by MSC core Director, Dale Whittington, the UW School of Pharmacy is excited to leverage this grant to further the mission of the MSC’s Imaging Core, including education and service for the public good. With such advanced technology at our fingertips, we aim to better our community and contribute to the broader scientific and global health landscape.

We extend our heartfelt thanks to the Murdock Charitable Trust for their support and belief in our vision. Together, we embark on a new era of scientific research and innovation, shaping a healthier, well-founded world for all to thrive.

2024 PAA Distinguished Alumni Award Nominations

The UW School of Pharmacy and the Pharmacy Alumni Association (PAA) invite you to recognize exceptional School of Pharmacy alumni by nominating one or more colleagues for the School’s 2024 Distinguished Alumni Awards. Presented annually by the Pharmacy Alumni Association, these awards recognize graduates who demonstrate excellence in the profession, are connected to the School, and have a positive impact on the pharmacy and research community regionally and/or nationally. Awards will be presented in spring 2024.

In recognition of both our professional and graduate programs at the School of Pharmacy, two awards are given to exceptional alumni each year. One award honors an outstanding graduate working in Pharmaceutical Sciences/Research, while the other recognizes an outstanding graduate working in Pharmacy Practice.

UWSOP PhD, MS, PharmD and BS graduates are all eligible for nomination.

For questions, please email rxalumni@uw.edu or call 206-616-7613

2021 Distinguished Alumni Award Presentation


CHOICE PhD Student Presents at American Society of Human Genetics Meeting

Joyce Jiang

Shangqing (Joyce) Jiang, 5th-year PhD student at the CHOICE Institute, presented her work with Drs. David Veenstra and Greg Guzauskas as a podium presentation at the American Society of Human Genetics (ASHG) annual conference in Nov 2023. This research project focuses on uncertainty in predicted risk in economic evaluations of polygenic risk scores (PRSs).

In recent years, PRSs have shown promising predictive power in identifying individuals at high-risk for disease to guide personalized screening and treatment. However, the accuracy and precision of PRS are limited by issues inherent in observational genome-wide association studies, which results in uncertainty in estimated disease risk. Understanding how uncertainty in estimated disease risk influences projected clinical and economic outcomes is needed before clinical adoption and reimbursement of PRS. Yet it is unclear whether and how published economic evaluations to date have incorporated these considerations.

To answer this question, Joyce Jiang, advised by Dr. Veenstra, led a project of a targeted review for PRS decision modeling studies. Among 16 included articles, only 2 articles explicitly examined uncertainty in PRS-predicted risk in sensitivity analyses and found that uncertainty in PRS-predicted risk was one of the most influential factors impacting the value of PRS. This project identified significant knowledge gaps in the economic evaluations of PRS: to date, published economic evaluations have not consistently incorporated the uncertainty in PRS-predicted risk or examined how this uncertainty impacts the value of PRS. This study calls for future studies to explicitly incorporate these considerations to facilitate evidence-based policy making for PRS.

Joyce Jiang presenting at ASHG 2023 in Washington, DC.
Joyce Jiang presenting at ASHG 2023 in Washington, DC.

Additional information:

  • Research group: RIPS (Rational Integration of Polygenic Risk Scores) research group across University of Washington, Vanderbilt University, and Geisinger Health Systems.
  • Funding agency: NHGRI. R01HG012262. Rational Integration of Polygenic Risk Scores.

CHOICE PhD Student Contributes to APhA-CDC Project Addressing Immunization Access Disparities

Rachel Wittenauer

In November, 4th-year CHOICE Institute PhD student, Rachel Wittenauer, was invited to attend a meeting hosted by the American Pharmacists Association (APhA) at their headquarters in Washington, DC for an APhA-CDC project, “Improving Standard Immunization Practices Among Pharmacists and Other Healthcare Providers.” She joined a group of other pharmacy practitioners and researchers to think through the design and construction of a new CDC-funded public-facing mapping tool to close gaps in immunization access by helping patients identify pharmacies that can provide immunizations and illustrating key differences in pharmacy-based immunization policies between states. This meeting topic is directly linked to Rachel’s dissertation research, titled, “Equitable access and reimbursement for pharmacy-based services: A case study of adult vaccinations” which she expects to defend in Spring 2024.

Rachel Wittenauer pictured with the APHA meeting group.
Rachel Wittenauer pictured with the APHA meeting group.

UWSOP faculty co-author study on how Medicare is overpaying for generic drugs

Disturbing financial practice by Medicare Part D sponsors revealed in University of Washington study of data from the Centers for Medicaid and Medicare Services

Medicare is the single largest provider of health insurance in the United States, serving 63.8 million senior citizens as of 2022. Three-quarters of these recipients are enrolled in optional Medicare Part D plans, which provide outpatient prescription drug coverage to seniors through private insurance companies. In 2022, Medicare paid more than $160 Billion for prescription drugs, making it the single largest payer of pharmaceuticals in the US. While Medicare is meant to keep healthcare affordable for seniors, millions of Americans still face steep costs for prescription medications. Researchers from the CHOICE Institute, University of Washington, the University of California San Diego and West Health Policy Center have now explained part of the problem.

The researchers found evidence that the private insurers that sponsor Medicare Part D (through their Pharmacy Benefit Managers [PBMs]) are inflating the costs of some generic drugs by overpaying pharmacies. The findings are published in the December 5, 2023 issue of the Journal of the American Medical Association. The researchers gathered and analyzed data from the Centers for Medicare and Medicaid Services (CMS), focusing on spending and reimbursement data for the 50 generic drugs that Medicare Part D spent the most on in 2021. They found that some Medicare Part D sponsors were reimbursing at much higher rates than what pharmacies spent to acquire the drugs.

To fill prescriptions, pharmacies purchase drugs wholesale and are reimbursed by insurers. In order to be reimbursed, pharmacies must adhere to contractual obligations that allow insurers to take back money in certain circumstances, such as when the reimbursement to the pharmacy is higher than a certain threshold, or if the pharmacy’s cost of acquisition is very low. These ‘clawbacks’ by Part D Plans can be financially devastating to a pharmacy.

“It doesn’t make sense that insurers would overpay for drugs, then use claw backs to retroactively adjust payments after the patient has paid their co-payment,” said co-author Sean D. Sullivan, PhD, professor of pharmacy at the University of Washington. “This practice is opaque and ultimately harms patients and pharmacies.”

That harm also extends to relationships between pharmacists and their patients, according to UW Department of Pharmacy Associate Professor and Interim Chair Ryan N. Hansen, PharmD, PhD.

“Not only have PBM business practices bankrupted community pharmacies, they damage the important relationships between pharmacists and their patients by creating unaffordable out-of-pocket costs, resulting in difficult decisions to forego important treatments at the pharmacy counter,” said Hansen.

Generic over-reimbursement is one of the areas targeted for reform by the United States Senate, after anecdotal evidence submitted earlier this year by the non-profit manufacturer CivicaRx raised concerns about Part D sponsors potentially over-reimbursing pharmacies for abiraterone, a cancer drug. The concern: that patients are ultimately impacted by these reimbursement practices because of how out-of-pocket costs (e.g., co-payments and deductibles) are calculated.

“For instance, if a patient pays 30% as a co-payment for a drug, that 30% would be applied by the PBM to the inflated price, not the price the pharmacy paid or the price the PBM pays the pharmacy, which means higher out-of-pocket costs for seniors,” said corresponding author Inmaculada Hernandez, PharmD, PhD, professor at UC San Diego Skaggs School of Pharmacy and Pharmaceutical Science. “This is the first study to investigate whether these PBM practices actually take place in the Medicare Part D program,” added Hernandez.

“The results are alarming,” said Hernandez. “We are talking about significant markups in some cases.”

In one of the most dramatic examples, the researchers found that insurers were reimbursing pharmacies an average of $126 per tablet for a cancer drug that cost $4.20 per tablet to the pharmacy. This corresponds to an average markup of 3,000%, or $3,600 per 30-day prescription. Some insurers paid even more.

“Seniors are clearly paying more for their medications as a result of these markups,” said Hernandez. “More research is needed to confirm the scope of these practices, but the evidence we present in the paper is concerning.”

Full link to study: https://jamanetwork.com/journals/jama/newonline

Co-authors include: Nico Gabriel at UC San Diego, Anna Kaltenboeck at ATI Advisory, and Cristina Boccuti at West Health Policy Center.

This study was funded by West Health Policy Center.

###

Media Contact: Scott Braswell, +1-423-741-5697 braswels@uw.edu

 

UW Rho Chi Society 2023 Induction Ceremony 

UW Rho Chi Society 2023 Induction Ceremony 
The UW chapter of the Rho Chi Pharmacy Honor Society held its annual induction ceremony last week welcoming new members from the 2025 graduating class. The national society recognizes excellence in intellectual achievement in the field of pharmacy. It seeks universal recognition of its members as lifelong intellectual leaders in pharmacy and instills the desire to pursue intellectual excellence.

And in case you didn’t know—every quarter UW Rho Chi offers free tutoring to PY1 and PY2 students! This is a great resource to help you stay on top of studying. Students and tutors are usually matched on a first-come, first-served basis.

Use this link for more information or to contact the UW chapter.

Jayanth Panyam selected as Dean of the School of Pharmacy

Jayanth Panyam
Jayanth Panyam was appointed the new Dean of the School of Pharmacy.

University of Washington Provost Mark Richards this week announced the appointment of Jayanth Panyam as the new Dean of the School of Pharmacy beginning August 15, pending approval by the Board of Regents.

Panyam fills the position vacated last year by Sean Sullivan who returned to the faculty after more than eight years in the role. Peggy Odegard has been serving as interim dean.

Panyam comes to the UW from Temple University School of Pharmacy where he has been dean since 2019. Prior to that, he was an endowed professor and head of the Department of Pharmaceutics in the College of Pharmacy at the University of Minnesota.

“We welcome Jay’s extensive experience in discovering new therapeutics, advancing the pharmaceutical profession, broadening access to students and supporting faculty,” Richards said.

At Temple, Panyam focused on pharmacy education and research. He has extensive experience training pharmacists and pharmaceutical scientists, supporting faculty in their advancement, and with student recruitment and admissions.

Panyam’s research is primarily focused on investigating the mechanisms of drug delivery with an emphasis on understanding how various biological factors influence the effectiveness of delivery systems. The ultimate goal, Panyam said, is to use the knowledge derived from these studies to devise advanced delivery systems that can be effectively translated to the clinic.

“The UW School of Pharmacy has a long history of leadership in all aspects of pharmacy and pharmaceutical sciences — education, scholarship and practice,” Panyam said. “I am honored and excited to serve as the next dean.”

In his role as dean, Panyam has been an advocate for pharmacists and has been actively engaged in advancing the profession. His efforts, in collaboration with the deans of the other pharmacy schools in Pennsylvania, led to changes in pharmacy practice regulations in the state, especially during the COVID-19 pandemic. He has also been instrumental in exploring and creating new practice sites, shared positions and billing models for pharmacy practice faculty members.

Panyam earned his bachelor’s in pharmacy from The T.N. Dr. MGR Medical University in Chenai, India, and his master’s in pharmacy from Banaras Hindu University in Banaras, India. He earned his doctoral degree in pharmaceutical science from the University of Nebraska Medical Center in Omaha, Neb.

UWSOP Faculty to Receive Distinguished Teaching Award

UWSOP Faculty to Receive Distinguished Teaching AwardA very special congratulations to Jennifer Chang, Seohyun “Claudia” Choi, Jennie Do, Karan Dawson and Leigh Ann Mike, who will receive UW’s Distinguished Teaching Award for Teams at the 53rd annual Awards of Excellence Ceremony next month. Each year, the awards honor outstanding alumni, faculty, staff, students and retirees who contribute to the richness and diversity of our University community. The ‘Distinguished Teaching Award for Teams’ is a new honor granted to outstanding instructional teams.

“The inspiration these faculty provide to our community is palpable, and this award is a testament to that,” said UWSOP Interim Dean and Professor, Peggy Odegard. “This team exemplifies instructional collaboration, reflective teaching practice, and an inclusive approach to learning that fosters an individual and transformative experience for each student. Their dedication to learning and student support is absolutely exemplary.”

The winners will be honored from 3:30 to 5:30 p.m. on June 8 at the Katharyn Alvord Gerlich Theater in Meany Hall. UW President Ana Mari Cauce and Provost Mark Richards will host a one-hour ceremony, followed by a reception with hors d’oeuvres, desserts and a chance to connect and celebrate with the UW community.

This event is free and open to the public. Please invite your colleagues, friends and family!

Complete list of award winners:

https://www.washington.edu/facultystaff/2023/05/04/the-uw-announces-2023-awards-of-excellence-recipients/

Pharmacy Team

  • Jennifer Chang (she/her), Clinical Associate Professor, School of Pharmacy
  • Claudia (Seohyun) Choi (she/her), Assistant Teaching Professor, Clinical Practice, School of Pharmacy
  • Karan Dawson (she/her), Clinical Associate Professor Emeritus, School of Pharmacy
  • Jennie Do (she/her), Clinical Assistant Professor, School of Pharmacy
  • Leigh Ann Mike (she/her), Clinical Associate Professor, School of Pharmacy

UWSOP P&T Team Awarded Second Place at 2023 Finals

UWSOP Pharmacy & Therapeutics (P&T) TeamThe School of Pharmacy is proud to announce the UW AMCP Chapter P&T team placed second at the National Student Pharmacist Pharmacy & Therapeutics (P&T) Competition finals! The event, which took place March 22 during the annual AMCP conference in San Antonio, is an annual team competition designed to provide an immersive experience in the skills necessary for effective formulary review and management.

“We are extremely grateful for both the financial support our team received to attend the conference and the mentorship and coaching we were provided,” said UWSOP team member Jonathan Luong, following the competition.

In addition to Jonathan, the 2023 P&T team also includes second-year PharmD students Tiffany Tran, Regina Meng, and Reda Ali.

“We received so many positive comments about the strength of our chapter, and it is undoubtedly due to the continued support that we receive from UWSOP,” Jonathan added. “We are very thankful for this experience and are excited for future opportunities to represent the school.”

Learn more about the UWSOP AMCP student chapter here.

Volunteers Needed for Pharm 501

Each year, first-year UWSOP students complete an assignment in PHRMCY 501: Foundations of Being a Pharmacist I called the “Friends and Family Assignment.” This assignment requires students to either practice their clinical interview skills or learn how to collect medical and medication information from a patient by working with a friend or family member who takes at least 3 medications daily. We typically have a small number of students who experience difficulty finding a friend or family member to participate and are looking for alumni interested in volunteering to help these students.

We are seeking alumni who take a minimum of 3 medications daily and who are willing to support our first-year students’ learning by participating in one 60-minute interview in mid-October via Zoom or telephone. During the interview, students will conduct a comprehensive medication review and will ask questions about the volunteer’s medical and medication history. Volunteers can refuse to answer any question they are not comfortable sharing. The student will not submit any identifiable or personal health information as part of their assignment.

Alumni who are interested in volunteering or would like more information, please contact Dr. Jenni Bacci via email by Friday, October 14th.

Peggy Odegard Appointed UWSOP Interim Dean

Peggy Odegard
Peggy Odegard

UW Provost Mark Richards announced today that Dr. Peggy Odegard has agreed to serve as interim dean for the UW School of Pharmacy, effective September 1, 2022, until a new dean is selected. Richards and his team will appoint a search committee and launch a national search for a new dean this spring quarter.

Current UWSOP Dean Sean D. Sullivan announced last fall that he would step down as dean this summer and take a year of sabbatical at the London School of Economics. He plans to return to his UW faculty position at the completion of his sabbatical. Odegard and Sullivan will work closely together in the next few months to assure a smooth transition.

The Lynn and Geraldine Brady Endowed Professor of Pharmacy, Odegard also serves as the School’s vice dean for professional pharmacy education, where she has overseen the development and implementation of the School’s new PharmD curriculum.

“Peggy is a valued colleague and champion for our community,” said Sullivan. “I have had the pleasure of working with her in multiple capacities during my time as dean, and I am confident her leadership will successfully guide the School during this transition period.”

UWSOP Alum Tim Fuller passes away

Tim FullerWe are deeply saddened to report that our friend and colleague Tim Fuller passed away unexpectedly this week. Tim graduated from the UW School of Pharmacy in 1969 and went on to complete a residency and MSc degree in Hospital Pharmacy at Ohio State University in 1974. He also completed two residencies at the US Public Health Hospital in San Francisco and Ohio State University Hospital. Tim served as Director of Pharmacy at Seattle Children’s Hospital from 1981 to 1991 and as a Pharmacist Consultant to the Washington state Board of Pharmacy from 1992 until he retired in June 2014.

Tim enjoyed a long and distinguished career in the pharmacy community. Founder of Timothy S. Fuller & Associates, Inc., Consulting, he is recognized as the Father of Pharmacist Collaborative Drug Therapy for his extensive and continued research, advocacy, and publication on the subject. He is a Past President of the Washington Society of Hospital Pharmacists, a Fellow of the American Society of Health System Pharmacists, and the Washington State Pharmacists Association Pharmacist of the Year in 1997.

Tim served the School of Pharmacy community as a Preceptor and Adjunct Professor for 31 years. In 2018, Tim was awarded the UW Pharmacy Alumni Association Distinguished Alumni award for his generous and illustrious service to the School.

Tim’s UW graduating class (’69) was the first class in the history of the University of Washington to endow a scholarship fund in honor of their class. Should you want to make a donation in Tim’s memory, you can support the Class of 1969 fund here.

On behalf of the UW School of Pharmacy, we extend our heartfelt condolences to Tim’s wife Karli and the entire Fuller family. Our thoughts are with them during this very difficult time. Details on funeral arrangements will be shared as they’re made available.

Commitment To Community

Katterman’s Pharmacy immunizes hundreds of children against COVID-19.

Child Vaccine
Even a cold, rainy November morning in Seattle can’t dampen the enthusiasm of volunteers on hand at Katterman’s Pharmacy for its inaugural pediatric COVID immunization clinic. According to Katterman’s co-owner and UWSOP alumna Bev Schaefer ‘70, the event showcases both the strength of local volunteerism and how integral neighborhood pharmacies are to the health and success of the communities they serve.

“This is something that has a huge effect on our community and really enhances the ability for people to recognize that pharmacy plays a vital role in staying healthy,” she said. “To pull this off requires an army of volunteers and a lot of planning. Luckily, we recruited students from the UW School of Pharmacy, retired physicians, neighbors and parents – it’s a wonderful event.”

If the line of parents and children stretching around the block well before the clinic’s 9 a.m. opening is any indication, all that effort paid off in spades.Vaccine

“We’re expecting about 350 kids coming through,” said Katterman’s pharmacist Lisa Garza. “We’re very experienced in vaccinating children of all ages, so when the COVID vaccine for kids was announced, we knew we had to have it available here. The sooner we can get kids vaccinated, the sooner families can go enjoy the holidays, the sooner schools will be safer.”

In an effort to ease any anxieties for both children and parents, Bev and her team have created a welcoming environment, complete with a bevy of lollipops for the successfully vaccinated and a purple “badge of courage” that reads “Ready To Hug Grandparents! – I Got Vaccinated.”candy

Operation Immunization, an initiative UWSOP Clinical Professor Don Downing helped pioneer as a training program for students to provide vaccines to local communities, also played a part in Sunday’s festivities. First-year Pharmacy student Zoe Amaris was among the first batch of volunteers on hand to help prepare vaccines and witness the initial wave of satisfied customers trot out the door fully vaccinated with lollipops in hand. Zoe was inspired to volunteer for the clinic due to her background and interest in process development.

Zoe Amaris
UWSOP volunteer and first-year student, Zoe Amaris.

“Before attending UW, I was working in pharmaceutical development, so it’s great to see the manufacturing side come into practice in terms of application and giving vaccine doses to patients,” she said. “Just seeing kids being able to get their vaccinations – that’s really awesome. I’m so happy to help and give back to the community.”

Watch the new Pharmacy Frontline video on the pediatric COVID immunization clinic, hosted by Katterman’s Pharmacy.

Dr. Dawn Ipsen, ’01, Dr. Han Kiat Ho, ’05, Receive PAA Distinguished Alumni Awards

The UW Pharmacy Alumni Association proudly recognizes Dr. Dawn Ipsen, PharmD ’01, and Dr. Han Kiat Ho, PhD ’05, as the 2020 Distinguished Alumni Award recipients. Started in 1973 and originally presented at Commencement, the Distinguished Alumni Awards have a rich history of honoring UW School of Pharmacy graduates who demonstrate excellence in the profession, are connected to the School, and have a positive impact on the pharmacy practice and research community. Over the years, we have honored more than 50 deserving alumni, granting them the status of Alumni Legend.

2021 Awards Presentation

Dr. Dawn Ipsen, PharmD ‘01
Dr. Dawn Ipsen, PharmD ‘01

Dr. Dawn Ipsen’s contributions to the education of future Husky Pharmacy leaders transcends precepting and her lifelong professionalism has impacted students, peers and the Puget Sound community in far-reaching ways. A Washington State Native, Dawn is the owner of Kusler’s and Clark’s Compounding Pharmacies, where she precepts PharmD students on their APPE rotations. In addition to providing custom compounded medications, pharmaceutical supplements and consultations for people, their pets and health care providers, Dawn and her teams seamlessly and rapidly transitioned to provide COVID-19 vaccines across Snohomish County starting on January 2021. In all, over 50 volunteers have provided 500 hours of service, administering over 4,000 doses to community members, health care providers and educators across the county.

In 2020, Dawn established the WSPA’s Compounding Special Interest Group, dedicated to legislative action and expanding opportunities for new, compounding professionals both within Washington State and across the nation. Dawn’s dedication to compounding pharmacy practice extends, too, through her service on the national Advisory Council for the Professional Compounding Centers of America, where she works to increase patient health and access, and to amplify pharmacy business health and vitality.

The UW School of Pharmacy and PharmD program are grateful to Dawn for her many years of service on the Student Preceptor Experiential Advisory Committee, working with faculty and students to develop student engagement activities through precepting. Dawn’s commitment to the next generation of Husky Pharmacists is evident in her 15 years of service as a preceptor at Kusler’s Compounding Pharmacy.

Dawn’s Award Video

Dr. Han Kiat Ho, PhD ‘05
Dr. Han Kiat Ho, PhD ‘05

A 2005 PhD graduate of the Department of Medicinal Chemistry, Dr. Han Kiat Ho, PhD 05, is currently the Deputy Dean of Students and Associate Professor in the Department of Pharmacy at the National University of Singapore. Also the Vice President of the Toxicology Society of Singapore, Han has published over 90 papers, which have been sited more the 3,000 times. He has been recognized with numerous honors as the 2020 Outstanding Educator Award by the National University of Singapore; the six-time recipient of the Faculty Teaching Excellence Award at the National University of Singapore; and the Liew Weng Chee Scholarship recipient through the Institute of Drug Safety Sciences at the University of North Carolina.

Inspired by the passion and dedication of former UW School of Pharmacy Dean and Professor Dr. Sid Nelson, Han has dedicated his career to educating students. In his current role, Han oversees academic and residential activities for all 40,000 students at the National University of Singapore while maintaining rigorous academic research exploring various aspects of liver diseases, including the management of drug-induced liver toxicity, liver fibrosis and liver cancer. Before his appointment as Deputy Dean of Students, Han served as the Deputy Head of the Department of Pharmacy, where he oversaw the creation of the Pharmaceutical Science bachelor’s degree program. Han is instrumental in ensuring the efficacy of pharmaceutical research by serving on the Health Sciences Authority of Singapore’s Advisory Panel, which facilitates the decision for approving the use of specific medications, including those for COVID-19 cases.

Han’s Award Video

SOP Class of 2020 Has Stellar Showing In Latest NAPLEX & MPJE Results

NAPLEX (Basic Science and Clinical Skills Examination)

Our class of 2020 graduates achieved a first-time pass rate of 97.94%, which is well above the national first-time pass rate (88.43%) and roughly on par with our pass rates for the previous two graduating classes (98.72% & 98.8%, respectively). The pass rate for our graduates ranks #8 nationally and puts us at #1 (out of 7) in our region1 and #4 (out of 11) in our national peer comparison group2.

MPJE (Washington State and Federal Law Examination)

Our class of 2020 graduates achieved a first-time pass rate of 96.25%, which is also well above the national first-time pass rate (84.59%) and represents a marked increase over the pass rates for the previous two graduating classes (87.3% & 85.5%, respectively). The pass rate for our graduates ranks #10 nationally and puts us at #1 (out of 6) in our region3 and #2 (out of 9) in our national peer comparison group4.

 

1 Regional Schools: Idaho State University, Oregon State University, Pacific University Oregon, The University of Montana, University of Wyoming, Washington State University

2 National Peer Comparison Group: The Ohio State University, The University of Arizona, The University of Iowa, The University of Texas at Austin, University of California San Diego, University of California San Francisco, University of Kentucky, University of Michigan, University of North Carolina at Chapel Hill, University of Wisconsin-Madison

3 Idaho does not require the MPJE

4 Graduates who elect to practice in California take a modified version of the MPJE

 

The School of Pharmacy Mourns the Passing of Dr. Joy Plein

Joy PleinJoy (Bickmore) Plein, ’51, ’57, a beloved UW School of Pharmacy colleague, mentor and true pioneer in the field of geriatrics, passed away peacefully at Virginia Mason Medical Center on February 19, 2021. She was 97.

“For 48 years, Joy was the heart of the UW School of Pharmacy,” said SOP Professor and Dean Sean Sullivan. “Everyone who knew her felt her deep commitment to excellence in education, practice and research. She forever changed the field of pharmacy practice, and her passion has inspired generations of pharmacists and researchers.”

Joy earned both a master’s and doctoral degree at the University of Washington. In 1952, she married Dr. Elmer Plein, a professor in the School of Pharmacy, beginning a partnership that would create an entirely new field of pharmacy research and practice. One of the School’s first female faculty members, Joy was appointed to a full-time position as associate professor in 1972 and was promoted to full professor in 1974. She continued to teach nursing students fundamentals of pharmacotherapeutics until 1985.

Joy is widely credited for creating the momentum for senior-care pharmacy in Washington State at a time when there were few pharmacists who were geriatricians, and few resources to advocate for older patients. Along with Elmer, Joy developed the first course to be offered in nursing home pharmacy in 1973, which led to the establishment of the Certificate Program In Geriatric Pharmacy Practice in 1986.

The Pleins established three endowed funds to carry on their pioneering legacy in education, research and practice. In 2015, Joy was given the Pharmacy Alumni Association’s Lifetime Achievement Award for her exemplary service in the field of pharmacy, and in 2017 she was selected as the recipient of the UW-UWRA Distinguished Retiree Excellence award.

Joy’s dedication to geriatric pharmacy and practice, and her expertise in the field, culminated with the creation of the Plein Center for Geriatrics in 2016. Today, the Plein Center is a global leader in transformative pharmacy research, education and outreach, and has expanded the School’s role as a leader in promoting healthy aging.

“Her life-long commitment to supporting training and research in optimizing care for older adults has advanced the field of geriatrics pharmacotherapy,” said Plein Center Director Shelly Gray. “She has inspired generations of dedicated pharmacists.”

“Joy was an educator, an innovator and a pioneer, but most importantly, she was a dear friend and champion of the School and of Pharmacy,” Sullivan added. “Both professionally and personally, she embodied the best of us. We will strive to honor her kindness, passion and humanity, both in our profession, and in our daily lives.”

In memory of Joy, we have provided a link for those interested in supporting her passions and impact at the School of Pharmacy.

 

We’ve selected a few of the many memories of Joy that have been shared with us since her passing by the countless colleagues, mentees, and friends she impacted in her 97 years of life.

 

  • “Dr. Joy Plein had a profound and immeasurable impact on my life, both professionally and personally, as a dear mentor and friend. In addition to being an inspiration to me in all she had done to advance the field of geriatric pharmacy, Joy was continuously one of my greatest supporters and advocates. I would not be where I am today in my career if it weren’t for the incredible influence that Joy had on me. I will continuously strive to honor Joy’s legacy as a pioneer in geriatric pharmacy, as well as her kindness, passion, tenacity, and humility.”
    • Laura Hart, ’14

 

  • “Beyond being a quintessential professional with an unparalleled commitment to clinical practice, and to our students, Joy was a fine human being. She was a pioneer, role model, and leader. She was kind and compassionate; generous of spirit in every sense of the word. Joy was thoughtful and caring; a loyal and true friend. Joy was a loyal Husky football fan, fun-loving and adventurous, and a great conversationalist. She was brave, cheerful and persevering in the face of adversity. She loved her family and friends dearly and touched so many of our lives with her unwaveringly cheerful spirit. We now have the privilege of carrying out her legacy. Joy lives on in each of our hearts.”
    • Beth Devine, ’01

 

  • Joy was a teacher, mentor, colleague and friend to me for 43 years. In addition to me, she mentored every student, other faculty members, and our profession. I got to witness how Joy encouraged students and practicing pharmacist by pointing out opportunities such as organizations to join, conferences to attend, faculty and community projects, grants, and employment opportunities. Joy was a powerhouse of vision paired with gentle and persistent determination. Her influence, service, thoughtfulness, and love cannot be adequately captured by words. She had to be experienced.
    • Karan Dawson, ’70, ’78

 

  • “During my early training with the Pleins, Joy asked me to be her teaching assistant in the pharmacotherapeutics course for nursing and dental hygienist. This stimulated an interest in teaching which was to carry through my entire career. When it came time to write my thesis, Joy and her red pencil completed my sentence fragments, joined then in succinct paragraphs and pages of somewhat literate understanding of my research work. In short she taught me how to write.”
    • David Bailey, ’70

Jennifer Bacci Selected as 2021 Recipient of the Albert B. Prescott Pharmacy Leadership Award

Jennifer BacciThe Pharmacy Leadership and Education Institute has named UWSOP’s Jennifer Bacci the 2021 recipient of the Albert B. Prescott Pharmacy Leadership Award. Dr. Bacci is recognized for her outstanding leadership example in the Academia-CPESN Transformation (ACT) Pharmacy Collaborative Task Force by the American Association of Colleges of Pharmacy (AACP), as a Flip the Pharmacy coach, and as a network facilitator for Community Pharmacy Enhanced Services Network (CPESN) Washington.

A nationally recognized researcher in implementation science and community pharmacy practice advancement, Dr. Bacci trains the next generation of pharmacists through a high level of involvement in community residency training, mentoring students in research and teaching, and leadership contributions to UW School of Pharmacy’s curricular innovation.

“Jenny has demonstrated exemplary leadership qualities as a young pharmacist passionate about advancing community pharmacy practice and training the next generation of pharmacists,” said UWSOP Dean and professor Sean D. Sullivan. “She envisions and is actively working toward a future where community pharmacists are positioned to take responsibility for the medication-related needs of the communities in which they practice and serve as an integral member of each person’s healthcare team.”

As a faculty member at the UWSOP, Dr. Bacci has been heavily involved in the PharmD curriculum redesign effort, co-chairing the Fundamentals Work Group, a group of faculty and staff across three departments. She also serves as the faculty advisor to three registered student organizations, guiding the professional development of student and future leaders of the profession outside of the classroom. She was recently appointed to the University of Washington’s Population Health Initiative by University President, Dr. Ana Mari Cauce. In this role she joins an interdisciplinary group of faculty and public health advocates representing the diverse University community to guide this effort to advance the health of people globally and in her region.

Dr. Bacci is also a respected leader of practice advancement within Washington state through her research program, which addresses the application of implementation science to advance innovative patient care models in community pharmacy practice. Her work has resulted in over 25 peer-reviewed publications at this early point in her career. But more importantly, her work has drawn the attention of community pharmacy leaders in Washington state and beyond. Dr. Bacci is regularly asked by community partners to advise and collaborate on their pharmacy practice models.

Dr. Bacci will receive her award and deliver a scholarly address during a webcast of the APhA Annual Meeting in March 2021. Details of date, time, and access will be announced later.

UWSOP student nominated to take part in LCH Student Scholars Fellowship program

Roberto Rodriguez headshot

Roberto Rodriguez, a 4th-year UWSOP PharmD student, has been nominated to be a part of the 2nd Annual Latino Center for Health (LCH) Student Scholars Fellowship program. This program recognizes outstanding students who have demonstrated a strong commitment to promoting the health and well-being of Latinx communities in Washington State.

“This fellowship program empowers students like me to continue making a difference in Latinx communities,” said Roberto, who grew up in a small agricultural town just outside of Yakima, WA, and began working in fields and warehouses when he was 13 years old.

“Most of the people I worked with were Hispanic, and my community was predominantly people of Latin descent,” he said. “As I grew older, I realized that there were many disparities in Latinx communities. These experiences directly influenced my commitment to promote the holistic well being of Latinos.”

For his Introductory Pharmacy Practice Experience (IPPE), Roberto returned to Yakima so he could serve the community in which he grew up. This turned out to be an extremely rewarding experience.

“Because the patient population was predominantly Hispanic, I was able to use my Spanish to provide vaccinations and medication counseling to patients,” said Roberto. “As a future Latino health care provider, I believe it’s my responsibility to give back to my community, and I hope my efforts and commitment will continue to positively impact future generations.”

The LCH Student Scholars Fellowship program includes a stipend of $6,000 distributed throughout both winter and spring 2021 quarters.

Bev Schaefer Receives Memorial Trailblazer Award From NCPA

UWSOP alumna Bev Schaefer, co-owner of Katterman’s Sand Point Pharmacy in Seattle, has received the Sharlea Leatherwood Memorial Trailblazer Award from the National Community Pharmacists Association Foundation.

The Trailblazer Award – named in honor of Sharlea Leatherwood, former NCPA and NCPA Foundation president – recognizes an outstanding pharmacy owner whose practice has set the standard for the current and future generation of independent pharmacy owners.Bev Schaefer

“It is an incredible honor to be chosen as the inaugural recipient of this new award,” said Schaefer. “Community pharmacy is my passion and keeping our entire neighborhood healthy is my goal. I am always looking for ways pharmacy can be a resource for helping people lead healthy lives and I continue to make changes in my practice to meet that goal.”

Named Distinguished Alumnus by the School in 2000,  Bev was presented with the UWSOP Alumni Legend Award earlier this year. In 2007, she was named NCPA Willard B. Simmons Community Pharmacist of the year.

Katterman’s Sand Point Pharmacy is an urban neighborhood pharmacy offering many patient care services, including immunizations of all kinds to all ages. Schaefer is a clinical community pharmacist with prescriptive authority for 30 legend drugs, including most drugs prescribed for use while traveling. In 2015, Cardinal Health chose Katterman’s as their Retail Advantage award winner for the wide array of innovative travel services and goods offered in the pharmacy.

Schaefer is a 40-year member of NCPA. She has served on many NCPA Steering Committees, provided numerous hours of continuing education to NCPA Annual Convention attendees, and mentored pharmacy students participating in the annual Good Neighbor Pharmacy NCPA Pruitt-Schutte Student Business Plan Competition.

With Schaefer’s leadership, Katterman’s Sand Point Pharmacy continues to blaze trails, providing appointment-based patient care services, educating customers about smart choices for long-term health, and helping people embrace a healthier lifestyle. Schaefer and her team are a valued source of education, advice and products, and serve as an essential health safety net in their community.

UWSOP Dean Sean D. Sullivan Elected To NAM

University of Washington School of Pharmacy Dean and Professor Sean D. Sullivan has been elected to the National Academy of Medicine (NAM). Considered one of the highest honors in the fields of health and medicine, the election recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

“I’m truly honored to be elected to the NAM, and to join the ranks of so many distinguished colleagues in the fields of health and medicine,” Sullivan said.

One of the few persons from pharmacy ever elected to the NAM, Sullivan is being honored for pioneering evidence-based drug coverage and reimbursement policies, creating value-based guidelines for coverage and reimbursements, and being the first health economist to serve on global clinical guidelines (asthma and COPD) panels, incorporating economic considerations into recommendations.

“This diverse class of new members is a truly exceptional group of scholars and leaders whose expertise in science, medicine, health, and policy will be integral to helping the NAM address today’s most pressing health challenges and inform the future of health and health care for the benefit of everyone around the globe,” said National Academy of Medicine President Victor J. Dzau. “It is my privilege to welcome these esteemed individuals to the National Academy of Medicine.”

New members are elected by current members through a process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health. A diversity of talent among NAM’s membership is assured by its Articles of Organization, which stipulate that at least one-quarter of the membership is selected from fields outside the health professions — for example, from such fields as law, engineering, social sciences, and the humanities.

“Sean is an innovative national and global leader in the economic evaluation of health care technologies and practices and pharmaceutical and medical technology pricing and policy,” said Andy Stergachis, NAM member and UWSOP Professor of Pharmacy and Public Health. “This is a well-deserved high honor that recognizes Sean’s demonstrated professional leadership, vision, impact and dedication.“

Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, the National Academy of Medicine addresses critical issues in health, science, medicine, and related policy and inspires positive actions across sectors. NAM works alongside the National Academy of Sciences and National Academy of Engineering to provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions.

Pharm 501 Seeking Volunteers

The first year students are currently completing a Friends and Family Assignment for PHRMCY 501: Foundations of Pharmacy I. Through this assignment, the students are working with a friend or family member who takes at least 3 medications daily to practice their clinical interviewing skills. We have a number of students who are experiencing difficulty finding a friend or family member to participate and are seeking alumni volunteers to help students.

first year students
Pharm 501 Students Seek Volunteers

Alumni should volunteer if they are taking at least 3 medications daily and are willing to support our first-year students’ learning by participating in two, 60 minute encounters. The first encounter will take place the week of October 19th. During this first encounter, the students would be conducting a comprehensive medication review and would be asking questions about their past medical and medication history. The second will be a follow-up interaction during winter quarter (late Feb/ early March). Volunteers are only asked to answer questions with which they feel comfortable and students will not submit an identifiable or personal health information to us as part of their assignment.

Please express interest to Professor Jenni Bacci by Wednesday, October 21st. Questions can also be directed to Dr. Bacci.

Volunteer

Gear Sales Benefit Student Conference Fees

(UPPOW) have opened their annual gear sale.
T-shirts available for purchase in support of UPPOW

Students in the Unified Professional Pharmacy Organizations of Washington (UPPOW) have opened their annual gear sale. Purchases of UW School of Pharmacy t-shirts and sweatshirts support student conference reimbursement and the annual Red Square Health Fair. Items can be shipped anywhere in the U.S. and sales are open until October 19th.

 

PAA Creates First Endowed Student Support Fund

Scholarships at the UW School of Pharmacy support 72% of current students. With over 4,900 alumni across the globe, the UW School of Pharmacy alumni community remains committed to supporting student scholarships. In celebration of the UW School of Pharmacy’s 125th Anniversary, the Pharmacy Alumni Association (PAA) matched gifts from 95 alumni and donors to create the first PAA Endowed Student Support Fund. This fund will continue PAA’s PharmD scholarship giving, which supports 2 students annually.

Together, our alumni continue the legacy of innovative Pharmacy education through the PAA Endowed Student Fund. 

You can support PAA Scholarships by giving today.

Support Students

UW Breaks Ground On New Health Sciences Education Building

HSEB Groundbreaking
Attending the ceremonial ground breaking of the new Health Sciences Education Building on UW’s Seattle campus Thursday, Aug. 27, were (left to right) Dean Edwina Uehara, School of Social Work; Dean Sean D. Sullivan, School of Pharmacy; Executive Dean Azita Emami, School of Nursing; Dean Gary Chiodo, School of Dentistry; and Dean Hilary Godwin, School of Public Health. Dennis Wise/University of Washington

On August 27, UW School of Pharmacy Dean Sean D. Sullivan, Washington State Senator David Frockt and other UW Health Sciences deans took part in the official groundbreaking ceremony for the new Health Sciences Education Building. The state-of-the-art facility, scheduled to be completed in May 2022, will serve as an interdisciplinary environment for pharmacists, doctors, dentists, nurses, social workers and public health experts to learn and work together.

“This new facility will enable our students across the full range of health sciences to work in a setting that better mirrors the way they’ll be engaging in patient care as professionals,” said UW President Ana Mari Cauce. “This will result in better care for the patients they serve, because we’ve seen the benefits that come from coordinating various health disciplines, rather than keeping them siloed.”

Visit the HSEB website for more information on the project: https://lnkd.in/eqQvakn

UW HSEB website unveiled

This week the #UW debuted a website devoted to the construction of the new $100M+ Health Sciences Education Building, one of the few structures nationwide created to intentionally foster collaborative teaching and learning. Once completed, the building will be shared among the UW’s six health sciences schools and is expected to catapult those programs to the forefront of interprofessional education. Groundbreaking will take place August 27, 2020, with the finished building scheduled to open two years later.

UWSOP Professor Allan J. Ellsworth Retires

Allan J. EllsworthAfter 39 years of distinguished service to the University of Washington School of Pharmacy, Professor Allan “Al” Ellsworth retired June 30, 2020.  Over the course of his career, Professor Ellsworth made many notable contributions to the Department, School, University, profession and community. He has been an outstanding educator and colleague, devoted to providing exceptional clinical instruction to the many students and residents he has trained. We are sincerely grateful for his years of service to the Department and School of Pharmacy.

A graduate of Brigham Young University, University of Utah, and the University of Washington School of Medicine, Professor Ellsworth earned Bachelor of Science degrees in the fields of Zoology (1972), Pharmacy (1975) and a Masters of Clinical Health Services degree through the MEDEX Northwest Physician Assistant Program (2002). Following graduation from the University of Utah, Al went on to complete his Doctor of Pharmacy degree in 1977 at the Philadelphia College of Pharmacy and Science. Additionally, he completed internships as a pharmacy intern at Payless Northwest in Portland, Oregon (1974), the Holy Cross Hospital in Salt Lake City, Utah (1972 – 1975), and served as a Commissioned Officer (COSTEP) at the Seattle Public Health Service Hospital (1974.)  His career in education as a faculty member begin at the Cedar Rapids Medical Education Program in Cedar Rapids, Iowa in 1977, where he concurrently served as a Clinical Assistant Professor in the University of Iowa’s College of Pharmacy through 1981. Upon relocating to Washington state, Al joined the University of Washington as an Assistant Professor in the School of Pharmacy in 1981, and progressed to Associate Professor in 1989. He was promoted to Professor of Pharmacy in 1997. While at the University of Washington, Al also maintained appointments with the UW School of Medicine and Creighton University in Omaha, Nebraska as an Assistant Clinical Professor (1985- 1989), Associate Clinical Professor (1989-1996) and Professor (1997-2016). He has also recently retired from medical practice as a Physician Assistant with the EvergreenHealth Primary Care, Sultan group, which was originally Sky Valley Family Medicine.

In the area of scholarship, Professor Ellsworth has made many contributions to our understanding and treatment of altitude sickness, diabetes and hypertension.  He has served as the Principal Investigator (19) or co-investigator (3) of 22 clinical trials, the results of which have been the subject of numerous publications including 27 peer-reviewed articles.  In addition, he has contributed to the publication of over 50 clinical trial reports and authored 12 books and six book chapters.

Over the course of his tenure at UW, Professor Ellsworth has received numerous awards including: 1994 Fellow of the American Society of Health-System Pharmacists; 1994 UW Department of Family Medicine Teacher of the Year Award;  1995 Bristol-Myers Squibb Family Medicine Research Award; 1997 Fellow of The American College of Clinical Pharmacy; 2000 Clinical Practice Award from the American College of Clinical Pharmacy; the 2007 Golden Apple Award from the UW School of Medicine MEDEX Northwest Physician Assistant Program; 2009 MEDEX Northwest 40th Anniversary Program Award from the UW School of Medicine MEDEX Northwest Physician Assistant Program.

Throughout his noteworthy career, Professor Ellsworth served the University, School, Department and Community with distinction, and played an integral role in the education of the next generation of healthcare providers including his leadership of the PharmD-PA concurrent Program. Most recently, Al served as Co-Course master of Pharm 558, and Lecturer in Pharm 301, 560, 561 and 562, providing valuable instruction with focus in Therapeutics, Contraception, Diabetes, Rheumatology and Men’s Health. Additionally, Al served as Preceptor for PharmP 573 Advanced Practicum. In his role as a clinical mentor, Professor Ellsworth has mentored 11 Pharmacy Practice Residents in Family Medicine and served as an advisor to six Family Medicine Residents. He has also been actively engaged in mentoring the research projects of six PharmD and five Medical Students and served as a supervisor to 22 Physician Assistant Capstone Projects.  Through this work, Professor Ellsworth’s legacy as an educator and mentor will be felt for decades to come.

In service to the Pharmacy Community, Al is currently a member of the Washington State Pharmacists Association and Washington State Medical Association, and his previous appointments include Chair (1995) and Vice Chair (1994) of the Primary Care Pharmacy Practice Special Practice Group of the American Society of Health-System Pharmacists, and President (1975) and Vice-President (1974) of the Student Chapter of the American Pharmaceutical Association. Al has also served as a member of the American College of Clinical Pharmacy and American Association of Colleges of Pharmacy over the course of his career.

Please join us in congratulating Professor Ellsworth on the tremendous impact he has made as an educator, scholar and valued colleague throughout his career.

A Message from UW Health Sciences Deans

Dear UW Health Sciences Community,

Our country is once again experiencing the tragic realities of the racism present in our society.

The slaying of Ahmaud Arbery while jogging in Brunswick, GA; the shooting death of Breonna Taylor by police in Louisville; the false and racist accusation of violence against Christian Cooper in New York City; and most recently, the tragic killing of George Floyd as he was restrained by a police officer in Minneapolis.

These are only the most recent manifestations of the racist ideologies we all need to confront and eliminate.

All this is happening in the context of the coronavirus pandemic that is disproportionately impacting the health and economic well-being of Black families and communities in our state and country.

These events are terrifying and exhausting for our Black colleagues, who are more likely to have experienced the loss of someone in their family and community, and to feel the very real heightened threat of racism.

This isn’t something that only happens in other parts of our country.  Our Black colleagues and students here at UW experience racist behaviors in their daily lives here in Seattle that are heartbreaking and wearing.

In times like these, we want to affirm all of the feelings you are experiencing. They are real and valid. It is important that all of us, and in particular our White leaders and members of our community, express and show support for our Black colleagues by standing against these continued injustices.

Each of us needs to consider how best to do this within the context of our own roles and circumstances, but we all need to engage in action to create the healthy, equitable and inclusive community we desire.  And we must urgently address law enforcement violence and inequities in our criminal justice system as public health issues.

We hope you will join us for a virtual community meeting on Wednesday June 3rd to further discuss what it means to be part of an institution that lifts up anti-racism as a core value and how the UW Health Sciences community can come together to best support Black students, staff, and faculty through these difficult times.

Please look for an announcement in a special email to be sent early next week.

In solidarity,

Paul G Ramsey Signature
Paul G. Ramsey, M.D.
CEO, UW Medicine
Executive Vice President for Medical Affairs and
Dean of the School of Medicine,
University of Washington
Hilary Godwin Signature
Hilary Godwin, PhD
Professor and Dean
University of Washington School of Public Health
Edwina Uehara Signature
Edwina S. Uehara, PhD, MSW
Professor and Ballmer Endowed Dean in Social Work
University of Washington School of Social Work
Azita Emami Signature
Azita Emami, PhD, MSN, BSN, RN, FAAN
Robert G. and Jean A. Reid Executive Dean
UW School of Nursing
Gary T. Chiodo Signature
Gary T. Chiodo, DMD, FAACD
Professor and Dean
University of Washington School of Dentistry
Sean D Sullivan Signature
Sean D. Sullivan, BScPharm, PhD
Professor and Dean
University of WashingtonSchool of Pharmacy

UWSOP rises to #7 in U.S. News and World Report rankings

The U.S. News and World Report today released the 2021 edition of its Best Graduate Schools rankings, and UWSOP has been named the No.7 pharmacy program in the nation.

The report, which is released every four years, ranked the school No. 9 in 2017.

“To see our program evolve the way it has over the last four years, and to continually garner the respect and admiration of our peers is inspiring,” said Sean D. Sullivan, professor and dean of the School of Pharmacy.

Sullivan noted that though he’s proud the program has consistently ranked in the report’s top 10 over the last decade, this year’s designation is particularly meaningful. The global threat of the COVID-19 pandemic has been a call to arms for the School – from faculty and researchers to students and alumni – and they have taken up the challenge head-on.

“I am extremely proud of our entire school community,” said Sullivan. “With the COVID-19 pandemic sweeping our communities and introducing new challenges to our health care systems, our stellar team of faculty, students and alumni are pooling their talents and expertise to care for our patients and inform the public.

“Whether it’s utilizing the potential of the virtual classroom, or exploring innovative solutions in the research lab – or in the field – our team is leading and inspiring one another in the face of this new challenge with compassion and conviction.”

UW’s new WE-REACH center to accelerate development of the ‘most exciting’ biomedical discoveries

With well over a billion dollars in research funding annually, the University of Washington is an engine of discovery and generates more than $15 billion in the state’s economy. Now, with a $4 million grant from the National Institutes of Health, UW has created a new integrated center to match biomedical discoveries with the resources needed to bring innovative products to the public and improve health.

“The University of Washington and regional partner institutions produce some of the most exciting biomedical discoveries and technologies in the world, but we always find it challenging to support their product development as they move into the early commercialization phases,” said the new center’s executive director Rodney Ho, a professor in the UW School of Pharmacy.

UW’s newly funded Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH), with an annual budget boosted to $1.4 million by contributions from other partners, is organized to mentor and support biomedical entrepreneurs as well as provide project funding to fuel four to six biomedical startups a year with up to $200,000 each. Those projects will include innovative disease treatments, new drugs, diagnostics, genetic testing and health technologies. Ho said the center will support innovation steps not typically supported by research grants, such as human clinical trials or the development of and access to products.

In addition to the NIH, WE-REACH partners include the Institute of Translational Health Sciences, UW CoMotion, the Institute for Protein Design, the School of Pharmacy, and in collaboration with the UW’s Population Health Initiative Innovators will also receive guidance from multiple academic departments and regional institutions. Those institutions include the Fred Hutchinson Cancer Research Institute, Seattle Children’s and other universities in the five states that make up the WWAMI region.

“We are delighted to welcome WE-REACH as a partner,” said Tong Sun, executive director of the Institute of Translational Health Sciences. “At ITHS we are committed to accelerating the translation of discoveries to the clinic. WE-REACH investigators will be able to leverage ITHS programs and resources, so they can help us in our mission to improve health in our communities. This is a very exciting area of translation that we are happy to support.”

WE-REACH is one of five national commercialization hubs selected for funding by the NIH in 2019.

“The journey of biomedical discoveries to products that improve people’s health is expensive and risky. The process requires strategic investment of know-how as well as financial support from public-private partnerships,” said Ho.

“Spinning life science innovations out of research institutions requires expertise and funding that is hard to source in the academic environment,” adds Fiona Wills, assistant vice president, innovation development at CoMotion, UW’s collaborative innovation hub. “WE REACH builds on the infrastructure CoMotion has developed, including our gap fund and training, to provide  critical resources needed to de-risk promising technologies into pre-clinical and clinical development.”

The new center will be located in the South Campus Center on the University of Washington’s Seattle campus and at the Institute of Translational Health Sciences in UW Medicine South Lake Union. It will be staffed by Professor Rodney Ho, Executive Director; Terri Butler, Associate Director of Outreach and Partnerships; Matthew Hartman, Coordinator; Christine Jonsson, Administrator; and new hires in project management and technology management roles.

For information on the new center and how to submit a grant submission, please contact Matthew Hartman at WEREACH@uw.edu or 561-339-0676.

Announcement event: On Jan. 31, WE-REACH Executive Director Rodney Ho will formally launch the new center at the ITHS quarterly All-hands meeting at UW Medicine’s South Lake Union campus, 850 Republican Street Seattle, in the Orin Smith Auditorium. The meeting starts at 8 a.m.

NIH Grant: 1 U01 HL152401-01

We-Reach

Faculty Legend Wendel Nelson Retires

After over 50 years of distinguished service at UWSOP and wide-ranging contributions to the profession of pharmacy, Professor Wendel Nelson retires this month.

Wendel Nelson
Wendel Nelson

Wendel joined the School as an Assistant Professor in 1965 in the Department of Pharmaceutical Chemistry, prior to its split into the current Departments of Medicinal Chemistry and Pharmaceutics in 1976. After promotion to Associate Professor, and then to Professor, Wendel served as Chair of the Department of Medicinal Chemistry from 1985-1999. As Chair, he provided vision for the design and construction of then ‘new’ H-wing space and our move from Bagley Hall in 1994. From 1978 until 2000, Wendel served as Director of the interdepartmental Training Program in Pharmacological Sciences, which has received over 40 consecutive years of continuing support from NIH. This grant provided support for many of our students, now alumni, of our PhD programs over the years.

Wendel’s contributions to PharmD training were also significant. Several generations of first and second year PharmD students learned the importance of medicinal chemistry in Pharmacy practice.  Wendel held PharmD students to a high standard that demanded a real knowledge of chemistry and pharmacology.

Wendel’s scholarly activities and research were highly impactful. His research provided fundamental insights into the regioselectivity of the metabolism of several important -blockers. Wendel’s lab also championed the use of synthetic active site-directed electrophilic probes to characterize opioid receptors, which provided deeper insight into their structure and function. More recently, Wendel participated in the determination of the stereochemical course of the metabolism of retinoic acid. In total, Wendel’s research included fundamental discoveries about the metabolism of therapeutic drugs, mechanisms of pharmacologic receptors, and the basic biochemistry of endogenous regulators of cell growth through the application of the principles of organic and synthetic chemistry.

Wendel’s scientific influence is evident in other ways, and he served on numerous review panels and editorial boards. Most notably, Wendel was the Senior Editor of the prestigious Journal of Medicinal Chemistry from 1989-2007, and he served as Chairman of the Division of Medicinal Chemistry of the American Chemical Society in 1966.  As a result, Wendel is nationally and internationally recognized for his research and editorial contributions in the field of Medicinal Chemistry.

The Department and the School are fortunate to have been the professional home of Professor Nelson. Please join us in congratulating Wendel on a remarkable career and in wishing him a very happy retirement.

Click for more information about our Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

Pharmaceutics student, Kendan Jones-Isaac honored at the UW Health Sciences Martin Luther King Tribute

Kendan Jones-Isaac Community Service AwardThe award honors individuals or groups who exemplify Martin Luther King’s principles: a commitment to the needs of communities, particularly communities of color and low income; to programs that improve the human condition; and efforts to protect and empower all individuals.

Kendan Jones-Isaac was honored with a service award at this year’s UW Health Sciences Martin Luther King Tribute.

Kendan joined the UW Department of Pharmaceutics with the focused goal to earn his PhD and become an expert in pharmaceutics and drug discovery. During the last 2 years, he has participated in several ambitious projects, including the development of a bioengineered kidney tissue chip that will improve the safety and efficacy of drugs in development, and sending the tissue chip to the International Space Station to explore the effects of microgravity and space travel on kidney function.

In 2021, Kendan will lead the team that will send a new model of the kidney distal tubule to the Space Station to test the effects of microgravity on kidney stone formation. He was recognized for his scientific expertise with an NIH-funded Diversity Supplement (parent grant: UH3TR002178). Despite his highly ambitious and time consuming scientific goals, Kendan has utilized his position as a leader and graduate student to reach out to undergraduate students from under-represented and/or low-resource groups to encourage them to enter the STEM fields.

To date, Kendan has mentored six (6) undergraduate students- all of whom will continue on to graduate or professional programs following their undergraduate graduation. His mentee, Matthew Phoenix Chen, was recently accepted into the University of Washington PharmD program (early decision). Other mentees are currently applying to medical school or PhD programs across the nation. When Kendan mentors a student, he becomes invested in their academic lives and professional futures and is generous with his time. His involvement is not limited to instruction of lab instrumentation and protocols; he also advises them on coursework, extra-curricular activities, and professional advancement opportunities.

Kendan has been instrumental in outreach activities at the UW School of Pharmacy. In addition to participating in existing outreach activities (Society for Advancement of Chicanos/Hispanics and Native Americans in Science, and Annual Biomedical Research Conference for Minority Students national meetings), he has initiated outreach to other institutions (Bellevue College, Chehalis STEM Academy, visiting high school students with UW Medicine Strategic Marketing & Communications, MLK day talk at Benson Hill Elementary). His outreach efforts are aimed towards young people in low-income communities or communities of color, with the goal to lift entire communities by encouraging academic achievement.

Kendan’s ability to build a community among young people is remarkable. De has the vision to recognize that it takes more than “cheerleading” to turn a young student into a scientist. He is a teacher, mentor, and friend and brings out the best in his mentees.

Congratulations to Kendan for this recognition of the profound impact he is having in the lives of his mentees, classmates and fellow scientists.

Learn More

Marcum first pharmacist to receive prestigious Beeson Award

Zach Marcum, Bailey Faculty Fellow and Assistant Director of Research for the Plein Center for Geriatric Pharmacy
Zach Marcum, Bailey Faculty Fellow and Assistant Director of Research for the Plein Center for Geriatric Pharmacy

Zachary Marcum, PhD, PharmD was recently awarded the Paul B. Beeson Emerging Leaders Career Development Award (K76) from the National Institute on Aging (NIA) and The John A. Hartford Foundation.

Notably, Zach is the first pharmacist to receive the grant, which is typically awarded to physician-investigators. This initiative is focused on clinically trained, early-stage investigators who take an active leadership role in creating transformative changes that will lead to improved health care outcomes in the field of aging and geriatrics research.

Granting the Beeson Award to a pharmacist acknowledges the important role pharmacists play on the health care team, particularly for older adults. Four out of every five people over age 65 take more than one prescription medication, making it vital to have pharmacists’ medication expertise included in their care teams.

Zach’s research looks at whether certain blood pressure medicines are protective against dementia. Mounting evidence suggests that certain antihypertensives may reduce one’s risk of dementia if taken during mid-life. This research is important as there are currently no disease-modifying treatments for dementia. Finding preventative therapies like these already-approved medications may help stave off dementia for certain patients and could offer a new preventative option for people at risk for dementia.

“In addition to the support for my research, this grant also provides many opportunities for training, particularly in methods that will be important for observational studies,” Zach shared. “How do we know if a relationship, such as lower rates of dementia in patients on a particular drug, is associated or causal? For that training, I will complete both didactic courses and mentored experiences led by experts in the field to learn more.”

Understanding the relationship between blood pressure medicines and dementia is vital for finding drugs that could be effective in delaying or reducing the effects of dementia.

We want to employ the most robust methods to ensure that our results and meaningful and impactful in people’s lives.

“We want to employ the most robust methods to ensure that our results and meaningful and impactful in people’s lives.”—Zach Marcum, Bailey Faculty Fellow and Assistant Director of Research for the Plein Center for Geriatric Pharmacy

Zach will use data from the Adult Changes in Thought (ACT) study, led by Kaiser Permanente Washington Health Research Institute, which focuses on studying how cognition changes with aging and thus offers opportunities to study dementia prevention. In addition, he will work with researchers in UW’s Neuropathology department.

This 3-year, approximately $700,000 grant, will investigate the association between long-term antihypertensive use and brain health, including Alzheimer’s disease and other dementias.

Using Data and Economics to Transform Health | Celebrating 25 Years

CHOICE faculty and students at the 2019 retreat
CHOICE faculty and students at the 2019 retreat

Celebrating 25 years, The CHOICE Institute continues to grow and transform, expanding its impact on population health.

“At CHOICE, we work to advance the study of health economics, pharmaceutical outcomes research, and policy to improve population health in the U.S. and around the world.”—Anirban Basu, Stergachis Endowed Director, Choice Institute

The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute at UWSOP began largely out of a response to a student and workforce needs. In 1989, Andy Stergachis, now Associate Dean at UWSOP, was advising David H. Smith, ’90, ’98, who wanted to earn a PhD studying the impact of healthcare policies on population health.

At that time UW did not offer a Pharmacy PhD, so David created his own interdisciplinary program of study. Andy and Dean Milo Gibaldi, decided to create a doctoral program in Pharmacy. In 1990, Andy was awarded the Burroughs Wellcome/American College of Preventive Medicine Scholar in Pharmacoepidemiology Award, which provided much-needed seed funding for the program, including support for visiting faculty, such as epidemiologist Jackie Gardner, PhD, and a newly-minted PhD from UC Berkeley named Sean D. Sullivan.

When Sean and Andy first met, Sean was looking forward to his new position at Wolfson College at Oxford University. But fate (and Andy) had a different plan. Andy presented Sean with the vision of a world-class program in pharmaceutical outcomes research. Sean was intrigued. When Andy showed up—in person—at Berkeley a few weeks later, Sean said yes to Andy and then, “I had to write the most difficult letter of my professional career. After all, who says ‘no’ to Oxford? But it changed my life.”

Sean and Jackie joined the faculty team with Dale Christensen and Bill Fassett, ’69. The development of the new Pharmacy PhD program began in earnest. About 25 years ago, the team had attracted top scholars and built enough support to be officially designated the Pharmaceutical Outcomes Research and Policy Program (PORPP) at the UW.

In 2014, Sean became Dean of UWSOP, which meant finding a new Director, now named the Stergachis Family Endowed Director, thanks to a generous gift from Andy and JoAnn Stergachis. Anirban Basu, Ph.D, was selected and in 2017, he announced the launch of The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, an expansion of PORPP that organizes research and training activities and resources in the fields of health economics, policy analysis/big data sciences, economics of precision medicine, drug and vaccine safety, and global medicines issues.

CHOICE continues to thrive with world-class researchers and leaders in health economics like Professor Emeritus Lou Garrison, Professor Dave Veenstra, Professor Beth Devine, Associate Professor Josh Carlson, Associate Professor Aasthaa Bansal, who earned a prestigious 7-year NIH MERIT Award, 2011 PAA Distinguished Alumni Award recipient Ryan Hansen, ’03, ’12, Research Assistant Professor Doug Barthold, Shelly Gray and Zach Marcum from the UW Plein Center, and many more affiliates and leaders in outcomes and health economics research.

CHOICE Alumni have become leaders in academia, industry, and government, such as Jonathan Watanabe, ’98, ’08, ’12, faculty member at UC San Diego and the first pharmacist named to the National Academy of Medicine Emerging Leaders in Health and Medicine Scholars Program, and Mitch Higashi, ’01, who established the Health Tech Fund, and now is an industry leader.

 

To study with UWSOP’s top faculty in health economics and outcomes, medicinal chemistry, and pharmaceutics, click here for more information about our Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

Want to earn your PharmD professional degree at the UW? Start here to learn more.

Enhancing the way epilepsy is managed by engaging community pharmacists

Community pharmacists can play a key role in managing care for people living with epilepsy.Mike Mozart/Flickr
Community pharmacists can play a key role in managing care for people living with epilepsy.Mike Mozart/Flickr

The University of Washington’s School of Pharmacy today announced a collaboration with global biopharmaceutical company UCB to improve access to care for people living with epilepsy.This interdisciplinary project will explore ways in which community pharmacists can better support people living with this neurological disorder.

The roughly 3.4 million people nationally and 75,000 people in Washington state who live with epilepsy often get fragmented and uncoordinated healthcare and community services.

Steve White
Co-investigator H. Steve White, Professor & Chair, UWSOP Dept of Pharmacy

“For the growing population of people living with epilepsy, this fragmentation of resources makes it harder to manage multiple co-existing health conditions and take anti-seizure drugs,” said Steve White, professor and chair of the UW department of pharmacy, and a global expert on epilepsy. “And given the importance of medication adherence to manage epilepsy, poor adherence can have profound effects including injury, hospitalization, even unexpected death.”

The project isled by White; Jennifer Bacci, Assistant Professor, Department of Pharmacy; Andy Stergachis, Associate Dean for Research, UW School of Pharmacy; and Sabra Zarâa, CHOICE Institute PhD student and builds upon the funding grant from the UW Population Health Initiative announced earlier this year.

Epilepsy is a complex and devastating disease in which patients experience spontaneous and recurrent seizures. This condition can impair daily routines, such as driving and working, which can often result in substantial socioeconomic disparities. Medications to treat the condition can be associated with serious side effects, and the seizures themselves can lead to on-going health challenges.

Co-Principle Investigator and Assistant Professor Jennifer Bacci
Co-Principle Investigator and Assistant Professor Jennifer Bacci

“Community pharmacists are among the most accessible healthcare providers for many in Washington state, and have extensive knowledge of drug therapy as well as the ability to support people in managing complex medication regimens, yet are seldom leveraged to close the gaps in epilepsy care,” said Jennifer Bacci, assistant professor at UW School of Pharmacy. Moreover, “community pharmacists educate patients about their disease, ensure dosing accuracy, monitor for side effects and drug interactions, and encourage medication adherence.”

At a population level, community pharmacists collaborate with other healthcare providers and assess medication use patterns and patient outcomes data to ensure medications are used effectively, safely and in a cost-effective manner. No models exist for engaging community pharmacists in population health approaches to epilepsy care.

“The UW Population Health Initiative seeks to accelerate new collaborations between diverse disciplines to find innovative solutions to the complex challenges society faces,” said Ali Mokdad, the UW’s chief strategy officer for Population Health and professor of Health Metrics Sciences. “We are excited to support the UW and UCB in bringing together the expertise and resources of the public and private sectors to develop a novel approach to increasing access to care for people living with epilepsy.”

The team will develop an intervention by conducting a needs assessment, including interviewing stakeholders and performing a literature review. They will (1) identify best practices to address the needs of persons living with epilepsy and their caregivers; (2) develop a community pharmacy intervention using a stakeholder driven and consensus building approach; and (3) evaluate the acceptability, appropriateness, feasibility and potential effectiveness of the intervention.

“Community pharmacists are increasingly at the front line of healthcare delivery in the US.” Said Mike Davis, Head of U.S. Neurology at UCB. “With these tools to facilitate better conversations with their community living with epilepsy they can play an important role in ensuring that more people living with epilepsy get to the right treatment at the right time. The University of Washington is doing great work in this area and UCB is proud to collaborate with them on this initiative.”

Project Team
Jennifer Bacci, UW Assistant Professor, Department of Pharmacy
H. Steve White, UW Professor and Chair, Department of Pharmacy
Andy Stergachis, UW Professor and Associate Dean for Research, Graduate Programs and New Initiatives
Sabra Zarâa, The CHOICE Institute at UW School of Pharmacy, PhD student
John Miller, UW Medicine, Neurology
Edward Novotny, UW Medicine, Neurology and Seattle Children’s Hospital
Bryan Weiner, UW, Departments of Global Health and Health Services

Matt Schumacher, UCB, Head Neurology Healthcare Strategy

Lawford Ricafort, UCB, Neurology Ecosystem Lead – Pacific West

Grant Simic, UCB, Population Health Partner

 

For more information, contact Jake Ellison at University of Washington News at jbe3@uw.eduor 206-543-2580, or Allyson Funk at UCB at uscommunications@ucb.com.

 

###

About UW School of Pharmacy:
Ranked in the top 4 in the world for pharmacy and pharmaceutical sciences research, the UW School of Pharmacy is comprised of three departments: Medicinal Chemistry, Pharmaceutics, and Pharmacy, offering Ph.D., M.S., and PharmD degrees, post docs and certificate programs. The UW School of Pharmacy is a global leader in pharmacy education, research and service, committed to providing a transformative learning experience in a collaborative and diverse environment focused on improving the health and well-being of the communities we serve.

About UCB
At UCB, we come together every day to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Patient value is not just what we say, but how we how we live. It is our culture of care, embodied by our patient value strategy. That’s because how we do business – from discovery to development to delivery – has been transformed and redesigned around the patient and their individual experience. Patients are at the heart of everything we do, inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. By fulfilling our commitment, driving innovation, and providing patients a meaningful experience, more impactful solutions are on the horizon.

With a team of approximately 7,500 employees and operations in approximately 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research to meet unmet patient needs. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia. Additional U.S. UCB sites include global clinical development in Raleigh, North Carolina, research supporting UCB’s pipeline in Boston, Massachusetts and Seattle, Washington, and offices in Washington, D.C., Durham, North Carolina as part of our acquisition of Element Genomics.

Nina Isoherranen named Chair of Pharmaceutics Department

On July 1, 2019, UW School of Pharmacy Professor and Dean Sean D. Sullivan appointed Professor Nina Isoherranen to the Milo Gibaldi Endowed Chair of Pharmaceutics. Her appointment makes her the first woman to chair the department.

“From her first days here as a post-doctoral fellow, Dr. Isoherranen demonstrated the standard of excellence and innovative research that are the hallmarks of our faculty. I am looking forward to working with her as we continue to grow the outstanding international reputation of the UW Department of Pharmaceutics.”—Sean D. Sullivan, Professor and Dean, UW School of Pharmacy

Dr. Isoherranen assumes the role of chair from Professor Kenneth Thummel, who led the growth of the department to over 100 personnel and annual research funding of $13.6M. This growth is one of the key reasons why the UWSOP is ranked #3 nationally among Schools of Pharmacy in NIH grant awards. Ken will return to the faculty to continue his research program and teach in the graduate and professional degree programs.

Dr. Isoherranen earned her bachelor’s degree in chemistry and her master’s degree in Analytical Chemistry in 1998 from the University of Helsinki, Finland. She obtained a PhD in Pharmaceutical Sciences from the Hebrew University of Jerusalem in 2003.

She began her career in the UW Pharmaceutics department in 2003 as a post-doctoral fellow with Dr. Thummel then became Acting Assistant Professor in November 2004 and Assistant Professor in 2006. In 2012 Dr. Isoherranen was promoted to Associate Professor and in 2017, she was named Professor of Pharmaceutics.

The Department of Pharmaceutics has long been recognized for its expertise in drug metabolism and transport kinetics. Its faculty are innovators in targeted drug delivery, physiologically-based pharmacokinetic modeling and microphysiologic human organ systems.

Dr. Isoherranen and her team are actively involved in collaborations with scientists at the University of Washington and with investigators in other US institutions. Her lab’s research projects are highly translational and extend out basic research findings to clinical importance.

The three main research areas in the lab entail characterization of vitamin A metabolism and the processes that regulate cell and tissue concentrations of retinoic acid the active metabolite of vitamin A, evaluation of drug disposition during pregnancy and fetal exposure and effects of xenobiotics, and methods of in vitro to in vivoprediction, simulation and rationalization of drug-drug and drug-disease interactions.

Dr. Isoherranen has mentored many accomplished alumni and students, including these recent projects we reported on:

  • John Amory MD, MS, and graduate student Faith Stevison find breakthrough treatment for male infertility Story
  • Sara Shum and collaborators unveil new maternal and fetal health risks associated with shellfish toxin Story

In 2013, Dr. Isoherranen was presented the Richard Okita Early Career Award in Drug Metabolism and Disposition from the American Society for Pharmacology and Experimental Therapeutics and in 2014, she was awarded the International Society for the Study of Xenobiotics (ISSX) Young Investigator Award.

The Department of Pharmaceutics has long been recognized for its expertise in drug metabolism and transport kinetics. Its faculty are innovators in targeted drug delivery, physiologically-based pharmacokinetic modeling and microphysiologic human organ systems. To ensure the continued outstanding research and training in the Department of Pharmaceutics, we invite you to support the Pharmaceutics Fund for Excellence.

 

To study with researchers like Pharmaceutics’ Professors Nina Isoherranen and Kenneth Thummel, click on the links for more information about our Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

Link to Pharmaceutics archived news

Ken Thummel returns to faculty after 13 years of success as Chair

After thirteen years leading the Department of Pharmaceutics to international success, Professor Kenneth Thummel will return to faculty full time and Professor Nina Isoherranen will become the Milo Gibaldi Endowed Chair of Pharmaceutics.

Dr. Thummel was appointed Chair of the Pharmaceutics Department in 2006. He assumed that role from the Department’s founding Chair, Dr. Rene’ Levy and was the first Milo Gibaldi Endowed Chair of Pharmaceutics.

In his leadership role as chair, Dr. Thummel made substantial scientific and administrative contributions to the department and the field of Pharmaceutics.

“I am grateful to Ken for his leadership and collaboration over the years. His impact on the School, our students, and alumni is profound. His mentorship and life-changing research have had a profound impact on the School, the Northwest, and around the world—and even outer space.”—Sean D. Sullivan, Professor and Dean, UW School of Pharmacy

At the time of his appointment, the Department consisted of 7 full time faculty, 5 temporary or part-time faculty, 16 post-doctoral fellows, 20 graduate students and a limited number of research and instructional support staff.  Its annual extramural funding totaled approximately $2.7 million.

As he steps down as Chair, the Department’s annual research funding stands at $13.6 million (2018), with over 100 departmental personnel working collectively to meet instructional, research and service missions. These successes are a key reason why the UWSOP is ranked #3 nationally among Schools of Pharmacy in NIH grant awards

The Department of Pharmaceutics also is recognized as a leader in drug-drug interaction science and the faculty are innovators in targeted drug delivery, physiologically-based pharmacokinetic modeling and microphysiologic human organ systems. Under the leadership of Dr. Isabelle Ragueneau, the Drug Interaction Solutions (formerly Drug Interactions Database) database team produces a commercialized software product licensed by the University to pharmaceutical companies and other academic and clinical programs worldwide. The database produces annual revenue in excess of $1.0 million and supports graduate student training in the pharmaceutical sciences arena.

 

To ensure the continued outstanding research and training in the Department of Pharmaceutics, we invite you to support the Pharmaceutics Fund for Excellence.

 

To study with researchers like Pharmaceutics’ Professors Nina Isoherranen and Kenneth Thummel, click on the links for more information about our Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

Link to Pharmaceutics archived news

Dean Sullivan named OSU Icon of Pharmacy

On the evening of May 4th, 2019, Oregon State University College of Pharmacy alumni and friends gathered at Portland City Grill to honor the recipients of the 2019 Icons of Pharmacy Award including Sean D. Sullivan, a truly dedicated leader in the pharmacy profession.

Sean was recognized for his leadership at the UW School of Pharmacy where his engagement has helped transform the profession. When asked about his experience leading a college of pharmacy and being Dean, he responded, “This is a job none of us are trained for. Most days, it’s challenging. Some days, it’s extremely difficult. And on a few occasions, it is glorious.”

After completing his pharmacy degree at OSU College of Pharmacy in 1983, Sean practiced pharmacy in his hometown of Hollister, CA, where he obtained a deeper understanding of his profession. He then obtained a master’s degree in administrative and economic sciences at the University of Texas and a PhD in health economics and policy at the University of California, Berkeley.

Coming to University of Washington in 1992 as a Research Associate, Sean co-founded the UW School of Pharmacy’s Pharmaceutical Outcomes Research and Policy Program (PORPP), now known as The CHOICE Institute. Under Sean’s leadership, the program grew to become the premier outcomes research and policy program, with its faculty and students regularly receiving national and international recognition for excellence.

He has since become Dean and Chief Academic Officer at University of Washington School of Pharmacy. He is also joint Professor in the Schools of Pharmacy and Public Health, University of Washington, while also holding adjunct appointments in the School of Medicine, the Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, and at the Kaiser Permanente Washington Health Research Institute. Sean served as President of ISPOR, the leading global professional society for health economics and outcomes research and has been nationally recognized for his research and leadership with the 2014 Stephen G. Avey Lifetime Achievement Award from the Academy of Managed Care Pharmacy and the 2015 American Pharmacists Association (APhA) Academy of Pharmaceutical Research Sciences (APRS) Research Achievement Award.

A stalwart believer in the pursuit of higher learning, he acknowledges that there were many individuals that inspired him and shaped his path. Specifically, former OSU College of Pharmacy Dean, Richard Ohvall had a huge impact on Sean’s work ethic in the way he balanced his professional role with an approachable, open door policy. To this day, it is a model and practice that he adheres to for his own students. It was Dr. Lee Strandberg who impressed upon Sean that he should think of pharmacy, not just as a clinical profession, but about its broader impacts. It was these two standout individuals, among many others, that had a lasting impact on Sean’s career.

It was in understanding his own professional trajectory that he could focus on what he is proudest of, the success of the students that he has had the opportunity to train. That group includes his first grad student, Joe Ness, who is now Senior Vice President and Chief Operating Officer of OHSU Healthcare, as well as PharmD students, many of whom are in very successful positions up and down the west coast. Over his career, Sean has also mentored over 100 PhD graduates and post doc fellows, now in academic and leadership roles around the world. Sean truly believes that public universities such as Oregon State University and University of Washington are engines of social and economic mobility with the main purpose of lifting people up. He attests that the impact of these universities on him in particular was transformational, “I would not trade it for anything.”

Sean lives in Seattle with his wife, Catrena (Howlett) Sullivan, also an OSU College of Pharmacy graduate (Class of 1990), whom he holds great admiration and appreciation for in her support and partnership in raising their two children, Kiera and Aidan, before returning to work as a practicing pharmacist.

Recognition as an OSU College of Pharmacy Icon of Pharmacy is an honor reserved for those who have demonstrated dedication to the College of Pharmacy and distinguished themselves through sustained, meritorious contributions to pharmacy throughout their careers. Sean’s  influences on the profession are meritorious and inspirational.

Congratulations, Dean Sullivan!

Advance your career in pharmacy practice, scientific and outcomes research at the University of Washington School of Pharmacy. Learn more about our Graduate (PhD and MS) degree programs and click here for more information about the UW PharmDprogram.

Link to Department of Pharmacy archived news

Kidney on a Chip has gone to outer space..and returned to Earth!

Ed Kelly spoke at NASA a few days before the launch happened, explaining why the team is sending Kidney on a Chip to the International Space Station.
Ed Kelly spoke at NASA a few days before the launch happened, explaining why the team is sending Kidney on a Chip to the International Space Station.

What did it take to send delicate kidney cells into space to be studied by astronauts wearing big, clunky gloves who may, or may not, have a background in biochemistry? We popped into the lab to talk to Ed Kelly and Cathy Yeung to find out.

Dawg Scripts: Why did you put kidney cells on a chip?

Associate Professor Ed Kelly: As a Toxicologist, we talk about the “Three Rs” when it comes to our research: reduce, refine, and replace. That means we are looking for ways to reduce animal testing, refine processes, and—where we can—replace animal testing. With Kidney on a Chip, we have a better model than testing kidney cells on plates under the microscope, in petri dishes, or with animals. The tubules—about the size of a human hair—housing the cells in the chip mirror the tubules in the kidney in the body and, like the kidney in the body, we can move fluid through the tubules and have more information than we would otherwise. For example, we did some testing using a powerful antibiotic. We knew the antibiotic was toxic but we didn’t know why. By using Kidney on a Chip, we were able to identify the biomarkers of toxicity, showing that the antibiotic was indeed toxic to renal tubular cells.

“We are planning for failure, even though that’s not an option.”—Ed Kelly, Associate Professor of Pharmaceutics

DS: So then why send chips to space?

Research Assistant Professor Cathy Yeung, ’05: Kidney disease can take years to develop. Microgravity accelerates kidney disease or dysfunction, and other conditions in astronauts, so the goal is to see the impact low gravity will have on the cells in the microphysiological chips. We anticipate learning more about how kidney stones, osteoporosis, and proteinuria (an abnormally high amount of protein in urine which indicates kidney damage) begins and develops. There aren’t many effective treatments for kidney stones currently. Last year, the main “recommendation” for treatment was to ride a roller coaster in hopes of dislodging the stone (we don’t recommend this course of treatment). Instead, we hope to gain some insights into how they develop that may lead to improved therapies. 

DS: What can you tell us about the cell samples you are using? 

CY: The kidney cells used come from two men and two women so we will be able to see gender differences, which is important for diseases like osteoporosis which has a higher incidence among women. All of this research is important for people on Earth, as well as the future of missions to Mars when people will be in microgravity for years. We have questions about how kidneys process Vitamin D and hope to gain insight about osteoporosis and how to prevent it from this research.  

Cathy Yeung and Ed Kelly were asked when the launch would happen after the third launch delay. They responded in a precise scientific way.
Cathy Yeung and Ed Kelly were asked when the launch would happen after the third launch delay. They responded in a precise and scientific way.

DS: What are some of the challenges of sending the chips to space?

EK: We’ve had a lot of logistical challenges. First of all, we have to make the level of science very easy for
astronauts who will be working with large gloves. Some of the astronauts have advanced degrees in science, but we had to make sure that whoever is running the experiment that day could do the work needed. Another challenge was taking the 50 cubic feet of space we use to run the experiments in our lab down to a box about the size of a microwave to fit in the rocket and space station, which is why we partnered with BioServe Space Technologies at University of Colorado Boulder.

DS: Will there be a lab in space? 

Very early Friday morning May 3, 2019, the team gathered to watch the launch...which was scrubbed 15 minutes before go time. It was rescheduled for very early in the morning Saturday, May the 4th.
Very early Friday morning May 3, 2019, the team gathered to watch the launch…which was scrubbed 15 minutes before go time. It was rescheduled for very early in the morning Saturday, May the 4th.

CY: There will be experiments running at precisely the same time on the ground as in the Space Station while the Chips are in space. Our team of faculty and graduate students will be on site at Kennedy Space Center in Florida running the experiments on Earth. So we have to create labs that will go to space and also recreate our lab in Florida. The box going to space with the chips has to be specially designed to handle the stressors of coming in and out of atmosphere, the vibrations in breaking the sound barrier, and dropping to Earth on its return. The kidney cells have to be kept at a constant 37 degree C temperature, which requires three different power sources from the time the chips are built on the lab on Earth, transferred to the rocket, and launched into space. We don’t know what will happen and we are doing our best, working with our BioServe partners, to anticipate as many obstacles as possible. 

DS: What’s special about this project?

EK: We are proud that the University of Washington is the only university with two projects launching to the International Space Station as part of this nationwide Organ on a Chip project funded by the NIH and CASIS. Our project will be the first to launch and the Heart on a Chip by Deok-Ho Kim in Bioengineering will be the second. 

Below are scenes from the Launch that happened on May 4, 2019. May the Fourth Be With You, was the rally cry of the day after multiple delays.

To watch the launch video, click here for a link to the SpaceX YouTube page.

See NASA’s photos of the Kidney on a Chip experiment in space!

The team reconvened Saturday, May the 4th, 2019...ever hopeful that this time the launch would be successful.
The team reconvened Saturday, May the 4th, 2019…ever hopeful that this time the launch would be successful.
AND WE HAVE LIFT OFF!!!
AND WE HAVE LIFT OFF!!! Photo: Sarah C.B. Guthrie/NASA TV

Read more about the Kidney on a Chip project

To study with researchers like Pharmaceutics’ Associate Professor Ed Kelly and Pharmacy’s Research Assistant Professor Cathy Yeung, click on the links for more information about our Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

Link to Pharmaceutics archived news

Henderson wins poster award at national AsPET Conference

Lindsay Henderson with her award-winning poster
Lindsay Henderson with her award-winning poster, “Functional Characterization of Novel CYP2C9 Variants Found in an Alaska Native Population”

Congratulations to PharmD and Pharmaceutics PhD student Lindsay Henderson who received the 2nd place graduate student poster presentation award for the Drug Metabolism and Disposition Division of ASPET (American Society for Pharmacology and Experimental Therapeutics).

Lindsay Henderson, here pictured with Med Chem Professor Allan Rettie
Lindsay Henderson, here pictured with Med Chem Professor Allan Rettie

Her poster titled, “Functional Characterization of Novel CYP2C9 Variants Found in an Alaska Native Population,” focuses on genetic polymorphisms in CYP2C9, an important cytochrome P450 responsible for the metabolism of medications across many therapeutic classes including non steroidal anti-inflammatories, angiotensin II blockers, as well as narrow therapeutic index drugs such as (S)-warfarin and phenytoin. 

Comprehensive in vitro experiments were performed to elucidate the function of novel CYP2C9 protein variants found in an Alaska Native population.

The team’s findings suggest that carriers of the CYP2C9 N218I and M1L variant alleles would be at risk of exacerbated therapeutic effects from narrow therapeutic index drugs that rely on CYP2C9 for their metabolic clearance.

Her co-authors include UWSOP researchers, Matthew G McDonald, Catherine K Yeung, ’05, Allan E Rettie, and Kenneth E Thummel, who served as Senior Author.

Congratulations, Lindsay!

5/3 UPDATE: 5/3 11:48 PM PDT launch for Kidney on a Chip project to the International Space Station!

Updated May 3, 11:29 am Pacific: NASA has pushed back the launch to Friday, May 3 at 11:48 PM Pacific time…weather dependent.  

PHOTO DATE: July 06, 2018 LOCATION: Bldg. 2 Lobby SUBJECT: NIH Tissue Chip. PHOTOGRAPHER: Josh Valcarcel
Photo credit: Josh Valcarcel Photo: Josh Valcarcel

May 3 update:

Welp. It seemed like it was going to go and then about 15 minutes before launch, the flight was scrubbed. It’s rescheduled for tonight 11:48 PM Pacific Time. Here is an update on NASA’s blog.

May 2 update:

The International Space Station crew fixed the power problem and is ready to catch the SpaceX rocket. What we don’t know right now is if the weather with abide and allow for lift off at 12:11 am Pacific time. We will be live tweeting tonight with our fingers crossed. Follow here.

–End May 2 update

Want even more detail about the precautions being taken to ensure a successful mission? Get out your electrical engineering hat, and read more/view schematics here: “Electrical issue on Station delays Dragon launch

The launch date may be subject to change, again. We will continue to update this page as we get more news!

A kidneys-on-a-chip experiment is being readied at Cape Canaveral, Florida, to fly aboard a SpaceX Dragon C19/Falcon 9 supply shuttle to the International Space Station.  At an altitude of 250 miles, the chip technology will be used to study reduced gravity and other space flight conditions on kidney physiology.

The unmanned SpaceX mission CRS17, contracted with NASA, was slated for late April and is delayed until May 1. The launch date will not be official until after the Flight Readiness Review

Three other organs-on-chips will be on-board for studies of lung host defenses, the blood-brain barrier, and musculoskeletal diseases. Developed by research groups nationwide, the four projects are part of the Tissue Chips in Space program. This will be the second time that National Institute of Health tissue chips have been flown into space.  The first study was on aging and the immune system.

The National Center for Advancing Translational Sciences at the National Institutes of Health spawned the creation of these small, bioengineered tissue chips, which model the physiology of human organs on a living, 3-D microscale.  They have been developed to speed the search for new drugs and therapies and get these treatments to patients faster. Researchers use the tissue chip systems to study healthy and diseased states, and to test medications and other treatments.

Scientists at UW Medicine and the University of Washington School of Pharmacy, with collaborators in industry and other agencies, designed the kidney-on-a-chip component.

Pharmaceutics PhD student Kendan Jones-Isaac working on the Kidney on a Chip project in Ed Kelly's lab
Pharmaceutics PhD student Kendan Jones-Isaac working on the Kidney on a Chip project in Ed Kelly’s lab Photo: Alex Levine

Several of them are at Cape Canaveral now preparing the devices.

The credit-card size chips contain fluid microchambers lined with human-derived kidney cells. For this space mission, these chips will simulate one type of kidney tubule.

In actual kidneys, similar anatomical structures regulate absorption and release of substances in the blood, among them medications and toxins.  Vitamin D metabolism, important for bone strength, takes place in kidneys.  Kidneys also protect against fluid retention and other biochemical imbalances.

Aboard the International Space Station, where they will be exposed to microgravity for about two weeks, the organs-on-a-chip might reveal why kidney problems occur often and quickly among astronauts.

The chief scientists are Ed Kelly, associate professor of pharmaceutics, UW School of Pharmacy; Jonathan Himmelfarb, kidney disease specialist at UW Medicine and professor of medicine, Division of Nephrology, UW School of Medicine; and Cathy Yeung, research assistant professor of pharmacy.

They noted that this space study could provide insights into the development and overall health implications of kidney diseases on Earth, in less time than is possible with terrestrial research in humans.

The Tissue Chips in Space program findings may help protect astronaut health during longer space explorations.
The Tissue Chips in Space program findings may help protect astronaut health during longer space explorations. Photo: Alice Gray

Kidney disease occurs in about 10 percent of adults. Treatment can diminish quality of life. New tools, like the kidney chips, could help find ways to prevent or treat kidney problems in astronauts, as well as in people who will never venture into space.

“Certain conditions related to poor kidney health appear more rapidly in space and could have life-long consequences,” Himmelfarb said. These include protein in the urine, bone loss, and kidney stones.

“Aging of cells accelerates in space,” he added, indicating that organ-on-a-chip space research could uncover medical knowledge useful beyond a specific disease.

“We’ll be able to see in a matter of days what might take months on Earth,” the researchers said.

While microgravity alone might harm kidneys, the scientists also pointed out that astronauts are confined to a closed environment, are exposed to questionable chemicals, eat an unusual diet, and conserve and recycle water for drinking. Any of these could be rough on already vulnerable kidneys.

Research Assistant Professor Cathy Yeung (center) and the BioServe team work out how to pack an experiment for a space flight.
Research Assistant Professor Cathy Yeung (center) and the BioServe team work out how to pack an experiment for a space flight. Photo: Alex Levine

According to Kelly, the kidney-on-a-chip technology will evaluate how diminished gravity affects the ability of tubules, in both males and females, to conduct the basic work of kidneys.  He explained that kidney cells sense gravitational forces in ways that direct the cells to carry out their activities.

“Kidney tubules are polarized,” explained Yeung, “and have an inside and outside. We are curious to see if the cells still stay polarized without Earth’s gravity, and what effect this might have on kidney cell function and on disease progression.“

The cells’ shape, spatial orientation and response to fluid flow could be disrupted in space. This distortion could alter how the cells that line the tubules transport water, electrolytes, vitamins and toxins, and could make tubules prone to damage from proteins or other biochemicals.

The researchers plan to send 24 Nortis Triplex Chips to the International Space Station in temperature and carbon dioxide pump assemblies.

While intergalactic space missions are still a stargazer's dream, kidney studies in Earth's orbit will likely make better treatment a reality on our planet.
While intergalactic space missions are still a stargazer’s dream, kidney studies in Earth’s orbit will likely make better treatment a reality on our planet. Photo: Alice C. Gray

After berthing, these will be placed in incubators and later put in a Life Sciences Glovebox. At the end of the experiment, they will be preserved and cooled to await transport back to Earth.

“We had to shrink the size of our usual equipment to fit the tight quarters of the space station,” Himmelfarb said.  It was like shoehorning a refrigerator into a microwave oven, while maintaining proper environmental conditions for the experiment.

“We had to make some 270 modifications to fit the setting of the International Space Station,” the researchers explained.  Precautions were taken to keep the chips from shattering and creating a free-floating fragment hazard.

“On Earth, studies can be repeated. On the ISS, we have only one shot to get this experiment right. It will be a tense time for us,” Himmelfarb said.

The set up took into account the realities of working in orbit. The astronauts will perform experiments while wearing cumbersome gloves and space suits. Miniaturization and automation, however, should simplify their tasks – and provide new ideas for making such experiments easier to perform on Earth.

“One of the cool things about being at Cape Canaveral is that we can watch the astronauts do the experiments in real time,” Himmelfarb said.

Meanwhile, in normal gravity on Earth, a UW team will conduct the same protocols on kidney chip cells from the same donors, to obtain comparative, control data.

This summer, a second tissue chip launch to the ISS will test potential drug therapies for the biological changes observed during this mission.

Future research, led by UW bioengineering associate professor Deok-Ho Kim, will send hearts-on-chips to the International Space Station.  Those studies will look at the influence of extended periods in space on heart muscle contractions. Besides causing kidney changes, space flight reduces cardiovascular fitness.

The National Center for Advancing Translational Sciences at the National Institutes of Health and the International Space Station United States National Laboratory, are funding Tissue Chips in Space, in collaboration with the National Aeronautics and Space Administration.

Kim and Kelly are scientists at the UW Medicine Institute for Stem Cell and Regenerative Medicine Research. Kelly and Himmelfarb are investigators at the Kidney Research Institute, a collaboration of Northwest Kidney Centers and UW Medicine.

Kelly also admits he is a sci-fi space exploration nerd who has a Star Trek Next Generation Borg Cube in his office.

 

Learn more about the NIH’s NCATS Tissues in Space Program

https://ncats.nih.gov/research/research-activities/tissue-chip/projects/space

Additional information on the Space X cargo resupply mission flight 17 to the ISS, as well as  information on its live webcasts and YouTube viewings is available at its website, www.spacex.com

NASA astronaut Jack Fischer tweeted this photograph from the International Space Station on June 3, 2017
NASA astronaut Jack Fischer tweeted this photograph from the International Space Station on June 3, 2017. Photo: NASA

Read more about the Kidney on a Chip project

To study with researchers like Pharmaceutics’ Associate Professor Ed Kelly and Pharmacy’s Research Assistant Professor Cathy Yeung, click on the links for more information about our Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

Link to Pharmaceutics archived news

Advice from UW pharmacists on senior use of marijuana

marijuana foliage

Marijuana use among older adults has soared in recent years despite little being known about the effectiveness and safety of the drug in people 65 and older. That’s resulted in more seniors asking health care providers about marijuana use: Is it safe? How much to use? Where to buy?

Now, a group of University of Washington professors has gone on the record to recommend ways to answer some of these questions and reduce the potential harm from marijuana use in this vulnerable population.

Zach Marcum
Zach Marcum, Assistant Director of Research for the Plein Center for Geriatric Pharmacy

“Start low, go slow,” said Zach Marcum, assistant director of research for the Plein Center for Geriatric Pharmacy at the UW School of Pharmacy. He’s the lead author of a letter to the editor about marijuana use in older adults recently published in the Annals of Pharmacotherapy. “We discourage marijuana use, especially in the elderly. But we also acknowledge the reality that people, including seniors, are trying marijuana. If they’re going to use, use safely.”

Researchers realize that older adults are using weed, even to just try it out. If seniors are going to try marijuana, they should keep some basic safety guidelines in mind:

  • Buy from a reputable source and avoid buying marijuana products over the internet or on the street. Remember that even the most reputable-seeming retailers are selling an unregulated product that may or may not contain the exact amounts of the chemical compounds on the label.
  • Choose a product with a high CBD to THC ratio to limit the psychoactive effect. The experts recommend topical or transdermal preparation over anything that’s inhaled or eaten.
  • Start low and go slow. Use one-quarter to one-half of the recommended dose and monitor for potential adverse effects.

There are good reasons for older adults to worry about potential unforeseen consequences of using marijuana. Despite heavy marketing from the marijuana industry to older adults, this same group often is excluded from clinical research and trials. Changes to the body as one ages includes kidney and liver function that may alter the way the body reacts to the chemicals in weed. And little is known about how marijuana works with other medicines people might be taking.

While there’s much interest in marijuana use for a number of ailments, much more research is needed, Marcum said.

“There is still a need for quality studies regarding potential risks and benefits,” he writes in the journal.

Health care providers should ask their patients about marijuana use and employ risk reduction strategies, helping patients to make informed decisions. Pharmacists, Marcum notes, are uniquely positioned to engage older adults in these conversations as part of an overall medication management process.

Co-authors on the letter to the editor include Sarah Tu, and Dr. Lianne Hirano and Carol Crawford of UW Medicine.

Jackson Holtz


Learn more about cannabis use in older adults at out upcoming public lecture.
In Case You Missed It! Medications Update for 2019
Medication Headlines & Your Health
May 34, 2019 | 5:00 PM | Foege Auditorium, UW Seattle Campus
More information and registration online

Bacci, White, and Zaraa awarded UW Population Health grant to study integrated care models for people living with epilepsy

Co-Principle Investigator and Assistant Professor Jennifer Bacci
Assistant Professor Jennifer Bacci

Congratulations to Jennifer Bacci, Assistant Professor, Department of Pharmacy; H. Steve White, Professor and Chair, Department of Pharmacy; and Sabra Zarâa, CHOICE PhD student, Pharmacy on receiving one of the 2019 pilot research grants awarded by the UW Population Health Initiative. The interdisciplinary team’s project is titled, “Community pharmacist integrated population health management of people living with epilepsy.”

Epilepsy is a complex spectrum of seizure disorders, affecting approximately 3.4 million people nationally and 75,000 people in Washington state; and the number is increasing. It affects quality of life and leads to significant health and socioeconomic disparities. The experiences of a person with epilepsy involves managing multiple co-existing health conditions and taking anti-seizure drugs, the mainstay of treatment that are often accompanied by significant adverse effects. Yet, healthcare and community services are often fragmented and uncoordinated.

H. Steve White, Professor and Chair, Department of Pharmacy

Community pharmacists are among the most accessible and trustworthy healthcare providers with extensive knowledge of drug therapy, yet are seldom leveraged to fill the gaps in epilepsy care or many other non-communicable diseases. Community pharmacists educate patients about their disease, ensure dosing accuracy, monitor for side effects and drug interactions, and encourage medication adherence. At a population level, community pharmacists collaborate with other healthcare providers and assess medication use patterns and patient outcomes data to ensure medications are used effectively, safely, and in a cost-effective manner. No models exist for engaging community pharmacists in population health approaches to epilepsy care.

Sabra Zarâa, CHOICE PhD student

This project seeks to develop a community pharmacist integrated population health intervention for people living with epilepsy by (1) identifying best practices to address the needs of persons living with epilepsy and their caregivers; (2) develop an intervention using a stakeholder driven and consensus building approach; and (3) evaluate the acceptability, appropriateness, and feasibility of the intervention. The intervention developed from this project will be piloted and evaluated for effectiveness in future research.

Investigators
Jennifer Bacci, Assistant Professor, Department of Pharmacy
H. Steve White, Professor and Chair, Department of Pharmacy
Sabra Zarâa, CHOICE PhD student, Pharmacy
John Miller, Neurology and Neurological Surgery
Edward Novotny, Pediatrics and Neurology
Bryan Weiner, Global Health and Health Services

 

Advance your career in pharmacy practice, scientific and outcomes research at the University of Washington School of Pharmacy. Learn more about our Graduate (PhD and MS) degree programs and click here for more information about the UW PharmD program.

Link to Department of Pharmacy archived news

Claw honored for service at Martin Luther King Tribute

Dr. Katrina Claw’s research builds on a six-year UW Northwest-Alaska Pharmacogenomics Research Network (NWA-PGRN) and University of Alaska Fairbanks Center for Alaska Native Health Research (CANHR) collaboration.
Dr. Katrina Claw’s research builds on a six-year UW Northwest-Alaska Pharmacogenomics Research Network (NWA-PGRN) and University of Alaska Fairbanks Center for Alaska Native Health Research (CANHR) collaboration. Photo: Alex Levine

We are thrilled that Pharmaceutics’ post doc Katrina Claw, PhD, will be honored with a service award at this year’s UW Health Sciences Martin Luther King Tribute on Thursday, January 17, 12:30 pm-2pm in Hogness Auditorium. The event will include a panel discussion.

To be recognized for my outreach and mentorship of Native American and other historically underrepresented students and my commitment to continue working with these communities is an honor.—Katrina Claw, PhD, Postdoc, Department of Pharmaceutics

Katrina’s research has focused on pharmacogenomics and the ethical implications of genomic research in Indigenous communities. Her current projects focus on hepatic variation, tobacco pharmacogenomics, and perceptions of genetic research in American Indian communities.

Her first project explored genetic and transcriptomic variation in the human liver, and identified and functionally characterized regulatory elements that influence pharmacogene expression in the liver. The liver is an ideal system to study due to its role in defining the efficacy and toxicity response to drugs that target the liver (e.g., warfarin and statins).

Her second project focused on the pharmacogenomics of nicotine metabolism, in particular identifying novel genetic variation in the CYP2A6 and CYP2B6 enzymes in Alaska Natives and American Indian populations. It is known that genetic factors account for variance in smoking cessation success, and pharmacogenetic testing brings the potential to optimize dosing for individual patients in order to improve drug response and limit adverse drug reactions.

Her third project is qualitative and has focused on examining the perspectives of American Indian tribes regarding genetic/genomic research. There is a history of research misconduct with Indigenous populations, and her work has examined attitudes and perspectives of tribal members with the eventual goals of developing community-driven genetic research projects and policies.

Ken Thummel, Milo Gibaldi Endowed Chair of the Department of Pharmaceutics, with Katrina Claw who was honored for her service to the community at the 2019 Martin Luther King Tribute
Ken Thummel, Milo Gibaldi Endowed Chair of the Department of Pharmaceutics, with Katrina Claw who was honored for her service to the community at the 2019 Martin Luther King Tribute

“This award was completely unexpected but I was extremely honored and moved after reading the nomination letter submitted by the UW School of Pharmacy, my advisors, and team,” said Katrina. The award honors individuals who exemplify Martin Luther King’s principles. Truth be told, I don’t think I ever directly sought out to enact any of these principles…they embody the Diné (Navajo) values of respect and reciprocity, of which I’m always conscious of and strive to follow. My outreach activities over the years were essential to creating a community in Seattle away from my home and tribal community and were also a way to be surrounded by the people and community that I needed to survive and thrive throughout my academic journey. I’m so thankful, honored, and humbled to be chosen for this award. Tʼáá íiyisíí ahéheeʼ (Many thanks)!”

Katrina is finishing up her postdoc this academic year and will be joining the University of Colorado School of Medicine as an Assistant Professor in the Department of Medicine, Division of Biomedical Informatics & Personalized Medicine, Colorado’s Center for Personalized Medicine at the University of Colorado Anschutz Medical Campus.

We are very excited for Katrina as she continues to advance research that has a profound impact on the health of Alaska Natives and American Indian populations.

CHOICE director Anirban Basu and collaborators receive NIH grant to study costs of dementia care

Team seeks to improve the projections of the future burden of the disease.

PORPP Dir & Prof Anirban Basu
CHOICE Institute at UWSOP Director & Professor Anirban Basu

Anirban Basu, director of the CHOICE Institute at UWSOP, and professor in the schools of Pharmacy and Public Health at the University of Washington, received more than $230,000 from the National Institutes of Health to measure the current and future costs of care for people with dementia. The research is part of a sub-grant from the University of Pennsylvania.

Dementia care has substantial economic costs, with consequences for health care systems as well as for the health and well-being of families who provide care for loved ones with dementia.

Anirban, also an adjunct professor of economics, will work with Paul Fishman and Lindsay White, a professor and postdoctoral fellow, respectively, in the Department of Health Services at the UW School of Public Health. In this study, the research team will take steps to improve the measurement of current dementia care and improve the projections of the future burden of the disease.

Researchers aim to estimate the direct and indirect costs of dementia care, including costs to caregivers, and to assess how costs vary with insurance and care providers. They also plan to develop a forecasting model to estimate the future costs of dementia care in order to inform resource allocation decisions.

The study will be conducted in collaboration with Norma Coe, associate professor of medical ethics and health policy at the Perelman School of Medicine at the University of Pennsylvania, who leads the parent grant.

This research was supported by the National Institute on Aging under award number R01AG049815.

This story was written by Ashlie Chandler and shared with the permission of the UW School of Public Health.

Advance your career in patient-centered outcomes research at the University of Washington. Learn more about studying Pharmaceutical Outcomes Research and Policy at The CHOICE Institute at UWSOP.

Link to CHOICE Institute archived news

Werth receives prestigious Young Investigator Award from SIDP

Brian Werth, assistant professor of pharmacy, in his lab
Brian Werth, assistant professor of pharmacy, in his lab Photo: Alex Levine

Congratulations to Assistant Professor Brian Werth who received this year’s Young Investigator Award from the Society of Infectious Diseases Pharmacist (SIDP). The prestigious award  is given to a young investigator who shows research promise in the broad area of infectious diseases.

Brian has demonstrated tremendous research productivity over the past 5 years at the University of Washington School of Pharmacy. His multidisciplinary, translational research program has focused on antimicrobial dosing strategies that optimize efficacy and prevent or overcome resistance in multidrug resistant pathogens. He has made significant contributions to infectious diseases research through education, mentorship, and service.

Since beginning his academic appointment, he has published 22 peer-reviewed papers and received research support from SIDP, pharmaceutical industry, and the National Institutes of Health. He was recently awarded a 4-year, $1.86 million NIH R01 grant as principal investigator, which is an exceptional accomplishment for a young investigator.

Brian and grant coinvestigator UWSOP Medicinal Chemistry’s Libin Xu will continue their novel research into antibiotic resistance mechanisms in the superbug, methicillin-resistant Staphylococcus aureus(MRSA). With Libin’s expertise in ion mobility-mass spectrometry (IM-MS) analysis of lipids and Brian’s expertise in antibiotic resistance, they are working to understand the mechanisms of cross-resistance among antibiotics that target the bacterial cell membrane and cell wall. This work could lead to the identification of novel targets for resistance-modifying therapeutics or more sensitive diagnostics to detect resistance. In addition, the team received a UW Royalty Research Fund award of $38,175 for their project, “Targeting Altered Lipid Metabolism in Antiobiotic-Resistant Staphylococcus Aureus.” The RRF is funded from royalty and licensing fee income generated by the UW technology transfer program. The fund supports UW faculty seeking to advance new directions in research in disciplines for which external funding opportunities are minimal; for faculty who are junior in rank; and if the award might provide opportunities to increase applicants’ competitiveness for subsequent funding.

To read more about Brian’s collaboration with Libin Xu began with an outing to the College Inn Pub and a new UWSOP Faculty Innovation Grant, click here.

 

To study with researchers like Drs. Werth and Xu, click on the links for more information about our Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

UW Researchers Gray and Phelan to study the impact of deprescribing to reduce falls in older adults

Older adult hands holding medication

UW Pharmacy’s Shelly Gray and UW Medicine’s Elizabeth Phelan are teaming up to identify ways to prevent falls in older adults. Their study, “Reducing Central Nervous System (CNS)-active Medications to Prevent Falls and Injuries in Older Adults (STOP-FALLS),” will identify medication safety improvements to reduce fall-related injuries and other adverse health outcomes.

“Falls in older adults are a significant public health issue, and many older adults are on risky medications that may cause falling because they cause side effects such as dizziness, drowsiness and impaired cognitive abilities. This study will help health care providers and patients reduce use of these risky medications, including opioids and benzodiazepines, to prevent falls. Finding ways to optimize medication use and safety in older adults is the major mission of the Plein Center.”—Shelly Gray, Director, Plein Center for Geriatric Pharmacy and Shirley & Herb Bridge Endowed Professor at UWSOP

Shelly Gray, Director, Plein Center for Geriatric Pharmacy and Shirley & Herb Bridge Endowed Professor at UWSOP
Shelly Gray, Director, Plein Center for Geriatric Pharmacy and Shirley & Herb Bridge Endowed Professor at UWSOP

Gray and Phelan received a $3M grant from the Centers for Disease Control and Prevention (CDC) to study the effect of reducing the use of medications, such as benzodiazepines and opioids, on preventing falls and other unintentional injuries in older adults. These medications are prescribed for conditions such as pain, anxiety and sleep disorders. The team will study the impact that deprescribing can have on people’s safety and reducing the risk of falling, particularly given the impact multiple medications can have on a person’s physical and cognitive functioning.

Deprescribing is a process whereby the pharmacist and physician review a person’s medications to see if any medications may be causing harm or may no longer be helping the patient. Sometimes a medication that was safe when the person was younger now may pose a risk as they age because the body changes. By going through this review and making adjustments, some patients experience reduced side effects.

“There has been surprisingly little attention as yet to addressing the role of medications in falls and injuries by the practice community. We need practical, patient-centered, and health-system-relevant approaches to curtail unnecessary use of CNS-active medications, and prevent their future use, if we are to ever see sustained reductions in fall-related injury rates and avert the adverse, life-changing consequences that result when an older person is seriously injured from a fall,” —Dr. Elizabeth Phelan, geriatrician and medical director, Fall Prevention Clinic, Harborview Medical Center, and an Associate Professor of Medicine, University of Washington School of Medicine.

Dr. Elizabeth Phelan, geriatrician and medical director, Fall Prevention Clinic, Harborview Medical Center, and an Associate Professor of Medicine, University of Washington School of Medicine
Dr. Elizabeth Phelan, geriatrician and medical director, Fall Prevention Clinic, Harborview Medical Center, and an Associate Professor of Medicine, University of Washington School of Medicine

Reducing fall rates is important. In just ten years, from 2007 to 2016, the death rate caused by falls for older adults has increased 30% in the U.S. If rates continue to rise, the Centers for Disease Control and Prevention (CDC) says we can expect seven fall deaths every hour by 2030. One in five falls causes a serious injury such as broken bones or head injury and sends about three million older adults to the emergency room every year at a cost of about $50 billion dollars, most of which is shouldered by Medicare and Medicaid.

The grant is one of three funded by the CDC’s National Center for Injury Prevention and Control (Injury Center) that will focus on medication management of opioids and benzodiazepines to reduce falls among adults aged 65 years and older. The research will be conducted at Kaiser Permanente Washington with Dr. Karen Sherman serving as the site lead.

This award is one of three extramural research cooperative agreements funded (RFA-CE18-004) to focus on medication management of opioids and benzodiazepines to reduce falls among adults 65 and older.

 

Are you interested in working with the top-rated faculty and studying geriatric pharmacy with preeminent student peers?

Click here for more information about the Plein Geriatric Pharmacy Certificate or click these links to learn about the UW PharmD program.

Researchers at UW and USC find a type of medication used to treat high blood pressure may reduce the risk of Alzheimer’s disease

Doug Barthold, Research Assistant Professor, The CHOICE Institute at the UW School of Pharmacy
Doug Barthold, Research Assistant Professor, The CHOICE Institute at the UW School of Pharmacy

Researchers Doug Barthold of the University of Washington and Julie Zissimopoulos of the University of Southern California published the first study to compare multiple types of blood pressure medications and the beneficial effect they may have on different populations. Unlike other studies, they looked at how Alzheimer’s disease risk was reduced across race, ethnicity, and sex.

Their study findings suggest that hypertension management in older adults with a type of anti-hypertensive called ARBs (angiotensin-II receptor blockers) could reduce the risk of Alzheimer’s disease for black women, and white women and men. (The study was inconclusive for black men, and Hispanic men and women).

As of press time there are no medications known to prevent or delay the onset or progression of Alzheimer’s disease. Increasingly, researchers are looking to existing medications, used for treatment of other chronic conditions, to see if they could be repurposed to fight against cognitive decline and lower the risk of Alzheimer’s disease.

Repurposing existing drugs could be an inexpensive means to reduce the large and disparate burden of Alzheimer’s disease. By analyzing commonly used prescription drugs in Medicare claims data, we can identify relationships with Alzheimer’s disease onset across diverse populations.

There is strong evidence that managing high blood pressure is an important step to lowering the risk of Alzheimer’s disease and that some antihypertensive drugs may be more protective than others.

The research team’s retrospective cohort analysis looked at how different classes of anti-hypertensives are protective against Alzheimer’s disease. They looked at over 1 million Medicare enrollees and found antihypertensive drug types called ARBs, angiotensin-II receptor blockers, such as Valsartan (Diovan), Candesartan (Atisan), and Losartan (Cozar), are more protective than other anti-hypertensives, such as ACE inhibitors and four other classes of drugs.

The team concluded that the results were significant enough to warrant additional observational studies and randomized control trials that include men and women from diverse racial and ethnic groups, to investigate if there is a causal effect.

Alzheimer’s disease is a growing public health problem. Right now over 5 million Americans aged 65 and older are living with Alzheimer’s disease and that number is expected to grow to 7.1 million in 2025, and 13.8 million in 2050. At those levels, even small delays in the onset of Alzheimer’s disease could substantially reduce the financial ($300+ billion in 2010) and caregiving burden (18+ billion hours of care in 2016—over forty percent of which is provided by informal caregivers, often family and friends).

Add to those statistics the fact that there is a higher incidence of Alzheimer’s disease for women and racial and ethnic minorities, who are also more likely to require high intensity care and have unmet care needs, and you have an emerging public health crisis ahead.

Researchers worldwide are looking for solutions to stop or mitigate the impact the disease has on population health. Targeted hypertension treatment could reduce the large, growing, and disparate burden of Alzheimer’s disease on the afflicted individuals, their caregivers, and the health system as a whole.

This study indicates that if there is a choice in anti-hypertensive medications, there is a potential additional benefit for using targeted treatments against Alzheimer’s disease, but that it needs to be confirmed by additional research.

“Alzheimer’s disease is an enormous public health concern and while more than a hundred potential drug treatments are in clinical trials, there are still no treatments available to prevent or slow the progression of the disease.  Research is building that AHTs reduce risk of dementia and this study suggests a potential pathway independent of blood pressure effects.  All else being equal, for patients who are already being prescribed antihypertensives these findings highlight a potential differential effect on their risk of acquiring Alzheimer’s which a clinician may want to take into account,” said Zissimopoulos who is the director of the aging research program at the USC Schaeffer Center and Vice Dean of Academic Affairs at the USC Price School of Public Policy.

The paper, titled “The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity,” was published in the journal PLOS ONE on November 1, 2018 with co-authors Geoffrey Joyce of USC, Whitney Wharton of Emory University, and Patrick Kehoe, University Bristol, UK. This research was supported by the National Institutes of Health (NIH), awards R01AG055401, RC4AG039036-01, P30AG043073-01, K01AG042498, R01HL126804, and R01HL130462

 

Are you interested in working with the top-rated faculty and studying geriatric pharmacy with preeminent student peers?

Click here for more information about the Plein Geriatric Pharmacy Certificate or click these links to learn about the UW PharmD program.

Lou Garrison named 2018 Value Assessment Challenge Award recipient

UWSOP Professor Emeritus Lou Garrison
UWSOP Professor Emeritus Lou Garrison
The PhRMA Foundation and the Personalized Medicine Coalition (PMC) announced that Lou Garrison is one of the first place recipients of the 2018 Value Assessment Challenge Awards. These awards are designed to encourage innovative approaches in defining and measuring value in health care. Lou and the other award recipients were recognized for submitting research proposals that focus specifically on novel methods for assessing the value of personalized medicine.
A total of $85,000 in funding was provided for the researchers, who answered the question: What are potentially transformative strategies and methods to define and measure value at all levels of decision making that are aligned with personalized/precision medicine?
Louis serves as faculty emeritus at University of Washington School of Pharmacy and Visiting Senior Fellow at the Office of Health Economics and collaborated with Adrian Towse, MPhil, MA, Office of Health Economics, London, England on the Research Proposal that garnered the $50,000 first place award.
“Adrian and I are really pleased and honored to receive this award.  Our proposed strategy weaves together various threads of our joint research over the past ten years—much of it in collaboration with others in our field.  We recognize the new challenges for health technology assessment and financing stemming from the exciting recent developments in precision medicine, and we call for greater focus on rewarding value creation to support optimal long-term innovation.”
—Lou Garrison, Faculty Emeritus, UWSOP
In their research proposal, “A Strategy to Support the Efficient Development and Use of innovations in Personalized and Precision Medicine,” Garrison and Towse call for a broadening of the concepts of value in personalized/precision medicine, laying out six basic policy principles as pathways to help determine value. These range from the need for flexible, value-based pricing to real-world evidence generation in personalized/precision medicine and the challenging implications for assessing and rewarding value.
The Challenge Awards, first offered in 2017, are one component of the PhRMA Foundation’s multi-faceted Value Assessment Initiative, which supports a variety of research and innovation projects to help the United States make a successful transition to a value-based health care system.
Concern over rising U.S. health care costs in recent years has increased interest in promoting high-quality care while avoiding low-value or inefficient care. In response, various efforts aimed at driving value in health care have emerged, but few have offered transformative solutions that reflect patient preferences and real-world clinical practice.
Recipients of Challenge Awards will be acknowledged during PMC’s 14th Annual Personalized Medicine Conference at Harvard Medical School on Thursday, November 15th. They will be asked to present their winning papers at a public forum, to be announced later, where they will be honored for their work.
Award recipients will also become part of the Value Assessment Research Network, which has been established to encourage collaboration and dissemination of findings that emerge from various projects the Foundation is supporting through its Value Assessment Initiative.
“Working with PMC, the PhRMA Foundation is delighted to recognize and reward the innovative approaches to value assessment demonstrated in these outstanding research proposals,” said PhRMA Foundation President Eileen Cannon. “The work of these outstanding researchers will make a significant contribution to the effort to create truly value-based health care in the United States.”
To learn more about these awards, go to the PhRMA Foundation site.
Advance your career in patient-centered outcomes research at the University of Washington. Learn more about studying Pharmaceutical Outcomes Research and Policy at The CHOICE Institute at UWSOP.

Link to CHOICE Institute archived news

CHOICE faculty member, Aasthaa Bansal, awarded highly coveted NIH Merit Award

Aasthaa Bansal, Assistant Professor, CHOICE Institute
Aasthaa Bansal, Assistant Professor, CHOICE Institute

Assistant Professor Aasthaa Bansal at the CHOICE Institute was recently awarded a $2.5M+, seven-year Method to Extend Research in Time (MERIT) (R37) award from the National Cancer Institute to develop a dynamic decision-making framework for identifying personalized risk-adaptive surveillance strategies for cancer survivors. This research seeks to shift the paradigm of how routinely collected patient information is used for clinical management, by innovatively coupling data-adaptive prediction modeling with value of information analysis. The decision-making framework will evaluate the value of future clinical information and guide patient-level decisions about the timing of treatment and frequency of biomarker testing on an ongoing basis. It will be implemented on rich electronic health record data from Kaiser Permanente Southern California and could lead to major advances in personalized medical decision making.

NIH MERIT awards are awarded to early stage investigators whose R01 was scored below 6th percentile. It is designed to “provide long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner.” In both 2016 and 2017 only eight proposals each year were converted to MERIT awards across all of NIH.

The interdisciplinary team includes CHOICE Institute faculty Dr. Aasthaa Bansal (PI), Dr. Anirban Basu and Dr. David Veenstra, as well as collaborators in the UW Departments of Biostatistics and Medicine, Fred Hutchinson Cancer Research Center and Kaiser Permanente Southern California.

Link to CHOICE Institute archived news

Organs-on-chips: Tiny technology helping bring safe new drugs to patients faster

File 20180525 90281 17z2fmg.jpg?ixlib=rb 1.1
It doesn’t look like a kidney, but this ‘kidney-on-a-chip’ is a breakthrough for new drug testing.
Alex Levine, CC BY-ND

Catherine Yeung, University of Washington; Edward Kelly, University of Washington, and Jonathan Himmelfarb, University of Washington

Getting a new pharmaceutical from an idea in the chemistry lab to market takes many years and billions of dollars. Each year just several dozen new drugs are approved for use in the United States.

Human “organs-on-chips” are leading a revolution in drug safety testing. These devices use human cells to model the structure and function of human organs and tissues. By testing the potential effects of drugs on different organs faster than traditional methods, organs-on-chips can reduce the need for animal studies and better predict which new drugs will effectively treat human disease.

As part of an interdisciplinary research team, with funding support from the National Center for Advancing Translational Sciences, we’re working on a kidney-on-a-chip to improve our understanding of how kidney diseases begin and which drugs can safely treat them.

Quicker and better testing

Historically, laboratory testing for new drugs is performed in cells grown in dishes or flasks. If a drug passes initial screening tests in vitro, researchers next test it in vivo in live animals to determine the effects of a new drug on a whole system instead of just one cell type at a time. Finally, after many years of laboratory investigation, researchers will test a promising new drug in people to see if it is safe and effective.

The problem is 9 out of 10 of these drugs never make it from small-scale human tests to the patient because they turn out to be ineffective or toxic, even if they showed promising results in early testing.

Organs-on-chips have the potential to completely transform that system. Ranging from the size of a fingernail to that of a credit card, they’re composed of fluid channels and tiny chambers that contain human cell samples. Organs-on-chips in development in labs around the country include kidney, lung, liver, intestine, skin, brain, heart, bone and reproductive systems.

In an organ-on-a-chip, flowing liquid supplies the cells with oxygen and nutrients, similar to the way blood sustains cells in the human body. It’s this constant flow that makes these devices special. Cells grown in organs-on-chips devices act more like cells in a human organ than do cells grown in flat dishes without flow.

Fluid circulates through a kidney-on-a-chip.
Alex Levine, CC BY-ND

Case of the kidney-on-a-chip

Kidneys are incredibly important to overall human health. The two fist-sized kidneys remove drugs and unwanted compounds from the body and play a critical role in maintaining proper salt and water balance, blood pressure and vitamin D and bone health. Genetic conditions and even commonly administered medications can, in some circumstances, damage the kidneys.

In the U.S., 15 percent of adults have kidney diseases. But most don’t even know it, because kidney diseases often display no symptoms until the condition is very advanced. There’s a pressing need to understand how kidney disease begins, and to develop new safe and effective treatments.

Here at the University of Washington, our kidney-on-a-chip research team is composed of scientists from many different disciplines, including pharmacy, pharmaceutical sciences, nephrology (kidney medicine), toxicology, biochemistry and bioengineering.

In partnership with Nortis, Inc., a local biotechnology company, our team has created a small device — the size of a business card — with up to three tiny tubes, each one-thousandth the size of a drop of water, containing 5,000 human kidney cells. When tiny amounts of fluid are pumped through the tubes, the kidney cells are exposed to important signals that help the cells in the chip behave as if they were in a live kidney.

We’ve found that the kidney cells release signals – called biomarkers – of injury when exposed to known kidney toxins. Our research showed that cells on the chip released markers of injury commonly seen in the urine of people with kidney damage. Testing with the older method, using cells on plates, did not show any damage with the same treatment. This suggests that the kidney-on-a-chip may be better than existing methods at predicting if a new drug will cause kidney damage in humans.

These devices do a better job of testing how molecules affect living human cells.
Alex Levine, CC BY-ND

Connecting organs-on-chips to mimic systems

Now that we’ve had these promising results, scientific teams across the country are starting to connect different organs together to replicate a more complex, multi-organ system, to give greater insights into how drugs affect people. For example, we were able to connect a liver-on-a-chip to a kidney-on-a-chip to learn how a plant extract used in some herbal medicines, called aristolochic acid, damages kidney cells. This chip-to-chip investigation reinforces the need for interconnected organs-on-a-chip to replicate the complex mechanics in the human body.

In the coming year, our kidney-on-a-chip project will be one of several sent to the International Space Station where low gravity speeds up changes in cells, sometimes causing health problems for astronauts. The Space Station could be the perfect place to find out more about kidney diseases in weeks, rather than years or decades.

The ConversationOrgans-on-chips can also be used to discover new drug targets. Our team is evaluating the kidney-on-a-chip as a tool to personalize drug selection and dosing in people with kidney cancer, polycystic kidney disease and chronic kidney disease. Other organs-on-chips labs around the country are studying diseases of the immune system, brain, lungs, heart and blood vessels. By working together, dozens of research teams are developing this new technology to revolutionize drug discovery, leading to the development of better and safer medications for all.

See how it all works in this video animation.

Catherine Yeung, Research Assistant Professor of Pharmacy, University of Washington; Edward Kelly, Associate Professor of Pharmaceutics, University of Washington, and Jonathan Himmelfarb, Director of the Kidney Research Institute and Professor of Medicine, University of Washington

This article was originally published on The Conversation. Read the original article.

Shum and collaborators unveil new maternal and fetal health risks associated with shellfish toxin

Pharmaceutics graduate student Sara Shum with her award-winning ASPET poster
Pharmaceutics graduate student Sara Shum with her award-winning ASPET poster

Pharmaceutics graduate student Sara Shum recently presented and won an award for the preliminary results from a study of the shellfish toxin domoic acid. The project is a collaboration with Professor Tom Burbacher and Senior Research Scientist Kimberly Grant of the Department of Environmental and Occupational Health Sciences in the UW School of Public Health and Sara and Professor Nina Isoherranen the Department of Pharmaceutics. Their findings suggest potential health risks associated with long-term exposure to low levels of domoic acid.

Domoic acid is a naturally occurring toxin produced by certain marine algae and it can cause fatal central nervous system toxicity in people and animals that consume highly contaminated shellfish. Although government policies limit exposure to DA by closing harvesting of shellfish when levels are over 20 ppm to reduce risks of toxicity from short-term exposure, the effects of long-term low-level exposure are not known.

In a study of 30 pregnant monkeys, the group found that chronic, low-level oral intake of domoic acid was associated with subtle signs of neurological effects, such as increased tremor frequency in adult females and delays in cognitive development of prenatally exposed infants.

The researchers note that these new findings suggest that the current government policies may need to be changed to protect communities from health effects due to chronic exposure to DA via shellfish consumption.

Sara received the second place award in the American Society for Pharmacology and Experimental Therapeutics (ASPET) annual meeting at Experimental Biology graduate student poster competition. The title of her poster was “Maternal Fetal Toxicokinetics of the Shellfish Toxin Domoic Acid.” Working with Nina Isoherranen, Sara’s research focuses on elucidating and predicting pharmacokinetics changes during pregnancy, especially predicting maternal to fetal transfer.

For more information, please contact: Tom Burbacher (tmb@uw.edu) and Kimberly Grant (ksg@uw.edu) in the Department of Environmental and Occupational Health Sciences in the UW School of Public Health or Nina Isoherranen (ni2@uw.edu) in the Department of Pharmaceutics in the School of Pharmacy.

 

To study with peers in Pharmaceutics like Sara Shum and faculty like Dr. Nina Isoherranen, click on the link for more information about our PhD Program in Pharmaceutics.

Link to Pharmaceutics archived news

Wienkers is keynote speaker at June 2018 AAPS-RMDG meeting at UW

Abstracts are due Friday, May 18, 2018

Keynote speaker Larry Wienkers is also a UWSOP Distinguished Alumni Award winner.
Keynote speaker Larry Wienkers is also a UWSOP Distinguished Alumni Award winner.

The American Association of Pharmaceutical Scientists – Rocky Mountain Discussion Group (AAPS-RMDG) Annual Meeting will be held at the University of Washington, Seattle, WA, on June 12-13, 2018. The deadline for abstract submission is May 18, 2018.

The RMDG provides a forum for interacting with scientists from industry and academia to promote basic and pharmaceutical sciences in the Rocky Mountain and Pacific Northwest regions. The highlights of this year’s annual meeting include:

  • Dr. Larry Wienkers, keynote speaker
  • Speakers from industry and academia, including students and postdoctoral fellows
  • Career panel
  • Poster reception

Tuesday, June 12 and Wednesday, June 13th at UW Seattle in the Alder Auditorium (1310 NE 40th Street, Seattle, Washington 98105).

For more information and to register or submit an abstract: http://bit.ly/aaps-rmdg-2018

Please note! Immediately following the RMDG conference, the 21st International Conference On Drug-Drug Interactions will be held at the University of Washington from June 14-16, 2018.

Certain drugs for muscle conditions may be linked to increased risk of dementia

Dr. Angela Hanson, geriatrics, reviewing medications with a patient at the Memory and Brain Wellness Center at Harborview Medical Center.

Shelly Gray editorial in The BMJ underscores importance of avoiding long-term use of anticholinergic drugs in older adults

UWSOP Plein Center for Geriatric Pharmacy Director Shelly Gray authored an editorial in support of new research about potential dangers of anticholinergic drugs for that help to control involuntary muscle movements for conditions such as epilepsy and Parkinson’s disease. The UK study, “Anticholinergic drugs and risk of dementia: case-control study,” published by The BMJ today, found these drugs are associated with an increased risk of dementia.

The study is the largest of its kind to date and the findings prompt the researchers to say that clinicians should avoid long term prescribing of some anticholinergics to patients aged 45 and over.

“This research “raises important issues about the best way to summarize anticholinergic burden for future research… Specifically, for most highly anticholinergic drugs, non-pharmacological and pharmacological alternatives are available and should be considered.” – UW Professor and Director Shelly Gray and Professor Joseph Hanlon at the University of Pittsburgh, in their editorial, “Anticholinergic drugs and dementia in older adults

In the meantime, Gray and Hanlon agree that anticholinergics in general should be avoided in older adults.

Anticholinergic drugs block chemical signals to the brain that control muscle movements. They are often used for conditions linked to involuntary muscle movements, such as urinary incontinence, epilepsy and Parkinson’s disease, as well as for depression, chronic lung disease (COPD) and asthma.

Several studies have reported associations between use of anticholinergics and future cognitive decline and dementia, but it is not clear whether this is due to the drugs themselves or the underlying conditions for which they were prescribed.

So a research team led by Kathryn Richardson at the University of East Anglia, set out to estimate the association between duration and level of exposure to different classes of anticholinergic drugs and subsequent dementia.

They analyzed data from the UK’s Clinical Practice Research Database for 40,770 patients aged 65 to 99 years who were diagnosed with dementia between April 2006 and July 2015. Each case patient was matched to up to seven control patients of similar age and sex, but without dementia.

Drugs were scored according to their anticholinergic activity using the Anticholinergic Cognitive Burden (ACB) scale. An ACB score of 1 was classed as possibly anticholinergic, while a score of 2 or 3 was definitely anticholinergic.

Daily doses of each drug were then compared for both cases and controls over an exposure period of 4 to 20 years before a diagnosis of dementia.

A total of 14,453 (35%) cases and 86,403 (30%) controls were prescribed at least one anticholinergic drug with an ACB score of 3 during this period.

After taking account of potentially influential factors, the researchers found that definite anticholinergic antidepressants, anti-Parkinson drugs, and drugs to treat urinary incontinence (ABC score of 3) were linked to increased dementia risk up to 20 years after exposure.

However, no increased risk was found for drugs with possible anticholinergic activity (ACB score of 1) – and for anticholinergic gastrointestinal or respiratory drugs (ACB score of 3).

Other antidepressants (mainly selective serotonin reuptake inhibitors) with an ACB score of 1 were linked to dementia, but only close to the time of prescription, which the researchers say is unlikely to represent a direct (causal) link.

This is an observational study, so no firm conclusions can be drawn about cause and effect, and the authors outline some limitations, such as possible misclassification of dementia cases and a lack of information on depression severity. Nevertheless, the study was large and was able to account for several potentially influential factors.

Marcum study finds metformin has mortality benefits even with low kidney function

Collaborative research between UW School of Pharmacy and VA Puget Sound looked at 175,000 patients

Assistant Director of the Plein Center and Bailey Faculty Fellow Zach Marcum

In a recent study, researchers at the University of Washington and the VA Puget Sound Health Care System have found that an important diabetes drug can be used safely among a high-risk patient population – those with poor kidney function. They concluded metformin should be prescribed preferentially over sulfonylureas in this group of patients based on overall mortality benefits.

In 1995, the FDA approved metformin for patients with Type 2 diabetes; however, the label advised clinicians to avoid prescribing metformin to patients with impaired kidney function because of concerns about lactic acidosis. But in 2016, the FDA endorsed metformin’s safety in patients with mild-to-moderate kidney function impairment.

To determine whether risk for death differs following initiation of metformin monotherapy or sulfonylurea monotherapy among veterans with Type 2 diabetes and chronic kidney disease, Zach Marcum, Assistant Director of the Plein Center for Geriatric Pharmacy and Bailey Faculty Fellow, and colleagues conducted this cohort study of 175,000 older adult patients with diabetes and chronic kidney disease who initiated these drugs at Veterans Affairs medical centers between 2004 and 2009.

Their results showed that metformin had significant benefits over sulfonylureas across the stages of kidney function. Metformin use was associated with a 36% lower risk for death overall.

 “This study should be reassuring to clinicians and to diabetic patients with impaired kidney function. Metformin should be prescribed preferentially over sulfonylureas in this group of patients.” – Paul Mueller, MD, MPH, FACP, reviewing the study for the New England Journal of Medicine Journal Watch

Metformin had been restricted as it was thought to have an unfavorable risk/benefit profile among people with low kidney function. However, in their research, Zach and the team found that metformin had mortality benefits.

Although residual confounding is possible, this study shows that initiation of metformin monotherapy versus sulfonylurea monotherapy among patients with Type 2 diabetes and mild-to-moderate kidney function impairment is associated with lower risk for death, which should be reassuring to clinicians and to diabetic patients with impaired kidney function.

The data reviewed were from 2003 to 2009, which is important because today people wouldn’t be prescribed a sulfonylurea as first-line treatment for type 2 diabetes, but during this timeframe there were substantial numbers of people being prescribed either metformin or a sulfonylurea as initial monotherapy.

The team grouped people into different levels of kidney function based on severity of impairment. They found benefits for people using metformin in both absolute and relative terms. Many studies stop at relative risk, but this one found a benefit to absolute risk as well. The largest absolute risk reduction was observed among individuals with the moderately-severely reduced kidney function. This is a group of patients for whom the FDA label currently advises to not start metformin. Future research is needed to confirm these findings.

Advance your career in patient-centered outcomes research, geriatric pharmacy or pharmacy practice at the University of Washington. Learn more about our Pharmaceutical Outcomes Research and Policy Graduate Programs in The CHOICE Institute at UWSOP.

Click here for more information about the Plein Geriatric Pharmacy Certificate or click these links to learn about the UW PharmD program.

Link to Department of Pharmacy archived news

Nath lab team takes aim at Alzheimer’s

“Alzheimer’s is such a challenging and scary disease. Any di erence we can make there would mean so much—a lot of us have been a ected and it’s only going to get worse as the population gets older,” remarks Abhi Nath (pictured right with David Baggett, le
“Alzheimer’s is such a challenging and scary disease. Any difference we can make there would mean so much—a lot of us have been a ected and it’s only going to get worse as the population gets older,” remarks Abhi Nath (pictured right with David Baggett, left) Photo: Alex Levine

Alzheimer’s disease affects about 5 million Americans, a number projected to roughly triple by 2050. The urgency of this grave population health challenge is with Abhi Nath and his team of researchers every day as they seek new options to treat and manage Alzheimer’s and related diseases. The key appears to lie with a process called protein aggregation, which links Alzheimer’s, Parkinson’s, and Chronic Traumatic Encephalopathy (CTE)—a disease that affects people, such as military veterans and football players, who have suffered concussions or traumatic brain injury.

“At the molecular level, particular proteins in the brain are misbehaving,” said Abhi. A major culprit in Alzheimer’s disease and CTE is a disordered protein called tau. “Proteins are supposed to fold like origami to function. When you have a misfolded protein, they tend to stick together—in the wrong way. That phenomenon of aggregation is the underlying cause of diseases like Alzheimer’s.”

Understanding how the disease begins and what happens at a molecular level would lead to improved diagnostic tools and therapies, but it’s a major challenge because proteins like tau are very exibly moving targets, making it hard to use traditional tools of structural biology. “Nothing in our current tool belt works well with these targets,” said Abhi. Instead, the team are developing new approaches, drawing on a variety of scientific disciplines in order to have the biggest long-term impact.

“We can manage symptoms, but we have a long way to go for a therapy for Alzheimer’s. It’s like playing Tetris with Jello—there are hundreds of thousands of chemicals that could t tens of thousands of gaps and we are looking for the right match.”—Abhi Nath, Assistant Professor of Medicinal Chemistry and Plein Center for Geriatric Pharmacy Researcher

Eri Nakatani-Webster, ’13, a KL2 scholar and post doc, is working to develop sophisticated mathematical models of protein aggregation that will make it easier to under- stand and predict how a drug or other binding partner will affect the process.

Hannah Baughman is a PhD student in Medicinal Chemistry, shown here working in the Nath Lab
Hannah Baughman is a PhD student in Medicinal Chemistry, shown here working in the Nath Lab Photo: Alex Levine

Graduate student Hannah Baughman is deeply focused on understanding how disordered proteins interact with the body’s own defense mechanisms against protein aggregation: molecular chaperones. These molecular machines can recognize when a protein is misfolding and help it refold into its correct structure, which may lead to new ways of helping our bodies protect us from these diseases.

Graduate student David Baggett’s computer models of tau can screen millions of compounds to identify new molecules capable of binding different stages in the aggregation pathway. In addition to accelerating the pace of drug discovery, David’s work could improve early diagnosis—a particularly important challenge in diseases like Alzheimer’s and CTE, where cognitive symptoms manifest well after the damage has been done at the cellular level and it may be too late to treat the illness.

Medicinal Chemistry graduate student Eleanor Vane at work in the Nath lab
Medicinal Chemistry graduate student Eleanor Vane at work in the Nath lab Photo: Alex Levine

Graduate student Eleanor Vane is taking a counter-intuitive approach by investigating whether aggregation-prone proteins could actually play a beneficial role by controlling bacterial infections and fungal growth.

“Here in Medicinal Chemistry, we take what we learn every day about the biophysics of misfolding proteins and connect that to improving human health,” shared Abhi. “It is incredibly hopeful and fulfilling work, with great promise.”

 

To study with researchers like Dr. Nath, click for more information about our Graduate Programs in Medicinal Chemistry.

Visit the Nath Lab website

Link to Medicinal Chemistry archived news

New fellowship will advance thoughtful health care innovation in Washington state

Partnership between Washington Research Foundation and The CHOICE Institute at UWSOP creates opportunities for students and researchers at non-profit research institutions in Washington state

The CHOICE Institute at UWSOP is pleased to announce a partnership with the Washington Research Foundation (WRF) that will create four new fellowships per year designed to support non-profit research institutions and life science researchers.

Health economics and outcomes research (HEOR) is increasingly being used at earlier stages of product development for healthcare and life sciences to inform decision-making. While this expertise is commonly available at larger companies it may be inaccessible or unaffordable to researchers and technology developers within non-profit research institutions that have arguably the greatest need for that kind of service.

Lotte Steuten, Ph.D.

The WRF-HEOR Fellowship aims to address this gap by providing high quality health economic and outcomes research services to technology developers (scientists, engineers, inventors and entrepreneurs) at non-profit research institutions in Washington state while also providing a valuable training activity for graduate students at Washington state research institutions. On the UW side, the Fellowship will be led by Lotte Steuten of The CHOICE Institute at UWSOP and Fred Hutch. Dr. Steuten specializes in developing and applying quantitative (Bayesian) methods for estimating and comparing the expected health and economic benefits of new approaches and interventions in disease prevention and treatment, and prioritizing data collection to efficiently build the evidence for such promising new interventions.

“At the Washington Research Foundation, we see a clear need for reliable health economic and outcomes research to support the advanced technical and scientific work happening in Washington state, “ said Will Canestaro, Manager of Strategic Investments at WRF. “As healthcare costs continue to rise it is increasingly important for researchers to understand how their innovations translate into real-world value for patients and the healthcare system.”

Through this fellowship program at The CHOICE Institute, we aim to increase the number of decision-making tools available to researchers and technology developers. Ultimately this is democratizing this expertise and making it available across the state—all to the benefit of patients and the healthcare systems in Washington.
–Will Canestaro, Ph.D., Washington Research Foundation

Washington Research Foundation logoFellows and projects will be selected by a committee of faculty in The CHOICE Institute based on academic merit. Generally, awards will be made to second and higher year students in CHOICE. Fellows will have a CHOICE faculty mentor as well as an advisor from WRF.

The projects will evaluate a health technology (such as a diagnostic, therapeutic, or software), with preference for the most novel and high-impact technologies for patients or the healthcare system. Each fellow will create deliverables for the technology developer they are working for with the ultimate goal of providing meaningful insight that can improve their research and development process. Examples of project types include creating a cost effectiveness model to estimate the value of a technology in real-world practice, measuring the budget impact on the healthcare system of a technology, and measuring the human and economic burden of disease to patients and society.

“We appreciate the partnership developed with the Washington Research Foundation,” said Anirban Basu, Director of The CHOICE Institute. “Our student fellows will now have a wonderful opportunity to advance their research and training in a way that helps their local community and the state. We look forward with great anticipation to the first class of fellows and seeing what their research helps advance in health care.”

 

Advance your career in patient-centered outcomes research at the University of Washington. Learn more about our Graduate Programs in Pharmaceutical Outcomes Research and Policy.

Link to Department of Pharmacy archived news

Alumnus Glen Schumock, ’89, named Dean of the University of Illinois at Chicago College of Pharmacy

Glen Schumock, '89, The CHOICE Institute at UWSOP alumnus
Glen Schumock, ’89, The CHOICE Institute at UWSOP alumnus

Congratulations to University of Washington School of Pharmacy alumnus Glen Schumock, ’89, who will become Dean of the University of Illinois at Chicago College of Pharmacy! His appointment is effective January 1, 2018, pending approval by the University of Illinois Board of Trustees. Schumock earned his baccalaureate in pharmacy from Washington State University and received his doctor of pharmacy from the University of Washington, Seattle. He earned an MBA and a Ph.D. from UIC, and completed residency and fellowship training at the University of Washington, Seattle and at UIC. He has held clinical pharmacist and managerial positions in hospital pharmacies and is a licensed pharmacist in Illinois and Washington. Congratulations, Glen!

Advance your career in patient-centered outcomes research at the University of Washington. Learn more about our Graduate Programs in Pharmaceutical Outcomes Research and Policy.

Link to Department of Pharmacy archived news

Alumna Kroetz named AAAS Fellow

Pharmaceutics alumna Deanna Kroetz, PhD, '90
Pharmaceutics alumna Deanna Kroetz, PhD, ’90

We are so proud of our Pharmaceutics alumna, Deanna Kroetz, PhD, ’90, who was among the 396 new fellows of the American Association for the Advancement of Science, announced this week. Election as a fellow of AAAS is an honor bestowed upon members by their peers. Fellows are recognized for meritorious efforts to advance science or its applications.

Deanna is a Professor at the University of California San Francisco faculty in the Department of Bioengineering and Therapeutic Sciences. As noted on her UCSF bio, her research seeks to understand the contribution of genetic variation to drug toxicity, to identify genetic biomarkers that can be used to guide effective use of drugs in the treatment of cancer and HIV, and to use genetics to unravel the molecular basis of drug-induced toxicity.

Congratulations, Deanna!

In addition to Deanna, eight University of Washington researchers were announced among the new fellows of the American Association for the Advancement of Science.

 

To study with leaders in Pharmaceutics, click on the link for more information about our PhD Program in Pharmaceutics.

Link to Pharmaceutics archived news

Pharmaceutics lab team learns why HIV prevention drug is not as effective in some women

Klatt lab team’s findings published in Science offer solutions to increase efficacy

UW Pharmaceutics Klatt Lab's graduate student Ryan Cheu, Associate Professor Nichole Klatt, and post-doc Alex Zevin
UW Pharmaceutics Klatt Lab’s graduate student Ryan Cheu, Associate Professor Nichole Klatt, and post-doc Alex Zevin

More than 1 million women are infected with HIV annually, and the majority of these new infections occur in young women in sub-Saharan Africa, with South Africa having among the highest incidence rates. Tenofovir is an antiretroviral drug that is used to prevent HIV infection (pre-exposure prophylaxis, “PrEP”). In clinical trials, tenofovir was effective for men, efficacy was highly variable in women.

In an article published in Science, UW School of Pharmacy Associate Professor of Pharmaceutics Nichole Klatt, along with UW graduate student Ryan Cheu, post-doc Alex Zevin, and Adam Burgener’s lab at the Public Health Agency of Canada found that tenofovir used as a topical vaginal gel for HIV prevention was more efficacious in women with healthy vaginal bacteria than bacteria associated with vaginosis, such as Gardnerella vaginosis. Furthermore, the team went on to determine that the reason tenofovir is less effective in women with G. vaginalis is because this bacteria can metabolize, or break down, the drug.

Their findings suggest that women with non–Lactobacillus-dominant vaginal bacteria may be more sensitive to the timing of gel application and adherence, whereas bacterial communities with Lactobacillus dominance may facilitate an environment more conducive to the topical PrEP efficacy.

The international team studied 688 women and investigated whether vaginal microbiota modulated tenofovir gel PrEP efficacy. It turned out that tenofovir reduced HIV infection by a 61% in women who were Lactobacillus-dominant—a staggering three-fold difference over women whose systems were non-Lactobacillus dominant. In non-Lactobacillus dominant systems, Tenofovir only reduced HIV incidency by 18%. Both groups had similar adherence to applying the gel.

The rapid depletion of tenofovir by G. vaginalis and other bacterial vaginosis (BV)-associated anaerobic bacteria by metabolism provides a biological mechanism likely contributing to a multifactorial process, including increased vaginal inflammation and adherence, leading to varying levels of HIV prevention efficacy observed across topical microbicide trials. Their data indicate that G. vaginalis is capable of decreasing the active drug by metabolizing tenofovir before drug uptake by target cells.

These findings provide evidence about the importance of vaginal microbial communities on prevention efficacy, which could help improve this HIV specific prevention strategy for women.

Because Lactobacillus dominance corresponds with a relatively low vaginal pH, typically below 4.5, vaginal pH testing may be a pragmatic approach to identify women most likely to benefit from topical tenofovir-containing microbicides and potentially other prevention strategies.

However, current treatment strategies for BV may not be sufficiently efficacious and better strategies that can both deplete anaerobic bacteria and support recolonization with Lactobacillus may be required. If validated in other trials, this could be a compelling reason for integrating topical microbicide implementation with sexual and reproductive health services so that vaginal health becomes an integral component of HIV prevention approaches.

Related: A microbiome variable in the HIV-prevention equation: Vaginal microbes thwart an antiretroviral microbicide

Associated Press Coverage: Women’s bacteria thwarted attempt at anti-HIV vaginal gel

To study with researchers like Dr. Klatt, click on the links for more information about our Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

Link to Pharmaceutics archived news

Team finds no adverse risk to use of common antimalarials in first trimester

Women and their children await medical care at a clinic.
Women and their children await medical care at a clinic. Photo: Photo courtesy of Malaria in Pregnancy Consortium

UW and international researchers publish the most comprehensive international analysis on artemisinin combination antimalarials safety in pregnancy

Malaria is more common and severe in pregnant women, increasing their risk of miscarriage and other adverse outcomes. The adverse consequences of malaria in pregnancy require prompt, safe, and effective treatment. However, limited data on the safety of the most efficacious and widely used antimalarial medications, artemisinin combination therapies (ACTs), has prevented ACTs from being recommended in the first trimester except in life-saving circumstances. The World Health Organization currently recommends the use of ACTs in pregnant women in the 2nd or 3rd trimester.

An international collaboration led by first authors Stephanie Dellicour of the Liverpool School of Tropical Medicine, UK, and Esperança Sevene of the Manhiça Health Research Centre/Eduardo Mondlane University, Maputo, Mozambique, and senior author Andy Stergachis of University of Washington School of Pharmacy and School of Public Health released the largest meta-analysis of all observational studies-to-date showing there was no difference in the risk of miscarriage, still births or major birth defects associated with the use of artemisinins anytime during the first trimester, compared with quinine. The study, “First- trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies,” was published in PLoS Medicine and coordinated through the Malaria in Pregnancy Consortium, established in 2007 at the Liverpool School of Tropical Medicine to improve the control and prevention of malaria in pregnancy.

“This study is clearly significant and reflects many years of work in Thailand and Africa by a large group of scientists,” said Liverpool’s Professor Feiko ter Kuile, head of the Malaria in Pregnancy consortium. “We have been able to show that artemisinins, which we know to improve outcomes in malaria, are as safe to use in the first trimester as quinine, which is currently recommended in the first trimester, but needs to be taken 3 times per day for 7 days. Quinine is associated with transient side effects such a ringing in the ears and dizziness, leading women not to complete their treatment course and risking inadequately treating their malaria. The artemisinin-based combinations are more efficacious, much better tolerated and can be taken over three days.”

The team analyzed data from five studies involving 30,618 pregnancies: four studies from Zambia, Tanzania, Rwanda, Kenya, Mozambique, Burkina Faso, and one large study from the Thailand based Shoklo Malaria Research Unit. They examined the records of women who had taken artemisinins for malaria, including during the first trimester of pregnancy. In malaria endemic countries, many early pregnancies are advertently or inadvertently exposed to artemisinins because women are not aware they are pregnant or do not report an early pregnancy.

The team summarized all available safety data on the effect of artemisinin exposure in the first trimester and compared the risk of miscarriage, stillbirth, and major congenital anomaly for pregnancies treated with artemisinin, quinine, or no antimalarials in the first trimester.

Through their meta-analysis, they determined the risk of miscarriages, stillbirths, and major anomalies associated with first-trimester artemisinin treatment versus quinine. The results were then combined with summary effect estimates from the Shoklo Malaria Research Unit on the Thailand–Myanmar border.

They found no increase in the risk of miscarriage, stillbirth, or major birth defects associated with the use of artemisinins anytime during the first trimester compared with the use of quinine during the same gestational period. These findings suggest that the artemisinin class of antimalarials should be considered for treatment of malaria in the first trimester of pregnancy. The limited data on the risk of birth defects require further observational studies.

Limited safety data on the use of artemisinins in human pregnancies have historically prevented health authorities from recommending these therapies for malaria treatment in the first trimester, except in life-saving circumstances. It is possible that this study may result in a major change to recommended guidelines for the administration of artemisinins in the first trimester of pregnancy.

“Our results show that artemisinins can now be formally considered for first trimester treatment,” said Andy Stergachis, Professor of Pharmacy and Global Health, University of Washington. While there is more work to be done in terms of monitoring birth defects, the available evidence suggests that the benefits of using this class of antimalarial are likely to outweigh any adverse outcomes and could help save the lives and maintain the pregnancies of women when they are most vulnerable to malaria.”

This project was supported by the Malaria in Pregnancy (MiP) Consortium, which is funded through a grant from the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine. The Malaria in Pregnancy Consortium consists of over 40 partner institutions in 29 countries around the world, joined in the fight against malaria in pregnancy and committed to improving its control and treatment in Africa, Asia and Latin America. The Shoklo Malaria Research Unit is part of the Mahidol Oxford University Research Unit, supported by the Wellcome Trust of Great Britain.

###

About Liverpool School of Tropical Medicine

The Liverpool School of Tropical Medicine (LSTM) is the world’s oldest centre of excellence in tropical medicine and international public health. It has been engaged in the fight against infectious, debilitating and disabling diseases since 1898 and continues that tradition today with a research portfolio in excess of well over £210 million and a teaching programme attracting students from over 65 countries. LSTM has been the international coordinating centre for the Malaria in Pregnancy (MiP) Consortium (https://www.mip.lstmed.ac.uk/) with over 40 research partners world-wide, established with a $30 million grant from the Bill and Melinda Gates Foundation and subsequent grants from European & Developing Countries Clinical Trials Partnership (EDCTP) and European Union. For more information please visit www.lstmed.ac.uk

About University of Washington School of Pharmacy

The UW School of Pharmacy is a global leader in pharmacy education, research and service, committed to providing a transformative learning experience in a collaborative and diverse environment focused on improving the health and well-being of the communities we serve. The UW School of Pharmacy is comprised of three departments: Medicinal Chemistry, Pharmaceutics, and Pharmacy, offering Ph.D., M.S., and PharmD degrees, post docs and certificate programs. The Department of Pharmacy leads in pharmacy education, research, professional and outreach initiatives, including the Pharmaceutical Outcomes Research & Policy Program (PORPP), which conducts research in pharmaceutical economics, drug safety and pharmaceutical policy. To study with researchers like Dr. Stergachis, click on the links for more information about our Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

About University of Washington School of Public Health

The UW School of Public Health, established in 1970, enrolls 1,500 students and has 270 primary and joint faculty members. Its mission is to create a world of healthy people in sustainable communities – locally, nationally and globally. Through its five departments, five interdisciplinary programs and more than 50 research centers, it carries out projects with partners in more than 130 countries.

About Shoklo Malaria Research Unit

The Shoklo Malaria Research Unit (SMRU) is a field station of the faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, and is part of the Mahidol-Oxford Research Unit supported by the Wellcome Trust, United Kingdom. The main objective of SMRU is to provide quality health care to the marginalized populations living on both sides of the Thai-Myanmar border in the Mae Sot area, Tak Province through the dual activities of research and humanitarian services, with an emphasis on maternal-child health and infectious diseases.

 

Roger Woolf receives Distinguished Alumni Award

 

Scott Herzog and Gary Harris of PAA present the Distinguished Alumni Award to Roger Woolf
Scott Herzog and Gary Harris of PAA present the Distinguished Alumni Award to Roger Woolf Photo: Matt Hagen

ROGER WOOLF, ’85, is passionate about the leadership role pharmacists can have in the U.S. health care system. Growing up, many of his family members were in healthcare professions, including pharmacy. “My uncle was a pharmacist in Yakima,” he reflected. “Talking with him about his work helped me to see the potential impact pharmacists could have when they can be patient-focused.”

In his position at Virginia Mason Medical Center, Roger provides leadership for a broad scope of pharmaceutical services within the Center’s integrated health care system. But he doesn’t stop there. He works diligently to teach and mentor student pharmacists to become leaders in health care and has been very committed to training UWSOP APPE/IPPE students and interns. “I always encourage students to get involved in leadership opportunities while in school. If we are to continue to advance the practice, we need people who can lead with passion, and not be afraid to try new and innovative ways for pharmacists to impact patient care.”

“I am very appreciative of the training I received at the UW and am a strong advocate for the quality of education for which the School of Pharmacy is well known. To be personally recognized in this way is a real honor.”  –Roger Woolf, UWSOP Alumnus

He has maintained his connection with the UWSOP since completing his PharmD degree in 1985. “From the moment I was accepted to the UWSOP, I knew I was part of something special,” he said. “The faculty challenged us to be innovative and push a progressive practice. It was at UW that I really started my passion for advancing the practice.”

He has collaborated with UW faculty and WSPA leadership for years to educate Washington state legislators on the benefits of having pharmacists as paid providers. “There were so many barriers to getting pharmacists credentialed. Working with Don Downing, Jeff Rochon, and many others, we were able to show the benefits to patients that come from having pharmacists as providers.” Now the team travels the U.S. sharing with providers and legislators how Washington led the way in advancing patient care by establishing pharmacists as full members of the health care team.

 

Interested in earning your PharmD degree at the UW? Click here to learn more.

Link to Department of Pharmacy archived news

UW Team develops an HIV therapy dose that lasts two weeks in test model

TLC-ART Team (from left to right): Rodney Ho, Josefin Koehn, Sarah Lane, Lisa McConnachie John (Jake) Kraft, Loren Kinman, Jesse Yu and Wonsok Lee.
UW TLC-ART Team (from left to right): Rodney Ho, Josefin Koehn, Sarah Lane, Lisa McConnachie John (Jake) Kraft, Loren Kinman, Jesse Yu and Wonsok Lee. Photo: Alex Levine

Collaboration between UW School of Pharmacy and UW Medicine leads to promising breakthrough to ease daily regimen

An interdisciplinary team led by Professors Rodney JY Ho of the UW School of Pharmacy and Ann Collier of the UW School of Medicine has been working to develop a long-lasting (7-day) therapy for HIV and are already making advances into long-term therapies to suppress the HIV virus.

In the March issue of the journal AIDS, the UW’s Targeted Long-Acting Combination Antiretroviral Therapy (TLC-ART) team reported that a dose that combines three HIV drugs—intended to overcome drug insufficiency in lymph nodes—lasted over two weeks in a macaque model, a remarkable breakthrough.

First author Jake Kraft, 4th year PhD graduate student in Pharmaceutics
First author Jake Kraft, 4th year PhD graduate student in Pharmaceutics Photo: Alex Levine

Currently HIV patients take multiple pills daily, which can create challenges for some HIV-positive people. Details of the study were published in the March 2017 issue of AIDS, one of the most respected HIV/AIDS journals. John Kraft, Lisa McConnachie, Josefin Koehn, Loren Kinman, Carol Collins, Danny Shen, Ann Collier and Rodney Ho lead the research team. The article is entitled, “Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.”

The two co-Principal Investigators and the TLC-ART team are developing innovative treatments to overcome limitations of current oral drug therapies. The UW’s Targeted Long-Acting Combination Antiretroviral Therapy (TLC-ART) Program led by is an innovative, translational medicine research designed to leverage existing knowledge and a world-class interdisciplinary team of academic, NIH, and industry researchers to deliver new, safe, stable, scalable, and tolerable antiretroviral combination treatments for HIV infection.

The Program has multiple projects designed to interact in a coordinated and collaborative way with the focused goal of producing injectable drug combinations that will achieve effective drug levels lasting more than seven days.

This study is sponsored by NIH Grant UM1 AI120176.

To study with researchers like Dr. Ho, click on the links for more information about our Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

Navajo genetic scientist Katrina Claw bridges cultures to advance research and underrepresented scientists

Dr. Katrina Claw’s research builds on a six-year UW Northwest-Alaska Pharmacogenomics Research Network (NWA-PGRN) and University of Alaska Fairbanks Center for Alaska Native Health Research (CANHR) collaboration.
Dr. Katrina Claw’s research builds on a six-year UW Northwest-Alaska Pharmacogenomics Research Network (NWA-PGRN) and University of Alaska Fairbanks Center for Alaska Native Health Research (CANHR) collaboration. Photo: Alex Levine

As a Navajo scientist trained in genomics, UWSOP post doctoral researcher Katrina Claw is on a two-fold mission to make a difference: As a scientist, she seeks to understand the role genetics play in Vitamin D insufficiency in Alaskan Native populations.

“I am like a bridge. I connect Native knowledge and Western science, but I am also walked over. It can be hard to connect the multiple cultures and ways of knowing, but I am sure this is the best path forward.”–Katrina Claw, Post Doc, Pharmaceutics

As a Native American, she wants to increase the number and impact of indigenous people pursuing science as a career. “It’s not enough just to get admitted to a program or school,” she says. “There are significant burdens on underrepresented students. We need mentors who can provide support, and guide us through the system, particularly to find funding. I was fortunate to find faculty mentors like Drs. Wylie Burke and Kenneth Thummel who believed in me.”

Katrina also found support in organizations like the Society for Advancement of Chicanos/Hispanics and Native Americans in Science (SACNAS). “When high school students meet me, they realize they can pursue science as a career and I want to encourage them in that work.”

Pharmaceutics’ post doctoral researcher Katrina Claw, PhD, leads the way with a collaborative approach to pharmacogenetics and scientific discovery, working closely with Alaska Native people (shown pictured in the Turnagain Arm near Anchorage, Alaska).
Pharmaceutics’ post doctoral researcher Katrina Claw, PhD, leads the way with a collaborative approach to pharmacogenetics and scientific discovery, working closely with Alaska Native people (shown pictured in the Turnagain Arm near Anchorage, Alaska).

Her life experiences inform her research. Working with tribal partners in the Northwest-Alaska Pharmacogenetic Research Network (NWA-PGRN), Katrina’s NIH fellowship research seeks to identify and functionally characterize variation in genes related to vitamin D metabolism. Vitamin D deficiency is a public health problem, particularly for northern latitude indigenous populations. Limited sunlight exposure and a shift to Western diets may be some of the driving causes of insufficiency, but gene variation modifies individual risk.

With all that’s known, there remains inter-individual variability that is not completely understood. As more Alaskan Native people suffer from vitamin D insufficiency, there may be increases in pathologies like cancer, heart disease, and bone disease. Knowledge of genomic variation associated with Vitamin D levels will be key to achieving optimal intervention strategies that reverse the insufficiency.

Another aspect of Katrina’s research is to actively engage with Native American partners, exploring their expectations for genomic medicine research. In the past, some Native communities lost trust in researchers who used tissue samples and data without permission.

“It needs to be a transparent, meaningful partnership. In particular for genomics, it is all about how you generate, store and share data,” said Katrina. “The core of UW’s NWA-PGRN mission is to form and deepen connections with the communities with whom they work.”

She wants to partner with more tribes in the future to help them benefit from health research. One possible outcome: a return to a more traditional diet that may improve Vitamin D levels and also support tribal efforts to keep traditions alive in the community.

“How we communicate findings is important. We have to go beyond academic papers and work with tribal leaders to inform the community.”

Advance your career in research or pharmacy at the University of Washington!

Click on the links for more information about our Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

Link to Pharmaceutics archived news

Sid Nelson’s legacy lives on in science and collaboration

Former SOP First Lady Joan Nelson with Sid Nelson Endowed Professor of Medicinal Chemistry, Bill Atkins
Former SOP First Lady Joan Nelson with Sid Nelson Endowed Professor of Medicinal Chemistry, Bill Atkins Photo: Alex Levine

Busulfan is one of our oldest anticancer drugs. Today, it is often used to prepare a patient’s body for a bone marrow transplant (hematopoietic cell transplant [HCT]) to fight various cancers. Busulfan kills some of the patient’s blood cells to ensure the donor cells will be accepted.

But busulfan is toxic.

The work to mitigate that toxicity has become central in three labs across UWSOP—a collaboration that would have brought cheer to the late Dean Sid Nelson. “Sid was fascinated by the biological and toxicological implications of chemistry,” shared Bill Atkins.

“Busulfan is a ‘goldilocks’ drug. The dosing has to be just right.”
–Jeannine McCune, Professor of Pharmacy

Pharmacy Professor Jeannine McCune
Pharmacy Professor Jeannine McCune

The collaboration began when Pharmacy Professor Jeannine McCune reached out to Bill in Medicinal Chemistry. For twenty years, Jeannine has studied the effects of busulfan on HCT patients to improve its efficacy and lower its toxicity. “ She approached Bill about using metabolomics, a new field that characterizes the small molecule metabolites in biological systems. She asked him to look at the data because of his expertise in the protective molecule glutathione, an antioxidant. (Glutathione is important to busulfan because it is metabolized by the glutathione S-transferases.)

“Sid might have called it ‘strange chemistry.’ Normally when a toxic drug modifies a protein, the drug stays around which makes it toxic—but busulfan modified a protein and then disappeared. It’s really awesome! I kept wondering why no one had studied this before.”
–Bill Atkins, Sid Nelson Endowed Professor of Medicinal Chemistry

Former UWSOP Dean, Sid Nelson
Former UWSOP Dean, Sid Nelson

Bill saw the potential for novel protein modifications. In some classic cases, including examples studied by Sid, drugs or their metabolites are toxic because they stick on to proteins covalently. But with busulfan, it reacts with the proteins, changes them, and then disappears—having changed the chemical nature of the protein. “To my knowledge, it’s unprecedented,” said Bill.

Busulfan converts cysteines in proteins into dehydroalanine. These reactions also may have utility in protein engineering or nanotechnology. “If you could get other things to react with the dehydroalanine, you could expand how proteins are used—including application of functional probes, drugs, or targeting moieties.”

“Busulfan is a legacy drug, with a mechanism of action based on World War I chemical warfare agents, but it’s still a frontline drug in pediatric cancer therapy,”
— Ed Kelly, Associate Professor of Pharmaceutics

Associate Professor of Pharmaceutics Ed Kelly
Associate Professor of Pharmaceutics Ed Kelly

The collaboration has expanded. Understanding the toxicity of busulfan led Jeannine and Bill to Ed Kelly in Pharmaceutics, whose work with the organ on a chip project is making him a leader in Toxicology. Ed is working to create a liver on a chip that integrates vascular cells so they can start identifying pathways, proteomics, metabolomics, and chemistry, specifically for busulfan toxicity in this example.

Jeannine, Bill, and Yvonne Lin (Associate Professor in Pharmaceutics) have an ongoing NIH R01 grant trying to improve the efficacy and lower the toxicity of busulfan. The team is eager to continue this project which embodies the collaborative spirit and science that were hallmarks of Sid’s leadership.

Advance your career in research or pharmacy at the University of Washington!

Click on the links for more information about our Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

UWSOP Alumnus Watanabe named National Academy of Medicine Fellow

Jonathan H. Watanabe, PharmD, PhD
Jonathan H. Watanabe, PharmD, PhD

University of Washington School of Pharmacy alumnus, Jonathan H. Watanabe, PharmD, Ph.D., ’08, ’12, has been selected as one of three outstanding health professionals for the class of 2016 Fellows National Academy of Medicine (NAM).

The NAM fellows were chosen based on their professional qualifications, reputations as scholars, professional accomplishments, and relevance of current field expertise to the work of the NAM and the Health and Medicine Division of the National Academies of Sciences, Engineering, and Medicine. There is only one pharmacy fellow nationally.

Watanabe earned both a master’s and doctoral degree in UW School of Pharmacy’s Pharmaceutical Outcomes Research and Policy Program, after earning his undergraduate degree at the UW. He was the first recipient of the prestigious UW/Allergan Post-doctoral Fellowship in Health Economics and Outcomes Research. His major research areas include: cost time to-event analysis, cost epidemiologic assessments, payer cost modeling, drug interactions impact, guidelines adherence assessment, and is interested in biostatistical methods (survival analysis) and applications of epidemiologic techniques to cost analysis.

The Class of 2016 NAM Fellows include: Pharmacy Fellow Jonathan H. Watanabe, PharmD, Ph.D., assistant professor of clinical pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego; Osteopathic Medicine Fellow Jennie H. Kwon, DO, Washington University School of Medicine; and James C. Puffer, M.D./American Board of Family Medicine (ABFM) Fellow Sean C. Lucan, MD, MPH, M.S., Albert Einstein College of Medicine, Bronx, N.Y.
The fellows will collaborate with eminent researchers, policy experts, and clinicians from across the country. They will help facilitate initiatives convened by the Academies to provide nonpartisan, evidence-based guidance to national, state, and local policymakers, academic leaders, health care administrators, and the public.

Each fellow will continue in his or her primary academic post while engaging part time over a two-year period in the Academies’ health and science policy work. Each will work with an expert study committee or roundtable related to his or her professional interests, including contributing to its reports or other products. A flexible research stipend of $25,000 will be awarded to every fellow.

Advance your career in patient-centered outcomes research at the University of Washington. Learn more about our Graduate Programs in Pharmaceutical Outcomes Research and Policy.


Link to Department of Pharmacy archived news

Class of 2017 Honors Professor Doug Black

UW School of Pharmacy's PharmD Class of 2017
UW School of Pharmacy’s PharmD Class of 2017 have decided to honor Dr. Doug Black with a gift to his endowment

UW School of Pharmacy’s PharmD class of 2017 announced their class gift this week. They will work together over the coming year to make a P4 Class Giving Fund donation to the Doug Black Endowed PharmD Award, a scholarship that is given each year to a UW School of Pharmacy student who exemplifies an outstanding commitment to learning and the profession of pharmacy.

“Scholarships are a huge benefit to current students as they allow us to participate in conferences and other events like Medical Brigades that we would have difficulty affording otherwise,” they shared in their announcement. “These experiences are invaluable to us and often help shape our future practice.”

The Class wanted to honor Dr. Doug Black who has been an important influence on them, both as a professor and a mentor, and has pushed them to become better students and pharmacists. “Doug has consistently gone above and beyond what is expected of a professor. He has always been happy to take time out of his day to meet with students and help in any way that he can. Last year, as the course master for our infectious disease therapeutics course, Doug would send out emails daily encouraging us in our studies and reminding us that no matter how hard things seemed, we could handle it. Doug’s emails were often what we would wake up to in the morning, as he gets up most mornings at 4 am, much earlier than any of his students.”

Below are a few excerpts from some of those emails that represent what a truly caring and encouraging professor he is:

  • Dr. Doug Black talks with students in the Bracken Lab.
    Dr. Doug Black talks with students in the Bracken Lab.

    “On my walk to my car on Boyer Ave (I hate paying for parking), I was thinking about you and I have to say, I’m proud of you–and I’m very happy with how things are going.”

  • “First and foremost, good luck on your exam today. Luck really shouldn’t be a part of it, but we all know how that goes. Anyway, I wish you logical thought and an unusually responsive memory.”
  • “Sometimes all you can do in times of adversity is soldier on. I know that is what you are doing this week. I wish you all the best in finishing up this hellish week. You’ve earned some downtime. I hope you can get some.”
  • “I don’t want our class to end, by the way.”
  • “Thanks for an unforgettable Spring.”

UWSOP alumni and friends are invited to join the Class of 2017 in honoring Doug’s commitment to students and scholarship by making a gift to the Doug Black Endowed Pharm.D. Award. To contribute toward the class’ gift total, please make your gift to Doug’s fund through the P4 Class Giving Fund today.

“Just as Doug has encouraged us, we look forward to encouraging future Pharm.D. students through our class gift.”

If you have questions about making a gift, please email rxalumni@uw.edu.

Give to the Doug Black Endowed PharmD Award through the P4 Class Giving Fund today.

UW researchers find revascularization provides greater improvements for patients with peripheral arterial disease

Peripheral arterial disease can cause pain in the legs and make walking uncomfortable.
Peripheral arterial disease can cause pain in the legs and make walking uncomfortable. Photo: ThinkStock

Study published in JAMA Surgery compares effectiveness of two ways to treat intermittent claudication by evaluating outcomes that are important to patients

UW researchers found that patients with intermittent claudication, a form of peripheral arterial disease, who had procedures to restore circulation called revascularization had better quality of life and fewer symptoms a year later than patients who underwent medical management.

Emily Beth Devine, PhD, PharmD, MBA, of the University of Washington School of Pharmacy, and colleagues compared the effectiveness of two treatments for intermittent claudication: a medical management program consisting of walking exercise, medicines, and smoking cessation counseling; and revascularization by surgically unblocking clogged blood vessels or by implanting tiny wire mesh tubes called stents into the vessels that help keep arteries open. The study focused on outcomes that matter most to patients: for example, can they climb stairs and walk farther and faster with less pain, has their quality of life improved, and do they experience fewer symptoms?

Dr. Emily B. Devine compared the effectiveness of a medical program against a procedural intervention, focusing on outcomes of greatest importance to patients with Intermittent Claudication.
Dr. Emily B. Devine compared the effectiveness of a medical program against a procedural intervention, focusing on outcomes of greatest importance to patients with Intermittent Claudication.

“Revascularization procedures such as surgery or stents are normally reserved for the most severe symptoms, but we looked at whether these interventions may benefit patients with less severe cases of intermittent claudication,” said Devine. “Our findings provide the best community-based evidence available to date and suggest that those with moderate cases of intermittent claudication may also benefit from surgery or stent placement.”

Peripheral arterial disease (PAD) is a disease affecting 8 million Americans in which plaque builds up in the arteries and limits the flow of oxygen. The peripheral arterial disease study, published in JAMA Surgery, looked at intermittent claudication, which limits the ability to walk. Both medical interventions and revascularization interventions such as angioplasty, stents, and surgical bypass aim to increase walking comfort and distance, but there is inconclusive evidence of the comparative benefit of revascularization given the possible risk of limb loss.

The study was conducted at 15 clinics associated with 11 hospitals in Washington state. Participants were 21 years or older with newly diagnosed or established intermittent claudication. A total of 323 adults were enrolled, with 282 (87 percent) receiving the medical treatment program. At the start of the study, the average duration of disease was longer for participants who received the medical intervention program, while those who underwent revascularization reported more severe disease.

At 12 months, this comparative effectiveness research (CER) study showed that intermittent claudication patients who had revascularization procedures experienced significantly higher function, better quality of life, and fewer symptoms.

“Patients who were treated with surgery or stents reported improvements in walking distance, speed, stair climb, pain, health-related quality of life, and symptoms. These improvements exceeded those of patients who were treated with medicines, smoking cessation counseling and exercise. Results suggest that revascularization is a reasonable alternative to medical management for patients with moderate to severe intermittent claudication, providing important information to inform treatment strategies in the community,” the authors write. Comparative effectiveness research is designed to inform healthcare decisions by providing evidence on the effectiveness, benefits, and harms of different treatment options.

The study was conducted under the auspices of an AHRQ grant written by David R. Flum, MD, MPH, Associate Dean for Research, UW Department of Surgery and the Director of the Surgical Outcomes Research Center (SORCE). He conceived of the research project and collaborated with a multidisciplinary research team called the Comparative Effectiveness Research Translation Network (CERTAIN) Collaborative. Devine, a faculty member in the UW School of Pharmacy Pharmaceutical Outcomes Research and Policy Program (PORPP) was the lead CER methods investigator.

This study is the first of several to come that build on research for Flum’s statewide quality improvement registry, the Surgical Care & Outcomes Assessment Program (SCOAP), which he launched in 2005 by enlisting over 91% of hospitals across the state of Washington. The data gathered in the registry identify best practices to improve patient care.

CERTAIN is a statewide research infrastructure that leverages SCOAP data to study the comparative effectiveness of treatment strategies for a variety of disease states through the lens of patient-centered care. The intermittent claudication study published in JAMA Surgery is the inaugural study of the CERTAIN Collaborative and the CERTAIN network.

This project was supported by grant number R01HS020025 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.

Advance your career in patient-centered outcomes research at the University of Washington. Learn more about our Graduate Programs in Pharmaceutical Outcomes Research and Policy.

Link to Department of Pharmacy archived news

Costs outlined of health plans that exclude contraception

A positive pregnancy test. Women ages 18 to 24 and those over 40 years old were most affected by having to pay out of pocket for birth control, the researchers found.
A positive pregnancy test. Women ages 18 to 24 and those over 40 years old were most affected by having to pay out of pocket for birth control, the researchers found. Photo: ThinkStock

Pharmacy study links lack of coverage to more unintended pregnancies, greater health expenses for employers

At companies whose health insurance plans exclude contraception coverage, female employees experienced 33 more unintended pregnancies per 1,000 women, and more unintended births and terminations. Such plans might also result in higher overall costs for employers.

Those were the primary findings of a study led by the University of Washington School of Pharmacy and Princeton University, recently published in the journal Contraception.

“The women who were most affected were ages 18 to 24 or over 40 years old,” said Will Canestaro, a UW graduate student and one of the study’s two lead authors. “Essentially, women at the start and end of their reproductive years were most sensitive to the costs for paying out of pocket for birth control.”

Elisabeth Vodicka and Will Canestaro, graduate students in UW's School of Pharmacy, led the study.
Elisabeth Vodicka and Will Canestaro, graduate students in UW’s School of Pharmacy, led the study.

Elisabeth Vodicka and Will Canestaro, graduate students in UW’s School of Pharmacy, led the study.

It’s well established that access to birth control lowers unintended pregnancies and terminations, and is cost-effective at the societal level. Under the Affordable Care Act (ACA), employers are required to cover birth control, but in recent years several employers have gone to court to opt out of the requirement.

Canestaro and colleague Elisabeth Vodicka were curious about the effects that private health insurers’ birth-control coverage had on plan costs and reproductive-health decisions of women on those plans.

The students reached out to Don Downing, a UW pharmacy professor, and health economist James Trussell, professor emeritus of economics and public affairs at Princeton University. He specializes in reproductive health and demographic methodology.

Read more on UW Health Sciences NewsBeat.

UW team finds key piece to HIV drug-effectiveness puzzle

Microscopic picture of vaginal epithelial clue cells coated with Gardnerella vaginalis, magnified 400 times.
Microscopic picture of vaginal epithelial clue cells coated with Gardnerella vaginalis, magnified 400 times. Photo: Wikimedia Commons | Dr. F.C. Turner

Pharmaceutics researchers detect bacteria that counteracts protective drug

Increasingly, people at risk for HIV infection are turning to preventive drug measures to help stave off the virus. Researchers from the University of Washington School of Pharmacy found that one such drug, Tenofovir, in the form of a topical vaginal gel, is metabolized, or broken down, by the common bacterium Gardnerella vaginalis.

This negative effect counteracts the gel’s intended protection. Women who apply the drug but who have that bacterium are more vulnerable to HIV infection.

The good news, however, is that Gardnerella, commonly associated with bacterial vaginosis, is relatively easy to detect and treat.
Nichole Klatt, center, with lab team members Ryan Cheu, left, and Alex Zevin, right.
Nichole Klatt, center, with lab team members Ryan Cheu, left, and Alex Zevin, right. Photo: Alex Levine Photography

The finding emerged in the lab of Nichole Klatt, UW assistant professor of pharmaceutics and pathobiology. Grad student Ryan Cheu and postdoctoral fellow Alex Zevin uncovered the mechanism. “These findings open up a whole new field of research in drug efficacy,” Klatt said.

Their analysis looked at 3,334 genital bacterial proteins from 688 women in the Centre for the AIDS Programme of Research in South Africa trial. The trial, a collaboration of the UW team and lead investigator Dr. Adam Burgener of the University of Manitoba and Public Health Agency of Canada, assessed the ability of Tenofovir gel to block new HIV infection.

Analysis showed the drug was less effective for a relatively large population of women, and Burgener and Klatt wanted to understand why. In most of the women, lactobacillus was the dominant vaginal bacterium. Burgener discovered that women who have a predominance of “good” lactobacillus in their reproductive tract were better protected by the Tenofovir gel but hadn’t figured out why until Klatt’s team identified Gardnerella’s role.

Read more: UW team finds key piece to HIV drug-effectiveness puzzle: Pharmacy researchers detect bacteria that counteracts protective drug

Interested in studying with preeminent faculty like Dr. Klatt? Apply for an MS or PhD in Pharmaceutics? Click here.

NACDS Launches Initiative to Improve Immunization Rates through Collaboration between UWSOP, Bartell Drugs, and QFC Pharmacy

Providing patient-centered care is a hallmark of best practices in pharmacy.
Providing patient-centered care is a hallmark of best practices in pharmacy.

Three demonstration projects aim to fulfill goals of $800,000 CDC grant to NACDS

The National Association of Chain Drug Stores (NACDS) announced that the University of Washington School of Pharmacy (UWSOP), Bartell Drugs, and QFC Pharmacy will partner with Washington State Health Care Authority in a unique demonstration project that aims to foster healthcare collaboration across the care continuum to increase pharmacy-based immunizations.

The demonstration project is one of three that aim to fulfill the goals of an $800,000 Centers for Disease Control and Prevention (CDC) grant to NACDS. The project will examine innovative healthcare collaborations designed to demonstrate increased rates of pharmacy-based immunizations including influenza, pneumococcal, pertussis and herpes zoster. It also focuses on improving pandemic planning among pharmacies and state health departments and improving access to vaccine resources and education for pharmacists.

Principle Investigator and Associate Dean Peggy Odegard
Principle Investigator and Associate Dean Peggy Odegard

The demonstration project is one of three that aim to fulfill the goals of an $800,000 Centers for Disease Control and Prevention (CDC) grant to NACDS. The project will examine innovative healthcare collaborations designed to increase immunization rates through pharmacies including influenza, pneumococcal, pertussis and herpes zoster vaccines. The UW-based project is aimed to help identify best practices to improve adult immunizations rates, implement innovative methods for sharing immunization information, align incentives across healthcare partners to promote optimal immunization care, and improve pandemic vaccine preparedness.

Increasingly, pharmacists are recognized as the front line of health care in communities. “Legislators and regulators at the federal and state levels often reference pharmacists’ success in promoting the necessity of vaccines and in increasing access to them,” said NACDS President and CEO Steven C. Anderson, IOM, CAE.

Co-Principle Investigator and Assistant Professor Jennifer Bacci
Co-Principle Investigator and Assistant Professor Jennifer Bacci

The state of Washington has lead the way when it comes to pharmacists practicing at the top of their license, thanks to the advocacy of UW pharmacy faculty. Pharmacist-provided vaccines were among the first of many practice innovations begun at the UW. This project brings together faculty researchers and practitioners who will tap into the diverse expertise at the UWSOP, from pandemic health to onsite coaching in patient care best practices, including principal investigator, Associate Dean Peggy Odegard, co-principal investigator, Assistant Professor Jenny Bacci, along with investigators Associate Dean Andy Stergachis, Research Assistant Professor Ryan Hansen, and Research Assistant Professor Aastha Bansal and Washington State Pharmacy Association’s Director of Pharmacy Practice Development, Jenny Arnold as a key consultant

“We are excited about this demonstration project that brings together top community pharmacy providers and faculty from the School of Pharmacy with expertise in implementation science and population health. This project will build on our legacy of improving community access to pharmacist-administered vaccinations and evaluating the impact of these important services on population health outcomes,” said Sean D. Sullivan, professor and dean of UWSOP.

“Bartell Drugs has been a regional leader in promoting and providing convenient, affordable access to immunizations and this project will further our ability to reach more audiences in need of immunization,” says Billy Chow, Bartell Drugs’ Vice President of Pharmacy Operations and Clinical Services.

“We are thrilled to continue to improve the shopping experience and add convenience for our patients through this NACDS project,” said Chuck Paulsen, pharmacy merchandiser for QFC Stores. “The increased awareness and transparency of community based will further our mission of improving the health of our patients and local communities we serve.”

NACDS showed its strong commitment to this $800,000 grant by contributing an additional $300,000 to execute the demonstration projects. The project will take place over a 13-month period beginning in August 2016. More information about NACDS’ engagement on related issues is available through the “vaccinations” and “preparedness” tags on NACDS.org.

# # #

NACDS represents traditional drug stores and supermarkets and mass merchants with pharmacies. Chains operate more than 40,000 pharmacies, and NACDS’ chain member companies include regional chains, with a minimum of four stores, and national companies. Chains employ more than 3.8 million individuals, including 175,000 pharmacists. They fill over 2.7 billion prescriptions yearly, and help patients use medicines correctly and safely, while offering innovative services that improve patient health and healthcare affordability. NACDS members also include more than 800 supplier partners and nearly 40 international members representing 13 countries. For more information, visit www.NACDS.org.

University of Washington School of Pharmacy is a global leader in pharmacy education, research and service, committed to providing a transformative learning experience in a collaborative and diverse environment focused on improving the health and well-being of the communities we serve. Our mission is three-fold: inspiring education: developing exceptional, innovative and diverse pharmacy leaders and scientists; discovering solutions: advancing the science, development, implementation, and outcomes of safe and appropriate treatments; and serving people and communities: promoting the health and well-being of the public, locally and globally. For more information, visit sop.uw.edu.

Bartell Drugs: Family-owned since 1890, Seattle-based Bartell Drugs is proud of its more than 125-year history based here in the Northwest. Four generations of the Bartell family have continuously focused on the future – and how the drugstore chain could better serve its customers. Operating 64 locations in King, Snohomish and Pierce counties, it is the nation’s oldest family-owned drugstore chain. For more information on Bartell Drugs, visit www.bartelldrugs.com.

QFC Stores: Founded in 1954, based out of Bellevue, Washington is a division of the Kroger Company. QFC has 64 stores throughout the Puget Sound, Southwest Washington, and Northwest Oregon. They currently operate pharmacies in 32 of their stores. For more information on QFC, visit https://www.qfc.com

 

UWSOP faculty and alumni elected to ISPOR leadership

UWSOP faculty and alumni past, present and future leaders of ISPOR (From left to right): Past President (2003-2004) Sean D. Sullivan, President Lou Garrison, President-elect Shelby D. Reed, Immediate Past President Daniel Malone, Past President (2010-2011) Scott Ramsey
UWSOP faculty and alumni past, present and future leaders of ISPOR (From left to right): Past President (2003-2004) Sean D. Sullivan, President Lou Garrison, President-elect Shelby D. Reed, Immediate Past President Daniel Malone, Past President (2010-2011) Scott Ramsey

Five UWSOP faculty and alumni have led ISPOR over the past 20 years

UW School of Pharmacy faculty and alumni are again recognized as leaders in health care. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced the election of the Society’s 2016-2017 Board of Directors that assumed office on July 1, 2016. Many of the new leadership team are part of the UW School of Pharmacy family. This recent election marks an historic time when UW School of Pharmacy is represented in the past, current and future presidential leadership roster for ISPOR, showcasing our outstanding alumni and preeminent faculty.

Lou Garrison, PhD, assumes the role of President for 2016-17 after most recently serving as the Society’s President-Elect. Lou is a highly-respected Professor in the Pharmaceutical Outcomes Research and Policy Program in UWSOP. “I am honored and privileged to have the opportunity to serve as President of ISPOR this coming year as we enter our third decade.  My priorities will be:  supporting our global network to expand capacity in outcomes research, continuing to improve the science of outcomes research through our task forces and journals, and collaborating with allied organizations, such as ASHEcon, HTAi, AMCP, DIA, SMDM, and AcademyHealth.”

Daniel C. Malone, RPh, PhD, who had completed his post doc work at UWSOP, becomes Immediate Past President. Dan serves as Professor of Pharmacy, College of Pharmacy and Associate Professor in Mel and Enid Zuckerman College, University of Arizona in Tucson, Arizona.

ISPOR’s global membership elected Shelby D. Reed, RPh, PhD, who had also completed her post doc work here at UWSOP, to serve as President-Elect for the Society for 2016-17. Shelby is Professor, Duke University in Durham, North Carolina. Shelby’s election With Shelby’s election as ISPOR President-elect, UW School of Pharmacy has five faculty and alumni who have gone on to serve as President of ISPOR.

The new ISPOR Board of Directors also now includes alumnus John Watkins, MPH, PharmD, ’79, ’11, Formulary Manager, Premera Blue Cross in Mountlake Terrace, Washington. John received the UWSOP’s Award for Excellence in Clinical Teaching in 2014 for being an exemplary practitioner, role model, coach, facilitator, and team player for over 20 years.

ISPOR is an organization with tremendous influence in global health economics. In the words of our own Lou Garrison: ISPOR has “over 20,000 members in some 120 countries.   When you absorb that fact, you realize that ISPOR as an organization has tremendous potential to have a positive impact on health globally—and not just by sheer numbers but also by the quality of our science. The medical product and decision processes that ISPOR members study are based on information—about how a molecule affects the body or about how well an health technology assessment process works—and this knowledge is a global public good, potentially benefiting 7 billion people on the planet.”

ISPOR’s Board of Directors are elected by its global membership. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that promotes health economics and outcomes research excellence to improve decision making for health globally.

 

Student’s enterprise yields 3 “essentially paid” for degrees

Blythe Adamson whiteboards a problem in health economics research with colleagues Nathaniel Hendrix, left, and Wei-Jhih Wang.
Blythe Adamson whiteboards a problem in health economics research with colleagues Nathaniel Hendrix, left, and Wei-Jhih Wang. Photo: Alex Levine Photography

Pharmacy Ph.D. candidate shares tips for self-funding success

You would think three degrees from the University of Washington would take an enormous financial toll, but School of Pharmacy grad student Blythe Adamson, one of the UW’s Husky 100, has been energetic and enterprising about finding funding.
“I will graduate with all three of my degrees essentially paid for through a variety of public and private support,” she shared.

Her secret: She applies for everything. “It’s a numbers game of sorts,” she figures, influenced by a colleague’s suggestion that if the average grant or fellowship acceptance rate is 13 percent, applying for at least 10 opportunities should land at least one. (The colleague had applied for 10 scholarships and received two.)

Over the past 18 months, Adamson applied for 20 scholarships. She initially received nine rejections in a row. “It was disheartening, but it gave me a thick skin about my research and writing.” Finally, the tide of turned and she received five awards.

Read the full story on UW Health Sciences NewsBeat: Student’s enterprise yields 3 ‘essentially paid for’ degrees: Pharmacy Ph.D. candidate shares tips for self-funding success

Advance your career in health care economics research at the University of Washington. Learn more about our Graduate Programs in Pharmaceutical Outcomes Research and Policy

 

Link to Department of Pharmacy archived news

UW and Teva partner to increase provider access to critical drug interaction data

UW Pharmacy alum Erik Johnsen reviews a patient's electronic health records with a colleague.
UW Pharmacy alum Erik Johnsen reviews a patient’s electronic health records with a colleague. Photo: Alex Levine Photography

Clinical content from UW School of Pharmacy’s Drug Interaction Database to be integrated into Teva’s DDI+ platform to help improve health care delivery

The University of Washington (UW) announced today an exclusive partnership that will allow the university’s unique, comprehensive and high-quality pharmacokinetic and pharmacogenetic Drug Interaction Database (DIDB) clinical content to be integrated into the DDI+ platform. DDI+ is a cloud-based platform that complements electronic health records systems to help avoid adverse drug reactions. DDI+ was developed through Teva and is deployed by Mediseen, a wholly owned subsidiary of Teva.

Pharmaceutical companies and drug developers have been able to subscribe to the UW DIDB for many years. The DIDB is unique as it integrates highly detailed information regarding the experimental conditions and results of drug interaction, pharmacogenetic, and organ impairment studies from peer-reviewed journal articles and FDA New Drug Application Reviews.

Each year, about 100,000 U.S. patients die from adverse drug interactions, and 6 to 10 percent of hospitalizations stem from the phenomenon.
Each year, about 100,000 U.S. patients die from adverse drug interactions, and 6 to 10 percent of hospitalizations stem from the phenomenon. Photo: ThinkStock

Later in 2016, clinicians will have access to important pharmacokinetic, safety and efficacy information for their patients within DDI+. The platform’s extensive clinical content will pull from the DIDB and synchronize with data extracted from other leading databases, providing health care providers with information to help them detect, prioritize and solve adverse drug reactions quickly. Consideration can be given to multiple data points including the individual patient’s vital signs, preexisting health issues, available genetic markers and more against known drug-drug interactions and other drug precautions.

Adverse drug reactions exert a huge impact on patients’ health and on health costs and are among the top 10 causes of mortality in the US, more than car accidents, alcohol-induced fatalities and homicide. Each year, about 100,000 patients die and between 6 to 10% of hospitalizations are due to this phenomenon in the U.S. alone.

Personalized medicine will make drug interactions more complex, said Isabelle Ragueneau-Majlessi, who oversees the UW School of Pharmacy drug-interactions database.
Personalized medicine will make drug interactions more complex, said Isabelle Ragueneau-Majlessi, who oversees the UW School of Pharmacy drug-interactions database. Photo: Alex Levine Photography

“Adverse drug reactions are preventable, but personalized prescription is complex and requires a strong understanding of the various physiological processes involved,” notes Pharmaceutics Clinical Professor and CoMotion Presidential Innovation Fellow, Isabelle Ragueneau-Majlessi, who directs the UW DIDB program. “We need to do a better job translating research findings into actionable clinical information for health care providers. It is critical to understand the potential magnitude and cascading effects of drug interactions.”

Bringing synthesized and current information to the point of care, along with a user-friendly and intuitive interface, positions the DDI+ system to help clinicians evolve patient-specific care. “The DDI+ platform provides real time, comprehensive, patient-specific and easy-to-understand information regarding drug-related problems and offers a simple, quick and efficient solution to a real need of physicians and pharmacists,” said Dr. Roni Shiloh, Head of the DDI+ program at Teva. “The DDI+ platform has the potential to improve medical decision-making with timely and accurate information.”

Bringing together a novel approach to deliver synthesized, accurate and up-to-date data points in an efficient and user-friendly system was a key consideration to both UW and Mediseen while exploring the exclusive partnership. “Innovation is our imperative,” states UW’s Vikram Jandhyala, Vice President for Innovation Strategy and Executive Director of CoMotion, the collaborative innovation hub. “We have been working with the DIDB Team since 2002 and see the new relationship as accelerating the impact of UW technology on healthcare. Hospitals and doctors need better tools for identifying and managing adverse drug interactions.”

###

About UWSOP, the DIDB, and UW CoMotion

The University of Washington School of Pharmacy (UWSOP) is a global leader in pharmacy education, research and service, committed to providing a transformative learning experience in a collaborative and diverse environment focused on improving the health and well-being of the communities we serve. UWSOP is comprised of three departments: Medicinal Chemistry, Pharmaceutics, and Pharmacy, offering Ph.D., M.S., and PharmD degrees, post docs and certificate programs. The Metabolism and Transport Drug Interaction Database™ (DIDB™) and the Pharmacogenetics Database (e-PKGene™) are part of a knowledge base (“DIDB Platform™“) designed for scientists and clinicians working in the field of drug development, drug disposition and drug-drug interactions (DDIs). The DIDB Platform was developed at the University of Washington’s Department of Pharmaceutics, School of Pharmacy with input from pre-clinical and clinical pharmaceutical scientists. The DIDB was first licensed in 2002 and is currently used by a large number of pharmaceutical companies, regulatory agencies, contract research organizations and academic institutions worldwide. For more information, visit www.druginteractioninfo.org. CoMotion at the UW is the collaborative innovation hub to expand the societal impact of the UW community by developing and connecting local and global innovation ecosystems. http://comotion.uw.edu

About Teva and DDI+

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies, such as DDI+. DDI+ was developed through a wholly owned subsidiary of Teva. For more information on Teva, visit www.tevapharm.com.

 

New UW dual-campus PharmD-MBA concurrent degree program to launch Fall 2016

UWSOP Professor Jen Danielson, PharmD, MBA
UWSOP Assistant Professor Jen Danielson, PharmD, MBA Photo: Alex Levine Photography

Unique collaboration between UW and UW Bothell brings together the top of executive education value with the top pharmacist training program in the region

Student pharmacists at the University of Washington now have a tremendous opportunity to earn their PharmD and MBA degrees in just five years. The unique partnership between Schools at two different UW campuses allows students to weave MBA courses in with their pharmacy degree coursework, saving time and money.

The UW School of Pharmacy and the UW Bothell School of Business recently announced the new program opportunity, available to first-year students who are already in the PharmD program. “We are so pleased with this partnership between our two schools,” said Sean D. Sullivan, Professor and Dean of the UW School of Pharmacy. “We share a mission to develop leaders in the healthcare profession and together are uniquely positioned to support our students in launching their career as leaders in the field.”

Cap photoThe concurrent degree program goes beyond the business basics. With UW Bothell’s top-ranked educational value, choice of concentration, and the world-renowned faculty at UW School of Pharmacy, this program offers a new approach to health care leadership training. Students choose the Leadership or Technology track for their MBA, making them stand out in the market upon graduation.

Students will benefit in a number of ways, in both the short and long-term. Most immediately, they need only apply for the MBA program, as they are already enrolled in the School of Pharmacy. Given their proven academic credentials as UW PharmD students, UW Bothell School of Business is waiving the GMAT and GRE exam requirement.

Over the long term, they will gain the skills needed to manage community pharmacies, direct pharmacy operations in health systems or agencies, or step into other leadership roles. According to studies from the University of Buffalo and this one from South Carolina School of Pharmacy and The Citadel, PharmD-MBA graduates earn about 25% more, on average, than graduates with a PharmD degree alone.

Dr. Sandeep Krishnamurthy, Dean, School of Business, UW Bothell, says, “The School of Business at UW Bothell looks forward to welcoming PharmD students in our program. These students bring with them strong analytical abilities and a unique perspective into the healthcare sector. PharmD/MBA students are likely to rise to eminent leadership positions in the healthcare sector. We are delighted to be a partner in this effort.”

Current first-year UW PharmD students who have a bachelor’s degree were eligible to apply for this fall’s initial cohort. The MBA classes will kick off with a special leadership skills retreat in mid-September.

 

Interested in earning your PharmD-MBA degree at the UW? Click here to learn more.

# # #

The UW School of Pharmacy is a global leader in pharmacy education, research and service, committed to providing a transformative learning experience in a collaborative and diverse environment focused on improving the health and well-being of the communities we serve. Our mission is three-fold: inspiring education: developing exceptional, innovative and diverse pharmacy leaders and scientists; discovering solutions: advancing the science, development, implementation, and outcomes of safe and appropriate treatments; and serving people and communities: promoting the health and well-being of the public, locally and globally. The UW School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education. For more information, visit sop.uw.edu.

The UW Bothell School of Business is a dynamic, passionate and ambitious community of students, scholars, business leaders and staff. We inspire business excellence and enhance the vitality of the community through innovative research and exceptional educational programs with a strong commitment to ethical leadership, critical thinking and communication. The UW Bothell School of Business is independently accredited by The Association to Advance Collegiate Schools of Business (AACSB), representing the highest standard of achievement for business schools worldwide. The school is a signatory to the Principles of Responsible Management (PRME) initiative, a UN Global Compact program. For more information, visit www.uwb.edu/business.

2016 Highlight: UW PharmD students organize health sciences Interprofessional Education Health Fair

2016 UWOSP IPE Health Fair
Dental and pharmacy students had opportunities for hands-on learning at the inaugural Interprofessional Health Sciences New Years Health Fair organized by UW PharmD students Photo: Sarah C.B. Guthrie

2016 Highlight Stories: These stories highlight showcase the great work, service and achievements of our preeminent faculty and students in 2016.

In November 2015, student leaders in Phi Lambda Sigma met with Director of Student Leadership Programs, Nanci Murphy, to brainstorm how best to use a $2000 leadership grant awarded to create opportunities for pharmacy student leadership.

By the end of the meeting, the students had an ambitious idea: to create a health fair for the community—an interprofessional one that included pharmacy students as well as groups from across the UW Health Science disciplines—and to do it within just two months.
There was just one small problem: none of them had organized a health fair from scratch before.

The students reached out to faculty, administrators and students across UW’s Health Sciences. “It was daunting, especially when we started talking with people who had organized health fairs before. But people were really generous, sharing their time and expertise,” said Nick Larned, one of the three lead organizers. “In a couple of weeks, we booked a site and connected with students in medicine, dentistry, audiology, and physical therapy and had a plan.”

Students from across the UW Health Sciences shared information and educated visitors at the Health Fair
Students from across the UW Health Sciences shared information and educated visitors at the Health Fair Photo: Sarah C.B. Guthrie

“UWSOP is regularly held up as a national leader for interprofessional education because we’ve been doing it so well for so long.”
–Jennifer Danielson, Assistant Professor and Director of Experiential Education in Introductory Practice

The New Year’s Health Fair took place on Sunday, January 24, 2016, in Magnuson Park, near multiple transitional and lower income housing units. The students saw about 50 patients the morning of the NFL playoffs. They took advantage of the time to learn more about each other and their training. “The great part of this event,” said Assistant Professor Jennifer Danielson, Director of Experiential Education in Introductory Practice for UWSOP, “was that the students learned so much about each other’s disciplines and had the chance to share their skills and knowledge. Pharmacy students showed first year medical students the basics of how to take blood pressure and glucose testing. Dental students examined pharmacy students.” Co-organizer Arianne Duong shared, “I had no idea how much you could learn from a thorough dental, head and neck exam. Dentists are a great first line check for blood pressure problems.”

Students from across the UW Health Sciences greeted visitors to the Interprofessional Health Fair
Students from across the UW Health Sciences greeted visitors to the Interprofessional Health Fair

Interprofessional Education (IPE) has been a key part of UWSOP’s curriculum for over twenty years, ahead of other schools of pharmacy and health sciences. “When I first applied to the UW for pharmacy, I didn’t fully understand the advantages of an IPE curriculum,” said co-organizer Phoebe Stracener. “But through my training, I see the difference it makes to be so close to the other health sciences. It will be less intimidating when I’m on my rotations next year, now that I have learned how differently each of the professions approach health care problems and know what each of us brings to the table to help patients.”

 

Interested in earning your PharmD degree at the UW? Click here to learn more.

Lee lab uses 3D electron microscopy to visualize influenza virus invasion

For the first time, researchers have images showing how a virus pries its way past host membranes

The Lee lab team at work decoding the influenza virus’ secrets (from L to R: Associate Professor Kelly Lee, James Williams, and Nancy Horn, PhD).
The Lee lab team at work decoding the influenza virus’ secrets (from L to R: Associate Professor Kelly Lee, James Williams, and Nancy Horn, PhD). Photo: Alex Levine Photography

Three to five million people worldwide suffer from the flu each year—and it’s deadly. The World Health Organization (WHO) estimates that 250,000 to 500,000 people a year die from the flu. The people most at risk are those with compromised immune systems: children, older adults, people with immunosuppressive illnesses, and the unvaccinated.

But if you get the flu, those numbers just don’t seem to matter. You feel terrible—like you’ve been slammed by a giant bag of concrete. You lose strength and collapse into bed with fever, chills, aches, pains and more. Your body is all out of sorts. You feel like a zombie. Total dysfunction.

When you have the flu, you are out of sorts—right down to the molecular level.

Thanks to some advanced electron microscopy from UW School of Pharmacy’s Associate Professor of Medicinal Chemistry Kelly Lee’s laboratory, we are starting to understand how the influenza virus aggressively pries its way into cells. The team’s research may eventually lead to improvements in prevention and treatments for the flu and other similar viruses like HIV, herpes, dengue and Zika—diseases that affect millions worldwide every year.

The Journal of Virology published this break-through study in which, for the first time, Lee’s team captured 3-dimensional nanoscopic images of the molecular events that the flu virus carries out in order to fuse itself with a host cell and start a new infection. To create the 3D images, the team is riding a wave of new applications of cryo-electron microscopy (cryo-EM). These powerful electron microscopes, and the next generation cameras they use, are making it possible to obtain unprecedented glimpses into structures of protein machinery and viruses.

They take the protein and virus in a buffer and without fixing or staining the specimen, flash freeze it by plunging the specimen into cryogenic liquid ethane. With that kind of cold, the sample freezes before the water can crystallize, which preserves the proteins and membranes in their native states. Like in an X-ray CAT scan, they tilt the samples to get different views of the viruses undergoing fusion and then use powerful computational methods to reconstruct the 3-dimensional image.

Flu viruses are “enveloped” viruses, and like HIV, herpes, dengue and the Zika viruses, they have a lipid membrane that protects their genetic material. To deliver its genome into cells, the virus needs to merge this membrane “envelope” with the host’s cellular membrane. With better insight into the mechanics of this process, researchers may gain an understanding of how to interfere with this stage of cell entry and prevent infection. Indeed, antibodies produced by our immune systems target and in some cases jam the protein machinery that viruses use to gain entry into cells.

How the influenza virus engages with membranes as it would in infecting a host cell
How the influenza virus engages with membranes as it would in infecting a host cell Photo: Kelly Lee

Flu viruses are covered in spikes. Their external membranes are decorated with fusion protein, known as “spike complexes”— because they look just like that – little spikes arrayed across the virus’ surface. As the virus makes its way through your body, those spikes make contact with healthy cells. They grapple onto the membrane of the healthy cell (or target) and then draw the target membrane towards the virus, creating a dimple in the target surface. The spikes then attach, or pinch, the membrane and draw it closer to the virus, not unlike a tractor beam out of science fiction. When the target membrane is pulled tight, or docked, to the surface of the virus, there is a fusion that happens between the cell’s membrane and the virus’ membrane. These cell and viral leaflets join together to open a channel through which the virus delivers its genome to the cell.

This breakthrough study allowed the team to look at the different stages of the membrane fusion event and figure out the sequence in which they occur. Prior to this, “The field had a lot of indirect information from lower resolution techniques but now for the first time we are able to look at these processes at pretty high resolution and see the proteins, the membranes and how they become contorted and remodeled as the virus carries out membrane fusion. Most of the structures we see for membranes and how they get deformed are somewhat unexpected. It’s surprising and exciting when you see how these events are taking place at the molecular level,” said Lee.

The team’s research continues. “We hope go further in our research with enveloped viruses and are working with other departments to bring more electron microscopy resources to the UW,” shared Lee. “There is strong demand among researchers in many areas of biological sciences to use these types of microscopes and harness their capabilities to help us understand cellular processes at the nanoscopic level.” Beyond enveloped viruses, membrane fusion also is at the heart of basic cell biology and is a critical step in sperm-egg fertilization and signaling across nerve synapses, for example. The Lee lab hopes that their work on the influenza virus case may also help to improve the understanding of these fundamental functions in the life of cells.

Also: UW Health Sciences NewsBeat Lab uses electron microscopy to visualize flu virus invasion: Pharmacy team’s images are first to capture virus infecting healthy cell

Are you interested in studying with preeminent scientists like Associate Professor Kelly Lee?

Apply to our Medicinal Chemistry PhD Program

Link to Medicinal Chemistry archived news

UWSOP Announces Groundbreaking Plein Center for Geriatric Pharmacy Research, Education & Outreach

UWSOP student pharmacists train to be part of the patient care medical team in the Bracken Pharmacy Learning Center
UWSOP student pharmacists train to be part of the patient care medical team in the Bracken Pharmacy Learning Center. From left to right: Tien Nguyen, Lawrence Narayan, PharmD (PGY1 Pharmacy Resident at Swedish), Christopher Kim, Stephanie Heeney and Jason Hitchcock. Photo: Alex Levine Photography

Research shows that medication-related problems are one of the top reasons for hospitalizations and for older adults losing the ability to live independently, either due to competing side effects, falls, over prescribing, or improper adherence. Increasingly, people are living longer with chronic illnesses such as high blood pressure, high cholesterol and diabetes—illnesses that are primarily treated with medications. The Pew Research Center reported that roughly 10,000 Americans turn 65 every day, and that by 2030, eighteen percent of the U.S. population will be over 65 years of age.

Alumna Laura Hart, PharmD, meets with a patient
Alumna Laura Hart, PharmD, meets with a patient

As drug research advances and medications become more specialized, personalized, and complicated to select, the need for providers with expertise in medication choices, chronic illnesses, and drug interactions grows. An under-utilized resource in managing patient medication therapy and chronic illnesses in older adults is the pharmacist. Joy, ’51, ’56, and Elmer Plein, along with other UW faculty colleagues, pioneered the education and training of geriatric pharmacy care specialists, a specialty that is increasingly in high demand. Clinics, health systems, nursing homes, assisted living facilities, and hospitals in Washington and nationwide are turning to pharmacists for their specialized medication knowledge to improve patient health, particularly for chronic illnesses that can be managed through proper use of medications.

Professor emerita, Joy Plein
Professor emerita, Joy Plein

In May 2016, the UW School of Pharmacy proudly announced the establishment of the Plein Center for Geriatric Pharmacy Research, Education & Outreach. The Plein Center will expand the School of Pharmacy’s role as a leader in the field of geriatric pharmacy to encompass the breadth of disciplines within the School of Pharmacy and beyond. The Pleins have also established the Plein Endowed Faculty Fellowship for the Director of the Center.

The new research center will promote the discovery and optimal use of medications in older adults through research, education, and outreach. Research will bring together the depth of UWSOP’s practice, outcomes and bench science research in basic biomedical, translational, clinical, and health services studies. Researchers will collaborate on projects that look at optimizing medication use including medication management, adherence, and safety; the role of drugs in prevention and treatment of health conditions affecting older adults (e.g., falls, fracture, cognitive decline, dementia diabetes, neurodegenerative disorders); and methods for enhancing pharmacists’ impact on improvement of care for older adults and underserved populations. The Plein Center will also include training programs in geriatrics for PharmD students and others, building on the existing Plein Certificate Program in Geriatric Pharmacy.

“With the addition of the School of Pharmacy’s Plein Center for Geriatric Pharmacy Research, Education and Outreach, the University of Washington continues to lead the way in geriatric health care,” said Sean D. Sullivan, professor and dean of UW School of Pharmacy. “Our School is co-located with UW Medicine, Nursing, Social Work – each offering geriatric specialty training and highly regarded research centers. With our collaborative, interprofessional approach to training, the School of Pharmacy is positioned to fully participate in a comprehensive approach to healthy aging.”

Joy and Elmer Plein
Joy and Elmer Plein

Joy and Elmer have devoted their lives to the field of pharmacy. Individually, both were trailblazers in the field. Elmer joined the UW School of Pharmacy faculty in 1938. He was responsible for a number of major initiatives, including founding the UW’s clinical pharmacy program in 1968, one of only two such programs in the West. Joy is widely credited for creating the momentum for senior-care pharmacy in Washington state, at a time when few pharmacists were geriatricians and there were even fewer resources to advocate for older patients. In 1973, she and Elmer developed a nursing home pharmacy course, leading to the establishment of the Certificate Program in Geriatric Pharmacy, now named for the Pleins.

Click here to learn more about the Plein Certificate in Geriatric Pharmacy.

Click here learn more about the unparalleled education offered in our PharmD program.

Bennette, Sullivan find cancer drug prices rise rapidly after market launch

UW School of Pharmacy researchers’ found large increases in oral anticancer drugs even in the face of increasing market competition

A new study published in the May issue of Health Affairs and authored by UW School of Pharmacy’s faculty members, Caroline Bennette and Sean Sullivan, illuminates the complexity of anticancer drug pricing and several market forces that underlie large price increases in the years after a drugs’ launch.

Caroline Bennette, PhD
Caroline Bennette, PhD

As Caroline Bennette was finishing her dissertation in the Pharmaceutical Outcomes Research and Policy Program (PORPP), she read a highly publicized paper that documented rising prices for cancer drugs. The paper claimed that the prices for innovative cancer drugs did not change much after launch. “I remember the news headlines covering that paper—they really emphasized the idea that launch prices was where all the action was. But that didn’t fit with what I was hearing from pharmacists and patients, ” said Bennette, now on faculty in the UW School of Pharmacy.

“I was just curious. What was happening to cancer drug prices after launch? But I couldn’t find the answer in the published literature,” said Bennette, “With encouragement and support from my mentors, Sean Sullivan and Scott Ramsey at the Fred Hutchinson Cancer Center, I started looking at the trends directly.” Using a large database of pharmaceutical claims housed in PORPP, Bennette looked at the prices of oral anticancer drugs approved by the Food and Drug Administration (FDA) between 2000 and 2012 in the years after they’d been introduced. What she found went against the narrative that launch price was where all the action was. On average, the prices of these drugs continued to grow—roughly 5% per year over inflation—for years after their launch.

She shared these initial findings with her mentors and several other faculty members in PORPP. “They thought I might be on to something, but immediately challenged me to dig deeper. Not all of the drugs in our analysis showed the same increases in price over time – some rose much faster and others slower. The real story was going to be explaining those differences.” So Bennette dug deeper. Ultimately, she found that changing prices were associated with certain changes to the market, rising an additional 10 percent with each new FDA-approved indication for the drug and declining 2-3 percent with the approval of a competitor drug.

Bennette points out that many new anticancer drugs are first shown to work in advanced or metastatic cancer – where the clinical benefits are often relatively small – and later approved for use in patients with earlier stages of the disease. In these cases, a supplemental indication for a drug may reflect a larger clinical benefit than in the original indication, which might warrant a higher price. But drugs currently have a single price across indications. Raising the price of a drug for patients with the original indication seems unfair if the value of the drug for those patients hasn’t similarly increased. “There is a lot of discussion around the idea of using a value-based, indication-specific reimbursement system for anticancer drugs in particular,” said Bennette, who recently began working with Peter Bach from Memorial Sloan Kettering Cancer Center on this front.

Sean Sullivan
Sean D. Sullivan, PhD

In addition, the research team found that the introduction of a competitor drug had only a minimal impact on a drugs’ price and concluded that competition is unlikely to rein in the escalating costs of oral anticancer drugs in the near future. Why? Cancer drugs are often used in combination so a new drug won’t necessarily replace an older drug like it might in other conditions. In addition, several policies and regulations require many insurers to include nearly all oral anticancer drugs on their formularies, which further limits competitive pressure on manufacturers.

Bennette says she’s looking forward to further research on the complexities of drug pricing and the tradeoffs in ensuring patents’ access to affordable medications with the goal of fostering pharmaceutical innovation. “I feel very fortunate to be studying this issue at UW. I can walk down the hall and talk with several other faculty members who are interested in this topic, but who all come from different backgrounds and can offer unique perspectives.”

Click to read: Steady Increase in Prices for Oral Anticancer Drugs after Market Launch Suggests a Lack of Competitive Pressure.

Are you interested in the UW Pharmaceutical Outcomes Research & Policy Program?

Click to learn more about our master’s and doctoral degree offerings.

Link to Department of Pharmacy archived news

UW Symposium on Past Present and Future of ADME Sciences Dedicated to Deans Sid Nelson and Tom Baillie

(L to R): Juan Cantu, Dean Sid Nelson, Rene Levy, and Dean Tom Baillie
(L to R): Juan Cantu, Dean Sid Nelson, Rene Levy, and Dean Tom Baillie

“Thanks to the strong academic programs in the Department of Pharmaceutics and Medicinal Chemistry at the University of Washington, I have been well prepared for an exciting career in the pharmaceutical sciences,” said alumnus Ian Templeton. “Because of these strong programs, I now have classmates spread across many institutions, both public and private, as well as all over the world.”

In recognition of Dean Sidney Nelson’s contributions and to honor Dean Tom Baillie’s recent retirement, this event will provide a forum for scientific and social exchange between current faculty and students, alumni, and colleagues of the UW School of Pharmacy.

The program of speakers will deliver historical perspectives, describe the latest advances in research, and offer a vision for the future of research and training in drug metabolism and drug interactions. The program includes a gathering to celebrate Sid at The College Inn Pub, student poster session for networking with students and post docs, and dinner at the UW Faculty Club.

“An event like this is very special,” said Sean D. Sullivan, Professor and Dean of the UW School of Pharmacy. “I look forward to reconnecting with our scientific alumni who are involved in ground-breaking research worldwide, as we celebrate Sid’s and Tom’s leadership.”

Morning Session

8:30 AM Welcome and opening Remarks Sean Sullivan and Kent Kunze
8:45-9 AM From the past to the present in Drug Metabolism Wendel Nelson, UW
9-9:30 AM Structural investigations into the mechanism of carbon-mercury bond cleavage by the organomercurial lyase MerB Jim Omichinski, University of Montreal
9:30-10 AM The Current State of Biotransformation Sciences: enzymes, reactions and mechanisms Cyrus Kojastech, Genentech
10-10:30 AM Coffee break
10:30-11 AM Genetic Approaches to Understanding Drug Toxicity Deanna Kroetz, UCSF
11-11:30 AM Cinnamaldehyde-based Inhibitors of CYP2A6 and Estimation of Interactions with Nicotine and Letrozole John Harrelson
11:30 AM-12 Noon Lunch

Afternoon Session

12:45-1 PM Afternoon session opening remarks Kent Kunze
1-1:30 PM Presentation Rene Levy
1:30-2 PM Valproate and Beyond Mark Grillo
2-2:15 PM Coffee break
2:15-2:45 PM Midazolam as a CYP3A phenotyping probe: new insights on an old friend Mary Paine, Washington State University
2:45-3 PM Closing Remarks and look into the future Ken Thummel
3-5 PM Campus/school tour with current students and gathering at College Inn
5-6 PM Poster session at UW club with current students
6-8 PM Dinner

 

UWSOP ranks #9 in U.S. News & World Report

Interprofessoinal training for UW School of Medicine and Health Sciences students at ISIS at Harborview Medical Center in Seattle, WA. Medicine, nursing and pharmacy students are participating in hands-on, simulated training in realstic critical care scenarios.
Interprofessional training for UW School of Medicine and Health Sciences students at ISIS at Harborview Medical Center in Seattle, WA. Medicine, nursing and pharmacy students are participating in hands-on, simulated training in realistic critical care scenarios. Photo: Clare McLean

UW continues its consistent record by ranking in the top ten nationally
of Schools of Pharmacy. One of the smallest Schools at the UW, Pharmacy has been well-known for providing transformative training to pharmacy practitioners and researchers since its founding as one of the first three colleges at the UW.

“I am so pleased that our peers have recognized our continued excellence in pharmacy education,” said Sean D. Sullivan, professor and dean of the School of Pharmacy. “This ranking validates that we are on the right track in our vision to be the global leader in pharmacy education and our mission to develop exceptional, innovative and diverse pharmacy leaders and scientists. I am proud and honored to be a part of this terrific team of faculty, staff, students, and alumni.”

US News and World Report ranks UWSOP #9Schools of Pharmacy are ranked by peer institutions every four years by U.S. News and World Report. In 2013, the last time U.S. News & World Report ran the survey, UWSOP ranked No. 10, amongst 125 schools of pharmacy. In this 2017 survey, UWSOP improved to No. 9 amongst a larger field of 135 schools of pharmacy.

“There has been enormous growth in the last 15 years in the number of schools of pharmacy, but very few have the advantage of being co-located with their collaborative sister health sciences schools—who also rank in the top ten nationally,” continued Sullivan. “This showcases the unique and transformative opportunities an interprofessional health sciences education from UW offers.”

Interested in earning your PharmD degree at the UW? Click here to learn more.

Read more:
UW Health Sciences NewsBeat: Medicine, Nursing programs earn top spots in national rankings

UW Today:
Medicine, nursing programs top national rankings; dozens more UW programs highly rated

Totah and CHRU collaborate to find novel treatments for cardiovascular disease

Rheem Totah, Associate Professor, Medicinal Chemistry, UWSOP
Rheem Totah, Associate Professor, Medicinal Chemistry, UWSOP in her lab

UW School of Pharmacy and UW Medicine bring population and basic science together for novel approach to drug research

Heart disease remains a leading cause of death in the United States. While there have been advances in treatments, it is hard to know if someone is at risk for a heart attack until they show symptoms—which for many is too late. Researchers at the UW School of Pharmacy (UWSOP) and UW Medicine’s Cardiovascular Health Research Unit (CHRU) hope to change that.

Rheem Totah, Associate Professor in UWSOP’s Department of Medicinal Chemistry, is the co-lead investigator on two NIH funded grants totaling almost $6M with faculty from CHRU. Totah and Nona Sotoodehnia MD MPH (Cardiology) will co-lead “CYP2J2 Mediated Eicosanoids in Arrhythmias and Sudden Cardiac Arrest.” Totah and Rozenn Lemaitre PhD MPH (Internal Medicine) will co-lead “Epoxyeicosatrienoic acids, diabetes, and cardiovascular disease.”

Nona Sotoodehnia, MD MPH, Co-Director, CHRU
Nona Sotoodehnia, MD, MPH, Co-Director, CHRU

Collectively, these two grants will provide comprehensive information on the epidemiology of epoxyeicosatrienoic acids (EETs) in three large National Heart, Lung, and Blood Institute of the National Institutes of Health (NHLBI-NIH) funded prospective studies, including association with cardiovascular and cardiometabolic disease outcomes. The projects will additionally investigate the molecular mechanism of EETs protection, discover pathways that regulate EET biosynthesis in cardiac tissue, and identify EETs-related pathways affected by diabetes, with the ultimate aim of identifying a novel, potentially modifiable drug targets to improve cardiovascular health.

“These grants perfectly merge population and basic science so that we can comprehensively elucidate the role of EETs in cardiovascular disease and diabetes complications,” said Totah. “The two grants were high risk-high reward and we are excited that they were selected for funding.”

The first study, with Totah and Sotoodehnia, brings together population and basic science to identify a possible biomarker to predict and prevent sudden cardiac arrest. This step is followed by animal and cellular work to determine druggable pathways affecting EET biosynthesis. Using a novel approach, Totah’s team identified a possible marker that could indicate whether or not someone has a higher risk of sudden cardiac arrest.

Rozenn Lemaitre, PhD, MPH, Research Associate Professor
Rozenn Lemaitre, Ph.D., MPH, Research Associate Professor

The second grant, with Totah and Lemaitre, will look at EETs in patients with diabetes to determine the relationship between EETs and cardiovascular disease in this population. Lower levels of EETs may be associated with increased risk of cardiovascular disease in type II diabetes patients. The investigators will also investigate the regulation of various pathways related to CYP2J2 metabolism of arachidonic acid under the stress of diabetes in human cardiomyocytes.

Totah is passionate about translational research and the opportunity to directly affect human health. “Being at the UW School of Pharmacy which is co-located with the UW Medical Center, and the unique collaborative atmosphere in UW Health Sciences allows us to do work that will make a difference in people’s lives,” she extolled.

Research reported in this press release was supported by National Heart, Lung, and Blood Institute of the National Institutes of Health (NHLBI-NIH) under award numbers R01RHL128709 (CYP2J2 Mediated Eicosanoids in Arrhythmias and Sudden Cardiac Arrest) and R01RHL130880 (Epoxyeicosatrienoic acids, diabetes, and cardiovascular disease). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Do you want to study Medicinal Chemistry with researchers like Rheem Totah? Click here to learn about MedChem and to apply

Link to Medicinal Chemistry archived news

 

 

 

 

 

 

Award season comes to UWSOP!

Don Downing is presented the Community Service award at the 2015 Martin Luther King, Jr., Recognition Ceremony
Don Downing is presented the Community Service Award at the UW Health Sciences 2015 Martin Luther King, Jr., Recognition Ceremony Photo: Alex Levine Photography

It’s award season–not just for film, also for the UW School of Pharmacy!

Many of our School’s faculty, students, post docs and alumni have been recognized in the past few months for their accomplishments.

Don Downing, Martin Luther King, Jr. Community Service Award

Institute for Innovative Pharmacy Practice (I2P2) Endowed Clinical Professor Don Downing was honored with the 2016 Martin Luther King, Jr. Community Service Award by UW Health Sciences for his commitment to service. The awards are given to students, faculty or staff in each Health Sciences school to honor Dr. King’s commitment to addressing community needs. Don “embodies a service attitude for his students and his peers, encouraging everyone to become involved to improve access to services for those who are less fortunate,” the presenter noted. Don began his career as a pharmacist in tribal health care here in Washington and continues to give time on weekends and evenings to numerous community-based health fairs. In addition, he developed the nation’s first pharmacist-provided flu shots, vaccines, and emergency contraception programs, pharmacist-initiated ongoing hormonal contraception services, and most recently was a key advocate for patients gaining increased access to pharmacists as members of their health care team.

ITHS announce KL2 Scholar award winner from MedChem

Eri Nakatani-WebsterEri Nakatani-Webster, PhD, a research associate in the Department of Medicinal Chemistry, has been named to the 2016 cohort of KL2 Scholars. The Institute of Translational Health Sciences (ITHS) KL2 Multidisciplinary Clinical Research Career Development Program, funded by the NIH, provides the time, funding, and rigorous mentorship necessary to foster the early career development of clinical and translational researchers. The ITHS KL2 program is a multidisciplinary program, up to three years in length, tailored to the research and career development needs of each scholar. Investigators are trained in-depth in a specific area of research, while also gaining knowledge of the full spectrum of clinical research. Nakatani-Webster’s research project is, “Staphylococcus aureus biofilm regulation from a protein folding perspective: exploring amyloid disruption as a novel therapeutic strategy.”

Students and faculty shine at Washington State Pharmacy Association (WSPA) award ceremony

UWSOP was very well represented at this year’s WSPA Award Ceremony. Congratulations to our alumni and faculty winners including:

Greg Hovander, UWSOP AlumnusGregory Hovander, ’72, RPh – The Bowl of Hygeia Award recognizes an exemplary pharmacist who has made outstanding contributions in the area of community service. In the mid-1970s, Greg started the first Class A pharmacy and implemented clinical pharmacy services for the Farm Workers Family Health Center in Toppenish, Washington. He also served as the chair of the first task force considering prescriptive authority for pharmacists. Greg continues his 43-year career as a pharmacist as the sole proprietor of Sultan Pharmacy & Natural Care, which specializes in natural, dietary, and self-care in conjunction with medical care.

Glenn Adams, '97Glenn Adams, ’97, ’98, PharmD – The Pharmacist of the Year Award honors a pharmacist who possesses qualities of excellence in routine practice and association activities, is an exemplary role model and who has contributed to the service and skill of WSPA during the past year. Glenn has been an outspoken advocate for pharmacists and was involved in pharmacy rules and legislation to ensure pharmacists can continue to provide high quality care to patients and the community.

Steven Erickson, PharmD, BCPSSteven Erikson, ’72, ’94, PharmD – The Bill Mueller Outstanding Mentor Award recognizes a pharmacist or technician who has been an outstanding mentor in the field of pharmacy. Steven worked collaboratively with colleagues to establish a clinically focused community pharmacy in Monroe, Washington, where he has practiced for the past 34 years. He was one of the first pharmacists in the state of Washington to practice under a collaborative practice agreement. His pharmacy has been a community residency site for UWSOP students since the late 1980s and is now the longest continuously operating pharmacy residency program in the country.

Sean D. Sullivan, BScPharm, MSc, PhDSean D. Sullivan, BScPharm, PhD, Dean and Professor, UWSOP – The David Almquist Award recognizes outstanding work in the endeavors of WSPA and the community in general. In addition to his career as professor and dean at UWSOP, Sean has been a strong advocate for the WSPA and demonstrated his support in efforts such as SB5557 and multiple WSPA events, including its annual scholarship fundraiser.

I2P2 Endowed Clinical Prof Don DowningDon Downing, ’75, RPh, I2P2 Endowed Clinical Professor, UWSOP – The Rodney D. Shafer Award acknowledges a pharmacy professional who has made pioneering and sustaining contributions to the profession. Don has long advocated for pharmacists as covered providers to increase patient access to care. In June 2015, the American Pharmacists Association (APhA) recognized his role in this effort here in Washington state and named him a Pharmacists Provide Care Champion.

Sheila Shapouri, PharmD studentSheila Shapouri, UWSOP PY4 – The Pharmacy Student of the Year recognizes a student member who made consistent, sustained and outstanding contributions toward the growth and development of pharmacy student participation on both a local and state level. Sheila has been very active in UWSOP and WSPA student groups, including serving as the Student Director on the WSPA Board of Directors and the UWSOP Dean’s Student Experience Advisory Committee. Her extensive involvement in community outreach and student organizations has inspired her peers to go beyond the classroom.

Steve Singer, ’81, RPh – The Generation Rx Champions Award recognizes a pharmacist who has demonstrated excellence in community-based prescription drug abuse prevention. Steve is actively involved in the pharmacy community, serving on advisory panels and as a member of the WSPA Board of Directors. Steve is an advocate for pharmacists and their role in Opioid Overdose Rescue and will assist any trained pharmacist in obtaining a CDTA for Opioid Overdose Rescue.

American Society for Health-System Pharmacists (ASHP) Award

Nick Larned, PharmD studentASHP Chapter President Nick Larned won the Outstanding Professional Development Project Award at the ASHP Midyear Clinical Meeting in New Orleans. His poster showcases the chapter’s Multi-Institutional Shadowing Program utilizing 23 pharmacists from 6 organizations in the Seattle area. Fifty-six UW School of Pharmacy students traveled to New Orleans for the ASHP Midyear Clinical Meeting. Events included continuing education talks about advancing clinical practices, networking opportunities, and student development sessions. Our PY4 students Ashley Warcola and Hannah DeMeritt also competed nationally in the clinical skills competition on behalf of the UWSOP.

UWSOP grad students and post doc excel at ISSX

UWSOP graduate students Marc Vrana, Jenny Sager) and Li Wang at ISSX award ceremony
UWSOP graduate students Marc Vrana, Jenny Sager, and Li Wang at ISSX

At the 20th North American ISSX meeting in Orlando, UWSOP graduate students won three of the six awards that ISSX presents to students, reflecting the high caliber of our post docs and graduate students’ research. UWSOP had four predoctoral abstracts selected–Marc Vrana, Jenny Sager, Michael Liao, and Vineet Kumar–one postdoc finalist, Li Wang, and a grad student podium presentation given by Gabriela Patilea-Vrana.

Marc Vrana (Prasad lab) won first place, the Best Presentation Award: Predoctoral Research, for his poster titled “Differential Tissue Expression of ADME Proteins in Humans.” Jenny Sager (Isoherranen lab) won second place in the predoctoral category for her poster titled, “New Metabolic Pathways of Bupropion in vivo Reveal an Important Role of CYP2C19 and 11B-HSD in Bupropion Clearance; CYP2B6 Contribution to Bupropion Clearance is Minor.”

In addition, two of our grad students were finalists for best poster: Michael Liao (Mao lab), “The differential roles of P-glycoprotein (mdr1) in limiting brain and fetal exposure to norbuprenorphine in pregnant mice” and Vineet Kumar (Unadkat lab), “Quantification of transporter expression in the plasma membrane vs. intracellular compartments using biotinylation and LC-MS/MS based proteomics.”

Li Wang (Unadkat lab) won was selected as a postdoctoral finalist and  awarded third place in the Best Presentation category “Quantification of transporter expression in liver tissue from subjects with alcoholic or hepatitis C cirrhosis.”

Pharmaceutics grad student Gabriela Patilea-Vrana (Unadkat lab) was selected to give a podium presentation titled: “Importance of Hepatic Transporters in Understanding and Predicting Hepatobiliary Clearance And Hepatic Concentrations of Drugs: Introducing the Novel Concept of FTNET

Advance your career in research or pharmacy at the University of Washington!

Click on the links for more information about our PharmD program or Graduate Programs in Medicinal Chemistry, Pharmaceutics, Pharmaceutical Outcomes Research and Policy, and Biomedical Regulatory Affairs.

UW PharmD students to host New Year health fair on Jan. 24th, 2016

Map of Magnuson Community Center: The Brig
New Year’s Health Fair will be held at the Magnuson Community Center: The Brig on Sunday, January 24 from 9:30AM – 1:30 PM

FREE health services Sunday, January 24, 9:30AM – 1:30PM at Magnuson Community Center: The Brig

Student health professionals & mentors from UW Schools of Pharmacy, Medicine, & Dentistry, Physical Therapy Program, and Speech & Hearing Sciences have teamed up to offer a range of health services to the Seattle community. The event is open to the public and no insurance is required.

Faculty pharmacists, physicians, and dentists will be on-site mentoring students. Services will include:

HEALTH SERVICES

  • Blood pressure reading
  • Blood glucose/cholesterol screening
  • Osteoporosis and BMI screening
  • Falls prevention
  • Fluoride application
  • Dental screening
  • Head and neck exams

HEALTH EDUCATION

  • Medication safety
  • Over-the-counter and prescription medications education
  • Hearing education
  • Hand washing
  • Health insurance resources

Magnuson Community Center: The Brig (Near the Dog Park)

6344 NE 74th Street, Seattle, WA 98115

Served By Bus Lines: 30, 74 And 75

New Year Health Fair Flyer

 

 

 

 

 

 

 

 

 

Download a PDF New Year Health Fair Flyer

Learn more about our PharmD program.

Steve White Named Chair of UWSOP’s Dept of Pharmacy

UW School of Pharmacy's Department of Pharmacy's chair, Dr. Steve White

The UW School of Pharmacy is pleased to announce the appointment of H. Steve White, RPh, Ph.D. as the new chair of the School’s Department of Pharmacy, effective January 18, 2016.

White earned his baccalaureate degree in Pharmacy and a M.S. in Pharmacology at Idaho State University and began his career as a practicing pharmacist in the small town of Salmon, Idaho, until his mentor invited him to a career-changing pharmacology conference. From there, he earned his Ph.D. in Pharmacology at the University of Utah where he rose through the academic ranks after joining the College of Pharmacy faculty in 1986.

“It gives me great pleasure to welcome Steve White to the University of Washington School of Pharmacy,” said UWSOP Dean Sean D. Sullivan. “A nationally-known researcher, responsible for significant advancement in the treatment and prevention of epilepsy, Dr. White is a compassionate leader and a great colleague with a passion for collaboration, science, patient care and student mentoring. I look forward to working with him as we continue to grow our School’s mission as a global leader in pharmacy education, research and service.”

A leader in translational research in anticonvulsant drug therapies, White is the principal investigator and scientific director of the NIH-sponsored Anticonvulsant Drug Development (ADD) Program that was established in 1975 to identify novel anticonvulsant drugs using established animal seizure and epilepsy models. Over the years, the efforts of this program have contributed to the successful development of nine new antiepileptic drugs for the treatment of refractory partial epilepsy including felbamate, rufinamide, topiramate, retigabine and lacosamide.

White’s research is focused on understanding the factors that contribute to the initiation, propagation, and amelioration of seizure activity. He has collaborated with faculty from UW School of Pharmacy’s Department of Pharmaceutics, including Associate Professor Nina Isoherranen and Professor Emeritus Rene Levy.

His laboratory, which will relocate to the UW as a partnership between the School of Pharmacy and UW Medicine, features a broad-based research program aimed at gaining a further understanding of the factors that contribute to the expression and prevention of seizure activity. The results obtained from these investigations are likely to lead to the design and development of more efficacious and less toxic therapies for the prevention and treatment of epilepsy.

“The University of Washington School of Pharmacy has provided significant leadership to the profession of pharmacy and played a critical role in the education of the next generation pharmacists, educators and researchers,” observed White. “In support of this mission, I look forward to working closely with the faculty and other invested stakeholders in the execution of the School’s Strategic Plan. The vision set forth by this thoughtful five-year plan will benefit students, patients and the pharmacy community for decades to come.”

In 2014, he was named the 2014 recipient of the Epilepsy Foundation’s Lifetime Accelerator Award, in recognition of his commitment and pioneering contributions to the field of epilepsy and seizures. In 2011, White received an Honorary Doctor of Science from The University of Copenhagen Faculty of Pharmaceutical Sciences, Copenhagen, Denmark.

White has been the recipient of significant research funding from the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), and he and his collaborators have published over 170 original papers pertaining to the mechanism of action and the pharmacology of antiepileptic drugs. In addition to his academic service, he has served as Research Director of CURE (Citizen’s United for Research in Epilepsy), the largest non-governmental provider of epilepsy research funding, since November 2011 where he has assisted in the development of strategic programs that advance transformative epilepsy research that may someday lead to a cure or disease modifying therapy for the patient at risk for developing epilepsy. He has been a co-organizer of two NIH-sponsored workshops on models of refractory epilepsy and epileptogenesis and currently serves on the organizing committee of the biannual Eilat Conferences on Antiepileptic Drug Development. Additionally, White has been actively engaged as a mentor for the next generation of neuroscientists and epilepsy educators and is frequently invited to speak at national and international congresses.

* * *

The UW School of Pharmacy is comprised of three departments: Medicinal Chemistry, Pharmaceutics, and Pharmacy, offering Ph.D., M.S., and PharmD degrees, post docs and certificate programs. The Department of Pharmacy leads in pharmacy education, research, professional and outreach initiatives, including the Pharmaceutical Outcomes Research & Policy Program (PORPP), which conducts research in pharmaceutical economics, drug safe and pharmaceutical policy. The department supports general and specialized pharmacy residencies, and research fellowships in select areas of pharmacotherapeutics. The department educates 60 students in Ph.D. and M.S. programs, 177 in certificate programs, has 8 post docs, and, with MedChem and Pharmaceutics, contributes to the training and education of 386 PharmD students in the 4-year professional program.

The UW School of Pharmacy is a global leader in pharmacy education, research and service, committed to providing a transformative learning experience in a collaborative and diverse environment focused on improving the health and well-being of the communities we serve. Our mission is three-fold: inspiring education: developing exceptional, innovative and diverse pharmacy leaders and scientists; discovering solutions: advancing the science, development, implementation, and outcomes of safe and appropriate treatments; and serving people and communities: promoting the health and well-being of the public, locally and globally.

Link to Department of Pharmacy archived news

Pharmaceutics welcomes six new students with a passion for discovery

Pharmaceutics graduate students (L to R): Ryan Cheu, Olena Anoshchenko, Jessie Yu, Antonio Quinones-Lopez (not pictured here: Marc Vrana and John Amory).
Pharmaceutics graduate students (L to R): Ryan Cheu, Olena Anoshchenko, Jessie Yu, Antonio Quinones-Lopez (not pictured: Marc Vrana and John Amory). Photo: Alex Levine Photography

 

UWSOP’s Department of Pharmaceutics welcomed six new students this fall, here to join a great tradition of life-changing research. These researchers share a passion for discovery and come to our school from all over the world, and from all sorts of backgrounds: from English majors to chemists and biologists.

Originally from the Ukraine, Lena Anoshchenko finished her International Baccalaureate degree in Pearson United World College in Victoria, Canada, with 200 students from 100 countries around the world before going to college at Lewis & Clark in Portland, Oregon. She earned her BS in Biology and came to appreciate the value of multicultural and liberal arts education. After graduation, she moved to Seattle and worked at Gilead Sciences, Fred Hutch, and Infectious Disease Research Institute (IDRI) on projects related to drug discovery and development. She is interested in drug research and elucidation of relevant biological mechanisms.

Marc Vrana, who grew up in California and Washington, earned his undergraduate degree at the UW in English Literature and Education. From there, he pivoted and enrolled at UW Bothell to earn a second bachelor’s degree, this time in Biology. He worked in a lab researching experimental evolution of microbial co-cultures before moving into the lab of Pharmaceutics’ assistant professor Bhagwat Prasad. He is currently working on characterizing the inter-tissue variability in expression of ADME proteins, and will be likely be focusing on carboxylesterases. At the most recent North American ISSX conference, Marc received a best poster award as well as placing first in the pre-doctoral poster/podium presentation award competition.

Antonio Quinones-Lopez was born in Puerto Rico and grew up in the Austin Texas area. He earned his bachelor of science in Chemistry and Spanish at Southwestern University, a small liberal arts college in central Texas. He has mainly worked on synthesis of inorganic metal complexes and their in vitro interaction with DNA. In 2014-2015, he was named an American Chemical Society Scholar. His general research interests are in drug transport and delivery.

Originally from Hawaii, Ryan Cheu received his bachelors in Biochemistry from Santa Clara University. He spent a summer as a medical intern in Nepal at the Hospital for Rehab and Disabled Children. For the last two years, he worked at Genentech using FT-NIR and chemometrics for determining residual moisture in lyophilized drug products. He’s developed IEC, iCIEF, and MCE-SDS methods for late-stage drug analysis of Genentech’s drug products and drug substances.

Jesse Yu was born in Montreal, Canada. He earned his B.S. in Pharmaceutical Sciences and Pharm. D from Duquesne University. His research experiences includes solid state and liposomal formulation. He spent a summer with Amgen at their Cambridge, Massachusetts, site working as an intern in a preclinical PK lab and also spent 10 weeks at the FDA working as an intern in regulatory affairs.

Dr. John Amory
Dr. John Amory

Dr. John Amory earned his Medical Degree from the University of California, San Francisco where he also completed his residency in Internal Medicine. Currently, he is Professor of Medicine and Section Head of General Internal Medicine here at the UW where he works as an attending physician on the inpatient medicine wards and in the General Internal Medicine Clinic. His research interests are the development of novel forms of male contraception and new approaches to the treatment of men with infertility. John has published more than 115 peer-reviewed papers in the field of male reproduction, and holds current funding from the NIH grant for male contraceptive research examining the potential utility of inhibitors of testicular retinoic acid biosynthesis as reversible male contraceptives.

Interested in applying for an MS or PhD in Pharmaceutics? Click here.

Pharmaceutics’ Carol Collins part of drug risks in pregnancy mobile app team

A pregnant woman considers the medication she is about to take.
A pregnant woman considers the medication she is about to take. Photo: Thinkstock

Carol Collins, Clinical Associate Professor in Pharmaceutics, will bring her expertise in drug safety information and the design of drug safety databases to this important project that seeks to create a mobile app that will help convey information about drug risks for pregnant women in collaboration with faculty from UW Medicine, UW HCDE and right answer.com.

Janine Polifka, manager of UW Department of Pediatrics The Teratogen Information System, heads the UW component. TERIS contains up-to-date, authoritative information about the effects of drugs and chemicals on prenatal development.  The database covers peer-reviewed scientific research on the safety or toxicity of more than 1,600 agents. Among them are about 95 percent of the most frequently prescribed medications.  TERIS’s review board of fetal toxicology experts evaluate the magnitude of risk for each agent listed.

To create a mobile app that fits with clinicians, Gary Hsieh, assistant professor of human centered design and engineering at the UW College of Engineering, will gather information requirements of healthcare providers who treat pregnant women. Their viewpoints will shape the specifications for the mobile application.

Carol Collins, Clinical Assoc Prof, Pharmaceutics
Carol Collins, Clinical Assoc Prof, Pharmaceutics Photo: Alex Levine Photography

Joining Hsieh on the clinical usability trials and the app development is Carol Collins, clinical associate professor of pharmaceutics at the UW School of Pharmacy.  She has extensive experience in drug safety information and the design of drug safety databases. Collins has worked on the UW School of Pharmacy Drug Interaction Database and the University of Pittsburgh Drug Interaction Knowledge Base.

“Providing accurate and usable information to healthcare providers at point-of-care is very challenging,” she remarked. “We have to understand what the relevant questions are that healthcare providers have and address the challenges associated with providing information on the small screen format of mobile phones.”

Read the full story on UW Health Science NewsBeat.

Intercollegiate team will study natural product-drug interactions

Green tea is one of the products in the drug-interaction center's initial study set.
Green tea is one of the products in the drug-interaction center’s initial study set. Photo: ThinkStock

Herbal remedies are a multi-billion dollar industry. Sales of natural product supplements have nearly tripled in the past twenty years since passage of the Dietary Supplement Health and Education Act in 1994. Fueled in part by the assumption that “natural” means “safe,” as well as rising costs for conventional health care, many people turn to these supplements to both alleviate symptoms and illnesses as well as reap perceived health benefits, often without consulting their health care provider.

However, natural doesn’t always mean safe. In fact, little is known about how natural products may alter the therapeutic effects and safety of prescription and over-the-counter medications. “Viewed as a whole, these kinds of interactions can range from mild to severe or even life-threatening. So far, the data in the field has been highly variable in quality and/or relatively sparse, ” notes D. Craig Hopp, Ph.D., Program Director for the NIH’s National Center for Complementary and Integrative Health (NCCIH).

Studies in the late 1990's showed that St. John’s wort and grapefruit juice had dangerous interactions with a variety of medications.
Studies in the late 1990’s showed that St. John’s wort and grapefruit juice had dangerous interactions with a variety of medications. Photo: ThinkStock

Studies in the late 1990s showed that St. John’s wort and grapefruit juice had dangerous interactions with a variety of medications. “For many years, pharmacists have had to deal with counseling patients on the safe and effective use of many herbal supplements without the benefit of reliable data from the literature and definitive guidance from authoritative sources,” commented Sean D. Sullivan, BScPharm, Ph.D., Professor and Dean of the UW School of Pharmacy.

A national team of researchers from the UW School of Pharmacy, the WSU College of Pharmacy, and the University of North Carolina at Greensboro (UNCG) Department of Chemistry and Biochemistry has partnered to study potential interactions between select natural products and commonly used medications. The cross-institutional collaborative team, known as the Natural Product Drug Interaction (NaPDI) Center, was funded by a $10M five-year grant from NCCIH.

The goal for the team is multi-fold: assess existing gaps in the scientific literature regarding the potential for natural products to significantly interact with common medications; investigate how natural products may interact with common medications; establish a set of best practices to address the unique challenges in the study of natural product drug interactions; and develop and maintain a database accessible through a public web portal. “Establishing research best practices in this arena is of significant public health importance,” said Gary M. Pollack, Ph.D., Professor and Dean of the WSU College of Pharmacy.

NaPDI Grant Team Member
NaPDI Grant Team Members: Front rows (L to R): Danny Shen, Mary Paine, Zhu Zhou, Isabelle Ragueneau-Majlessi, Jeannine McCune; Middle rows: Vanessa Gonzalez-Perez, Jash Unadkat, Barbara Kavanaugh, Jingjing Yu, Laura Shireman, Yvonne Lin, Rebecca Cooney; Back rows: Ken Thummel, Carol Collins, Chris Kinsella, Bruce Pinkleton, Allan Rettie; Missing: Nicholas Oberlies, Nadja Cech Photo: Alex Levine Photography

There are four sub-teams managing the project’s work, involving administrative, pharmacology, analytical, and informatics aspects. The administrative team, led by Co-Principal Investigator Dr. Danny Shen and Co-Investigator Dr. Jeannine McCune of the UW School of Pharmacy, will provide overall administrative coordination and support and will develop and disseminate best practices on natural product-drug interaction research.“

The pharmacology team, led by Co-Principal Investigator Dr. Mary Paine of the WSU College of Pharmacy, will identify and prioritize the 4-6 natural products to be studied, including green tea and cannabinoids (marijuana), seek to uncover the mechanisms of natural product-drug interactions, and design appropriate preclinical and clinical studies to address scientific gaps.

The analytical team, led by Dr. Nicholas Oberlies, a natural products chemist at UNCG, will acquire the materials for study and ensure their consistency and sufficient supply. “An improved understanding of these interactions requires natural products chemistry expertise, as unlike with drug products, natural products vary considerably in biochemical composition both between brands and batches of the same brand,” observed Patricia H. Reggio, Ph.D., Marie Foscue Rourk Professor and Head of UNCG’s Department of Chemistry and Biochemistry.

The informatics team, led by Dr. Isabelle Ragueneau-Majlessi of the UW School of Pharmacy, will ensure that the results and research best practices are clearly communicated by creating a data and information repository available to researchers, practitioners and the public through a website, app and blog. UW and WSU will collaborate on this aspect of the project—bringing together investigators from WSU’s Edward R. Murrow College of Communication and the seasoned team working with the UW’s Drug Interaction Database (DIDB), currently the largest manually-curated repository of preclinical and clinical drug-drug interactions.

“Interactions may occur between prescription drugs, over-the-counter drugs, dietary supplements, and even small molecules in food—making it a daunting challenge for scientists to identify all interactions that could be harmful,” wrote NCCIH Director Dr. Josephine Briggs. “The bottom line here is that there’s a lot we don’t know and much more study needed.”

The NaPDI Center plans to have initial results available within two years, with more to follow over the remainder of the project. The five-year, $10M NCCIH grant was funded as a large-scale research program of the National Institutes of Health under a cooperative agreement award (1U54AT008909-01).

A version of this story also appeared in UW Health Sciences NewsBeat

Are you a #HUSKYPHARMACIST?

Student Pharmacist in UWSOP’s Bracken Pharmacy Learning Lab
Student Pharmacist in UWSOP’s Bracken Pharmacy Learning Lab Photo: Alex Levine Photography

Celebrate American Pharmacists Month and share your #HUSKYPHARMACIST pride this October!

Whether you are an alum, student, faculty member, preceptor, graduate, friend, parent, patient or supporter, we want to see your #HUSKYPHARMACIST pride!

Pharmacy Practice Changes in Washington

2015 was a big year for Pharmacists in Washington state. Under new legislation, patients will have increased access to the kind of specialized care and knowledge pharmacists can provide. We would love to see your pictures and hear your stories about #HUSKYPHARMACIST work in a variety of practice settings!

Alumna Elyse Tung mentors a UWSOP student pharmacist
Alumna Elyse Tung mentors a UWSOP student pharmacist Photo: Alex Levine Photography

Join in the fun and share your pride!

  1. Click to print your #HUSKYPHARMACIST sign.
  2. Take a photo.
  3. Post it to Facebook (tag @UWSOP) or Twitter (tag #HUSKYPHARMACIST)

That’s it! We will share and retweet your photos and show our pride as Huskies and Pharmacists!

What makes a #HUSKYPHARMACIST so special? We are:

  • Smart
  • Compassionate
  • Medication experts
  • Patient care advocates
  • Change agents
  • Undaunted
  • BOUNDLESS
UWSOP student pharmacists learn from the best–Clinical Assistant Professor Leigh Ann Mike
UWSOP student pharmacists learn from the best–Clinical Assistant Professor Leigh Ann Mike Photo: Alex Levine Photography

Rettie Seeds the Future of Precision Medicine

The Rettie Lab team in the Mass Spectrometry Center. From L to R: MedChem grad students John Kowalski and Amanda Johnson, Professor Allan Rettie, and Senior Fellow Sutapa Ray. (Missing: Matt McDonald, Research Scientist)
The Rettie Lab team in the Mass Spectrometry Center. From L to R: MedChem grad students John Kowalski and Amanda Johnson, Professor Allan Rettie, and Senior Fellow Sutapa Ray. (Missing: Matt McDonald, Research Scientist) Photo: Alex Levine Photography

“It’s a micro-farm,” said Allan Rettie recently, talking of the home where he and his wife, Shannon, nurture a menagerie of creatures great and small. “If I was not doing science, I might have been a farmer” he said tongue-in-cheek. But it’s impossible to imagine Rettie “not doing science.” For 30 years he has been at the forefront of what’s happening in drug metabolism and drug interactions. And now he wants to quantify the impact of variants in your genes.

Rettie came to Medicinal Chemistry as a postdoc in 1985, joined the faculty in 1987, and became department chair in 2000. He serves on the editorial boards of scientific journals, NIH grant review panels, and organizations like the International Society for the Study of Xenobiotics. He teaches classes on drug metabolism and organic medicinal agents and runs an expanding research group that has its roots in drug metabolism.

Rettie and grad student Amanda Johnson
Rettie and grad student Amanda Johnson in the Mass Spectrometry Center Photo: Alex Levine Photography

“We plan to create an encyclopedia of gene variations in important drug-metabolizing enzymes that affect drug responses and make it available to the clinical community in an easily accessible format.”
–Allan Rettie

Rettie is currently focused on examining the role genetics plays in drug response, a field called Pharmacogenomics. Some people carry potentially harmful gene variants, and for these people an average drug dose can pose significant health risks.

Consider the commonly prescribed drug warfarin, a “blood thinner” used to treat heart patients and others. The wrong dosage can have a number of negative effects, like excessive bleeding, with disastrous results for patients. Understanding how drug metabolism genes affect the response to warfarin can help health care providers target the dose specifically to individual patients. However, there is currently no easy way for clinicians to know how new gene variants affect treatment with warfarin and other drugs with low safety margins.

With their latest NIH grant, Rettie; Doug Fowler; and colleagues in the UW Department of Genome Sciences aim to create a comprehensive database of drug-metabolizing enzyme variants that affect a patient’s reaction to commonly used drugs. The project, called Functionalization of Variants in Clinically Actionable Pharmacogenes (F-CAP), will catalog the functional effects of all amino acid variation for five important pharmacogenes during the three-year grant period and make the data available to the clinical community in an easily accessible format. “It’s quite ambitious, but we are capitalizing on new, high-throughput experimental approaches that should help us reach the target,” Rettie said.

Perhaps it’s the farmer in Rettie that inclines him to look ahead, even as he grows F-CAP. He is also working on a ‘suicide gene’ system for personalized T-cell applications in cancer therapy. “Collaborators in Germany provide the immunology expertise while we focus on the drug metabolism side of the project.” Finally, Rettie is interested in the genetics of people in historically isolated and underserved populations. “Everyone should be given the opportunity to be included in the precision medicine revolution.”

–Caryl Corsi

Want to study Medicinal Chemistry with researchers like Allan Rettie? Click here to learn about MedChem and to apply

Link to Medicinal Chemistry archived news

The Chiba Morio Family: Undaunted in the Face of Adversity

 

Bain Chiba with his father Yasukichi, '17, at Bain's graduation from UW School of Pharmacy in 1937.
Bain Chiba with his father Yasukuchi, ’17, at Bain’s graduation from UW School of Pharmacy in 1937. Photo: Seattle PI 6/15/1937

Second year PharmD student Beau Chiba comes from a long line of UW School of Pharmacy pharmacists. When he graduates in 2018, it will be 101 years since his great-grandfather, Yasukuchi Chiba graduated. Beau is the sixth member of his family to attend UWSOP and his family’s story echoes the social, political, and economic ups and downs of the last century.

Beau’s great-great-grandfather on his father’s side of the family, Shirosabura Chiba, was a pharmacist who emigrated to the U.S. from Japan with his young family, including his son, Yasukuchi, Beau’s great-grandfather. When Yasukuchi graduated from UW School of Pharmacy in 1917, he went to work with his father. They owned several pharmacies in the Seattle-Tacoma area, including Main Drug in Nihonmachi (Japantown) in Seattle’s International District. Twenty years later in 1937, Yasukuchi’s son, Bain, graduated with his degree in pharmacy, likely making them the first father-son graduates from the UW School of Pharmacy. Bain began working as a pharmacist at the family’s Main Drug after graduation. Bain’s brother-in-law, Noboru “Nibs” Morio, began his studies at UW School of Pharmacy just before WWII. Mary Shimoda, who would later marry Nibs, was also a student at UWSOP. 

In 1941, all four members of the family were practicing or learning pharmacy, helping their neighbors and advancing health care. But in February 1942, just three months after Pearl Harbor, all of that ended when President Roosevelt signed an executive order to relocate 120,000 Japanese Americans to isolated relocation centers. 

And sadly the Chibas, Morios, and Shimodas were no exception. 

Beau’s great-grandfather, grandfather, grandmother, and great-aunt were forced to leave their homes in south Seattle and Beacon Hill for the harsh conditions of the internment camps. Automobiles were impounded. Homes and property sold. Families even donated their Japanese trees and shrubs to the UW Botanic Garden for safekeeping. Businesses were lost…including Main Pharmacy. 

The Chibas were initially sent to the short-term detention center at the Puyallup fairgrounds. The Army called it Camp Harmony, and it was anything but that. The family spent months living in close quarters in shacks with limited rations and poor facilities. 

The UW President and faculty advocated for their students. President Seig wrote a letter to 25 college presidents begging them to take UW’s Nikkei students. The Army initially permitted a few students to transfer. Most schools didn’t want the students and some rescinded offers as the story broke in the press. In December 1941, there were 450 Nikkei students enrolled at the UW, including Nibs and Mary. By May 1942, there were none. One dean went to Puyallup to hold an informal graduation ceremony for the Nikkei students who were just one month from commencement. Weeks later, the group was moved to Minidoka internment camp in Idaho. Among them was Mary Shimoda, Nibs’ future wife.  She was a remarkable student and was made a member of Rho Chi, an honor she received in absentia in 1942. She was in Puyallup, on her way to Idaho where she spent the war with her mother and sister. 

Nationwide, there was a shortage of labor. In some cases, people were able to get out of the internment camps—some worked farms in the Midwest and many health professionals were able to go to other parts of the country. As a knowledgeable pharmacist, Bain transferred out of the camp. He worked at the University of Michigan Hospital as a pharmacist until he could afford to move his family to safety in Michigan, where they lived out the war. 

Nibs took a different path. He enlisted to serve with the 442nd Infantry Regiment. With the motto, “Go for Broke,” the Japanese-American regiment was the most decorated in U.S. military history for its size and length of service. Nibs was in the 2nd Division, G Company, and was sent to Italy and then France to fight. He earned two Purple Hearts and a Bronze Star. In 1946, Nibs married his college sweetheart, Mary Shimoda. While Mary was able to leave the camp by transferring to Idaho State University to complete her education, Nibs eventually retired from the Army where he worked as a hospital pharmacist (without a degree!). He returned to the UWSOP to finish the education he had started 20 years prior. Upon graduation, he moved with Mary to Bellevue where they continued practicing pharmacy. She worked at Group Health and he at Overlake Hospital.

Beau Chiba, '18, photographed across from his grandfather, Bain Chiba's, '37, pharmacy location in Japantown, Seattle
Beau Chiba, ’18, photographed across from his grandfather, Bain Chiba’s, ’37, pharmacy location in Japantown, Seattle Photo: Alex Levine Photography/Uknown

Bain and his family returned home to Seattle a few years after the war ended. He was able to resume ownership of Main Drugs, but times were still hard post-War for Japanese-Americans in the Northwest. Many didn’t return. For the Chibas, the International District community came together and provided a safe harbor. In 1966, twenty years after they married, Nibs’ and Mary’s son—Beau’s cousin—Dave Morio enrolled at the UW School of Pharmacy, graduating in 1971. In 1980, he apprenticed with Bob and Maxine Sowders at Fife Pharmacy and Gifts, with the expectation that he would buy the pharmacy. He did just that in 1985. He worked closely with the Puyallup Tribal Health Authority serving PTHA contract-care patients. Dave also served on the UWSOP Pharmacy Alumni Association Board (PAA) as President. As a Clinical Assistant Professor, he helped precept many students. Being a staunch supporter of pharmacy and his community, Dave served as President of WSPA as well as the Fife-Milton Rotary Club. 

In 2008, the UW Board of Regents voted to issue 450 honorary degrees to the students who were pulled from the classroom and sent to camps and war. Among the 2008 honorary graduates were Nibs and Mary Morio. Mary finally gained her full-fledged status as a Husky. 

The Chiba-Morio family history reflects the pharmacy profession’s changes over the last century. Main Drugs closed in 1978 and now there are condos in its place. As physicians left the area and drug reimbursements continued to dwindle, Dave closed Fife Pharmacy in 2010 after 25 years. He now works for Safeway Pharmacy. 

2015 marked a new era in pharmacy practice with the change in Washington state legislation. In fall of 2014, Beau Chiba picked up the family mantle by enrolling at UWSOP. “I never got to meet my grandfather, but I’ve been told he was a character, and that I’m just like him. I chose UW School of Pharmacy to stay connected to my family history. It feels like home.”  

Link to Department of Pharmacy archived news

UW-led team to develop innovative HIV treatment lasting at least 7 days

New regimen would make it easier for patients and potentially clear residual virus

Pharmaceutics Professor Rodney Ho
Pharmaceutics Professor Rodney Ho

 

An interdisciplinary team led by Professors Rodney JY Ho of the UW School of Pharmacy and Ann Collier of the UW School of Medicine received $14M from the National Institutes of Health (NIH) to develop a long-lasting (7-day) therapy for HIV. The two co-Principal Investigators and the team will develop innovative treatments to overcome limitations of current oral drug therapies. The UM1 NIH grant is one of first that the NIH recently awarded as part of its key initiatives to address unmet medical need in HIV/AIDS. Dr. Ho was a recipient of the Milo Gibaldi Endowed Professorship, which funded part of the research in developing this program.

The HIV virus is a formidable opponent for researchers. It constantly mutates, making it harder to create drugs for prevention and treatment. HIV lives not only in the blood stream, but in tissues, making it hard to eradicate from the body. It is possible to greatly reduce the presence of the virus in the blood, but finding a way to reduce its presence in tissues has been significantly more challenging.

While current drug combination therapies have significantly improved the length and quality of patient life, they present two main challenges: 1) they must be taken one or more times a day lifelong; and 2) they are not as effective at removing residual viruses from tissues.

Taking treatment as prescribed, known as medication adherence, can be a challenge for many patients. A 2004 study showed that while over 80 percent of HIV patients take their medications as prescribed, two-thirds of older patients who missed a dose said they ‘simply forgot.’ As former surgeon general C. Everett Koop famously said, “Drugs don’t work in patients who don’t take them.”

Dr. Ann Collier of UW Medicine
Dr. Ann Collier of UW Medicine

With the global, U.S. and Washington state goals to eliminate HIV transmission and end the HIV/AIDS epidemic, achieving treatment success for all infected persons is an important component. If adherence is poor, HIV can develop resistance to antiretroviral drugs, which in turn means that higher drug levels or different drugs are needed. Insufficient drug levels may also occur in some tissues. These issues may lead to treatment failure with subsequent progression of HIV to AIDS.

The UW’s new Targeted Long-Acting Combination Antiretroviral Therapy (TLC-ART) Program is an innovative, translational medicine research designed to leverage existing knowledge and a world-class interdisciplinary team of academic, NIH, and industry researchers to deliver new, safe, stable, scalable, and tolerable antiretroviral combination treatments for HIV infection.

Based on the discovery at UW that some antiretroviral medications taken by mouth do not provide sufficient drug exposure and are linked to residual HIV replication, a team led by Drs. Ho and Collier developed the TLC-ART Program that has now received support from the NIH.

The Program has multiple projects designed to interact in a coordinated and collaborative way with the focused goal of producing injectable drug combinations that will achieve effective drug levels lasting more than seven days. In addition to laboratory-based research, the Program incorporates innovative behavioral science studies that will gather information from potential users of long-acting antiretroviral treatments.

Long-acting antiretroviral treatment would provide a new option to help improve patient adherence, especially for those with adherence challenges. With the ability to direct drugs to lymphoid tissue and potentially overcome drug insufficiency in tissues, this research may also help eliminate residual virus.

“We started out very early on in the battle against HIV/AIDS to find a treatment or a vaccine, but it continued to elude us. It is more than likely that a systems approach using innovative drug targeting to cell and tissue along with boosting of patients’ immune system may lead to a cure,” said Dr. Ho. “We cannot do this work alone and I look forward to collaborating with our partners and especially Dr. Collier, who has over 25 years of clinical trials experience.”

“Collaboration among researchers with many different types of expertise and with the affected community has led to major advances in treatment for HIV and I am optimistic that the TLC-ART Program will continue to advance treatment options,” said Dr. Collier.

The TLC-ART Program has investigators from the UW Schools of Pharmacy and Medicine, Fred Hutch, Seattle Children’s Research Institute, the Washington National Primate Research Center, as well as Harborview Medical Center, and will leverage resources of the UW/Fred Hutch Center for AIDS Research and the UW Institute of Translational Health Sciences.

Research reported in this press release  was supported by National Institute of Allergy and Infectious Diseases (NIAID) UM1 large-scale research program of the National Institutes of Health under award number  UM1AI120176. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
A version of this story also appeared in UW Health Science NewsBeat

Link to Pharmaceutics archived news

Ragueneau-Majlessi named UW CoMotion Presidential Innovation Fellow

2015 CoMotion Presidential Innovation Fellow Isabelle Ragueneau-Majlessi
2015 CoMotion Presidential Innovation Fellow Isabelle Ragueneau-Majlessi

UW School of Pharmacy Pharmaceutics Clinical Professor Isabelle Ragueneau-Majlessi has been named a UW CoMotion Presidential Innovation Fellow for 2015. The prestigious fellowship program debuted in 2011 to foster entrepreneurial thinking across UW.

Ragueneau-Majlessi is the co-author of the Drug-Drug Interaction (DIDB) and Pharmacogenetic (e-PKGene) Knowledgebase Applications, Principal Investigator and Director of the Drug Interaction Database program. She joined the faculty of the Department of Pharmaceutics as Clinical Associate Professor in 2009. Her publications look at drug-drug interactions (DDIs), drug disposition and clinical pharmacology, and the regulatory framework and clinical relevance of drug interactions.

The focus of her fellowship work will be to share her experience with the Database platform, which has been fully run at the University for almost 15 years through a successful licensing program.

Ragueneau-Majlessi was delighted to learn about the fellowship and the opportunity to become an active member of the University innovation community. In her Drug-Drug Interaction work, she is interested in continuing expanding the impact of the Database program within and outside the University. She strongly believes that the Database could, in the coming years, become a source of high-quality, unbiased information for clinically-oriented platforms and services, as part of a larger effort to promote drug safety.

Ragueneau-Majlessi earned her medical degree from St Antoine University in Paris, France, and specialized in Clinical Pharmacology. She designed and supervised clinical studies in the private sector and in academia for over six years, and started working at the University of Washington in 1999, first as a Research Associate, and then Principal Research Scientist and Project Manager for the Drug Interaction Database. She also graduated from the University of Washington’s Master’s Degree Program in Biomedical Regulatory Affairs in 2010.

UW Interim President Ana Mari Cauce announced the appointment of Ragueneau-Majlessi and 16 new members to the university’s prestigious CoMotion Presidential Innovation Fellows program. This year’s appointees join ten continuing fellows previously selected for success in fostering a culture of innovation at UW by initiating groundbreaking programs, collaborating with industry and sharing their ideas, knowledge and entrepreneurial thinking with other UW innovators.

“These 17 faculty members are an integral part of our innovation ecosystem and have encouraged industry, business and other academic institutions to take notice of UW and to consider us first when seeking partnerships to help address some of our world’s most challenging problems,” Cauce said.

Throughout their two-year terms, the 17 new fellows will serve as mentors to other UW faculty, researchers and staff pursuing entrepreneurial aspirations, and also share their experiences at campus innovation events. At the end of the term, fellows are encouraged to continue participation in the program and to serve as program and activity advisors to CoMotion.

“I am delighted to have the latest set of innovators at UW join the CoMotion Presidential Innovation Fellows,” said Vikram Jandhyala, UW Vice Provost for Innovation and Executive Director of CoMotion. “These innovation leaders exemplify what the UW and CoMotion are trying to build — scalable impact of the UW community for the benefit of all. I am proud to be able to work with such creative and innovative minds and welcome them to the broader innovation community.”

Link to Pharmaceutics archived news

Innovative Pharmacy Training Does a World of Good in Malawi

New Pharmacy Assistants Graduate, Improving Patient Care at Critically Understaffed Rural Health Centers

Pharmacy Assistant student attending to patients during practicum training in rural pharmacies in Malawi
Pharmacy Assistant student attending to patients during practicum training in rural pharmacies in Malawi Photo: Village Reach

When most of us think of our local pharmacy, we take certain things for granted. We expect that the medications prescribed to us will be in stock and that the well-educated pharmacist staff will give us clear instructions on how to take them, along with any appropriate warnings or side effects of which we need to be aware.

In other parts of the world, those basic assumptions are not the norm. In remote villages, it can be difficult to ensure essential medications are kept in stock and re-supplied as needed. Often there aren’t dedicated, trained pharmacy personnel, nor bottles and labels to dispense medications; pills, if they are in stock, might be wrapped in newspaper or plastic bags with little or no verbal instructions given.

Malawi College of Health Sciences, VillageReach, University of Washington and the Malawi Ministry of Health Collaborate

An innovative Pharmacist Assistant training program in Malawi seeks to change that norm. On June 19, 2015 in Lilongwe, Malawi, the first cohort of students graduated the program—the result of a collaboration between the Malawi Ministry of Health, the U.S. Government through the USAID | Deliver Project, the Malawi College of Health Sciences, University of Washington Global Medicines Program, and Seattle-based NGO VillageReach.

Malawi Pharmacy Assistant Graduation Ceremony
Malawi Pharmacy Assistant Graduation Ceremony Photo: Village Reach

The program produces a dedicated cadre of individuals with enhanced training in medicines management and supply chain practices who will eventually support each of Malawi’s 650 rural health centers. Through this new program, students are trained to dispense life-saving medications and provide patients with essential advice, and also gain the skills to effectively manage inventory to ensure a well-functioning supply chain.

“The Pharmacy Assistants will go a long way to improve the quality of health service delivery in rural areas, as well as strengthening health systems in the country through improved medicines information management that the government can rely on and use to serve people better,” says Albert Khuwi, Health Technical Support Services Deputy Director for the Malawi Ministry of Health.

Visionary Approach to Address Pharmacy Worker Shortages

During the two-year program, students complete two five-month practicums in district hospitals and rural health centers, in addition to the classroom-based learning. The emphasis in practical experience allows students to make an almost immediate impact in rural pharmacies where overburdened and undertrained personnel struggle to meet the demands placed on them. Initial results showed an 80% reduction in clinician time spent on logistics in health facilities with Pharmacy Assistant students, allowing health workers to devote more time to patient care.

Additionally, when a Pharmacy Assistant is working in a health center, the following measures may improve:

  • the quality of patient pharmaceutical care;
  • adherence to proper dispensing practices and drug management standards; and
  • the quality of data reported to higher levels in the supply chain.
Pharmacy Assistant Training Program Graduates
Pharmacy Assistant Training Program Graduates Photo: Village Reach

“This visionary program addresses one of the most critical issues facing many countries—shortages of qualified pharmacy workers. This partnership allows us to create a program that benefits people’s daily lives and well-being,” commented Andy Stergachis, Professor and Associate Dean of the UW School of Pharmacy.

The program launched in 2011 with funding support from the Barr Foundation, the USAID | DELIVER PROJECT, and Vitol Foundation. The current program will graduate two more cohorts, placing an additional 148 Pharmacy Assistants at rural health centers by 2017. The Malawi Ministry of Health has expressed the desire to place as many as 650 Pharmacy Assistants to meet the needs of its rural communities.

“The U.S. Government is proud of this successful partnership with the Government of Malawi, VillageReach, The Malawi College of Health Sciences, and the University of Washington, and very proud of the 20 USAID-sponsored students who graduated today. We are confident that these new Pharmacy Assistants will contribute greatly to the improvement of Malawi’s health sector,” noted USAID/Malawi’s Deputy Health Office Director Lilly Banda.

After graduation, the students will become employees of the Malawi Ministry of Health, which will place them for work in rural health centers throughout the country.

***

About VillageReach VillageReach is a non-profit global health innovator that develops, tests, implements and scales new solutions to critical health system challenges in low-resource environments, with an emphasis on strengthening the “last mile” of healthcare delivery. VillageReach combines expertise across public health, technology, and business to bring life-saving innovation – new systems, programs and technologies – to scale and sustainability in the world’s most underserved communities. www.villagereach.org

About Malawi College of Health Sciences Malawi College of Health Sciences provides education and training of the highest quality to a range of middle level health personnel essential to promote health and improve services through provision of quality training, consultancies and research.

About the University of Washington, School of Pharmacy, and Global Medicines Program Founded in 1861, the UW ranks 3rd in the world for Clinical Medicine and Pharmacy in the 2014 Academic Ranking of World Universities. The University leads the nation’s public research universities in receipt of federal support for research and training. The UW School of Pharmacy is committed to educating the next generation of leaders in pharmacy, pharmaceutical research, and health care—while seeking to ensure the safe, rational, and cost-effective use of medicines. The Global Medicines Program in the Department of Global Health works to improve the use, safety, quality, cost-effectiveness, and affordability of medicines in low- and middle-income countries through research, education, training and outreach. Visit http://globalmedicines.org, http://sop.washington.edu for more information.

 

Scenes from Commencement 2015

Dean Sean D. Sullivan presents class speaker Nancy Denini with her PharmD degree
Dean Sean D. Sullivan presents class speaker Nancy Denini with her PharmD degree Photo: Alex Levine Photography

Friday was a day of recognition and celebration! Over 100 graduate and PharmD students received their degrees and began a new phase in their professional careers.

Associate Dean Peggy Odegard presents Adrian Hughes with the Dean's Club Humanitarian Award
Associate Dean Peggy Odegard presents Adrian Hughes with the Dean’s Club Humanitarian Award Photo: Alex Levine Photography

Associate Dean Peggy Odegard welcomed the graduates telling them, “We are so proud of each of you. Completing a post-graduate degree at the University of Washington is not for the faint of heart. As faculty, we sought to challenge you. And you rose to the challenge, often exceeding our expectations. Know that when you exit this room, you leave with our confidence in your abilities in the profession and science of pharmacy.”

 

Professor and Dean Sean D. Sullivan
Professor and Dean Sean D. Sullivan Photo: Alex Levine Photography

“I hope you will become leaders in your chosen field,” Professor and Dean Sean D. Sullivan told the graduates in his address. “Everyone sitting on this stage is here to help you – have their numbers on speed dial. Know that you will always be a part of our Husky family and that I am proud of you.”

UW SOP Faculty
UW School of Pharmacy Faculty Photo: Alex Levine Photography

 

More images from the 2015 Graduate Recognition Ceremony

 

Alumnus Ryan Oftebro presents the Alumni Professional Excellence Award to Nancy Denini
Alumnus Ryan Oftebro presents the Alumni Professional Excellence Award to Nancy Denini Photo: Alex Levine Photography

 

2015 Plein Geriatric Pharmacy Certificate Recognition
2015 Plein Geriatric Pharmacy Certificate Recognition Photo: Alex Levine Photography

 

Plein Geriatric Pharmacy Faculty
Plein Geriatric Pharmacy Faculty Photo: Alex Levine Photography

 

Faculty Members Don Downing, Shabir Somani, John Horn, and Andy Stergachis
Faculty Members Don Downing, Shabir Somani, John Horn, and Andy Stergachis Photo: Alex Levine Photography

 

Faculty Member Joy Plein
Faculty Member Joy Plein Photo: Alex Levine Photography

 

2015-sop-graduation-18
Photo: Alex Levine Photography
Faculty Members Jennifer Danielson and Teresa O'Sullivan
Faculty Members Jennifer Danielson and Teresa O’Sullivan Photo: Alex Levine Photography

 

PORPP Students Ready for Graduation!
PORPP Students Ready for Graduation! Photo: Alex Levine

Hansen study finds for new users, sleeping pills may double car crash risk

UW School of Pharmacy Research Assistant Professor Ryan Hansen, PhD, PharmD
There’s a public safety concern that we want health providers and the general public to be aware of,” said Ryan Hansen, shown holding the prescription drugs involved in the study.

Three prescription sleeping aids are associated with an increase in motor vehicle crashes, according to a study by the University of Washington School of Pharmacy and the Group Health Research Institute. The research was published today in the American Journal of Public Health.

The research, led by Ryan Hansen, ’03, ’12, UW assistant professor of pharmacy, found that the risk of motor vehicle crashes was nearly double among new users of the medications temazepam (Restoril), zolpidem (Ambien, Ambien CR) and trazodone (Desyrel).

Dissertations don’t typically make the evening news. However, Ryan Hansen’s study on the impact of sleeping aids on motor vehicle accidents was not only published in the American Journal of Public Health in June 2015, it was featured in an NBC Nightly News broadcast.

The study grew out of a conversation with a family friend when Hansen was seeking a dissertation topic some years ago. The friend said that he had taken a sleep aid the night before, woke up in the kitchen, and noticed a bite was taken from a piece of raw pork in the fridge.

“As a pharmacist and a researcher, that had me wondering about the affect these sleep aids have and how we might measure their impact.”–Ryan Hansen, Assistant Professor, The CHOICE Institute at UWSOP

Ryan identified a way to link motor vehicle crash records with prescription drug data and identified a trend among people who had new sleep-aid prescriptions for these three drugs. Three prescription sleeping aids are associated with an increase in motor vehicle crashes, according to his research in collaboration the Group Health Research Institute. They found the risk of motor vehicle crashes was nearly double among new users of the medications temazepam (Restoril), zolpidem (Ambien, Ambien CR) and trazodone (Desyrel).

Study participants met the following criteria: had a drug benefit through Group Health Cooperative; were between 21 and 79 years old; were Washington state residents; and had Washington state driving licenses. The population’s medical encounters and prescription records were combined with Washington state driver’s license records and motor vehicle crash records.

For new users of all three prescriptions, exposure nearly doubled the risk of vehicle crashes. For new users, the increased risk could last for up to one year of continuous prescriptionfilling. Among the three drugs analyzed, temazepam appeared to offer the least risk for motor vehicle crashes, but may have other associated risks for some patients.

“Depending on an individual’s need to drive regularly, combined with a medical indication for sedative use, the choice of a particular sedative may affect the risk of crashing,” the scientists wrote. “Prescribers, pharmacists and patients should discuss this potential risk and consider the implications of this analysis when selecting a sedative hypnotic medication.”

“There are many approaches to the management of insomnia, including lifestyle changes such as cutting caffeine intake and exercising, which may alleviate the insomnia without medications,” Hansen said. “There’s a public safety concern that we want health providers and the general public to be aware of.”

The team emphasized the need for additional research to evaluate the risks and associations between overall medication use and traffic crashes. Noted Hansen: “People with questions or concerns about a new sleep aid prescription should talk with their physician, pharmacist, or health provider to understand the risks.”

Dr. Hansen interviewed by NBC News

NBC News coverage

Advance your career in patient-centered outcomes research at the University of Washington. Learn more about our Graduate Programs in Pharmaceutical Outcomes Research and Policy in The CHOICE Institute at UWSOP.

Link to Department of Pharmacy archived news

State of Washington first in pharmacy, again

Washington will be the first state in the country to require that pharmacists are included in health insurance provider networks under new legislation (SB 5557) signed by Governor Inslee on Monday, May 11, 2015. Pharmacists will be compensated for the patient care they provide within their scope of practice, just like nurse practitioners and physician assistants—improving patient access to care.

Lee lab pursues clues to HIV, flu in the moment of infection

Image of Nancy Horn and James Williams work with Med Chem Asst Professor Kelly Lee
Nancy Horn and James Williams work with Med Chem Asst Professor Kelly Lee Photo: Alex Levine Photography

In a basement lab deep within the Magnuson Health Sciences Building, a group of scientists works to decode the mysteries of two deadly viruses: influenza and HIV. Led by Kelly Lee, assistant professor of medicinal chemistry in the School of Pharmacy, they examine the viral fusion proteins found on the outside of “enveloped viruses” – viruses with membranes.

Kelly Lee is an assistant professor of medicinal chemistry in the School of Pharmacy. These proteins activate the fusion of disease-causing pathogens and host cells. During fusion, enveloped viruses merge their membranes with those of host cells to penetrate, and infect, the cell.

Proteins attached to the HIV virus membrane attempt to fuse with host cells.
Proteins attached to the HIV virus membrane attempt to fuse with host cells. Photo: ThinkStock

“We know how the proteins look before they carry out their function,” Lee said, “but we need to understand the structural changes that occur during fusion.”

By doing so, the lab hopes to develop more effective vaccines that will work with the body’s immune system to recognize and neutralize the harmful viruses.

Read the full story on UW’s Health Science NewsBeat.

Link to Medicinal Chemistry archived news

Solving Bietti’s Crystalline Dystrophy is mission of Pharmaceutics Prof Kelly

Image of Professor Ed Kelly and Graduate Student Cate Lockhart
Pharmaceutics Associate Professor Ed Kelly discusses BCD with graduate student Cate Lockhart, PharmD, ’13 Photo: Alex Levine Photography

Department of Pharmaceutics Associate Professor Ed Kelly and graduate student Cate Lockhart (UW PharmD, ’13) are undaunted by the challenge of researching the rare blinding eye disease, Bietti’s Crystalline Dystrophy (BCD). “Only one in 70,000 people has the disease and no one is doing basic research on BCD except our lab,” Kelly said. As he’s gotten to know people with the disease,  “what began as a curiosity, a ‘What if?’ has become a passion,” he shared. “I really want to find a treatment for this disease. It’s personal now.”

With such a low incidence rate, it is harder to get funding from traditional sources. The team instead is working directly with a patient driven biotechnology company, Reflection Biotechnologies, and has received funding from Institute for Translational Health Sciences (ITHS).

Ed Kelly’s BCD research is also supported by private funding. If you would like to make a gift to support Ed’s research into Bietti’s Crystalline Dystrophy, click here.

 

Read the full story on UW’s Health Science NewsBeat.

Link to Pharmaceutics archived news

New center to use novel method to screen chemicals’ toxicity

Image of pharmaceutics scientist preparing cell cultures for toxicity testing
Research scientists in the Department of Pharmaceutics prepare cell cultures to test chemicals for their potential risk to humans. Photo: Edward Kelly

The U.S. Environmental Protection Agency will provide $6 million in seed funding for a Predictive Toxicology Center at the University of Washington, enabling researchers, including Department of Pharmaceutics Associate Professor Edward Kelly, to develop more accurate in vitro models – organ-mimicking cell cultures – to test chemicals for their potential risk to humans and to help accelerate the evaluation of large numbers of chemicals and reduce the need for animal models.

The center’s research is important to establish novel methods that reflect the complexity of biological systems. Elaine Faustman and Terrance Kavanaugh, both UW professors of environmental and occupational health sciences, will co-direct the new center. Kelly will manage the project on the kidney cell culture. “These systems are being used in our lab studies to test drugs with known adverse effects on the kidneys, including antibiotics, chemotherapies, and immunosuppressants,” he said. Kelly is involved in another research collaboration at the UW to get organ models like the intestines, liver, and kidney to work together.

Preliminary testing shows that the device works as a kidney would, expressing critical proteins and demonstrating the polarity characterized by the type of cells found in this organ. “The cells attach, proliferate, and form the same shape they would in a human body and thus replicate many of a kidney’s normal functions,” he said.

Pharmaceutics graduate students in the lab
Graduate students in Pharmaceutics demonstrate how constant flowing media will go through microphysiological systems connected to pumps outside an incubator. Photo: Elijah Weber, Department of Pharmaceutics

When these cells are exposed to a heavy metal, Kelly explained, a “toxicant signature” or biomarker of tissue injury is evident, such as an increased level of protein molecules expressed.

“These systems are being used in our lab studies to test drugs with known adverse effects on the kidneys, including antibiotics, chemotherapies, and immunosuppressants,” he said.

Kelly and Eaton are involved in another research collaboration at the UW to get organ models like the intestines, liver and kidney to work together. That work is funded by the National Institutes of Health. The new EPA-funded Predictive Toxicology Center will build on this work and apply these organ models to assess environmentally relevant chemicals.

After validating these three-dimensional cell cultures using known toxicants, the Predictive Toxicology Center researchers will investigate biomarkers of cell injury or altered function that indicate an adverse outcome from an exposure to those chemicals for which insufficient data exists.

They will then use modeling techniques to assess and predict human health risks, linking laboratory data with human exposure pathways.

The center will use computational models to identify and characterize adverse outcomes from environmental chemicals, focusing on the importance of time of exposure, genetics and oxidative stress as mediators of toxicity. Such an approach will allow for connecting in vitromodel results with human physiological changes and better predict a chemical’s potential for human health effects.

Read more about in Health Science NewsBeat

Link to Pharmaceutics archived news

UW PORPP and Fred Hutch Researchers Receive $7.75M PCORI Award to Study Cancer Treatment

Image of Electron Microscopy of Human Neutrophils
Electron Microscopy of Human Neutrophils Credit: ThinkStock

 

A research team, led by Scott Ramsey, director of the Hutchinson Institute for Cancer Outcomes Research (HICOR), that includes UW Department of Pharmacy’s Pharmaceutical Outcomes Research and Policy Program (PORPP) faculty members Sean Sullivan, Jeannine McCune, Aasthaa Bansal, and Gary Lyman, who also serves as a co-director at HICOR, has been approved for a $7.75 million, four-year funding award by the Patient-Centered Outcomes Research Institute, or PCORI, an independent, nonprofit organization based in Washington, D.C. The award will be used to conduct a pragmatic clinical trial evaluating the use of colony stimulating factor to reduce the risk of serious infection in patients undergoing chemotherapy for breast, colorectal or lung cancer.

The study, titled “A Pragmatic Trial to Improve Colony Stimulating Factor Use in Cancer,” is one of five awards totaling $64.1 million approved by PCORI on Tuesday, Feb. 24, that aim to provide patients with information that will help them make better-informed decisions about their care. The result of conducting this important intervention study could lead to improved quality of life for individuals with breast, lung, and colorectal cancer. It is also one of the first studies selected for funding through PCORI’s Pragmatic Clinical Studies Initiative, an effort to produce results that are broadly applicable to a greater variety of patients and care situations and can be more quickly taken up in routine clinical practice.

This work will not only impact the profession of pharmacy, but also provide substantive benefit to cancer patients.  This trial will evaluate if the use of colony stimulating factors, abbreviated CSFs, can be improved by using a clinical guideline-informed approach implemented by pharmacists.  Appropriate use of the CSFs decrease cancer patients’ risk of experiencing low neutrophil, which fight off infection, counts and also decrease how often cancer patients experience a fever and a low neutrophil count (called febrile neutropenia), which can be life threatening.  CSFs are expensive, for the patient and at a national level. Unfortunately, the CSFs  have not been used according to clinical guidelines.  This work seeks to conduct a large-scale pragmatic trial to compare outcomes of the CSFs – filgrastim and pegfilgrastim – in cancer patients with select solid tumors, comparing outcomes in those patients receiving CSFs according to the guideline-informed pharmacist-implemented system compared to typical clinical practice.

Many clinical studies test whether a treatment works under optimized conditions in specialized research centers, but health care is rarely delivered in such idealized situations and settings. Pragmatic clinical studies test a treatment’s effectiveness in “real-life” practice situations, such as typical hospital and outpatient care settings, and also can include a wider range of study participants, which potentially makes their findings more generally applicable.

“This project was selected for PCORI funding not only for its scientific merit and commitment to engaging patients and other healthcare stakeholders in a major study conducted in real-world settings, but also for its potential to answer an important question about the use of colony stimulating factors and fill a crucial evidence gap,” said PCORI Executive Director Joe Selby, MD, MPH. “We look forward to following the study’s progress and working with Fred Hutch and the University of Washington to share the results.”

The HICOR/PORPP study and the other projects approved for PCORI funding were selected through a highly competitive review process in which patients, caregivers, and other stakeholders joined scientists to evaluate the proposals. Applications were assessed for scientific merit, how well they will engage patients and other stakeholders, and their methodological rigor among other criteria.

Ramsey’s award has been approved pending completion of a business and programmatic review by PCORI staff and issuance of a formal award contract.

# # #

The University of Washington School of Pharmacy is committed to educating the next generation of leaders in pharmacy, pharmaceutical research, and healthcare – while seeking to ensure the safe, rational and cost-effective use of medicines. Founded in 1894, the UW School of Pharmacy is ranked #3 in the world according to Shanghai Jiao Tong University. Follow the School of Pharmacy on Facebook or Twitter.

PCORI is an independent, nonprofit organization authorized by Congress in 2010. Its mission is to fund research that will provide patients, their caregivers, and clinicians with the evidence-based information needed to make better-informed healthcare decisions. For more information about PCORI’s funding awards, visit the Research and Results page on www.pcori.org. http://www.pcori.org/funding/opportunities

An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first and largest cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. For more information visit www.fredhutch.org or follow Fred Hutch on FacebookTwitter or YouTube.

 

Klatt Receives NIDA/NIH Award to Research Cannabis Impact on HIV

Image of Pharmaceutics Assistant Professor Nichole Klatt
Pharmaceutics Assistant Professor Nichole Klatt

Pharmaceutics Assistant Professor, Nichole Klatt is one of five scientists selected to receive the prestigious 2015 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. Dr. Klatt proposes development of HIV cure strategies by using non-psychoactive cannabinoids as potential therapeutic agents. “There is currently no cure for HIV infection,” notes Klatt. “Even with antiretroviral treatment, HIV decreases health due to chronic inflammation and gastrointestinal dysfunction, which leads to increased morbidity and mortality and a chronic HIV reservoir in infected individuals.”

Since cannabinoids, derivatives of cannabis, have been used to treat nausea and pain and have been shown to be anti-inflammatory in animal models, Klatt theorized that cannabinoids could be effective in reducing inflammation common in HIV patients. “Cannabis (marijuana) has been shown previously to have anti-inflammatory effects and positive benefits to the gastrointestinal tract. With the recent legalization of cannabis in select states, a comprehensive understanding of how cannabis affects HIV infection is imperative,” she added. “The goal of our Avant-Garde research is to understand how cannabis may alter gastrointestinal immunity, inflammation and viral reservoirs in HIV-infected people. We want to determine the mechanisms by which cannabis exerts its effects and develop non-psychoactive cannabinoids as a potential adjunct treatment for HIV infection.”

With proposals ranging from innovative therapies to the development of unique organoid models of the brain, the five scientists will each receive $500,000 per year for five years to support their research. NIDA’s annual Avant-Garde Award competition, now in its eighth year, is intended to stimulate high-impact research that may lead to groundbreaking opportunities for the prevention and treatment of HIV/AIDS in drug users. NIH’s awards showcase potentially transformative research on prevention, immune system, drug development, and “minibrain” models made of human tissue.

“Despite the success of combined antiretroviral therapies in the treatment of HIV/AIDS, HIV remains a chronic disease with a host of debilitating side effects that are exacerbated in those suffering from substance use disorders,” said NIDA Director Nora D. Volkow, M.D. “These scientists have proposed creative approaches that could transform the way we think about HIV/AIDS research, and could lead to the development of exciting new tools and strategies to prevent infections and improve the lives of substance abusers infected with HIV.”

Read more about the Avant Garde Awards

Link to Pharmaceutics archived news

Higher dementia risk linked to more use of common drugs

Image of UW School of Pharmacy Professor Shelly Gray
UW School of Pharmacy Professor Shelly Gray

Dr. Shelly Gray et. al. found a persistent link between dementia and some medications in a University of Washington/Group Health study published in JAMA Internal Medicine on January 26, 2015. The large study links a significantly increased risk for developing dementia, including Alzheimer’s disease, to taking commonly used medications with anticholinergic effects at higher doses or for a longer time. Many older people take these medications, which include nonprescription diphenhydramine (Benadryl). JAMA Internal Medicine published the report, called “Cumulative Use of Strong Anticholinergic Medications and Incident Dementia.”

The study used more rigorous methods, longer follow-up (more than seven years), and better assessment of medication use via pharmacy records (including substantial nonprescription use) to confirm this previously reported link. It is the first study to show a dose response: linking more risk for developing dementia to higher use of anticholinergic medications. And it is also the first to suggest that dementia risk linked to anticholinergic medications may persist—and may not be reversible even years after people stop taking these drugs.

“Older adults should be aware that many medications—including some available without a prescription, such as over-the-counter sleep aids—have strong anticholinergic effects,” said Shelly Gray, PharmD, MS, the first author of the report, which tracks nearly 3,500 Group Health seniors participating in the long-running Adult Changes in Thought (ACT), a joint Group Health–University of Washington (UW) study funded by the National Institute on Aging. “And they should tell their health care providers about all their over-the-counter use,” she added.

“But of course, no one should stop taking any therapy without consulting their health care provider,” said Dr. Gray, who is a professor, the vice chair of curriculum and instruction, and director of the geriatric pharmacy program at the UW School of Pharmacy. “Health care providers should regularly review their older patients’ drug regimens—including over-the-counter medications—to look for chances to use fewer anticholinergic medications at lower doses.”

For instance, the most commonly used medications in the study were tricyclic antidepressants like doxepin (Sinequan), first-generation antihistamines like chlorpheniramine (Chlor-Trimeton), and antimuscarinics for bladder control like oxybutynin (Ditropan). The study estimated that people taking at least 10 mg/day of doxepin, 4 mg/day of chlorpheniramine, or 5 mg/day of oxybutynin for more than three years would be at greater risk for developing dementia. Dr. Gray said substitutes are available for the first two: a selective serotonin re-uptake inhibitor (SSRI) like citalopram (Celexa) or fluoxitene (Prozac) for depression and a second-generation antihistamine like loratadine (Claritin) for allergies. It’s harder to find alternative medications for urinary incontinence, but some behavioral changes can reduce this problem.

“If providers need to prescribe a medication with anticholinergic effects because it is the best therapy for their patient,” Dr. Gray said, “they should use the lowest effective dose, monitor the therapy regularly to ensure it’s working, and stop the therapy if it’s ineffective.” Anticholinergic effects happen because some medications block the neurotransmitter called acetylcholine in the brain and body, she explained. That can cause many side effects, including drowsiness, constipation, retaining urine, and dry mouth and eyes.

“With detailed information on thousands of patients for many years, the ACT study is a living laboratory for exploring risk factors for conditions like dementia,” said Dr. Gray’s coauthor Eric B. Larson, MD, MPH. “This latest study is a prime example of that work and has important implications for people taking medications—and for those prescribing medications for older patients.” Dr. Larson is the ACT principal investigator, vice president for research at Group Health, and executive director of Group Health Research Institute (GHRI). He is also a clinical professor of medicine at the UW School of Medicine and of health services at the UW School of Public Health.

Some ACT participants agree to have their brains autopsied after they die. That will make it possible to follow up this research by examining whether participants who took anticholinergic medications have more Alzheimer’s-related pathology in their brains compared to nonusers.

Drs. Gray and Larson’s coauthors are Paul Crane, MD, MPH, an associate professor of medicine at the UW School of Medicine, adjunct associate professor of health services at the UW School of Public Health, and affiliate investigator at GHRI; Sascha Dublin, MD, PhD, a Group Health physician, GHRI associate investigator, and affiliate associate professor of epidemiology at the UW School of Public Health; Melissa L. Anderson, MS, and Onchee Yu, MS, senior biostatisticians, and Rod Walker, MS, biostatistician, at GHRI; Joseph T. Hanlon, PharmD, MS, a professor of medicine at the University of Pittsburgh; and Rebecca Hubbard, PhD, an associate Professor of Biostatistics at the Hospital of the University of Pennsylvania, who did this work while on staff at GHRI.

This work was supported by National Institute on Aging NIH Grants U01AG00678 (Dr. Larson), R01AG 027017, R01AG037451, P30AG024827, T32 AG021885, K07AG033174 (Dr. Hanlon), and R03AG042930 (Dr. Dublin) and by the Branta Foundation (Dr. Dublin).

For a list of medications highlighted in the study, please view this story from the AARP Bulletin.

# # #

University of Washington School of Pharmacy

The UW School of Pharmacy is committed to educating the next generation of leaders in pharmacy, pharmaceutical research, and health care—while seeking to ensure the safe, rational, and cost-effective use of medicines. Founded in 1894, the UW School of Pharmacy is ranked #3 in the world according to Shanghai Jiao Tong University. Follow the School of Pharmacy on Facebook or Twitter.

UW Medicine

UW Medicine is part of the University of Washington. Its mission is to improve the health of the public by advancing medical knowledge, providing patient care, and training the next generation of physicians and other health professionals. Its system includes Harborview Medical Center, Northwest Hospital & Medical Center, Valley Medical Center, UW Medical Center, UW Neighborhood Clinics, UW Physicians, UW School of Medicine and Airlift Northwest. UW Medicine is affiliated with Seattle Children’s, Fred Hutchinson Cancer Research Center, the Veteran’s Affairs Healthcare System in Seattle, and the Boise VA Medical Center. It shares in the ownership and governance of the Seattle Cancer Care Alliance and Children’s University Medical Group.

Group Health Research Institute

Group Health Research Institute does practical research that helps people like you and your family stay healthy. The Institute is the research arm of Seattle-based Group Health Cooperative, a consumer-governed, nonprofit health care system. Founded in 1947, Group Health Cooperative coordinates health care and coverage. Group Health Research Institute changed its name from Group Health Center for Health Studies in 2009. The Institute has conducted nonproprietary public-interest research on preventing, diagnosing, and treating major health problems since 1983. Government and private research grants provide its main funding. Follow Group Health research on Facebook, Twitter, or YouTube.

Why the Bad Taste? Dr. Joanne Wang’s Team Finds a Reason

Drugs-Yuck
TAKING A MEDICATION AS PRESCRIBED IS CRITICAL to a drug’s effectiveness. But for some people, taking medications literally turns their stomach – and if a medication leaves a persistently bitter taste, many people, especially children and elderly patients, will take it inconsistently or not at all. In the online Journal of Biological Chemistry, Joanne Wang’s research team in the University of Washington School of Pharmacy describe a novel mechanism for active drug accumulation and secretion in salivary gland epithelial cells that leads to the lingering bad taste of metformin, a frontline prescription drug used to treat type 2 diabetes.  Full story…

 

Link to Pharmaceutics archived news

Fulbright Scholar Researches Experiential Pharmacy Education at UW

IT’S NOT OFTEN A PROMINENT RESEARCHER FROM SERBIA comes to UW Pharmacy as a Fulbright Visiting Scholar. Dr. Jelena Parojcic is an associate professor in the Department of Pharmaceutical Technology at the University of Belgrade In Serbia. Her areas of research include Biopharmaceutical aspects of Drug Delivery; Drug Release Mechanisms In Vitro and In Vivo; and Bioperformance Dissolution Testing. She has a great interest in professional development of pharmacy faculty and the modernization of pharmacy curriculum and experiential education. We sat down with Dr. Parojcic to learn more about her six months here.

SG: How did you choose the UW School of Pharmacy?

JP: I came to Seattle four years ago and was deeply impressed by the city, especially the University of Washington campus and library. The Fulbright selection committee discourages scholars from choosing the most competitive schools, to improve their chances. I knew I wanted to be at UW School of Pharmacy as it has the best experiential education curriculum. Even though it was competitive, I approached colleagues here at UW with a project proposal and applied for and got the Fulbright Visiting Scholar grant, working with the Office of Pharmacy Professional Education.

Jelena Parojcic at one of her favorite campus spots - the Suzzallo Library.
Jelena Parojcic at her favorite  spot – the Suzzallo Library.

“I knew I wanted to be at UW School of Pharmacy as it has the best experiential education curriculum. Even though it was competitive, I approached colleagues here at UW with a project proposal and applied for and got the Fulbright Visiting Scholar grant, working with the School’s Office of Pharmacy Professional Education (OPPE). ”

–Jelena Parojcic, UW School of Pharmacy Fulbright Visiting Scholar

 

SG: What did you research here?

JP: I am part of a European Union (EU) project aimed at the modernization of pharmacy education in Serbia. We are expanding and improving the experiential education curriculum. The US has an established system for experiential pharmacy education; and Europe is still struggling to find a model.

DS: Besides the great weather, why did you come out in the spring and summer?

JP: I wanted to attend the American Association of the Colleges of Pharmacy (AACP) conference in late July to network with colleagues from all over the United States. The conference was very useful for my project. Unlike the EU version which does not have decision-making authority, the conversations that occur at AACP become recommendations and then guidelines for schools of pharmacy. There are new accreditation standards and I look forward to seeing in December how the process I observed influenced the outcome. Smaller countries, like Serbia, are trying to figure out whether to adopt national standards for pharmacy education or collaborate with other EU countries and create regional standards. It’s an area that needs more research.

SG: What was the academic highlight for you?

JP: I was very interested in faculty development and was able to meet with colleagues in the Department of Pharmacy to learn more. I’ve attended the Teaching Certificate Program in Pharmacy Education and was able to experience active learning first hand. To me, this is a way to transform our teaching – involving the students in their own learning more than through traditional lectures. When I return to Belgrade, I will work with my colleagues to introduce this approach to our courses. I will also work to establish the Teaching in Pharmacy Education program for faculty and preceptors at the University of Belgrade and look forward to continuing my collaboration with colleagues from UW School of Pharmacy on the development and delivery of the relevant curricula.

SG: How do you think the students will respond to a different approach to teaching?

JP: I think it will be difficult at first, but in the long run, I think they will see the benefits of this approach. I plan to share these techniques with my colleagues too, so they can incorporate them into their classrooms. The connections I made here are so important to me and I would like to continue and extend this collaboration between Southeastern Europe and the Pacific Northwest.

SG: What surprised you about your time here in Seattle?

JP: Seattle is such an exciting place with state of the art technology – one student wore Google glasses. My apartment building had a drone flying outside its windows a few weeks ago and it was all over the news. I was fascinated with all the different scientific research stories on UW Today email. Seattle is a beautiful, international city – Seattleites are very modest about how wonderful it is!

Sarah Guthrie (SG) is the Director of Communications for the UW School of Pharmacy and can be reached at gu3@uw.edu.

 

Link to Department of Pharmacy archived news

Klarissa Hardy Receives Major NIH Grant

KlarissaHardy

Congratulations to former UW School of Pharmacy Department of Medicinal Chemistry post-doctoral fellow, Klarissa Hardy, who received a $660,000 National Institutes of Health (NIH) grant to fight breast cancer! Hardy worked with Dean Sidney Nelson to study the affects of the anti-cancer drug lapatinib on the liver. “I learned a lot from Dr. Nelson, from his previous work and experience in this area.”

Dr. Hardy, now a researcher and assistant professor of pharmaceutical sciences at Lipscomb University, made history in receiving the first NIH grant for Lipscomb, and the largest research grant in the university’s history.

Hardy was part of the late Dr. Sid Nelson’s lab at Med Chem, where she studied the targeted breast cancer drug, lapatinib, to examine the role of cytochrome P450-mediated metabolic activation in the liver toxicity associated with lapatinib. “We examined how the liver metabolizes lapatinib and how the products formed from this process might be linked to the toxic effects of the drug on the liver,” she said.

Her current research is aimed at discovering genetic factors, such as metabolism, that may contribute to a patient’s risk of developing a toxic reaction to the drug, thereby limiting its use in certain patient populations. The goal is to improve the safety of the drug and discover ways to minimize toxic reactions.

“The Medicinal Chemistry Department at the UW School of Pharmacy is where all this work started,” said Klarissa.  “I thank everyone in Med Chem for their support and helpful contributions along the way.  I am especially grateful to my mentors, Dr. Allan Rettie and Dr. Sid Nelson, for their guidance, and to Dr. Michelle Wahlin for all of her work on the project during her graduate studies.”

See the complete story of Klarissa’s award at www.lipscomb.edu/news/archive/detail/101/28696.

Our congratulations to Dr. Klarissa Hardy for this well-deserved award!

 

Link to Medicinal Chemistry archived news

Congratulations Prof McCune!

10689435_851765621522652_1208858039025774071_n

Jeannine McCune, PharmD, was announced as the newest Associate Editor of the Clinical Pharmacology & Therapeutics the official scholarly publication of the American Society of Clinical Pharmacology and Therapeutics (ASCPT). Additionally, Dr. McCune was elected a Fellow of the American College of Clinical Pharmacy and will be recognized during the College’s 2014 Annual Meeting. Congratulations Prof McCune!

  

Link to Department of Pharmacy archived news

North American ISSX Meeting will award two of our faculty.

Screen Shot 2014-10-15 at 12.31.03 PM

Not one, but two of our faculty were selected to receive the only awards given by The International Society for the Study of Xenobiotics (ISSX). Dean Emeritus Tom Baillie was selected for the North American Scientific Achievement Award and faculty member Dr. Nina Isoherranen, was selected for the North American New Investigator Award. Both awards will be presented at the 19th North American ISSX Meeting at a special session on October 21 at 2 p.m., followed by scientific lectures by Baillie and Isoherranen. UW Pharmacy will host a reception for alumni, faculty, and friends at 5 p.m. on October 21. The 19th North American ISSX Meeting will convene October 18 – 23, 2014 at the Hilton Union Square San Francisco Hotel in San Francisco, California.

 

Click here for an archive of School of Pharmacy news stories.

How do you teach when the topic changes so fast? A Q&A with Dr. Doug Black

Doug Black

Doug Black, UW associate professor of pharmacy practice, confers with students in the Bracken Pharmacy Learning Center. From left are Zsolt Hepp, Mitul Patel and Tulip Younes.

With the Ebola virus grabbing headlines, we sat down to talk with UW Pharmacy professor Dr. Doug Black, an infectious-disease specialist, to learn more about how he teaches students about a topic that changes so fast.

Full story

 

Link to SOP news archive

Announcing our new Dean of Pharmacy: Dr. Sean D. Sullivan

Sean Sullivan

Provost Ani Mari Cauce announced the appointment of Dr. Sean D. Sullivan as our next Dean of the School of Pharmacy, effective September 15, 2014.

Sean came to the University of Washington in 1992 and was promoted to full professor in 2001 and associate dean for research in 2010. A pharmacist by training, Sean has held numerous leadership roles, including his most recent role as the Stergachis Endowed Director of the Pharmaceutical Outcomes Research and Policy Program (PORPP). Sean has a strong vision for the School, building on its strengths as we go forward together.

With expertise in pharmacy and graduate education, federally funded biomedical research and training, and pharmacy practice, he has the breadth of knowledge and skills to lead the School. We are excited that he brings into this important leadership position a passion and commitment for the UW, pharmacy, science, and the student experience. Please join us in congratulating Sean on his new role as Dean.

We are grateful to and thank Dean Baillie for his service and leadership over the past six years.

 

Link to SOP news archive

Diabetes-Education Project Honored for Community Impact

[one_half]Project_CHANCE_2014
[/one_half][one_half_last]
At the UW Medical Center Martin Luther King, Jr. tribute event on January 16th, a UW School of Pharmacy project will receive a Community Volunteer Recognition Award. The award-winning project is a diabetes-education program for homeless and low-income populations at UW Medicine Harborview Medical Center. It has been led by pharmacy students Paige Mathew, John Eckstrom and Steve Erickson (pictured in that order at left), pharmacy faculty members Nanci Murphy and Skye McKennon DeCato and multiple community partners.[/one_half_last]

This diabetes-education project kicked off in spring 2011 after then-first-year student Erickson and Associate Dean Murphy successfully secured a $10,000 Project CHANCE award from the American Pharmacists Association to implement a diabetes-care program. Project CHANCE awards help fund projects that work to promote safe medication practices and interprofessional collaboration and delivery of services to the underserved.

The UW Project CHANCE team recognized that homeless and low-income patients face additional difficulties when trying to manage their health within the constraints of unpredictable living and eating situations. So the team set out to offer diabetes-education programs tailored specifically to the needs of these populations.

Since 2011, the Project CHANCE team has worked with an interdisciplinary group of practitioners familiar with the needs of homeless and low-income patients to develop a tailored diabetes curriculum. The team implemented twice-weekly diabetes education sessions at the Jefferson Terrace Medical Respite Program/Edward Thomas House located near Harborview. The Thomas House provides recuperative care for homeless men and women who are too sick for the streets or shelters but not sick enough to be admitted to the hospital.

Session topics included “The Highs and Lows of Diabetes,” “Eating and Diabetes” and “Understanding Your Medicines.” The response to the education sessions has been overwhelmingly positive. The number of attendees has increased each week since the start of the program. Participants consistently rate the program as excellent. The participants’ healthcare providers have also remarked that the program is having a positive impact.

Members of the Project CHANCE team plan to continue to expand their health education efforts for the homeless and low-income patients. For starters, they will be offering new education sessions focused on tobacco cessation and pain education, at the request of program participants. The team members will also be working on further engaging UW health sciences students and faculty as well as continuing their efforts to study the effectiveness of their programming.

Multiple UW health sciences students and faculty have contributed to this project along the way. Currently, other key team members on this project are Pioneer Square Clinic pharmacists Mary Kelly, Joong Kim and Elaine Pappas; Edward Thomas House manager and nurse Tamera Stone; UW Master of Health Administration student Tiffany Young; and Harborview nurse and diabetes educator Karen Adler.

The UW Martin Luther King, Jr. Community Volunteer Recognition Award is honoring Project CHANCE for being an example of a successful community-based project that exemplifies a commitment to community service. For PharmD student Steve Erickson, who will graduate this June, winning this award for a project he helped found as a first-year student is quite meaningful.

“It’s been wonderful to work with so many passionate healthcare students and practitioners over the years of this project,” said Erickson. “My hope is that recognition of the team’s efforts by this award will not only fuel the growth and continual improvement of the project, but will also inspire other students and practitioners to develop and sustain new community outreach and education initiatives when they see a need.”

Erickson noted that his favorite part of this project has been getting to know the patients, hearing their stories and being able to be a resource to people who don’t often have the chance to participate in health-education programs. He and several of the other team members will be on hand to accept the Martin Luther King Award at the UW Medical Center tribute which takes place annually in the UW Magnuson Health Sciences Center.

~January 14, 2014

Bracken Family Expands Legacy with Scholarship

L.D. Bracken, a UW School of Pharmacy alumnus, was the original creator of the Blistex ointment. The School of Pharmacy has long benefitted from the generosity of L.D. and his family over the years, as noted in this UW Report to Contributors story.

 

Click here for an archive of School of Pharmacy news stories.

UW Faculty, Alums Receive Awards for Innovation

WSPA_logo_2013

This past weekend at its annual meeting, the Washington State Pharmacy Association (WSPA) announced its 2013 award winners — all of whom are individuals who demonstrate a commitment to the quality of patient care. Among this year’s honorees were UW School of Pharmacy faculty members Andy Stergachis and Ryan Hansen and clinical faculty members Steven Anderson, Ryan Oftebro and Steven Singer.

Andy Stergachis, UW professor of epidemiology and global health, adjunct professor of pharmacy and health services, and director of the UW Global Medicines Program, received the Pharmacist of the Year Award. A registered pharmacist, Stergachis has spent much of his career connecting pharmacists with the public health community. He is presently pharmacy adviser to the Public Health – Seattle & King County Preparedness Section and a member of the Public Health Reserve Corps. He has been instrumental in connecting local and state public health officials with the WSPA and pharmacy leaders to strengthen the role of pharmacies and pharmacists in emergency preparedness planning. He is also an affiliate faculty member with the Pharmaceutical Outcomes Research & Policy Program and former chair of our Department of Pharmacy. He currently serves as the editor-in-chief of the Journal of the American Pharmacists Association.

Ryan Hansen, ’03, ’12, acting assistant professor of pharmacy, and Ryan Oftebro, ’03, clinical associate professor of pharmacy, won the Cardinal Health Generation Rx Award, which recognizes excellence in community-based prescription drug abuse prevention. Ryan Hansen is vice president and director of technology at Kelley-Ross Pharmacy in Seattle, and he is an Agency for Healthcare Research & Quality/UW K12 Patient Centered Outcomes Research Scholar at the UW. Oftebro is a pharmacist and co-owner of Kelley-Ross Pharmacy. Both Hansen and Oftebro are highly involved in the WSPA and the American College of Apothecaries. Together, they led Kelley-Ross Pharmacy’s partnership with StopOverdose.org, Public Health – Seattle & King County, and the UW Alcohol and Drug Abuse Institute to provide Take-Home Naloxone in an effort to prevent opioid overdose. This program provides access to naloxone as an overdose rescue kit for anyone at risk of an opioid overdose, as well as anyone at risk of witnessing an opioid overdose.

Affiliate Assistant Professor of Pharmacy Steven Singer, ’81, received the Distinguished Leadership Service Award. His career in pharmacy practice has been diverse and has included community, hospital, managed care, long term care and now hospice. Throughout his career, he has always kept patient care as a top priority. He has served on advisory panels for pharmaceutical manufacturers and currently serves on two committees at our School. He is also a co-chair of the WSPA Community/Ambulatory Care Academy. Whether he is providing historical viewpoints or challenging the leadership to think ahead, Singer is a valued voice among pharmacy leaders. In 2009, he received our School’s Distinguished Alumnus in Pharmacy Practice Award.

Clinical Pharmacy Instructor Steven Anderson received the Bill Mueller Outstanding Mentor Award. As pharmacy manager at the Bartell Drug store in University Village in Seattle, he is deeply involved in the precepting and training of UW pharmacy students. In fact, throughout his career, Anderson has mentored and precepted nearly 80 pharmacy students. His students describe him as a passionate pharmacist who is never too busy to answer a question or offer an explanation. Understanding the importance of pharmacy’s involvement in patient care, Anderson began an immunization program at his facility in 2003 and a travel clinic in 2010. He became an American Pharmacists Association Immunization Instructor in 2012. He was awarded the Wayne Kradjan Award for Excellence in Clinical Teaching earlier this year from our School.

Alumnus and former affiliate instructor Glenn Adams, ’98, was also honored by the WSPA. He won the Health System Pharmacist of the Year Award, which recognizes outstanding health-system pharmacists and their services to the profession. He is the administrative director of pharmacy for Confluence Health in Central Washington.

The winners were recognized at the awards luncheon on November 9th during the 2013 WSPA Annual Meeting in Grand Mound, Washington.

~November 12, 2013

 

Link to SOP news archive

Initiative Increases Focus on Collaborative Healthcare

The six UW health sciences schools have formed a new interprofessional education initiative to improve the teaching and delivery of healthcare across disciplines—using a team-based approach to make health care more efficient and effective. Read more.

 

Click here for an archive of School of Pharmacy news stories.

Namibia Partnership Continues to Grow

A memorandum of understanding between the UW and the University of Namibia supports joint education and research activities, and opportunities for exchange in support of the newly established School of Pharmacy at the University of Namibia.
 

Click here for an archive of School of Pharmacy news stories.

Reception and Lecture Combine for One Special School of Pharmacy Event

This year, the School of Pharmacy is combining two of our signature events — the Dean’s Recognition Reception and the Don B. Katterman Memorial Lecture — into one special event. This new program is intended to encourage our alumni and other members of our community to engage with the School and with fellow practitioners in an even more impactful way. The event will take place on May 8th from 5:30 to 8 p.m. at the Museum of Flight.

SeanSullivan-sq

The 34th Annual Katterman Lecture, presented by the School of Pharmacy and the Pharmacy Alumni Association, will start the evening. Headlining is Sean Sullivan, UW Stergachis Endowed director and professor of the UW Pharmaceutical Outcomes Research and Policy Program. His talk is entitled “Better-Informed Patients, Better-Informed Pharmacists: Navigating the Changing Medication Information Landscape.”

Sullivan’s lecture will focus on the rapidly evolving and increasingly complex information needs of pharmacists. Rather than relying solely on industry and regulatory bodies for current information about medications and therapeutic technologies, pharmacists must now look to more diverse sources of information — including the information patients are finding through increasingly sophisticated research. What’s more, we are in the midst of a personalized medicine revolution in which an individual’s genetic make-up can be used to inform treatment options.

The Katterman Lecture will talk about what these changes mean for healthcare providers, patients and the healthcare delivery system. Sullivan will provide insight to help pharmacists be successful in their efforts to forge partnerships with patients and health care providers on the appropriate use of drugs and other therapeutic technologies.

Sullivan is a professor of pharmacy and associate dean for research at the UW School of Pharmacy. He has devoted much of his research to medical decision-making and economic evaluation of medical technology. The Washington State Pharmacy Association will provide one continuing-education credit for the hour-long Katterman lecture.

Immediately following the Katterman Lecture is the annual School of Pharmacy Dean’s Recognition Reception. Dean Thomas Baillie and his wife, Kathleen Baillie, will host this event in which the School recognizes our donors, alumni and preceptors. The Distinguished Alumni Award recipient will be announced at the event. In addition, the reception will be an opportunity to honor and celebrate the many accomplishments of the UW School of Pharmacy, our students and faculty. This year, this entire event will be free to all guests. Participants may attend both the lecture and the reception; or they are welcome to attend just one of the events.

Find out more about this event and register here.

~March 12, 2013

School Named No. 3 in Global University Ranking

The Center for World-Class Universities at Shanghai Jia Tong University has ranked the UW School of Pharmacy No. 3 in the world in its 2012 Academic Ranking of World Universities (ARWU). More than 1,200 universities are ranked by ARWU every year.

 

Click here for an archive of School of Pharmacy news stories.

School Scientists Play a Role in Science EXPO Day

The first-ever Seattle Science EXPO Day took place Saturday, June 2nd. Lots of UW programs and people were featured among about 150 interactive experiments, games, exhibits and performances. Faculty and grad students from our School were there to share their love of science and conduct a cool experiment. Read more.

 

Click here for an archive of School of Pharmacy news stories.

Second Annual All Health Professions Day a Hit

More than 450 students from the UW Schools of Medicine, Nursing and Pharmacy crowded into Hogness Auditorium at the UW Health Sciences Center March 6 to hear a nationally recognized physician and ethics expert and to talk about how to disclose errors to patients as an interprofessional team. Read more.

 

Click here for an archive of School of Pharmacy news stories.

UW School of Pharmacy Ranks Tenth in the Nation

The “Best Grad Schools: 2013” issue of ‘U.S. News’ hit the stands on March 14th. Our School ranked in the top 10 once again. Numerous other University of Washington professional and graduate programs were also among the top 10 in their respective categories — including the programs in medicine, nursing and social work. Read more.

 

Click here for an archive of School of Pharmacy news stories.

Chairs Corner: Pharmacists without Borders

The February Chairs’ Corner focuses on the School of Pharmacy’s impact locally, nationally and globally. Chairs’ Corner is a bimonthly message about various facets of the University from the chairs of the UW Foundation Board of Directors. These messages are distributed to Foundation Board members, UW deans and chancellors, and Advancement staff. Read more. (PDF)

 

Click here for an archive of School of Pharmacy news stories.

School of Pharmacy Announces Endowed Professorships

The University of Washington School of Pharmacy congratulates the recipients of the following endowed professorships. These prestigious professorships were made possible by the support of alumni and friends.

Clinical Professor of Pharmacy Don Downing
Institute for Innovative Pharmacy Practice (“I2P2”) Endowed Professorship

Don_Downing

Downing is a prolific advocate for pharmacists, patients and underserved populations. He has devoted his career as a professor and practitioner to moving the profession of pharmacy forward.

His practice and training interests have included the development of the nation’s first pharmacist-provided emergency contraception program and the first pharmacist-initiated ongoing hormonal contraception services. Further, Downing and then-Professor Jackie Gardner led the first-in-the-nation charge in the 1990s to educate and certify Washington state pharmacists to provide flu shots and other vaccines to large populations of vulnerable people.

He has also created pharmaceutical care and business strategy partnerships between the School of Pharmacy and the Nisqually, Skokomish and Shoalwater Bay Indian Tribes. His close relationship with area tribes stems from his previous role as pharmacy director of the Puyallup Tribal Health Authority for more than a decade.

Downing, along with now Professor Emeritus Jackie Gardner, co-founded the School of Pharmacy’s Institute for Innovative Pharmacy Practice in 2005. He currently directs the institute. As the I2P2 Endowed Professor, he will have increased opportunities to further enhance innovations in pharmacy practice and education.

The Institute for Innovative Pharmacy Practice is a premier center for pharmacy training, research and advocacy. It draws on the School’s strengths in senior care, pharmacy management and community health programs. It prepares well-rounded pharmacists who promote entrepreneurial solutions for better health and better business. It also creates research partnerships to help practicing pharmacists implement cost-effective, health-enhancing practice innovations.

Professor of Pharmaceutics Shiu-Lok Hu
Milo Gibaldi Endowed Professorship in Pharmaceutics

Shiu-Lok_Hu_2

Hu has established a vibrant research program in the areas of virology and AIDS/HIV vaccine development. He is currently part of three, multiyear National Institute of Allergy and Infectious Diseases HIV Vaccine Research and Design grants, for which his collaborative contributions total more than $9.5 million.

One such collaboration, with researchers at the University of Massachusetts Medical School and New York University Langone Medical Center, is exploring the development of protective antibodies targeting the part of the HIV virus that binds to immune cells — considered by many the Achilles heel of the virus. Hu and his colleagues are looking at how structural changes to the part of the virus that binds to the cellular receptor may impact the development of novel vaccines.

Hu is a member of the Scientific Organizing Committee for the AIDS Vaccine 2011 Conference in Thailand this September. He is also a member of the editorial board for the journal AIDS Research and Human Retroviruses and an associate editor for Current HIV Research.

The Gibaldi Endowed Professorship will support Hu as he pursues new directions in research and teaching, such as those emerging from the impact of biotechnology on pharmaceutical sciences.

The fund was created in 2008 in honor of the late School of Pharmacy Dean Milo Gibaldi. He was dean from 1978 to 1998 and was renowned for his work in pharmacokinetics. He helped make the UW School of Pharmacy one of the nation’s premier pharmacy institutions. He passed away in 2006.

Dean Emeritus and Professor of Medicinal Chemistry Sid Nelson
Drug Metabolism, Transport and Pharmacogenomic Research (DMTPR) Endowed Professorship

Sid_Nelson-credit_Dan_Lamont

Nelson is internationally renowned for his groundbreaking research in the elucidation of chemical and biochemical mechanisms of foreign compound metabolism. His pioneering translational research has resulted in 221 peer-reviewed articles and 48 invited reviews and book chapters. His studies have also led to a heightened understanding of how reactive drug metabolites are formed and how they react with cellular molecules to cause toxicities. The ultimate goal of this research is the development of safer medications.

In addition, during his 13-year tenure as dean, he helped the UW School of Pharmacy achieve national prominence in its research activities. Under his leadership, the School secured a top 10 ranking in National Institutes of Health funding among pharmacy schools

Nelson has been awarded two patents and has received the John J. Abel Award from the American Society of Pharmacology and Experimental Therapeutics. In recent years, he has held an NIH fellowship to conduct research in metabolomics/metabonomics at Imperial College London. This July, Nelson will accept the American Association of Colleges of Pharmacy’s Volwiler Research Achievement Award.

The DMTPR professorship will help Nelson strengthen the School of Pharmacy’s research mission and respond to critical industry needs in the areas of drug metabolism, transport and pharmacogenomics.

Created in 2003, DMTPR is a partnership between the School of Pharmacy and corporate and industry constituents. It seeks to provide the pharmaceutical industry with excellent future researchers and with training, analysis and research in drug metabolism.

Chair and Professor of Pharmacy Peggy Odegard
Shirley & Herb Bridge Endowed Professorship for Women in Pharmacy

PeggyOdegard_for_top_story

Odegard is known nationwide for her expertise in diabetes treatment and geriatric pharmacy and for her commitment to advancing the profession of pharmacy. Much of Odegard’s career has been devoted to highlighting the important role that pharmacists play in patient care and to promoting collaboration among health providers.

Both a practicing pharmacist and an educator, she was recently named the Chair of the School of Pharmacy’s Department of Pharmacy. In 2008, along with pharmacy faculty members Annie Lam and Jackie Gardner, she helped found the School’s consulting pharmacy program, UW Pharmacy Cares. Odegard has been active in UW Pharmacy Cares in forming business partnerships with area pharmacies and care facilities. She is a long-time faculty member and director of the School of Pharmacy’s Plein Certificate in Geriatric Pharmacy Program.

Odegard’s numerous honors include the Washington State Pharmacy Association’s Pharmacist of the Year Award and the UW School of Pharmacy Gibaldi Excellence in Teaching Award.

The Bridge Professorship helped Odegard to initially establish UW Pharmacy Cares. Now, it will allow her to further grow the program as well as the program’s medication-therapy-management training program for Pharm.D. students.

The Bridge Endowed Professorship was created in 2008 by the late Shirley Bridge, ’45, and her husband, Herb. After graduating magna cum laude from the School in 1945, Shirley Bridge became one of Washington state’s first female registered pharmacists. She continued practicing until 1982. She was a long-time supporter and friend of the School of Pharmacy.

These endowed funds represent the unwavering generosity of our alumni and the remarkable work of our faculty. If you would like to support one of these professorships, please click here

~June 9, 2011

 

Click here for an archive of School of Pharmacy news stories.

Health Sciences Students Focus on Collaboration

A recent UW training event for students in pharmacy, dentistry, medicine, nursing and social work was part of a larger effort at the UW to improve the model of health care. The goal of these interdisciplinary training programs is to create a system of care in which all providers work together as equals to improve patient safety. Read more. 

 

Click here for an archive of School of Pharmacy news stories.

School Honored for Community Service

 

The American Association of Colleges of Pharmacy announced in November that the UW School of Pharmacy has received the 2010-2011 Transformative Community Service Award. This honor recognizes exceptional community programs that go beyond the traditional service role of academic pharmacy. Read more:
The Daily article
UW Today article  
AACP Press release

 

Click here for an archive of School of Pharmacy news stories.

UW Honored at AACP Meeting

UW Takes Multiple Top Honors at AACP Meeting

Faculty, students and alumni from the University of Washington had an impressive showing at the recent American Association of Colleges of Pharmacy annual meeting in Boston. AACP, the national organization that represents pharmacy education and educators, has a membership of almost 60,000 people.

HoFamily
Rodney Ho, recipient of the Paul R. Dawson Biotechnology award, with wife, Lily Hwang-Ho and son, Martin Ho.
NicoleEven
Nicole Even, ’09, with the poster she presented at the AACP meeting.

Congratulations to the following members of the UW School of Pharmacy community for their AACP honors!

• Pharmacy student Andrew Berry, ’10 (with his faculty mentor, Clinical Assistant Professor of Pharmacy Jennifer Danielson), and pharmacy student Abby Frye, ’10 (with her faculty mentor, Associate Dean of Academic and Student Programs Nanci Murphy), were recognized as AACP/Wal-Mart Scholars at the meeting. The goal of these scholarships is to strengthen students’ commitment and skills for a career in academia by providing funding to attend the meeting.

• Students and recent graduates Andrew Berry, ’10, Nicole Even, ’09, and Megan Roseman, ’09, were invited to present posters at the meeting.

• Three School of Pharmacy posters — authored by Cynthia Clegg,Jennifer Danielson, Karan Dawson, Dana Hammer, Ellen Maddox,Nanci Murphy, Terri O’Sullivan, Peggy Odegard, Monica Sahn andStan Weber — were presented at the meeting.

• Three UW faculty members were installed in AACP leadership positions. School of Pharmacy Senior Lecturer Karan Dawson is now the chair of the AACP continuing professional education section. Senior Lecturer in Pharmacy Dana Hammer is the secretary of the council of faculties. Annie Lam is the chair of the geriatric pharmacy special interest group.

• A team of UW students was named a finalist in the Pruitt-Schutte Student Business Plan Competition, sponsored by the National Community Pharmacists Association (NCPA). The team — Alisha Fewins, ’11, Zsolt Hepp, ’12, Dana Ling, ’11, and Rachel Merrill, ’11 — will compete for first place against teams from the University of Arizona and the University of Georgia at the NCPA annual convention in October.

• Milo Gibaldi Endowed Professor of Pharmaceutics Rodney Ho accepted the AACP Paul R. Dawson Biotechnology Award. This annual award goes to a pharmacy educator who has made important contributions to contemporary teaching and scholarship in biotechnology.

• Alumnus and 2007 School of Pharmacy Distinguished Alumnus Duane Miller, ’69, accepted the Volwiler Research Achievement Award for his outstanding research and contributions to the field of pharmaceutical sciences.

• Associate Dean of Academic and Student Programs Nanci Murphy received an AACP Teacher of the Year Award. This honor stemmed from the Gibaldi Excellence in Teaching Award that she received from the Class of 2009 at the UW School of Pharmacy graduate recognition ceremony this past June.

 

Click here for an archive of School of Pharmacy news stories.

Message from Herb Tsuchiya, 2008 School of Pharmacy Distinguished Alumnus in Pharmacy Practice

Tsuchiya gave the following speech upon accepting his award at the School of Pharmacy’s Dean’s Recognition Reception on Wednesday, May 6th, 2009:

tsuchiya-baillie
Dean Tom Baillie presents the Distinguished Alumnus Award to Herb Tsuchiya at the Dean’s Recognition Reception on May 6th.
tsuchiya
Herb Tsuchiya gives his speech at the Dean’s Recognition Reception on May 6th. Photos by Team Photogenic

First, I thank God for keeping me alive for this long. He must have a purpose and work for me to do for a little while longer. Just like pharmaceutical drugs, we humans have an expiration date. We just do not know when it is.

I thank my wife, Bertha for enduring me, loving me, trying to train me, and being my best fan and encourager. I thank my entire extended family for their love and support. I thank my precious and special friends. Thank you to the Awards Selection Committee. Thank you to the University of Washington School of Pharmacy for providing me with the education to become a pharmacist. To everyone that I have just mentioned, I accept this award on your behalf because it is each of you who made it possible for me to receive this recognition. I accept this award because it inspires all of us to strive to be the best that we can be in our careers whether it is as a pharmacist or any other occupation. Thank you. Domo arigato.

I have three rules for life. Rule 1 is “Be kind.” Rule 2 is “Be kind.” Rule 3 is “Be kind.” I am the youngest of seven children that included one sister and five brothers. I was named Herbert after President Herbert Hoover during the first great depression. To illustrate how poor we were, our snack after school was a slice of white Wonder Bread sprinkled with sugar. Soup for dinner was salt water boiled potatoes, carrots, celery, onions with no meat but sometimes beef bones which were free from the butcher shop at the grocery store.

To give you a clue as to what kind of kid I was I caught a cat by its tail and twirled it before letting it fly. As a kid, I had many visits to the woodshed where logs were chopped into smaller sticks for kindling wood to start the fire in the stove for cooking and heating purposes. My frequent visits were for the purpose of bending over and getting whacked with a stick of kindling wood to the part of my body where it was supposed to do the most good.

At school I was very quiet and shy. The teachers loved me because I was so well-behaved. They believed that I was studious. I wasn’t. I struggled at every subject. My third grade teacher wrote on my report card, “In music class your son tries hard but he cannot carry a note.” Is this why I only sing in the shower? Is this why I finally am learning to play the piano now at age 76?

Except for three and half years spent in the concentration camp in Minidoka Hunt, Idaho, during World War II along with 120,000 Japanese Americans who were incarcerated in ten internment camps in remote locations in the United States, I have lived in Seattle. Working as a community pharmacist and dealing with the public as a “legal” drug dealer for over fifty years changed me from shy and quiet to not-so-shy and talkative and sociable. Pharmacy changed my life style.

I enjoy traveling with my family, languages, mentoring, reading, and piano lessons. But most of all, I enjoy volunteering and teaming up with organizations like churches, charities or nonprofits. It is a treat to hang out with family and dear friends to talk and share both good times and tough times, especially with food and dessert. I love people, dogs and life because it is filled with new, exciting adventures, discoveries and possibilities.

I see so much potential even in this room. That potential is within each of you. That potential is contained within your dreams and hopes for the future. I encourage you to follow your dreams and hopes with both optimism and passion. You will be surprised what will happen when you do just that. Go for it. You can do it! I know that you can. The light is green. GO! All you need is preparation, perspiration, enthusiasm, optimism and passion.

 
Click here for an archive of PharmD news stories.

2009 Dean’s Recognition Reception

Click thumbnails below to view full-sized images.

001-Program 002-BridgeBailliePlein 003-Dixons 004-MichaelsForsterBaillie

005-WelbornFriend 006-JWelbornFriend 007-VincenzisLevyBaillie 008-LevyAndersonOrrVincenz

009-BeachesKosel 010-HancockBarchiesi 011-TomTalking 012-LaiOSullivan

013-ToastingTom 014-Tsuchiya 015-WCandle
(All photos by Team Photogenic, copyright 2009)

More than 130 alumni, friends, faculty and staff of the UW School of Pharmacy attended the Dean’s Recognition Reception on May 6. It was Dean Thomas A. Baillie’s first year to preside over the event since joining the School this past October. The event took place at the Seattle Asian Art Museum and honored some of the School’s most loyal supporters and volunteers.

Dean Baillie presented 2008’s Distinguished Alumnus in Pharmacy Practice award to Herbert Tsuchiya, ’55. Tsuchiya practiced pharmacy in the Seattle area for more than 50 years and has devoted his life to serving underserved populations and being an active community volunteer and philanthropist. Read his acceptance speech here.

“Herb possesses a devotion to the practice of pharmacy and to patient advocacy,” said Dean Baillie, “He has also shown a commitment to supporting students, a dedication to community service, and an understanding of the importance of global health. He represents all that is good about our alumni.”

This School has amazing alumni, indeed.

 

Click here for an archive of School of Pharmacy news stories.

School Welcomes New Dean

levy-baillie

When the UW Board of Regents chose Dr. Thomas A. Baillie as the next dean of the School of Pharmacy, it welcomed back an old friend to the UW family. Baillie served as a professor of medicinal chemistry in the School from 1981 to 1994.

Baillie left the UW for Merck & Co. Inc. because of the opportunities it offered him to pursue his research in drug metabolism and pharmacokinetics. He has been with the company since he left the University, most recently as vice president and global head of drug metabolism and pharmacokinetics.

Throughout the years, the School of Pharmacy has continued to enjoy a close working relationship with Baillie, as he has collaborated with faculty on research and served on the School’s corporate advisory board.

Regarding his return to UW, Baillie is excited to take the helm of what he calls one of the premier schools of pharmacy in the nation. He also looks forward to Seattle’s scenery, seafood and climate. It is a climate, he points out, that rivals that of his native Scotland.

Baillie hails from the Hebridean island of Islay (pronounced “eye-la”) on the west coast of Scotland. The tiny island may be best known for its eight malt whisky distilleries, one of which Baillie’s father managed until he moved the family to Glasgow when Baillie was 5. That is where Baillie stayed through graduate school.

Baillie first came to the United States through a faculty appointment in the School of Pharmacy at the University of California, San Francisco.

When he later joined the UW Department of Medicinal Chemistry, it was still located in Bagley Hall on upper campus. Looking back on that time, he recalls the sounds of Drumheller Fountain outside his office and of “freshman students being tossed unceremoniously into Frosh Pond by their unsympathetic senior colleagues.”

Baillie counts his years at the School among the most enjoyable of his career. “I truly appreciated the highly collegial and supportive environment provided by the School and its faculty,” he said.

As he re-enters academia amid a new climate for health care, pharmacy and pharmaceutical sciences, Baillie knows he will face challenges. He plans to respond to these challenges, in part, by building on and emphasizing the School’s many strengths.

Dean Emeritus Sid Nelson, who stepped down last month, said that Baillie is the right choice to lead the School, especially given his work in both industry and academia.

Nelson added, “He’s a good teacher and a good administrator. Faculty and students will appreciate him.”

Baillie’s wife, Kathleen, who has her Ph.D. in medicinal chemistry from the School of Pharmacy, will join the new dean in Seattle. Baillie has two grown sons — a computer animator for the movie industry in the Bay Area and a Ph.D. candidate in chemistry at Emory University in Atlanta.

In his free time, Baillie can be found flying his single-engine Commander aircraft — which he recently piloted across the country to move from Pennsylvania to Seattle. He will not, however, be found playing golf. Although he comes from the birthplace of the sport, it is a hobby that he says he just never learned.

To learn more about Dean Thomas A. Baillie, read his inaugural Message from the Dean in the Fall 2008 Dawg Scripts.

In the photo above, Dr. Baillie (right) shares a laugh with Dr. Rene Levy (left), professor and former chair of the Department of Pharmaceutics, at a conference a few years ago. Baillie has maintained a relationship with the School since he left the Department of Medicinal Chemistry in 1994. He returned to the School of Pharmacy in the role of dean on October 1.

October 20, 2008

 

Click here for an archive of School of Pharmacy news stories.

Murphy Named APhA Outstanding Chapter Advisor for 2008

murphyDr. Nanci Murphy, associate dean of Academic and Student Programs at the University of Washington School of Pharmacy, has been named APhA-ASP Outstanding Chapter Advisor for 2008. This award, established to recognize advisers who have promoted with distinction the welfare of student pharmacists through various professional activities, is a great honor and could not go to anyone more deserving than Dr. Murphy.

“Nanci makes an effort with each student on a personal level. We are but one generation of students with countless stories of Nanci’s inspiration, dedication and boundless support,” say Emily Schulze,’09, a member of a team of students to nominate Dr. Murphy for this award.

Nanci Murphy is tireless in her efforts to support, train, mentor and care for our students. In addition to her role as associate dean, Nanci spends time teaching students in both the classroom and practice settings and supporting their many extracurricular activities at the University, community, state and national level. With such a busy schedule, Dr. Murphy still finds time to attend nearly every student function, organization meeting and event and her door always remains open for students with special circumstances, in need of encouragement, or simply seeking advice.

“Nanci will always take extra time out of her schedule to listen, give support, and provide a creative solution,” says Schulze.

Nanci Murphy creates leaders. In each student, she sees great potential for leadership, high achievement and success. One student says of Nanci’s unique ability to instill confidence and bring out the best in our students: “She listens, makes suggestions, and through that opens a student’s eyes to all the possibilities that we were blind to before. It’s like turning a prism in just the right way so that a rainbow appears. She takes obstacles and turns them into windows of opportunity and that is inspiring.”

Dr. Murphy may pull these talents from her own personal drive and commitment to pharmacy. She has held leadership roles in University and state-wide programs to include co-director of the University of Washington’s Center for Health Sciences Interprofessional Education, chair of the Faculty Council on Student Affairs, the Diversity Council, the Senate Executive Committee, the Faculty Leadership in Interprofessional Education to Promote Patient Safety, the Washington State Pharmacy Association’s Board of Directors, State of Washington Pharmacy Leadership Conference, and the Board of Pharmacy’s Task Force on Practitioner Competency.

As fortunate as we are to have Dr. Murphy, our school is not the only institution to benefit from her commitment to providing excellent resources, education and support to young pharmacists. Dr. Murphy has had a national impact as chair of the American Association of Colleges of Pharmacy (AACP) Joint Task Force on the Healthy Student Program, the Curriculum Special Interest Group, and the Student Services Special Interest Group. Dr. Murphy contributed to the development of the APhA-ASP/AACP Toolkit on Student Professionalism, the AACP Healthy Student Program Toolkit, Successful Practices in Student, Faculty and Staff Leadership, and the Pharmacy Practice CAPE Supplemental Educational Outcomes.

“I am very proud to be an adviser at the University of Washington School of Pharmacy where it is a joy and privilege to work with such inspirational student pharmacists, faculty, administrators, and staff,” says Dr. Murphy.

It is the University of Washington School of Pharmacy that is honored to have Nanci Murphy as one of its own and the school would like extend a personal thank you on behalf of generations of students, faculty and staff for her ongoing support of future pharmacists and the advancement of pharmacy. Dr Murphy will be formally recognized at the APhA 2008 conference in San Diego, March 14-17.

 

Click here for an archive of School of Pharmacy news stories.

UW School of Pharmacy Ph.D. Research Programs Rank #1

The University of Washington School of Pharmacy medicinal chemistry and pharmaceutical sciences research programs are the best in the nation according to a recent academic ranking. The findings, announced in the January 12 issue of The Chronicle for Higher Education, are based on faculty scholarly activities calculated by The Faculty Scholarly Productivity Index.

The Index looked at 104 programs at top ranked institutions from leading State Universities to elite private and ivy-league schools. The UW School of Pharmacy medicinal chemistry and pharmaceutical science programs ranked at the top despite tough competition.

“This is a well-deserved honor,” said UW School of Pharmacy Dean, Sid Nelson, PhD, “This ranking, the first based on benchmark data, provides a useful metric analysis of the exceptional work of our faculty.”

The Faculty Scholarly Productivity Index partly financed by the State University of New York at Stony Brook and produced by Academic Analytics, a for-profit company, rates faculty members’ scholarly output at nearly 7,300 doctoral programs around the country. It examines the number of book and journal articles published by each program’s faculty, as well as journal citations, awards, honors, and grants received. The Index is being hailed by some in academe for its objective benchmarks, its transparent methodology, and its commitment to regular and predictable reporting. The National Research Council’s rankings of doctoral programs, once the most respected in academe, have not been updated since 1995 and have never included pharmacy research programs in its rankings. Other annual graduate program rankings such as U.S. News & World Report’s have been criticized for years by academics as unscientific popularity contests.

The University of Washington ranked number one in five additional Ph.D. research programs: microbiology, genetics, zoology, business administration, and fisheries science and management.

The University of Washington School of Pharmacy Department of Pharmaceutics has instructional and research programs that emphasize a Physiologically-Based Approach to Drug Delivery and Disposition. This program includes a molecular evaluation of drug delivery, metabolism and transport processes, and the genetic and environmental factors that control enzyme and transporter protein function. The University’s Department of Medicinal Chemistry focuses research in the areas of mechanistic drug metabolism, toxicology, bioanalytical chemistry, molecular modeling, biological mass spectrometry and biological NMR. Learn more about the School, our doctoral programs and our faculty at on our website.

Dean Nelson Named Outstanding Dean of the Year

Sid_Nelson-credit_Dan_LamontUniversity of Washington (UW) School of Pharmacy Dean, Sid Nelson, has been named APhA Academy of Student Pharmacists Outstanding Dean of the Year for 2007. Dean Nelson was chosen from a pool of nearly 100 pharmacy deans across our nation to receive this honor.

Dean Nelson is well-respected and admired by his students, faculty, and peers. His leadership has not only resulted in the UW’s #1 ranking in NIH funding among pharmacy schools, but has also provided the support for students to serve in numerous regional and national leadership positions. “In order for pharmacy students to flourish as leaders, they must have an environment that inspires them to have confidence in themselves, provides the support they need to be successful, and values student involvement,” explains UW School of Pharmacy Dean, Nanci Murphy. “I believe no one accomplishes this better than Dean Nelson.”

Dr. Nelson is a professor of medicinal chemistry and dean at the UW School of Pharmacy and chair of the Board of Health Sciences Deans at UW. He received his BS in pharmacy from the UW in 1968 and his PhD in pharmaceutical chemistry from UC San Francisco in 1974. After three years at the National Institutes of Health (NIH), he returned to the UW as an assistant professor in 1977 where he was promoted to professor of medicinal chemistry in 1983. He was a visiting professor at the Karolinska Institute in Stockholm, Sweden from 1985-1986. Dr. Nelson became dean of the School of Pharmacy in 1995 and chair of the Health Science Deans in 2001. He teaches courses in organic medicinal chemistry and clinical chemistry and diagnostics to pharmacy students and lectures to graduate students on drug metabolism. He is funded by NIH for his research on reactive drug metabolites, structure-toxicity relationship and cytochrome P450 structure-function relationship. He received the John J. Abel Award for research from the American Society of Pharmacology and Experimental Therapeutics in 1981, and was elected a Fellow of the American Association for the Advancement of Science in 1986. In 1990, Dr. Nelson received the Alumnus of the Year Award from the UW School of Pharmacy, and in 1992 the Sato Memorial International Award from the Pharmaceutical Society of Japan for excellence in research. In 1995 he received the Gilbaldi Excellence in Teaching Award from the graduating class of pharmacy students. He has over 200 peer-reviewed research publications and over 40 published reviews and book chapters. In 2002 he was listed as an Institute for Scientific Information highly cited research author. The APhA Award is a great honor to add to an already very distinguished career and especially satisfying as it honors a commitment to the growth and mentorship of future pharmacy leaders.

APhA Academy of Student Pharmacists Outstanding Dean Award was established to recognize a School or College Dean who has made significant contributions to the APhA-ASP Chapter and promoted, with distinction, the welfare of student pharmacists through various community service, leadership and professional activities and represents APhA’s appreciation for the recipient’s leadership, inspiration, and outstanding guidance to APhA, the profession and pharmacy students.

“I am extremely honored to have been nominated by our students for this award and for their nomination to be supported by School of Pharmacy faculty, staff, and alumni,” said Dean Nelson. “It is all these people together who make the UW School of Pharmacy one of the top programs in the country and it is their support, and enthusiasm, along with that of my loving wife and family, that energizes me and makes me want to get up and go to work each morning.”

Dean Sid Nelson will be recognized at the upcoming APhA-ASP Awards Ceremony to be held Monday, March 19 at the APhA Annual Meeting in Atlanta, Georgia.

 

Click here for an archive of School of Pharmacy news stories.

Two Professors Named as Fellows, AAAS and ASCP

The University of Washington School of Pharmacy is proud to announce that two if its professors, Drs. Rene Levy and Peggy Odegard have been named as fellows of the Association for the Advancement of Science (AAAS) and American Society of Consultant Pharmacists (ASCP), respectively.

 
levyDr. Rene Levy, professor of pharmaceutics and former chair of the pharmaceutics department, is one of five UW faculty members to be named as a fellow of the American Association for the Advancement of Science (AAAS) Council. He and UW colleagues, Aimee H. Bakken, Toby Bradshaw Jr., Conway B. Leovy and Dennis P. Lettenmaier, are among 471 association members to be recognized for their scientifically or socially distinguished efforts to advance science and/or its technological applications.

Election as a Fellow of AAAS is an honor bestowed upon members by their peers. “I am grateful for this reconnection,” says Levy. “To be chosen as a Fellow by a group of my peers it a fulfilling honor indeed.”

Dr. Levy is noted for his contributions in the section of pharmaceutical science, where he is specifically recognized for his distinguished contributions to the treatment of epilepsy, and for fostering the development and rational use of new drugs and therapeutic modalities.

Levy joined the UW faculty in 1970, after earning his doctorate in pharmaceutical chemistry from the University of California, San Francisco. His work has included the Metabolism and Transport Drug Interaction Database presently licensed by UWTechTransfer to pharmaceutical scientists throughout the world. Levy and his colleagues will be recognized at the 2008 AAAS Annual Meeting to be held this coming February in Boston.

odegardPeggy Odegard PharmD, associate professor of pharmacy, has been named as a Fellow of the American Society of Consultant Pharmacists (ASCP). ASCP Fellowship is a special honor bestowed upon pharmacists who meet the highest standards in senior care pharmacy and have demonstrated an extraordinary level of service and dedication in professional practice activities. A Fellow of the Society must fulfill rigorous criteria established by the ASCP Board of Directors and demonstrate dedication and achievement in professional activities, education activities, professional innovation, advocacy, and civic activities.

Odegard is being honored for her commitment to go above and beyond the traditional pharmacy practice by distinguishing herself through extemporary service and contributions to the practice of senior care pharmacy and the community.

Dr. Odegard practices pharmacy in an interprofessional senior care clinic, provides community-based education on aging to older adults, and is a certified diabetes educator (CDE) working primarily with older adults with type 2 diabetes mellitus. Prior to her current position, Dr. Odegard was the clinical pharmacy manager for a 200-bed community hospital and was Assistant Dean for the UW School of Pharmacy’s Professional Programs. As a faculty member at the University of Washington, Dr. Odegard’s primary research and teaching interests are in the areas of diabetes, pulmonary diseases, and drug-induced problems with an emphasis on the care of the older adult. She is a member of the core geriatrics faculty and Director of the Certificate Program in Geriatrics. In development of the Geriatrics curriculum at the UW, Dr. Odegard is an active member of the task force to develop geriatrics training competencies for all doctor of pharmacy students using both the specialized geriatrics training sites and the general medicine and community sites. Her vision for geriatrics care is that all pharmacists will enter practice with the competency to provide the essential pharmaceutical care needed by older adults.

American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal, Science. AAAS was founded in 1848 and boasts 262 affiliated societies and academies of science. According to material from AAAS, Science has the largest paid circulation of any peer-reviewed general science journal, with an estimated readership of 1 million.

The American Society of Consultant Pharmacists (ASCP) is the international professional association that provides leadership, education, advocacy, and resources to advance the practice of consultant and senior care pharmacy.

 

Click here for an archive of School of Pharmacy news stories.

Dean Sid Nelson Quoted by U.S. News & World Report on Drug Interactions

Food and Drugs Can Create a Toxic Mix

By Deborah Kotz
U.S.News & World Report
Thursday, September 27, 2007
Posted September 26, 2007

Mix one part Red Bull with two parts vodka and what do you get? If a headache comes with the buzz, it may not be wise to add a Tylenol chaser—especially if you’re a heavy coffee drinker. A study published online today in the journal Chemical Research in Toxicology found that big doses of caffeine (found in Red Bull and regular coffee) combined with acetaminophen or Tylenol may well raise the risk of liver damage. When researchers from the University of Washington in Seattle mixed the caffeine-equivalent of 20 cups of coffee and the maximum daily allowable dose of acetaminophen with a liver protein, they found that the combination triples the output of a toxic byproduct made when the protein processes acetaminophen. Alcohol, already shown to be harmful in combination with Tylenol, could increase the toxic effects even more.

The study is a reminder that, when it comes to drugs and food, you have to consider the sum of the parts. The Food and Drug Administration keeps a list of common food and drug interactions. Here are some hazardous mixtures:

• Antihistamines: Don’t take these drugs with alcohol, since mixing the two can increase the level of drowsiness caused by some of the medications.

• Asthma medications: Avoid caffeinated beverages and foods because both caffeine and bronchodilators (theophylline, albuterol, epinephrine) act as stimulants, increasing nervousness and jitteriness. Alcohol should also be avoided when taking theophylline, since it can increase the risk of side effects such as nausea, vomiting, headache and irritability.

• Diuretics: Used to treat high blood pressure and edema, diuretics can interact with specific nutrients. Triamterene, for instance, shouldn’t be combined with potassium-rich foods like bananas, oranges, green leafy vegetables, or salt substitutes that contain potassium. An excess of potassium in the bloodstream can lead to heart palpitations.

• Heart medications: Beta blockers and nitrates shouldn’t be taken with alcohol because this can result in dangerously low blood pressure. Some ACE inhibitors (captopril and moexipril) shouldn’t be taken right before or right after eating. Cholesterol-lowering statins shouldn’t be taken with alcohol since the combination can increase the risk of liver damage. The blood thinner warfarin shouldn’t be combined with foods rich in vitamin K, like broccoli, spinach, kale, or cauliflower, since these may reduce the drug’s effectiveness.

If you find yourself dealing with a Red Bull-vodka headache, use aspirin or ibuprofen, recommends study co-author Sidney Nelson, dean of the school of pharmacy at the University of Washington. Both appear to be less problematic. But avoid combination painkillers like Excedrin, which contain acetaminophen, aspirin, and caffeine. The small amount of caffeine and acetaminophen in these products won’t normally pose liver risks, Nelson says, but they might be harmful when taken during a drinking binge.

 

Click here for an archive of School of Pharmacy news stories.

UW School of Pharmacy Mourns the Loss of Dean Emeritus Milo Gibaldi

 

gibaldi-colorDr. Milo Gibaldi, who served as dean of the UW School of Pharmacy from 1978 to 1995, died Jan. 13 in Chicago at the age of 67. He is remembered at the UW as a humble, warm, gracious teacher, and a visionary leader.

“Those of us who were fortunate enough to know Milo, will miss his friendship, wonderful insights and ability to inspire,” noted dean Sid Nelson.

As dean, Gibaldi played an instrumental role in making the UW School of Pharmacy a premier school of pharmacy, developing a more clinically oriented curriculum, integrating the school into the UW health sciences community, and launching the Doctor of Pharmacy program.  Although internationally honored for his accomplishments in pharmacy research and education, he once said, “I think of myself as a teacher, first and foremost. Even when I discover something in my research, I really get excited about telling my students about it.”

Gibaldi was a pioneer in the study of pharmacokinetics, pharmacodynamics, drug metabolism, bioavailability, bioequivalence, and transdermal drug delivery systems. He published more than 200 scientific papers and eight books, including the Drug Therapy Topics Supplement.  He served as scientific advisor to the Food and Drug Administration, the National Institutes of Health, and several pharmaceutical companies.

Over the course of his career, Gibaldi received many honors for his work. He was one of just seven U.S. scientists honored at the Millennial World Congress of Pharmaceutical Sciences in 2000. In 1986, he became one of only two pharmacists ever elected to the prestigious Institute of Medicine of the National Academy of Science. The International Pharmaceutical Federation bestowed the Erik Host Madsen Medal to Gibaldi in 1991 for distinction in pharmaceutical sciences. In 1996, he was elected a fellow of the American Association of Pharmaceutical Scientists (AAPS) and was a recipient of the association’s Research Achievement Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism.

As dean, he oversaw the planning construction of the School of Pharmacy’s long-sought permanent home in the Health Sciences Center H-Wing. Previously the School of Pharmacy had been in Bagley Hall and other locations on the UW campus.  In addition, Gibaldi implemented the two-year, post-baccalaureate Doctor of Pharmacy (Pharm.D.) program, which had been in the planning stages for some years, and graduated its first students in 1982. Combined with an American Society for Hospital Pharmacy accredited residency program, it was recognized as one of the foremost graduate programs in the nation.

Gibaldi received his undergraduate degree in pharmacy in 1960 and his doctorate in pharmaceutics in 1963 from Columbia University.  He was an assistant professor at Columbia until 1966 when he moved to the State University of New York at Buffalo. There he advanced to the rank of full professor and chair of the Department of Pharmaceutics and established a national and international reputation for research in biopharmaceutics and pharmacokinetics. A strong promoter of collegiality, Gibaldi’s leadership was recognized by UW appointments as associate vice president for Health Sciences (1982-1992), chair of the Board of Deans (1987-1995), and chair of the Board of Health Sciences Deans (1992-1995).

Gibaldi was dean of the School of Pharmacy for 17 years. He stepped down from the deanship on July 1, 1995 to return to the faculty as professor of pharmaceutics and dean emeritus. He moved to Chicago in 2003 to be closer to family and teach at Midwestern University and continue with his research. Throughout his tenure and much of his life he battled serious health problems, and was admired for his perseverance and courage that enabled him to still reach great heights as a scientist, leader and educator.

The Milo Gibaldi Endowed Professorship in Pharmaceutics was created in his honor in 1993, designed to focus on faculty and student research and education in advanced drug delivery systems.

Milo Gibaldi is survived by his wife, Florence, and daughter, Ann. The family has asked that in lieu of flowers, those wishing to make a condolence and memorial gift please do so with a donation to the Milo Gibaldi Professorship Endowment. Donations can be made online or by calling the University of Washington School of Pharmacy Office of Development directly at (206) 616-7613.

 

Click here for an archive of School of Pharmacy news stories.

UWSOP Brings Health Technology into the 21ST Century

The University of Washington School of Pharmacy, along with The Everett Clinic, have been awarded a $1.03 million dollar grant to evaluate how computerized prescribing in an out patient clinical setting improves medication safety and patient outcomes. The grant, funded by the US Department of Health and Human Services, is part of a federally mandated program to use Health Information Technology (HIT) as a means to improve the nation’s health care system.

According to the Institute of Medicine, medical errors cause 98,000 deaths each year in the US. This grant is part of a $139M funding initiative from the US Department of Health and Human Services, awarded through its Agency for Healthcare Research and Quality, to promote the use of Health Information Technology (computerized prescribing) as a means to reduce medical errors and improve the national health care system – by making it safer and more efficiencies.

The project is a collaborative effort by the University of Washington School of Pharmacy and its partners, The Everett Clinic, CliniTech (The Everett Clinic’s healthcare Information Technology Organization) and Providence Everett Medical Center. This is one of the first times a study like this has been done in an outpatient clinical setting, such as The Everett Clinic. Until now, most computerized prescribing studies have been done in large hospitals.

The team will test the efficiency and accuracy of computerized prescribing in reducing medication errors (pre- versus post- study); and will identify any links these errors may have to adverse drug events related to emergency department admissions. They will use interviews, focus groups and surveys to evaluate prescriber’s experiences.

In addition to reducing medication errors, the team expects the project to improve health information sharing between providers and pharmacies. This will make transitions between healthcare settings safer for patients. It is anticipated that improving the efficiency of community health services, medication safety, and patient outcomes will decrease the nation’s total healthcare costs.

The study will take place over the next three years. All information, strategies and lessons learned from the study will be documented and made available to the public.

“Medication safety is a priority at The Everett Clinic. We look forward to being a vital component of this project and helping others improve in this area,” explains Dr. Albert W. Fisk, medical director of The Everett Clinic and co-principal investigator.

“This study is an important step in creating a more technologically advanced infrastructure by which the national healthcare system will become more efficient, effective and safe” states Dr. Sean D. Sullivan, professor and director, Pharmaceutical Outcomes Research and Policy Program and co-principal investigator, UW School of Pharmacy.

For more information on this project, please contact the School at 206-543-3485.

Featured in The Seattle Times and the Everett Herald

 

Click here for an archive of School of Pharmacy news stories.

Faculty, Alumni Win Research Award

Several School of Pharmacy faculty and alumni collaborated on a paper that received the 2003 Drug Therapy Research Award from the American Society of Health-System Pharmacists (ASHP). Dave Veenstra, assistant professor of pharmacy, Mitch Higashi, Ph.D. ’01, Ann Wittkowsky, Pharm.D. ’88, and Allan Rettie, professor and chair of medicinal chemistry, collaborate on a paper titled “Association Between CYP2CP Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy,” which was published in the Journal of the American Medical Association in April 2002. The award was presented on Dec. 8, at the ASHP Midyear meeting in New Orleans.

The award recognizes an outstanding contribution to the scientific pharmaceutical literature of research primarily concerning drug efficacy and safety in human subjects. The study built upon original research conducted at the School under the Program Project Grant for Drug Interactions and was funded by the UW National Institute of Environmental Health Sciences Center for Ecogenetics and Environmental Health. Veenstra was also supported in part by a PhRMA Foundation Career Development Award, and Higashi was supported by a pilot grant from the UW Institute for Public Health Genetics.

 

Click here for an archive of School of Pharmacy news stories.

Pioneer in Drug Therapy Leaves School of Pharmacy: Dr. Milo Gibaldi Instrumental in Transforming SOP into Premier Pharmacy School

Dr. Gibaldi has imparted his vast knowledge to his final set of students in Spring 2003 and has taken a new position this July in Chicago where he will be teaching at the Chicago College of Pharmacy and continuing with his research. He will remain a part of the UW SOP in an affiliate faculty role. He and his wife, Florence, were motivated to move to the windy city because of family ties and will live close to their daughter, son-in-law and grandchild in Chicago.

Dr. Gibaldi is excited to begin a new chapter in his career. He called leaving the UW School of Pharmacy “a wrenching decision because we’re exceedingly happy here, and I am very happy with the School. We have a lot of ties here, but I do believe it is the right thing to do.”

Though he will turn 65 this December, Dr. Gibaldi said retirement is not even on the horizon right now.

“I’m not at a point where I want to retire,” he said. “I simply want to continue to have contact with students and this is a nice opportunity to do that.”

Dr. Gibaldi says his style of teaching involves reaching out to all his students in a way that draws their varied experiences into the classroom discussion.

“I try to explain things to my students in a way that provides context,” he said. “I have a wide range of backgrounds and experiences, so I try to provide information that will be stimulating and satisfactory to the breadth of my students. I present some things that are on the cutting edge and then a basic context so people with less experience can be a part of the discussion.

“My students are very bright and very enthusiastic and inquisitive. I like them pressing for answers and wanting to go beyond the surface.”

Former School of Pharmacy Dean Jack Orr said Dr. Gibaldi was integral in making this School what it is today.

“Milo Gibaldi leaves an indelible footprint on the history of the School,” Dr. Orr said. “It was through his persistence that physical integration with the Health Sciences Complex was achieved. He brought to fruition 50 years of efforts to construct a ‘Pharmacy Wing.’”

Dr. Joy Plein, a professor in the Department of Pharmacy, called Dr. Gibaldi “a legacy at the School. Milo involved all the stakeholders, practitioners and faculty in the planning and the process, avoiding the resistance that many schools went through. He is a scientist who not only understands but also appreciates the role of pharmacy and the contributions of pharmacists in healthcare and society.”

Manoj Bajpai, ’96 is one alumnus who credits Dr. Gibaldi for influencing his career path and leaving a strong impression on him. While a Ph.D. student in the Department of Pharmaceutics about 15 years ago, Dr. Bajpai said he realized Dr. Gibaldi’s “humility, warmth and graciousness. Here was a world-renowned faculty member, Dean of the College, well respected in both academia and industry, and yet as approachable as an office mate to all students.” Dr. Bajpai now works as a research scientist at Amgen in Thousand Oaks, California.

He remembers his last day at the School and a very pivotal encounter he had with Dr. Gibaldi.

“As I was picking up my belongings and wrapping up last minute formalities, Dr. Gibaldi stopped by my office on his way home to wish me well. He said that I was ready, and I knew I was.”

Reaching as many students as he can is a driving force behind his Drug Therapy discussion group. Held once a week with about 150 students now enrolled, this discussion group gives Dr. Gibaldi’s students and other interested guests an opportunity to hear about new classes of drugs and learn how they are shaping the pharmaceutical industry.

His journal club gives yet another opportunity for more students to learn from this giant in pharmaceutical research in a more intimate setting.

“There is a lot of interaction with this group,” Dr. Gibaldi said.

When not teaching, Dr. Gibaldi is conducting extensive research into numerous drug therapies, something he intends to continue at the Chicago College of Pharmacy. A prolific author, Dr. Gibaldi has gained widespread notoriety for his in-depth research and leadership in the fields of pharmacy and medicine. He is considered one of the leading thinkers in medicine.

But when you ask Dr. Gibaldi what he considers himself, he answers immediately a teacher.

“I think of myself as a teacher, first and foremost. Even when I discover something in my research, I really get excited about telling my students about it.”

While teaching has earned him the respect and admiration of his students, it is his research and extensive literature exploring the merits of drug therapies that has led to his widespread recognition among his peers and the pharmaceutical community as a whole.

He has been showered with awards and distinct honors. His expertise in the area of drug therapies has brought him international acclaim. He was one of just seven U.S. scientists honored at the Millennial World Congress of Pharmaceutical Sciences in San Francisco in the year 2000, and back in 1986, he became one of only two pharmacists ever elected to the prestigious Institute of Medicine. A few years later, in 1991, he received the International Pharmaceutical Federation’s Erik Host Madsen Medal for those who have achieved distinction in the pharmaceutical sciences.

While widely honored for his contributions to pharmacy research and education, Dr. Gibaldi has been especially recognized for his contributions in pharmacokinetics (the study of what happens to a drug in the body after it is swallowed or injected).

As for his notable accomplishments at the UW School of Pharmacy, Dr. Gibaldi said there are three that come to mind.

He lists them as playing an instrumental role in making the UW School of Pharmacy into a premier pharmacy school, the development of a more clinically oriented curriculum, and finally overseeing the relocation of the School of Pharmacy into the Health Sciences Center.

As Dr. Gibaldi prepares his final lectures and pens his last research literature while on the UW School of Pharmacy faculty, he remembers what drew him to this School.

“I could tell that there was a very strong pharmacy community and a lot of innovation, and a willingness to try new things,” he recalled. “The faculty wanted to build a really good professional program, and they did.”

He believes that these same winning qualities will enable the SOP to continue to be a leading pharmacy school and highly relevant to the pharmacy industry.

“The School is in great shape. To use a sports metaphor, we have solid bench strength. We have great people here who can step in and do an outstanding job. The best is ahead of us.”

In honor of Dr. Gibaldi and his contribution to the School of Pharmacy, gifts toward an endowed fund in his name are being accepted. For more information, contact the Development Office at (206) 543-3485.

Phonathon Gets Great Reception

One of the biggest volunteer turnouts to date at a School of Pharmacy Phonathon was held to raise funds for critical student programs and scholarships. The 2003 Phonathon, which was held on February 11th and 12th , brought together great teamwork on the part of our students, staff and alumni. Phonathon pledges given by phone continue to arrive into the office. Most of this year’s pledges are designated for the Dean’s Fund for Excellence.

More than 50 volunteers displayed a heartfelt commitment to the School of Pharmacy by devoting their time and energy to contacting alumni and securing much needed funds for the School. With the severe state budget crisis, and the twin challenges of dwindling state funds and rising tuition costs, Phonathon volunteers were charged with an ambitious task: to tap into the generosity of alumni to help ensure the financial viability of our scholarships and already strained academic programs.

Despite the recession plagued economy and a plummeting stock market, our alumni committed more than $11,000 to the Dean’s Fund for Excellence and other School funds. The focus for this year’s Phonathon was the Dean’s Fund for Excellence because it offers the greatest discretion in subsidizing student scholarships, emergency funds for students, student travel, and other School expenses not funded by the state budget.

The cornerstone of a successful Phonathon – the hard efforts of our volunteers, some of whom worked two shifts – paid off. Among the outstanding work done by our dedicated volunteers were those who secured top dollar pledges: Susan Bridwell, ’05, Derek Kuniyoshi, ’06, Tran Le, ’06, Alissa O’Connell, ’06, and those who secured the most pledges: Tina Choe, ’04, and, Cynthia Gierwatowski, ’03. Similarly, Georgia Gianacos, Pharm.D.’00 and Dana Hurley, ’97, received top commitments from their fellow alumni.

We owe a great deal of appreciation to Dana Hurley, alumnus and past president of the Pharmacy Alumni Association (PAA) who served as the Phonathon’s chair. Dana ensured both nights went smoothly and offered valuable insights into bringing greater efficiency to this fundraiser in the future.

“It was exciting to see the student callers actively competing with one-another to get pledges,” Dana said. “The student callers were thrilled when they had the opportunity to talk at length with the alumni they reached.”

We also owe thanks to Liz Fisher, a friend of the School of Pharmacy and wife of alumnus Bill Fisher. Liz served as lead of the earlier shifts both days. Liz offered guidance and effectively spelled out the Phonathon goals to the teams. Thank you Dana and Liz.

Many of our accomplished volunteers received door prizes such as Palm Pilots, large fruit baskets, and gift certificates to pizzerias, restaurants and drug stores. All of these gifts were donated by our generous area businesses.

Congratulations to all of our Phonathon volunteers for playing a vital role in ensuring the future viability and relevance of our School of Pharmacy.

 

Click here for an archive of School of Pharmacy news stories.